<SEC-DOCUMENT>0001062822-22-000022.txt : 20220506
<SEC-HEADER>0001062822-22-000022.hdr.sgml : 20220506
<ACCEPTANCE-DATETIME>20220505160905
ACCESSION NUMBER:		0001062822-22-000022
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		45
CONFORMED PERIOD OF REPORT:	20220331
FILED AS OF DATE:		20220505
DATE AS OF CHANGE:		20220505

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LEXICON PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001062822
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				760474169
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30111
		FILM NUMBER:		22896285

	BUSINESS ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381
		BUSINESS PHONE:		2818633000

	MAIL ADDRESS:	
		STREET 1:		2445 TECHNOLOGY FOREST BLVD.
		STREET 2:		SUITE 1100
		CITY:			THE WOODLANDS
		STATE:			TX
		ZIP:			77381

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON PHARMACEUTICALS, INC./DE
		DATE OF NAME CHANGE:	20070426

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	LEXICON GENETICS INC/TX
		DATE OF NAME CHANGE:	20000126
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>lxrx-20220331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:d7a1dbc6-b99b-4a1d-848b-92cec6605016,g:574c9470-43fb-4b26-864a-707e5ed846fe,d:1663458ba3974fd69ad7c84eebd167a7--><html xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:lxrx="http://www.lexpharma.com/20220331" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lxrx-20220331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV81LTQtMS0xLTIzNTk2_5e25db49-2bf8-4e4a-b006-a73939c3b0c9">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV85LTQtMS0xLTIzNTk2_82a4c9f9-218a-496b-856b-151f123237ee">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV8xMC00LTEtMS0yMzU5Ng_3a187d7f-9548-4ab6-8800-cd15dde50427">2022</ix:nonNumeric><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV8xMS00LTEtMS0yMzU5Ng_a0e92405-1fe1-4f14-af14-04e01a0fdb9d">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV8xNC00LTEtMS0yMzU5Ng_cc3e956a-f14b-4456-be4b-6ae151c4b8cd">0001062822</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="lxrx-20220331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ideb90240455b438fb9d26eff699c0fbc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30be9c3664634c46b415c3eebd5c5d7e_I20220504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54962a8013d14e668867895265609fcc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dad627e685144ca94f9ab63453ba29a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e8b6089596d46158956c93da1f84cfc_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieddfc4a55e8f4430b5893c77932b3f88_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d4e9a8b9a234321879ba71b0048f67c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0ffc3b01ab14d17ac3cdd4433fe2c5b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65c3369eb679457a8913dcaac302427c_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib10db76d45214c05b5efdc7b1a3cf613_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9d4d096474c4686a816df94e033a651_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9fa5363cf9e946eeb5596f97e3ae590b_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e6608c1aca34ce99ff1ae370e6c325e_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb0c568977f34053900263e77db2baaf_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10dfe24fc01a400fa7a0f7e7f958ad59_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic1a7dafcc5d543b98462aceef262d219_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id67531ad05e34e068f1cd490b916866a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66c91f48540d48699c74344733fb3ac1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4089c48d67b44b789b49ff9231f66610_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i085ee5a7929c45f489a3aecd04578b4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id365c25fcd8b48c0a0cf24853ebcfebe_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i848b624644c646a58412c3b2725ab8b5_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9bc9c0e23174f2995a516bfe55e91bb_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia6ada97105dc41999a86e557839e78a1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4691328755b94be283e8d276e74feb5d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1cfae56d0154e63a47ec27ca3d5dab8_I20210301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id22fce593ee9499987972bc373045887_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8243aca9d564e4f83796530f13c3383_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab72bef6ac48400897e99aead8b76e9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i873df727915d4fd29cd485502b673a49_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613127c1d0fe4c42bf53196b80bab0cc_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icc65cb33f8614f8686cae6c8db601bbf_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i269a16b2bad547b0933a05089ed034c8_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6057d7870b34586857e2a54b3264dea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4831626629fd4c0f89f3ee0635c996ea_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i754d1c94079544c5a4dbeca0b1a7070c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40803427d7d242d4aa9bd89cc640ef9c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2818027b81e84d5f83d453920e2c236a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia06866a79907412da012da019c3bdbf0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d1d7ebd972347b28a0590be373807d1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8839e3922754606a106d63fa91f9257_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a3594e189984ab887b31949bdb42d39_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63fccb8bd5334396afb7e01493bc4ff0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i107e88057aa14de4a9bfdadf17dea0e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i345a5ef75eae4b1dbfc66924f9141439_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65072cfc026e48afbf7cc86311e0945f_D20250101-20251231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb0a7747800c4993a006e9573429f517_D20260101-20261231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2026-01-01</xbrli:startDate><xbrli:endDate>2026-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32ff79bcead3411f88004dea3607340e_D20270101-20271231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2027-01-01</xbrli:startDate><xbrli:endDate>2027-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="rate"><xbrli:measure>utr:Rate</xbrli:measure></xbrli:unit><xbrli:context id="ibea33cce1ed8454ba1e53a958924c502_D20141101-20141130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2014-11-01</xbrli:startDate><xbrli:endDate>2014-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ede230fc7714aa6adbaa82ca6308ad6_I20141120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2014-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic85a31856cf447f699a3d934334e07e1_I20200928"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5e01daa001c4e169e255a6c6475516d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001062822</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i1663458ba3974fd69ad7c84eebd167a7_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV84Mg_827e9927-f001-49cc-a0a6-b990f0ff8a58">10-Q</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6M2M5MGMzZDI0MTJmNDc5YjgwOTFkM2NhMzE5YzY4YTkvdGFibGVyYW5nZTozYzkwYzNkMjQxMmY0NzliODA5MWQzY2EzMTljNjhhOV8wLTAtMS0xLTIzNTk2_a47de830-9089-4cb3-9e05-e720961996ba">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarterly Period Ended <ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8xMjk_49ac049a-fb52-431f-8ffc-cb3b005e9fb4">March 31, 2022</ix:nonNumeric> </span></div><div style="text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.175%"><tr><td style="width:1.0%"></td><td style="width:1.972%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.828%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MDg4MTllZmIxYzczNDRiMWI0NmMxNjVlMTE0OGU1YTUvdGFibGVyYW5nZTowODgxOWVmYjFjNzM0NGIxYjQ2YzE2NWUxMTQ4ZTVhNV8wLTAtMS0xLTIzNTk2_39ad3bb6-1876-42ad-bcac-2f9390044e83">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Transition Period from _____________ to _____________</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number:&#160;&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yMjU_489b5716-9647-4353-8368-b7f9620e2e3a">000-30111</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yMjg_51a839d2-2f52-47c6-bde5-3750f828d044">Lexicon Pharmaceuticals, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in its Charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6M2M1Y2UwOTczYmFhNDI5OGFiYjhmZjBiYTZhM2M5NDEvdGFibGVyYW5nZTozYzVjZTA5NzNiYWE0Mjk4YWJiOGZmMGJhNmEzYzk0MV8wLTAtMS0xLTIzNTk2_e48495ce-f0e8-40c6-8a4a-926bde9c32fb">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6M2M1Y2UwOTczYmFhNDI5OGFiYjhmZjBiYTZhM2M5NDEvdGFibGVyYW5nZTozYzVjZTA5NzNiYWE0Mjk4YWJiOGZmMGJhNmEzYzk0MV8wLTEtMS0xLTIzNTk2_b45c2791-6b3b-4389-a302-a0bf6bb1d770">76-0474169</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification Number)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yODc_cd9b6677-2701-4022-9bd5-4053e5d8af89">2445 Technology Forest Blvd.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yOTA_2445950b-e6f8-4cef-9587-4e9ca3084011">11th Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yOTM_76d62733-d3eb-48b5-a28d-346184e7f1b6">The Woodlands</ix:nonNumeric>, <ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yOTc_aa08be66-2fea-49ca-8763-1f72bc37d4aa">Texas</ix:nonNumeric> <ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8zMDA_caaf770f-dfed-4a31-a5f4-33ff673c3c38">77381</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Address of Principal Executive Offices and Zip Code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8zNTg_ab4c7b28-2700-4399-afe3-cb84ccbe6d02">281</ix:nonNumeric>) <ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8zNjI_957c2712-be83-49ea-ad09-b117a369ce19">863-3000</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.422%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.143%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MGFhY2I1ODRmNjU5NGJkMjlhNWM2NWIzNzIwZTEyMGMvdGFibGVyYW5nZTowYWFjYjU4NGY2NTk0YmQyOWE1YzY1YjM3MjBlMTIwY18xLTAtMS0xLTIzNTk2_89b7b234-0c62-484e-9850-be5531701139">Common Stock, par value $0.001</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MGFhY2I1ODRmNjU5NGJkMjlhNWM2NWIzNzIwZTEyMGMvdGFibGVyYW5nZTowYWFjYjU4NGY2NTk0YmQyOWE1YzY1YjM3MjBlMTIwY18xLTEtMS0xLTIzNTk2_1259781c-6fd9-431f-9595-136e43f86dc4">LXRX</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MGFhY2I1ODRmNjU5NGJkMjlhNWM2NWIzNzIwZTEyMGMvdGFibGVyYW5nZTowYWFjYjU4NGY2NTk0YmQyOWE1YzY1YjM3MjBlMTIwY18xLTItMS0xLTIzNTk2_f41f069f-810d-4f4a-b7a3-eeffa9089e77">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160; </span></div><div style="margin-bottom:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6YzY3ZTNlY2I5YWU5NDllNGE4Mjk3ODA4YTk1MGI4YzAvdGFibGVyYW5nZTpjNjdlM2VjYjlhZTk0OWU0YTgyOTc4MDhhOTUwYjhjMF8wLTAtMS0xLTIzNTk2_412e7864-8802-4b84-a38a-b0a4d34abbca">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)</span></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6YWMzNzYwNzZiMjA0NGI2Yzk1MTI2YTljYjQ3YTVkNWMvdGFibGVyYW5nZTphYzM3NjA3NmIyMDQ0YjZjOTUxMjZhOWNiNDdhNWQ1Y18wLTAtMS0xLTIzNTk2_ca11dc4b-171e-45d0-a941-507e52cbbc0a">Yes</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company.&#160;&#160;See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;     Accelerated filer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">          <ix:nonNumeric contextRef="ideb90240455b438fb9d26eff699c0fbc_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8xNjQ5MjY3NDQzOTU2_9a4e54ef-2121-4414-820a-7ae51211d713">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#9745;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yMjg5_a837f423-ae7e-4581-a3fc-e80a2d133157">&#9745;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     Emerging growth company </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yMjg4_248ae881-abff-4c63-9df5-7bed80d8c041">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registration has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  &#9744;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:30.263%"><tr><td style="width:1.0%"></td><td style="width:21.605%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.607%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Yes</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MDYxMzk5NWE5MjhhNDQ4OWE0ZmJmNDdkYjhiMjMzYWQvdGFibGVyYW5nZTowNjEzOTk1YTkyOGE0NDg5YTRmYmY0N2RiOGIyMzNhZF8wLTEtMS0xLTIzNTk2_0f8fe12f-d87f-40fd-85c7-7c5349c10821">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">No</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of May&#160;4, 2022, <ix:nonFraction unitRef="shares" contextRef="i30be9c3664634c46b415c3eebd5c5d7e_I20220504" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8xNjQ5MjY3NDQ0MDA3_0d469bd4-9849-4b88-b80d-f7dbb7de48d0">149,593,551</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.001 per share, were outstanding.  </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.208%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.783%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_10">Factors Affecting Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_10">2</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_13">Part I &#8211; Financial Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_13">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_16">Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_16">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets - March 31, 2022 (unaudited) and December 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_19">3</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Comprehensive Loss (unaudited) - Three Months Ended March 31, 2022 and 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_22">4</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Stockholders&#8217; Equity (unaudited) - Three Months Ended March 31, 2022 and 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_25">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows (unaudited) - Three Months Ended March 31, 2022 and 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_28">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements (unaudited)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_31">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_67">Management&#8217;s Discussion and Analysis of Financial Condition and Results&#160;of Operations</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_67">14</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_76">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_76">18</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_79">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_76">18</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_82">Part II &#8211; Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_82">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_85">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_85">20</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_88">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_88">20</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_874">Unregistered Sales of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_874">22</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_91">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_91">23</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_94">Signatures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i1663458ba3974fd69ad7c84eebd167a7_94">24</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lexicon name and logo are registered trademarks of Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;</span></div><div><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_10"></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Factors Affecting Forward Looking Statements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q contains forward-looking statements.  These statements relate to future events or our future financial performance. We have attempted to identify forward-looking statements by terminology including &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;can,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;should&#8221; or &#8220;will&#8221; or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks outlined under &#8220;Part&#160;II, Item 1A. - Risk Factors&#8221; and in our annual report on Form 10-K for the year ended December&#160;31, 2021, that may cause our or our industry&#8217;s actual results, levels of activity, performance or achievements to be materially different from any future results, levels or activity, performance or achievements expressed or implied by these forward-looking statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe that the expectations reflected in the forward-looking statements are reasonable, future results, levels of activity, performance or achievements may vary materially from our expectations. We are not undertaking any duty to update any of the forward-looking statements after the date of this quarterly report on Form 10-Q to conform these statements to actual results, unless required by law.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part I &#8211; Financial Information</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_16"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Financial Statements</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except par value)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:60.832%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.494%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNC0yLTEtMS0yMzU5Ng_c1656806-2582-4659-a133-0bf415f46b66">59,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNC00LTEtMS0yMzU5Ng_f0b5098c-ad8e-4c78-ac16-be8387f47045">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNS0yLTEtMS0yMzU5Ng_320406a0-4515-4735-adcc-7b06743d03a8">26,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNS00LTEtMS0yMzU5Ng_4803fc94-cb65-4da4-af60-c0a48311d48c">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNi0yLTEtMS0yMzU5Ng_b6b30ca7-7f18-47e6-a8f0-64f5c1614676">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNi00LTEtMS0yMzU5Ng_a1758dba-6df7-4351-a141-b5ac7665dd11">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfOS0yLTEtMS0yMzU5Ng_6629b0fb-b86f-4216-bf9b-8f27ca15c976">1,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfOS00LTEtMS0yMzU5Ng_970f8bd7-1672-4eff-90d6-13b177073f13">2,164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTAtMi0xLTEtMjM1OTY_5edbb90f-48b1-4bd0-8ed1-380922eadef2">88,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTAtNC0xLTEtMjM1OTY_8366de68-5f5f-42d3-b062-a4c3a415422e">88,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net of accumulated depreciation and amortization of $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjozMjkxZDQ2YWQzODY0ZjhjOWY5ZmI0ZTg3YzdhODhjYl84MA_f7a41966-1acb-4563-8f6f-c5f5e6c346c2">4,962</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjozMjkxZDQ2YWQzODY0ZjhjOWY5ZmI0ZTg3YzdhODhjYl84Nw_f785b651-72c9-43d1-8f05-e8a2b994c41e">4,853</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTEtMi0xLTEtMjM1OTY_1e1998f9-ef60-4201-b020-1e7bfa2a82b8">1,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTEtNC0xLTEtMjM1OTY_2985f7ee-2aeb-4110-8560-91b3a38dd575">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTItMi0xLTEtMjM1OTY_b2b47290-6f63-4df7-9436-5d87037e15b7">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTItNC0xLTEtMjM1OTY_3bfa0095-24e0-4f07-af90-bdf129151e2d">44,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTQtMi0xLTEtMjM1OTY_5b8a583f-0309-49f7-b5b1-0c87ed4c11a6">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTQtNC0xLTEtMjM1OTY_5d65b399-3462-4f65-9988-571216203a1c">2,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTUtMi0xLTEtMjM1OTY_d873751d-9157-44ad-89db-fe8feed6f95c">136,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTUtNC0xLTEtMjM1OTY_611ab307-fd47-4b96-9dab-867c42d28a6d">136,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTgtMi0xLTEtMjM1OTY_4537641f-58f8-45a0-a6b0-617609c3142d">9,321</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTgtNC0xLTEtMjM1OTY_27abd26f-8006-4663-9ccb-356335fb87ab">9,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTktMi0xLTEtMjM1OTY_c9976a20-633c-41b1-b49b-a5a0e605904d">9,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTktNC0xLTEtMjM1OTY_d5008b8e-0913-461f-8799-6cddbe868a2d">12,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjItMi0xLTEtMjM1OTY_49225f8d-6ab7-4f3a-9fbe-d91d5974bdd0">18,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjItNC0xLTEtMjM1OTY_85a34ad3-243b-4f38-b3d2-0cdc3301e1ed">22,124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjQtMi0xLTEtMjM1OTY_13a24b41-a4e6-481b-8637-657aebcb9580">23,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjQtNC0xLTEtMjM1OTY_d20592d6-4ffd-43dc-8129-620acf3ec10c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjYtMi0xLTEtMjM1OTY_1870b738-0213-43ae-8479-b622b61d97cf">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjYtNC0xLTEtMjM1OTY_41620b4b-a23c-4d1e-b8d4-ba4af126e77d">1,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjctMi0xLTEtMjM1OTY_ebfa8727-d06a-4786-9787-47140af4a860">43,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjctNC0xLTEtMjM1OTY_d793edba-8fb0-4637-9730-d4f5020a3028">23,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjgtMi0xLTEtMjM1OTY_120459e3-fe26-4e07-816f-a0967f75f9b9"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjgtNC0xLTEtMjM1OTY_e18764fb-f3bc-459f-a4c7-e716b18b2038"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl8yMg_60efd6c9-c5ef-4590-8395-c81a6d96af6c"><ix:nonFraction unitRef="usdPerShare" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="2" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl8yMg_c199501c-6893-49bd-8a77-0fb5030859db">0.01</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl8zNg_27ca4b00-af4f-4763-9c79-0719fd3eef36"><ix:nonFraction unitRef="shares" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl8zNg_d4fde9b3-a255-4800-8c1d-310849ddaa29">5,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl81OA_4b77ac6f-b196-47ab-8221-573623e447d9"><ix:nonFraction unitRef="shares" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl81OA_7ab81dfc-2e03-4689-941e-9f5353cba75c"><ix:nonFraction unitRef="shares" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl81OA_84ffd390-5644-4232-8ea3-645c8d357bfc"><ix:nonFraction unitRef="shares" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl81OA_e7e2cea2-16be-44f9-a3a4-3757fbc47f52">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMi0xLTEtMjM1OTY_7b3b8206-5318-4076-bc0e-815d253307da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtNC0xLTEtMjM1OTY_c7c6789d-02ba-40d9-97ed-738d07c603f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y18xOA_4fce9f91-6ead-444e-b2b3-6d94f68d468c"><ix:nonFraction unitRef="usdPerShare" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y18xOA_a37bad3f-5fe5-4b7b-b6da-e390eaf87ce7">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y18zMg_67b02031-2082-446f-9567-b3c52bd24335"><ix:nonFraction unitRef="shares" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y18zMg_6d0c10b3-d7a6-40ca-9548-8236afa66aa7">225,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y181NA_7b1586f3-3138-4b9d-ac48-ff14078a9fa3">150,082</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y182MQ_f7393268-e8dd-4ec7-9d49-623e2b07e9c4">150,082</ix:nonFraction> shares issued, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMi0xLTEtMjM1OTY_9fa2bd42-c80f-4589-b325-222b9605ba46">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtNC0xLTEtMjM1OTY_6c078099-694c-4d01-89e8-2a22e99bf0f6">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzItMi0xLTEtMjM1OTY_d302624b-da5c-4b58-8cbf-d905ab813b51">1,605,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzItNC0xLTEtMjM1OTY_9dc27558-ffba-4173-90ee-50a190d40f74">1,608,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzMtMi0xLTEtMjM1OTY_3bc1e73b-7a58-4783-8592-88619b9e9dc0">1,511,252</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzMtNC0xLTEtMjM1OTY_5a4b0519-ad1c-4a69-8d55-c913464b34c0">1,487,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzQtMi0xLTEtMjM1OTY_d0d7368d-36bf-4564-8f7c-60ea295ae276">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzQtNC0xLTEtMjM1OTY_49821aca-2081-41bb-a724-09fc8d34d0e6">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:TreasuryStockShares" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzUtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpmYjQwNzQ4MmMxMDE0Y2EwODIxMGMzYjNhODY1NjU3YV8yOQ_d5c96559-8b9f-4958-bb1a-03baac11e1a0">488</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzUtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpmYjQwNzQ4MmMxMDE0Y2EwODIxMGMzYjNhODY1NjU3YV8zNg_341f165b-b2f6-4686-ab4e-914d30190669">1,165</ix:nonFraction> shares, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzUtMi0xLTEtMjM1OTY_d4d146eb-3f56-438c-8394-2527f959a35e">2,061</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzUtNC0xLTEtMjM1OTY_e20937ae-9bca-408c-bba7-d6b60fa7308b">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzYtMi0xLTEtMjM1OTY_ecb524d1-0e33-46d8-a608-67338d7289ad">92,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzYtNC0xLTEtMjM1OTY_012e8d60-4efe-4a7d-82f0-246ff4a6c3e1">113,595</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzctMi0xLTEtMjM1OTY_ef64ecd9-3ae2-4f00-afac-e052be3b64f6">136,178</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzctNC0xLTEtMjM1OTY_c9ba2245-74d2-472f-a2bf-88460f1b7654">136,909</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:78.210%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties and other revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfNS0yLTEtMS0yMzU5Ng_d7179f12-db7b-40ff-83a3-5b0ab1c93568">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:RoyaltyIncomeNonoperating" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfNS00LTEtMS0yMzU5Ng_3b35b516-9b5d-4425-9831-c471a19aa69b">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfOS0wLTEtMS0yMzU5Ni90ZXh0cmVnaW9uOmEwNjBlNTJlYzI3NDQ2OTg4NjljMzkwM2M0YzAxZDdlXzY4_29ec2c2c-0bb6-41ee-a0bf-0f1f81b355d1">1,032</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfOS0wLTEtMS0yMzU5Ni90ZXh0cmVnaW9uOmEwNjBlNTJlYzI3NDQ2OTg4NjljMzkwM2M0YzAxZDdlXzcy_e6cf1fda-16af-44c7-8dc5-695367cf35fc">1,286</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfOS0yLTEtMS0yMzU5Ng_e52926b8-e722-4760-b50a-96511fa709ba">14,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfOS00LTEtMS0yMzU5Ng_e5f2de20-f721-4ed8-a27c-4397364fe386">12,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative, including stock-based compensation of $<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjo3NzBlNGMwMTQ4MGQ0ODA2ODY4ZDcyNTBlZGM0MTFiMV83OQ_7612fb95-def9-4426-9a54-7ac36cf67b56">1,740</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjo3NzBlNGMwMTQ4MGQ0ODA2ODY4ZDcyNTBlZGM0MTFiMV84Mw_40eeefe1-dadb-4042-8bcf-eae28c995207">1,565</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="lxrx:Sellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTEtMi0xLTEtMjM1OTY_88403866-b70d-4b0d-958f-2f7328c1323f">8,491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="lxrx:Sellinggeneralandadministrativeexpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTEtNC0xLTEtMjM1OTY_35dc77a4-7d7e-43b0-bead-344932e8e42d">8,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTUtMi0xLTEtMjM1OTY_87c6ca64-f648-4559-89f3-3f868fa10780">23,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTUtNC0xLTEtMjM1OTY_99a070d7-5707-478d-9063-606f1a348b3e">20,866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTgtMi0xLTEtMjM1OTY_12b0596f-5705-4074-b6f0-01eb2787da17">23,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTgtNC0xLTEtMjM1OTY_b31026f8-ef6f-41d4-b3f9-5b1792e582a7">20,839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjEtMi0xLTEtMjM1OTY_80d0b81c-3b11-4d8e-889f-dad173e53a4d">110</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjEtNC0xLTEtMjM1OTY_d96ccf1b-d0e3-4a2f-b76a-898469883646">167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjItMi0xLTEtMjM1OTY_3973431e-6e29-4b89-9075-20164fd27ba0">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjItNC0xLTEtMjM1OTY_a759f2bf-a64b-41a3-84b8-5112e1ee66c6">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjUtMi0xLTEtMjM1OTY_b380f98f-8a06-4181-8084-d399b01dbf1a">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjUtNC0xLTEtMjM1OTY_2ce698ce-bfe4-4290-a9c3-0d078e75af56">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjYtMi0xLTEtMjM1OTY_7bc0c84a-e859-4363-9cef-84624e6b8173">0.16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjYtNC0xLTEtMjM1OTY_4e10d254-6e83-4311-97cc-b374b4d97ef1">0.15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net loss per common share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjktMi0xLTEtMjM1OTY_6f840ea5-0a8b-4e06-a6fe-1297217e953f">149,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjktNC0xLTEtMjM1OTY_dcc4b34c-eba2-45c3-af39-a75de5ce588c">143,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMzMtMi0xLTEtMjM1OTY_004f8ef1-2ee6-4065-900b-42af1d680fc7">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMzMtNC0xLTEtMjM1OTY_938fc17e-70a5-4f27-a96a-0af17e3c2c5e">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMzQtMi0xLTEtMjM1OTY_604317df-eec6-4d18-8475-4c909af01e8c">23,503</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMzQtNC0xLTEtMjM1OTY_7670de56-7403-439a-8fb0-a50a3e3bed93">20,947</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.722%"><tr><td style="width:1.0%"></td><td style="width:37.352%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.946%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.644%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54962a8013d14e668867895265609fcc_I20201231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi0yLTEtMS0yMzU5Ng_b16f2ea1-e18c-4f88-a6c7-5ca789e8fd71">142,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54962a8013d14e668867895265609fcc_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi00LTEtMS0yMzU5Ng_931a7b28-2841-4010-8732-7eee9e6557b2">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dad627e685144ca94f9ab63453ba29a_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi02LTEtMS0yMzU5Ng_66c42efa-73f5-4faa-9ed9-83f4c783db0f">1,561,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e8b6089596d46158956c93da1f84cfc_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi04LTEtMS0yMzU5Ng_21efeb19-c1c3-4141-99c8-3c6928618e48">1,400,018</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ieddfc4a55e8f4430b5893c77932b3f88_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi0xMC0xLTEtMjM1OTY_7da4e5ff-48ce-4e6e-907d-ff67872dcbf5">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4d4e9a8b9a234321879ba71b0048f67c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi0xMi0xLTEtMjM1OTY_394d7467-eb18-4691-8574-4e200ac3b17e">4,843</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ffc3b01ab14d17ac3cdd4433fe2c5b_I20201231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi0xNC0xLTEtMjM1OTY_34084bea-9d57-4061-8e9b-2d947dd75c38">156,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS00LTEtMS0yMzU5Ng_faa53902-792d-4229-9019-ecc7389f1011">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS02LTEtMS0yMzU5Ng_eff3d3a7-19c8-4808-8f66-ac218e837105">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS04LTEtMS0yMzU5Ng_d795c450-ffdb-4f73-92ac-0ef1bfe7f3d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS0xMC0xLTEtMjM1OTY_ed93ae52-5fac-4857-8171-6823237fbf50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS0xMi0xLTEtMjM1OTY_3e5479b2-e1f0-4347-b551-5874d6231f1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS0xNC0xLTEtMjM1OTY_1afbdb52-64fc-457c-a412-6364bc79e182">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under Equity Incentive Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi0yLTEtMS0yMzU5Ng_7a3f52d5-1343-4138-879c-ad33d8f0dab7">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi00LTEtMS0yMzU5Ng_d2610954-4ac0-4afc-9869-9842078ba744">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi02LTEtMS0yMzU5Ng_c0495935-bd92-4546-ac29-62429f9113f2">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi04LTEtMS0yMzU5Ng_cb95653c-978d-49f2-bbaa-5cfe86cd9b21">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi0xMC0xLTEtMjM1OTY_2278e263-16cc-4bec-9f37-a6c97f002433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi0xMi0xLTEtMjM1OTY_b51f484d-57fa-4104-a6fe-2d235c0002b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi0xNC0xLTEtMjM1OTY_4d9dc2d5-cb90-4077-a71b-5f8324467cbb">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of common stock under an Open Market Sale Agreement, net of issuance fees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC00LTEtMS0yMzU5Ng_17b4a6b4-560a-446c-871d-2d9373dc217d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC02LTEtMS0yMzU5Ng_be0815f0-9b30-4c79-88d6-7adf19a07204">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC04LTEtMS0yMzU5Ng_fed717f3-5789-4520-84e8-2434e979b745">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC0xMC0xLTEtMjM1OTY_136aa02e-7cbf-4312-9efc-fa45207dbd3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC0xMi0xLTEtMjM1OTY_86f04d62-fda5-424d-b209-98b05ea3a6b6">2,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC0xNC0xLTEtMjM1OTY_15c962ba-47c6-4641-bdd4-0add55f4e95a">2,675</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS00LTEtMS0yMzU5Ng_21b1f06a-b2a6-4a22-aafa-3fe25ea56058">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS02LTEtMS0yMzU5Ng_024736bb-4ee2-4d55-b29f-8c03ae2605ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS04LTEtMS0yMzU5Ng_337a217b-41c6-448d-8361-ba6c1a0acbbb">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS0xMC0xLTEtMjM1OTY_fe6c68a9-5891-4c85-9157-a37e37c26d2e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS0xMi0xLTEtMjM1OTY_216860f8-d7e3-46c1-83fa-8c5c2b2e4af2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS0xNC0xLTEtMjM1OTY_fa009bd5-c248-470c-8439-4e003f4de0e7">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtNC0xLTEtMjM1OTY_63a3f6b3-ee6c-42de-a5ea-62fff0571fb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtNi0xLTEtMjM1OTY_f48c49ad-5745-41ec-bc3f-c7f6869c1520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtOC0xLTEtMjM1OTY_0c5c5a3d-8dad-485b-8e7f-8260a4627897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtMTAtMS0xLTIzNTk2_d1bf9169-5bc0-4b5e-bd4c-be75269737a6">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtMTItMS0xLTIzNTk2_df4779f9-caba-42a9-847a-7df2338a9a46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtMTQtMS0xLTIzNTk2_4db4c8d3-5cdb-4d79-ba60-36cbefee7523">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib10db76d45214c05b5efdc7b1a3cf613_I20210331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItMi0xLTEtMjM1OTY_6b04f64b-42e8-456a-82a7-c81eb1c8a3ee">145,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10db76d45214c05b5efdc7b1a3cf613_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItNC0xLTEtMjM1OTY_0e4aa28c-6ef1-4cba-bacb-65de1e589800">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d4d096474c4686a816df94e033a651_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItNi0xLTEtMjM1OTY_0475dec6-16c8-47ae-be0f-8edffed16dd9">1,580,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fa5363cf9e946eeb5596f97e3ae590b_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItOC0xLTEtMjM1OTY_80d2be8a-c17e-4ae0-9e9d-b5f48350a2ad">1,420,976</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e6608c1aca34ce99ff1ae370e6c325e_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItMTAtMS0xLTIzNTk2_9780c5b5-6e9e-4bc0-a646-49d43a94af4b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb0c568977f34053900263e77db2baaf_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItMTItMS0xLTIzNTk2_aaf6b1a3-9fe0-4d14-8ace-966bec8db3ae">7,518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dfe24fc01a400fa7a0f7e7f958ad59_I20210331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItMTQtMS0xLTIzNTk2_8d18f398-a837-4099-a1b8-4f35b4aad379">152,547</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.506%"><tr><td style="width:1.0%"></td><td style="width:37.325%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.378%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.664%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comprehensive Gain (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1a7dafcc5d543b98462aceef262d219_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi0yLTEtMS0yMzU5Ng_c426133f-70cd-46fa-a5c3-a54366f21ccb">150,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1a7dafcc5d543b98462aceef262d219_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi00LTEtMS0yMzU5Ng_3a922dbe-5117-42e4-80fd-45f6851d7a05">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id67531ad05e34e068f1cd490b916866a_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi02LTEtMS0yMzU5Ng_6cfd64f2-c276-4562-b1c1-53d22b9c5f20">1,608,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66c91f48540d48699c74344733fb3ac1_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi04LTEtMS0yMzU5Ng_4de7d30a-2526-4357-9e51-f9ca4bab3a3b">1,487,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4089c48d67b44b789b49ff9231f66610_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi0xMC0xLTEtMjM1OTY_ebb52557-d8c2-497a-9dae-8134cd09ad7d">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i085ee5a7929c45f489a3aecd04578b4e_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi0xMi0xLTEtMjM1OTY_1e2c885b-b39e-41c5-9058-e22734144fd8">7,518</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi0xNC0xLTEtMjM1OTY_88d8c6dc-50b6-404f-897c-e9b4885f84f2">113,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC00LTEtMS0yMzU5Ng_5fcc3b82-ffd7-4795-b79d-e13bb1d8c6ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC02LTEtMS0yMzU5Ng_4c45a19f-3a91-4a08-b270-470ebbc0684b">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC04LTEtMS0yMzU5Ng_1fc4ef28-e0c8-438d-a399-76b468311205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC0xMC0xLTEtMjM1OTY_c32c5cea-3bec-481a-a7de-9c9494bfe810">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC0xMi0xLTEtMjM1OTY_f22a2d97-9f21-4750-b6a6-05d158b5172c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC0xNC0xLTEtMjM1OTY_768ec413-a310-4282-9245-093a627a50d0">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of equity classified warrants</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS0yLTEtMS0yMzU5Ng_07376fae-29bc-454e-8d58-29dd73fc476a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS00LTEtMS0yMzU5Ng_19dd7bcb-ae01-4189-8a45-1881612ce5d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS02LTEtMS0yMzU5Ng_8b782e30-5768-4656-8d2d-f4fe28788f78">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS04LTEtMS0yMzU5Ng_0de71033-a80d-45d2-a65b-a619be986fbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS0xMC0xLTEtMjM1OTY_0c4671f7-e150-45a9-8e88-635099c9fa64">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS0xMi0xLTEtMjM1OTY_b08b9403-67e4-439a-8057-1301044399c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS0xNC0xLTEtMjM1OTY_fa640ff8-7223-497d-a865-13191da3eafe">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issuance of treasury stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,321)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,321&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi0yLTEtMS0yMzU5Ng_523d3927-9206-47fe-be4e-7cb0176fc4a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi00LTEtMS0yMzU5Ng_58a3c159-f95c-479e-90dc-55fb7591cdf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi02LTEtMS0yMzU5Ng_a77efdb7-b1cc-4b2e-934a-98fe18f54b99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi04LTEtMS0yMzU5Ng_ece941c2-ee81-420e-a879-e1c78fc5633e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi0xMC0xLTEtMjM1OTY_ddd35d6a-e152-466b-bf90-300f28be5ffd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi0xMi0xLTEtMjM1OTY_dcccfb10-a053-4cc1-b948-71490477f928">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi0xNC0xLTEtMjM1OTY_4c6613b1-f486-4160-8d0c-38d88419d91e">864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS00LTEtMS0yMzU5Ng_b02ad329-4bc1-4777-8a4f-29063d7e6015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS02LTEtMS0yMzU5Ng_b0e19de0-3220-4f91-82b9-80691b355759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS04LTEtMS0yMzU5Ng_9573563d-4e42-4604-bae8-28d81de80148">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS0xMC0xLTEtMjM1OTY_a88bd696-cecc-447b-bc98-f9244d4778b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS0xMi0xLTEtMjM1OTY_d101316a-d0e1-4005-9058-5fa1d2dd3676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS0xNC0xLTEtMjM1OTY_92af4eee-f1d6-4697-b120-a7381d536dc3">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtNC0xLTEtMjM1OTY_a65776ce-db32-4183-9f03-668b7d738779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtNi0xLTEtMjM1OTY_404363b2-57fe-49a9-85e1-8be7c138cf94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtOC0xLTEtMjM1OTY_381cadb9-237c-4203-9108-fd605008dd1b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtMTAtMS0xLTIzNTk2_2685761c-2e2c-47e6-a9c2-4db27d75913a">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtMTItMS0xLTIzNTk2_2eecddb3-a6d7-4925-b44f-cd65362647d4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtMTQtMS0xLTIzNTk2_6e5f871e-214b-4283-a09b-ae5e38042f46">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id365c25fcd8b48c0a0cf24853ebcfebe_I20220331" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItMi0xLTEtMjM1OTY_7f87c4a8-0cc3-458e-9d4f-84072125c275">150,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id365c25fcd8b48c0a0cf24853ebcfebe_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItNC0xLTEtMjM1OTY_b015aaf1-1abf-49f7-a53d-05ba9dba8965">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i848b624644c646a58412c3b2725ab8b5_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItNi0xLTEtMjM1OTY_4fe3bd36-bebf-4f8f-bdc3-bc7fbbaebd46">1,605,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic9bc9c0e23174f2995a516bfe55e91bb_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItOC0xLTEtMjM1OTY_1d325fce-d0d6-4cc1-afe6-8ee45cf3da02">1,511,252</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia6ada97105dc41999a86e557839e78a1_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItMTAtMS0xLTIzNTk2_6dfd546f-d168-413d-9a48-80980e243268">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4691328755b94be283e8d276e74feb5d_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItMTItMS0xLTIzNTk2_aeddc497-71fa-4931-9527-df86cace6c67">2,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItMTQtMS0xLTIzNTk2_e0defc75-3805-4e10-91f9-14930a5cf9c9">92,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:73.349%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.089%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMy0yLTEtMS0yMzU5Ng_5b51fa61-3295-4297-b976-59b9e97c10c7">23,476</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMy00LTEtMS0yMzU5Ng_e7edc028-f544-484a-9912-39bc5a06e0e6">20,958</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNS0yLTEtMS0yMzU5Ng_c7f0a426-02d3-400e-b953-f94ed51227b7">109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNS00LTEtMS0yMzU5Ng_d1f95f9f-143e-4cf5-a358-e6e4d641d3e9">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNi0yLTEtMS0yMzU5Ng_3882f2b3-69a7-4262-8e4e-433dce5e9195">2,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNi00LTEtMS0yMzU5Ng_fc621269-6c4c-45c1-ba23-de455fe08546">2,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNy0yLTEtMS0yMzU5Ng_1efd1db8-4a96-49a4-9f58-8db55c0a73e0">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNy00LTEtMS0yMzU5Ng_5eaff012-a7af-48a1-9300-0398a9c53d91">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Increase) decrease in accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTItMi0xLTEtMjM1OTY_323f3d66-0481-427e-b343-c83274d71d99">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTItNC0xLTEtMjM1OTY_55021d0d-3896-4135-8a03-d3a8947ac16a">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTQtMi0xLTEtMjM1OTY_ebc9a284-ab42-4956-b16c-54e486175930">273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTQtNC0xLTEtMjM1OTY_bd5026e0-7e18-4c77-8117-5300687dee0f">1,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTUtMi0xLTEtMjM1OTY_3821b932-a575-4ca0-9e93-66004e63b850">207</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTUtNC0xLTEtMjM1OTY_fb81fe4b-11e0-4480-a6af-2de23b0ab85f">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in accounts payable and other liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTYtMi0xLTEtMjM1OTY_2b90127b-ddd7-4c01-80af-35e415b40405">3,308</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTYtNC0xLTEtMjM1OTY_6c3be1b4-ea85-426c-9f7a-8bf1de880d96">8,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTgtMi0xLTEtMjM1OTY_eaaf5702-0a3b-4ec7-ab91-a19afef39057">23,421</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTgtNC0xLTEtMjM1OTY_b9b80a66-7478-4685-9e87-fba91b1f31f2">25,159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjAtMi0xLTEtMjM1OTY_b0bf3a55-361f-4ee7-8ea3-d09d32cd0aa6">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjAtNC0xLTEtMjM1OTY_cfc98aee-b0b1-4ba4-b264-41195eefac31">38</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjMtMi0xLTEtMjM1OTY_cce488e3-1c2e-4dab-ac65-4e4362d7868e">17,816</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjMtNC0xLTEtMjM1OTY_d21e54a6-52b9-42fb-bb2d-21fba91e13c4">21,686</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjQtMi0xLTEtMjM1OTY_cf08e786-7fd4-49c8-8970-a68edf99ba7a">13,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjQtNC0xLTEtMjM1OTY_e396e3ff-71a4-42c1-8415-1594d424006c">4,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjUtMi0xLTEtMjM1OTY_bd796810-b1f8-4983-949b-58ceed2b436e">4,408</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjUtNC0xLTEtMjM1OTY_f2d4d589-3bdb-44d3-9a91-ff58ee2ce168">17,724</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock, net of fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjctMi0xLTEtMjM1OTY_71c1ec7b-40ac-46fb-a9fe-a65ed9fe361d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjctNC0xLTEtMjM1OTY_84148cc5-5939-4727-a938-118583feae97">16,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjgtMi0xLTEtMjM1OTY_36916718-0735-48d8-960c-17a52404aad5">864</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjgtNC0xLTEtMjM1OTY_a801eed8-0af1-4d7f-8454-f0150922a00c">2,675</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from debt borrowings, net of fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjktMi0xLTEtMjM1OTY_a7717cab-924a-4a66-9b98-9f8271284803">24,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjktNC0xLTEtMjM1OTY_9558d18e-6f2f-43d4-a589-6e8c7163ead4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzItMi0xLTEtMjM1OTY_f10cc941-7435-4b42-af20-f05a6d5d5b13">23,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzItNC0xLTEtMjM1OTY_f687719d-e925-4f27-8ee7-0bb622f8a65c">14,272</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzMtMi0xLTEtMjM1OTY_cee413d5-9f5b-407e-b0ed-15f5aeb3a128">4,545</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzMtNC0xLTEtMjM1OTY_b62635a0-fd25-41a2-8269-1947935a11d5">28,611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzQtMi0xLTEtMjM1OTY_1d856c07-e106-48fd-86f4-5cd60b07cc77">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0ffc3b01ab14d17ac3cdd4433fe2c5b_I20201231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzQtNC0xLTEtMjM1OTY_4a6688d6-0904-41cf-a573-bbfa21f8b1d0">126,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzUtMi0xLTEtMjM1OTY_680c8753-6f89-4ade-adcc-39fa2a820cbb">59,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dfe24fc01a400fa7a0f7e7f958ad59_I20210331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzUtNC0xLTEtMjM1OTY_479c66b2-7db5-4c71-9d29-e4bb4c82bcb1">97,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="-3" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzgtMi0xLTEtMjM1OTY_dc6d71e5-5484-4206-97d5-1e60c747d611">85</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzgtNC0xLTEtMjM1OTY_bc68ac58-1bff-4592-a234-410042d7580c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Right-of-use asset</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:InitialRecognitionOfRightOfUseAsset" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNDEtMi0xLTEtMjM1OTY_1d4389c0-3550-44c8-8317-19bbbffba62f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10dfe24fc01a400fa7a0f7e7f958ad59_I20210331" decimals="-3" name="lxrx:InitialRecognitionOfRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNDEtNC0xLTEtMjM1OTY_667af294-5317-4e12-be98-1428c4a366f7">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Issuance of equity classified warrants</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="0" name="us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzMtMi0xLTEtMjY3ODM_d150a988-d3f2-491c-9e44-8b89d2477da1">698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzMtNC0xLTEtMjY3ODU_bd34e903-bbd1-4908-9123-d9185316f8a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Issuance of treasury stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="0" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzQtMi0xLTEtMjY3ODc_fbf4c441-0ef8-4305-a162-1f4be37316f3">6,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzQtNC0xLTEtMjY3ODk_aeb50159-4224-40d9-93e5-68c1e6ef8948">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Recognition of exit fee liability related to debt borrowings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="0" name="us-gaap:BusinessExitCosts1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzUtMi0xLTEtMjY3OTE_f951e689-60a1-4429-b767-57933d447915">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:BusinessExitCosts1" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzUtNC0xLTEtMjY3OTM_4536dca9-7e61-4766-bcb8-f0f573e355b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lexicon Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Consolidated Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_34"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4Mjc_68e0012d-1ae9-49b3-999c-243ff6d30d6c" continuedAt="i5af4f2ee3e5a4ce7a21fd0076e6240e4" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i5af4f2ee3e5a4ce7a21fd0076e6240e4" continuedAt="ibb16cc5202314f5cb8862d01238f1a37"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MjQ_6bdeac53-0bff-49a5-b367-c88e8d25e38c" escape="true">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</ix:nonNumeric></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM3ODg_65eab7b1-f65b-465f-9b74-282b3354d341" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MTM_be375c4e-aa85-461a-8ed3-89b4ad1414b5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MzI_208df8db-17a2-4ad3-9ff9-dff386cb094a" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:60.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.963%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfMy0yLTEtMS0yMzU5Ng_6809caa0-5eed-48ca-895c-fb57b1fb04f1">5,308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="lxrx:AccruedResearchAndDevelopmentServicesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfMy00LTEtMS0yMzU5Ng_8a3704ba-7b0d-43a1-9661-02f755f5ed51">3,669</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNC0yLTEtMS0yMzU5Ng_d436f0bf-59f5-491f-b241-a9a30dc9bf33">2,616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="lxrx:AccruedCompensationAndBenefitsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNC00LTEtMS0yMzU5Ng_244cce0d-c1c8-47ee-8f42-cdb99f43b81f">5,711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNS0yLTEtMS0yMzU5Ng_df620a50-565f-42b4-9c42-a86b98774304">940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNS00LTEtMS0yMzU5Ng_1a99a6b2-0248-475e-86ad-03442c6302b8">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNi0yLTEtMS0yMzU5Ng_3787f235-fc98-4698-b26f-90f2a5bc724b">720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNi00LTEtMS0yMzU5Ng_278c32a2-0e0f-4a69-a638-4715f083435d">2,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNy0yLTEtMS0yMzU5Ng_352ab6e3-5af4-4fc5-bcc7-e589778cbf9e">9,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNy00LTEtMS0yMzU5Ng_18067d10-308c-4490-914a-a9231876d9fd">12,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MDU_cd26de50-9c44-41fe-bb51-421ec346f4d4" continuedAt="i2105cc640b8c4d49a94f6c2aaa43dc62" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.</span></ix:nonNumeric></div></ix:continuation><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="ibb16cc5202314f5cb8862d01238f1a37" continuedAt="i79bb24e3ceb649868e8df5707cfa4def"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2105cc640b8c4d49a94f6c2aaa43dc62">Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of <ix:nonFraction unitRef="number" contextRef="ia1cfae56d0154e63a47ec27ca3d5dab8_I20210301" decimals="INF" name="lxrx:LexiconIncrementalBorrowingRate" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM3ODI_16c2c40b-2bb7-45a5-a076-2d4242e2ffde">9</ix:nonFraction>% at the commencement date in determining the present value of future payments.</ix:continuation> </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MDI_95b2a32a-a696-45fa-ac40-4ff81761cc26" continuedAt="iecb3bf4dd25f4220be201f43464efbeb" escape="true"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform the following five steps in determining the amount of revenue to recognize as we fulfill our performance obligations under each of our contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iecb3bf4dd25f4220be201f43464efbeb">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.</ix:continuation> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4Mjk_ac7455e6-9812-47af-a61a-5da4f44c9f2d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MDM_8ec980f3-344e-41b2-a0c2-0a30e0afead4" continuedAt="i6d2766a3cef44c1e96fc09e4564356d6" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><ix:continuation id="i79bb24e3ceb649868e8df5707cfa4def" continuedAt="ie42274892bfa4c0ca6b2e775a1069fdb"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6d2766a3cef44c1e96fc09e4564356d6">behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.</ix:continuation>&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the three months ended March&#160;31, 2022 and 2021:</span><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM3OTg_53e69425-0012-4ec4-9c0c-12c88b635a01" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:51.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.738%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.916%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMi0yLTEtMS0yMzU5Ng_119c5c08-02e9-4ea4-bd36-63c8edec33e3">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMi00LTEtMS0yMzU5Ng_b40e4b27-77f9-4995-8996-0872a7aafe59">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMi02LTEtMS0yMzU5Ng_3870ae6e-bfd2-4b9c-8e2f-d3afc13eea3f">4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMi04LTEtMS0yMzU5Ng_7bb10939-6d87-4085-983f-d9080160d0a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMy0yLTEtMS0yMzU5Ng_cf2c4404-2d97-4430-8998-23ef110f25eb">91</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMy00LTEtMS0yMzU5Ng_c56b221f-0cf5-4c18-97bf-9677e97f1cf7">1.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMy02LTEtMS0yMzU5Ng_976193b6-c3e5-4ecf-8f09-1a11f3c748b7">7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMy04LTEtMS0yMzU5Ng_ef00c654-e33e-41fb-8b89-346b1fcc37bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNS0yLTEtMS0yMzU5Ng_e49e7ff9-3d39-4573-a75d-d2c75e5f27e8">105</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNS00LTEtMS0yMzU5Ng_6161c508-de3d-45b5-ba4d-83bc481572b6">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNS02LTEtMS0yMzU5Ng_90ea4af9-0d7c-4d79-8aec-051fb0bc60f2">4</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNS04LTEtMS0yMzU5Ng_6498d3ff-9b6a-4c24-b646-118da1f4cc5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNi0yLTEtMS0yMzU5Ng_1e60bc9e-e56f-41f9-8855-8181dc76fb76">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331" decimals="3" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNi00LTEtMS0yMzU5Ng_aa92c415-1f10-4e68-9cba-1087315ef8d3">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNi02LTEtMS0yMzU5Ng_4e396104-f8da-4c87-93af-00ba24a828f3">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331" decimals="2" name="lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNi04LTEtMS0yMzU5Ng_cd090bad-f525-4980-8069-0c735c84d8fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MDQ_8bc77e52-315f-4e33-ab5e-655bf6cd50a0" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:66.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.470%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id22fce593ee9499987972bc373045887_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfMi0yLTEtMS0yMzU5Ng_8f501bb8-6e8a-4630-9d7f-0db138411efa">8,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id22fce593ee9499987972bc373045887_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfMi00LTEtMS0yMzU5Ng_199cf995-1dfd-470f-8f17-681f248f3be4">6.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfMy0yLTEtMS0yMzU5Ng_a82c2c6b-5484-47a0-b8f2-1ad2096501e7">3,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfMy00LTEtMS0yMzU5Ng_44cdaeca-f804-41e3-aab9-d4aec26d3587">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNS0yLTEtMS0yMzU5Ng_7cab56b6-d118-4c91-83e1-694fbfe7a74b">140</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNS00LTEtMS0yMzU5Ng_465c0de5-ddde-4570-93df-d909dee794f8">12.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNi0yLTEtMS0yMzU5Ng_8534edf2-7667-4fdc-8491-226fd5e94177">308</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNi00LTEtMS0yMzU5Ng_63ae3570-26a2-435f-a0d6-a20b19822b33">9.88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8243aca9d564e4f83796530f13c3383_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNy0yLTEtMS0yMzU5Ng_2477db01-0ae8-483f-9c2a-e75cef3c3a5d">11,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8243aca9d564e4f83796530f13c3383_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNy00LTEtMS0yMzU5Ng_be76760d-0793-4c12-97da-6f323c6a733c">5.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia8243aca9d564e4f83796530f13c3383_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfOC0yLTEtMS0yMzU5Ng_9b9e41e6-a71a-47c6-bddf-a609e66a9809">5,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia8243aca9d564e4f83796530f13c3383_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfOC00LTEtMS0yMzU5Ng_596937bb-e7c6-4032-89e8-df6c18b94214">7.57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, Lexicon granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2022:</span><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MzA_0b98ac6f-535d-490a-b0fc-e823d4812805" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:65.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.497%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab72bef6ac48400897e99aead8b76e9d_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfMi0yLTEtMS0yMzU5Ng_9836636e-c9b0-4bac-bd1d-a9ef8bf07001">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="iab72bef6ac48400897e99aead8b76e9d_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfMi00LTEtMS0yMzU5Ng_0b035374-c329-4084-a98c-d3f7bcb38c77">5.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfMy0yLTEtMS0yMzU5Ng_7f1105d2-83bb-4f21-9f7d-a0e673bcabf5">2,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfMy00LTEtMS0yMzU5Ng_9d986a53-b8cf-4181-b320-4129ac592966">2.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNC0yLTEtMS0yMzU5Ng_5c0e3996-820f-4911-99cc-36975b36fc8a">980</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNC00LTEtMS0yMzU5Ng_94e32109-0b84-4fef-b5ae-4d500e5235cb">4.86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNS0yLTEtMS0yMzU5Ng_76063d83-adb8-45f5-b737-c94e66ca7a80">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNS00LTEtMS0yMzU5Ng_84e6c182-1b40-4c9d-a106-d8ff6811ec71">3.54</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i613127c1d0fe4c42bf53196b80bab0cc_I20220331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNi0yLTEtMS0yMzU5Ng_77e137ad-4be0-42f2-88b5-382002bbae6c">2,949</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i613127c1d0fe4c42bf53196b80bab0cc_I20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNi00LTEtMS0yMzU5Ng_81ad275a-4993-49eb-95ef-88411dd8bd1f">3.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="ie42274892bfa4c0ca6b2e775a1069fdb" continuedAt="ie1cc18fc94024bc6ac5adb5b7afff77e"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM3OTI_a834a109-1f1c-4f96-9df7-059e95679600" continuedAt="i7cde3861a44e41e694656aac32b28dec" escape="true">Net Loss per Common Share:</ix:nonNumeric></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie1cc18fc94024bc6ac5adb5b7afff77e"><ix:continuation id="i7cde3861a44e41e694656aac32b28dec"> Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</ix:continuation></ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_37"></div><div style="padding-left:22.5pt;text-indent:-22.5pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNy9mcmFnOjI3MjBhMjk3NGI2OTQ2ZjY4ODhlMThlZWYyZjFhNzU0L3RleHRyZWdpb246MjcyMGEyOTc0YjY5NDZmNjg4OGUxOGVlZjJmMWE3NTRfODE4_c3c3a461-690d-4c7e-ba74-5905cec046e5" continuedAt="i18f2b122407c4f228f4bb55ff40c94d3" escape="true">Recent Accounting Pronouncements</ix:nonNumeric></span></div><ix:continuation id="i18f2b122407c4f228f4bb55ff40c94d3"><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on our condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_40"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:CashAndCashEquivalentsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RleHRyZWdpb246ODBjZjQ0NDcxYmViNDY0OTgzMmQ1NzlmNTQyYTg2NTZfMzI5_4fa21748-1aab-4fcc-8743-d3643ec94ec9" continuedAt="i49f80cfe9a1640878d21903f78a26659" escape="true">Cash and Cash Equivalents and Investments</ix:nonNumeric></span></div><ix:continuation id="i49f80cfe9a1640878d21903f78a26659"><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at March&#160;31, 2022 and December&#160;31, 2021 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RleHRyZWdpb246ODBjZjQ0NDcxYmViNDY0OTgzMmQ1NzlmNTQyYTg2NTZfMzM2_ba20877f-19f7-43f2-89c0-0f5b8b748fdf" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.047%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc65cb33f8614f8686cae6c8db601bbf_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMy0yLTEtMS0yMzU5Ng_74d46cbb-cf86-4e3a-86db-b4b65d84c420">59,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc65cb33f8614f8686cae6c8db601bbf_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMy00LTEtMS0yMzU5Ng_8cf3c676-057f-450f-b737-377825db8992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc65cb33f8614f8686cae6c8db601bbf_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMy02LTEtMS0yMzU5Ng_320952ef-fe08-4c4c-9910-6248a572b369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc65cb33f8614f8686cae6c8db601bbf_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMy04LTEtMS0yMzU5Ng_060501a8-3fa4-4854-bb5b-62478d1dee46">59,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269a16b2bad547b0933a05089ed034c8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNS0yLTEtMS0yMzU5Ng_e4b8506d-015d-4c9a-9461-8dd6555bab90">12,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269a16b2bad547b0933a05089ed034c8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNS00LTEtMS0yMzU5Ng_f597f22d-15ba-4f6b-a380-cb01f9cd7f71">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i269a16b2bad547b0933a05089ed034c8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNS02LTEtMS0yMzU5Ng_57b63c26-606a-49e5-a753-1e3f2015a2af">26</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269a16b2bad547b0933a05089ed034c8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNS04LTEtMS0yMzU5Ng_e1fcf29a-f9cf-41da-b6bb-533aca6a4249">12,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6057d7870b34586857e2a54b3264dea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNi0yLTEtMS0yMzU5Ng_f0ca2661-226a-472e-b4bd-b3ec87a81f32">14,533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6057d7870b34586857e2a54b3264dea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNi00LTEtMS0yMzU5Ng_f8ea5c96-0e02-467b-9227-ed69575ce93c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6057d7870b34586857e2a54b3264dea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNi02LTEtMS0yMzU5Ng_45a91ef5-0cfc-43bf-8de9-d63006de46c8">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6057d7870b34586857e2a54b3264dea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNi04LTEtMS0yMzU5Ng_4b726094-3647-4f0b-a6a4-43eddc64e865">14,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNy0yLTEtMS0yMzU5Ng_242961c4-05d9-4767-bdc2-4a89dae3cc59">27,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNy00LTEtMS0yMzU5Ng_1a1d71ba-5264-4706-8b9d-a152e9e4e6a1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNy02LTEtMS0yMzU5Ng_7a3f939a-9879-437e-8ddc-cd6f1e122b1a">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNy04LTEtMS0yMzU5Ng_d14c3909-3538-46c9-a9a3-100ef1e296d7">26,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4831626629fd4c0f89f3ee0635c996ea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfOC0yLTEtMS0yMzU5Ng_d5e095c3-6a87-4e6d-a664-9fcbd4b50754">86,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4831626629fd4c0f89f3ee0635c996ea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfOC00LTEtMS0yMzU5Ng_72345c53-aa6f-483f-aa6b-6169066cfb77">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4831626629fd4c0f89f3ee0635c996ea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfOC02LTEtMS0yMzU5Ng_086a1d17-e442-4ecc-a0f4-63f6b706095e">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4831626629fd4c0f89f3ee0635c996ea_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfOC04LTEtMS0yMzU5Ng_e1087e7a-eea0-4e5e-80db-e429b7bb3b30">86,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754d1c94079544c5a4dbeca0b1a7070c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTMtMi0xLTEtMjM1OTY_96d917ec-45a1-499b-a504-7d0e60052953">64,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754d1c94079544c5a4dbeca0b1a7070c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTMtNC0xLTEtMjM1OTY_7f9f222d-68e0-47d3-8785-d2a6301594ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i754d1c94079544c5a4dbeca0b1a7070c_I20211231" decimals="-3" sign="-" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTMtNi0xLTEtMjM1OTY_3015238f-07fd-42e8-b061-35cc73dd2893">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i754d1c94079544c5a4dbeca0b1a7070c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTMtOC0xLTEtMjM1OTY_76c4125c-1a0d-4f99-8ce6-e7c20cc0a0d3">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40803427d7d242d4aa9bd89cc640ef9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTUtMi0xLTEtMjM1OTY_27532be0-65e9-41e6-a68e-2a7339d3c4d0">7,562</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40803427d7d242d4aa9bd89cc640ef9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTUtNC0xLTEtMjM1OTY_8303374a-16e8-4c11-a84e-1ffdcb155297">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40803427d7d242d4aa9bd89cc640ef9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTUtNi0xLTEtMjM1OTY_d4eeb5f2-ee51-46d9-a866-052203619ee3">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40803427d7d242d4aa9bd89cc640ef9c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTUtOC0xLTEtMjM1OTY_266fff46-cfab-45f8-a989-06f515a07534">7,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2818027b81e84d5f83d453920e2c236a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTYtMi0xLTEtMjM1OTY_e3805862-82ba-42b9-8954-acbb809bbd45">15,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2818027b81e84d5f83d453920e2c236a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTYtNC0xLTEtMjM1OTY_0aafd82c-da5f-4a83-9b9c-51f8ed476e13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2818027b81e84d5f83d453920e2c236a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTYtNi0xLTEtMjM1OTY_8c8f003b-02fb-4bb9-b1ae-a9c5683184b8">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2818027b81e84d5f83d453920e2c236a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTYtOC0xLTEtMjM1OTY_c8dfff00-7d23-4f84-b417-3db45c357c0d">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTctMi0xLTEtMjM1OTY_824c4511-f4d3-49d6-a358-01a228bd1837">22,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTctNC0xLTEtMjM1OTY_e6666fd1-c685-49e9-99bf-1b1decff5015">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTctNi0xLTEtMjM1OTY_2d65b213-667b-43e7-90bc-f7b1165d433f">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTctOC0xLTEtMjM1OTY_27cbac89-f1b8-422e-a76d-77619bb28206">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia06866a79907412da012da019c3bdbf0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTgtMi0xLTEtMjM1OTY_cea0b501-4424-40d4-87f2-fb02ad27cae9">86,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia06866a79907412da012da019c3bdbf0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTgtNC0xLTEtMjM1OTY_f219c3c1-26ab-434d-bc4d-a478999c18e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia06866a79907412da012da019c3bdbf0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTgtNi0xLTEtMjM1OTY_06d3eaa5-251f-40eb-84d3-299e9ca8ea26">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia06866a79907412da012da019c3bdbf0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTgtOC0xLTEtMjM1OTY_39f3a904-e8b6-4e56-adc1-06339035fcea">86,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="0" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RleHRyZWdpb246ODBjZjQ0NDcxYmViNDY0OTgzMmQ1NzlmNTQyYTg2NTZfMTcw_5e65bc34-436d-45cf-8aa3-c765594514e8"><ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RleHRyZWdpb246ODBjZjQ0NDcxYmViNDY0OTgzMmQ1NzlmNTQyYTg2NTZfMTcw_cac3eeac-e012-4016-9c2a-84abfc6b602c">no</ix:nonFraction></ix:nonFraction> realized losses during either of the three months ended March&#160;31, 2022 and 2021, respectively.  The cost of securities sold is based on the specific identification method.</span></div></ix:continuation><div id="i1663458ba3974fd69ad7c84eebd167a7_43"></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:FairValueMeasurementInputsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RleHRyZWdpb246YzgxNmQ2YzkzZmVhNDNjYWE3NjIyNzFkNTUzMzE1NzJfMTU3Mg_0992631c-725a-4e0b-b51f-523dfe87a168" continuedAt="i7c884e569a5e4fa0b0a8775be6771b7a" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i7c884e569a5e4fa0b0a8775be6771b7a"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2022 and December&#160;31, 2021.</span></div><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RleHRyZWdpb246YzgxNmQ2YzkzZmVhNDNjYWE3NjIyNzFkNTUzMzE1NzJfMTU3NA_98e703cd-88a9-4b3d-a6dc-27e9e2a6cfca" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1d7ebd972347b28a0590be373807d1_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNC0yLTEtMS0yMzU5Ng_ca83204a-7e03-4777-a309-4277dafffcd0">59,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8839e3922754606a106d63fa91f9257_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNC00LTEtMS0yMzU5Ng_dbbe8ce6-a512-4b86-9f5a-5fdc3d7fe16a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3594e189984ab887b31949bdb42d39_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNC02LTEtMS0yMzU5Ng_75d2f3f2-5d89-4ea5-afa3-5080bc9711c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNC04LTEtMS0yMzU5Ng_9d324312-d013-48dd-8796-ee00320f1fee">59,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1d7ebd972347b28a0590be373807d1_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNS0yLTEtMS0yMzU5Ng_faeb9869-ed62-4bab-9476-d5affd6184ed">12,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8839e3922754606a106d63fa91f9257_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNS00LTEtMS0yMzU5Ng_b465d199-58a2-4360-be26-c0309e2acba1">14,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3594e189984ab887b31949bdb42d39_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNS02LTEtMS0yMzU5Ng_e22b6b3f-c501-4b0b-b743-49f89624d91d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNS04LTEtMS0yMzU5Ng_424a066c-a374-4922-a9b2-65d25ba38a59">26,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d1d7ebd972347b28a0590be373807d1_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNi0yLTEtMS0yMzU5Ng_3d20d726-c6a3-429a-a35e-1046cf957774">71,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8839e3922754606a106d63fa91f9257_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNi00LTEtMS0yMzU5Ng_6b2303ad-9a20-4aaa-adf4-b7fe2e9d1b41">14,522</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a3594e189984ab887b31949bdb42d39_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNi02LTEtMS0yMzU5Ng_65148c4a-21d7-4f34-a1a9-0cbac995b520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNi04LTEtMS0yMzU5Ng_c602acba-709d-45d4-9e42-e9a90ec568d9">86,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:46.623%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fccb8bd5334396afb7e01493bc4ff0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNC0yLTEtMS0yMzU5Ng_05c50d46-b699-4d10-af3c-2f65351ff10d">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107e88057aa14de4a9bfdadf17dea0e8_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNC00LTEtMS0yMzU5Ng_d1d4e378-8a5f-475e-8d67-4dafd4e3b54e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345a5ef75eae4b1dbfc66924f9141439_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNC02LTEtMS0yMzU5Ng_9b326ad7-0031-47d2-8cd2-a876b6e1131b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNC04LTEtMS0yMzU5Ng_2bfa6ad2-6966-4d64-8198-ed49c864211a">64,065</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fccb8bd5334396afb7e01493bc4ff0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNS0yLTEtMS0yMzU5Ng_bae7b8c2-1898-46ec-8a12-c7a498c1b0a0">7,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107e88057aa14de4a9bfdadf17dea0e8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNS00LTEtMS0yMzU5Ng_7293497d-4f72-4680-a430-0aaa9e49aba2">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345a5ef75eae4b1dbfc66924f9141439_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNS02LTEtMS0yMzU5Ng_a95d3d52-9543-49ad-b5a1-9dc837e29d95">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNS04LTEtMS0yMzU5Ng_23e054e2-1ced-48a7-a4bf-e23ad2832a88">22,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63fccb8bd5334396afb7e01493bc4ff0_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNi0yLTEtMS0yMzU5Ng_3a2b0910-fca9-4de8-9d28-2fe316e51622">71,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i107e88057aa14de4a9bfdadf17dea0e8_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNi00LTEtMS0yMzU5Ng_698e3ed5-8bb8-4442-93c2-b97859124629">15,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345a5ef75eae4b1dbfc66924f9141439_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNi02LTEtMS0yMzU5Ng_133f9b14-370c-458d-a865-e67edda02686">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNi04LTEtMS0yMzU5Ng_0d3bbd03-1f82-47df-8f25-222cc198faab">86,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2022 or December&#160;31, 2021. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div></ix:continuation><div id="i1663458ba3974fd69ad7c84eebd167a7_49"></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfNDcyNw_4801c260-01bf-44ca-b0ab-e523bc6a6cc6" continuedAt="i2649f967e379448a88f152947a6be45d" escape="true">Debt Obligations</ix:nonNumeric></span></div><ix:continuation id="i2649f967e379448a88f152947a6be45d" continuedAt="i6cbb4a1e2d794ed492d9537ecf02f3af"><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) that provides up to $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:OxfordLoanFacility" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDEzNg_087c6cd7-916a-43d3-9655-b88114899c66">150</ix:nonFraction>&#160;million in borrowing capacity (the &#8220;Oxford Term Loans&#8221;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#8217;s option to 48 months if Lexicon maintains compliance with a financial covenant relating to net sales of sotagliflozin following regulatory approval. The interest-only period will be followed by principal payments of $<ix:nonFraction unitRef="usd" contextRef="i65072cfc026e48afbf7cc86311e0945f_D20250101-20251231" decimals="-3" name="lxrx:A2027OxfordPrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2Mzg5OA_761a326e-b0e9-4880-bdc5-3b04ce0d23bb">8.7</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="ibb0a7747800c4993a006e9573429f517_D20260101-20261231" decimals="-3" name="lxrx:A2026OxfordPrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MzkwNg_c430e242-1e2a-4c08-bd5d-cd143b62e374">13.0</ix:nonFraction>&#160;million, and $<ix:nonFraction unitRef="usd" contextRef="i32ff79bcead3411f88004dea3607340e_D20270101-20271231" decimals="-3" name="lxrx:A2027OxfordPrincipalPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2NDE1Mw_a9ae2266-7cee-41eb-b4cb-ffe726598464">4.8</ix:nonFraction>&#160;million during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:TermLoanA" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDE1Ng_53cb5d44-c591-45eb-98f9-12f80d687d59">25</ix:nonFraction>&#160;million tranche was funded at closing. The second $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:TermLoanB" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDE3NA_afa04c7a-631d-4ec0-af2a-1a1b1acde50a">25</ix:nonFraction>&#160;million tranche is available for draw at Lexicon&#8217;s option prior to August 31, 2022, but within 30 days of acceptance of filing by the U.S. Food and Drug Administration of Lexicon&#8217;s resubmission of its application for U.S. regulatory approval of sotagliflozin for heart failure. The third $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:TermLoanC" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDE5Mg_c139c5c3-e244-4bd7-b0de-ec6ed871ad12">50</ix:nonFraction>&#160;million tranche is available for draw at Lexicon&#8217;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. The fourth $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:TermLoanD" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDIxMA_166cbeb7-5f66-4137-913e-cf8f6c30bbfc">50</ix:nonFraction>&#160;million tranche is available for draw at Lexicon&#8217;s option, subject to Oxford&#8217;s consent, at any time prior to the expiration of the interest-only payment period.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6cbb4a1e2d794ed492d9537ecf02f3af" continuedAt="i83a1a872e9694e82bdcc336b345b96e7"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan and security agreement provides that, upon funding of the first three tranches, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to <ix:nonFraction unitRef="number" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="lxrx:TermLoanABWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI4NA_17f03c39-fb12-4522-a981-57e92c7ea285">3.50</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="lxrx:TermLoanCWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI5MQ_34f936a3-ed6f-43fd-9d2f-7121e0f43828">1.75</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="lxrx:TermLoanDWarrant" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI5OQ_3160ad8d-38ab-440e-ab14-b2ede612983d">0.875</ix:nonFraction>%, respectively, of each such tranche, as determined by reference to a 10-day average closing price of the shares. Each warrant will have an exercise price equal to such average closing price, be exercisable for a five-year period from the date of issuance and feature a net cashless exercise provision. Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase <ix:nonFraction unitRef="shares" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="0" name="lxrx:TermLoanAWarrantsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTMxNw_595a5042-d3ea-4b43-a47c-df57c2083a37">420,673</ix:nonFraction> shares of Lexicon&#8217;s common stock at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="2" name="lxrx:TermLoanAWarrantExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI3NQ_27e80dfc-1e2b-4ea5-99ec-9f6dfcf1dd9d">2.08</ix:nonFraction> per share. The warrant is exercisable through March 1, 2027 and is classified as an equity instrument.  The Company allocated the proceeds from the first tranche to the warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants.  The fair value of the warrant of $<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTE3OQ_0bfc7f79-7278-4a38-98ec-1f3a3d88b62b">0.7</ix:nonFraction>&#160;million was recognized as equity with a corresponding debt discount of $<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI2MA_0bfc7f79-7278-4a38-98ec-1f3a3d88b62b">0.7</ix:nonFraction>&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus <ix:nonFraction unitRef="number" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDIzNg_ef76ee0a-79bc-4ab4-9b4a-32095d99aec4">7.90</ix:nonFraction>%, but not less than <ix:nonFraction unitRef="number" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:LongTermDebtPercentageBearingFixedInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDIyOA_fa63d1fd-4f22-4185-81f1-ce8dd1887f75">8.01</ix:nonFraction>%, subject to additional interest if an event of default occurs and is continuing.  As of March&#160;31, 2022, the interest rate was <ix:nonFraction unitRef="number" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="INF" name="us-gaap:SubordinatedBorrowingInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MzY5NA_8b488589-2dd9-48b1-8148-b0a989c3d259">8.14</ix:nonFraction>%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to <ix:nonFraction unitRef="rate" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="lxrx:FinalPaymentWithNoExtention" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDI0NA_5a3d49e1-1b26-4e9b-ab5e-55b516149541">6</ix:nonFraction>% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to <ix:nonFraction unitRef="rate" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="lxrx:FinalPaymentWithExtention" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDI1MQ_3d6a1038-9403-4941-b1d2-2245fc2a4621">7</ix:nonFraction>% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:TermLoanAFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDMwNg_e3cdeece-db89-4b3a-a9c6-a6962b74bde1">1.5</ix:nonFraction>&#160;million was recorded as a debt discount on the closing date of the first tranche.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2022, in connection with the first tranche of the loan and security agreement, the Company received cash proceeds of $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:TermLoanANetCashReceipt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1ODA0MQ_d5c49686-df74-4a0a-81f5-15d6d56fc760">24.2</ix:nonFraction>&#160;million, net of debt issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:TermLoanADebtIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1ODA2Mg_97fc09d0-0e10-4e63-922b-203bef7fd94a">0.4</ix:nonFraction>&#160;million and a facility fee of $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:OxfordFacilityFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MzgzOQ_e615ab05-0fd7-408d-94cd-30842ef772d8">0.5</ix:nonFraction>&#160;million. The debt issuance costs and facility fee have been recorded as a debt discount on the Company&#8217;s condensed consolidated balance sheet, which together with the final payment exit fee of $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:TermLoanAFinalPayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1ODA5Mw_e3cdeece-db89-4b3a-a9c6-a6962b74bde1">1.5</ix:nonFraction>&#160;million and warrant fair value of $<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDUxNQ_0bfc7f79-7278-4a38-98ec-1f3a3d88b62b">0.7</ix:nonFraction>&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.  As of March&#160;31, 2022, the balance of the debt discount was $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="lxrx:TermLoanADebtDiscount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDUyMA_dceaafc2-4977-48e5-b0fc-dfcabeb6a016">3.0</ix:nonFraction>&#160;million. During the three months ended March&#160;31, 2022, the Company recognized interest expense of $<ix:nonFraction unitRef="usd" contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" decimals="0" name="lxrx:TermLoanAInterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDg0MA_a91487e7-f227-47d5-9679-67f4fc6d36b0">0.1</ix:nonFraction>&#160;million.  As of  March&#160;31, 2022, the carrying value of the Oxford Term Loans was $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2Mzg2Ng_4e8891a0-65a6-4d9a-9ce5-c5eafe41554c">23.5</ix:nonFraction>&#160;million.  The fair value of the Oxford Term Loans approximates its carrying value and was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.       </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon&#8217;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenant, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of March&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $<ix:nonFraction unitRef="usd" contextRef="ibea33cce1ed8454ba1e53a958924c502_D20141101-20141130" decimals="-5" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTAz_f67b8381-1074-400b-aba8-525a7fb025fb">87.5</ix:nonFraction> million in aggregate principal amount of its <ix:nonFraction unitRef="number" contextRef="i9ede230fc7714aa6adbaa82ca6308ad6_I20141120" decimals="4" name="lxrx:ConvDebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTQz_e724d5ec-b644-4ee6-a67a-b30ad9460a4e">5.25</ix:nonFraction>% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div></ix:continuation><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i83a1a872e9694e82bdcc336b345b96e7">In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $<ix:nonFraction unitRef="usd" contextRef="ic85a31856cf447f699a3d934334e07e1_I20200928" decimals="-3" name="lxrx:ConvertibleDebtExchangeTotalPrincipalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfNTU3_d4cdade4-763e-458e-ace0-6af5c13fd425">75.8</ix:nonFraction> million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes. In 2020, the Company issued 10,368,956 shares of the Company&#8217;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes. In December 2021, the remaining balance of $<ix:nonFraction unitRef="usd" contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231" decimals="-3" name="lxrx:ConvertibleDebtExchangeRemainingNotes" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTM1NQ_85f8c510-cb18-40bc-8225-68b2cb9755bf">11.6</ix:nonFraction> million was repaid in cash.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RleHRyZWdpb246NzEwZTVlMmVjY2NlNGFjYjk1MjhlODc5OGQwZGZiNjFfNDE3Mg_c4c2ca36-639c-4fdf-95a9-6e623fea5f6b" continuedAt="ifc853442a0564e2a9446208431450d80" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="ifc853442a0564e2a9446208431450d80"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include office space in The Woodlands, Texas and Basking Ridge, New Jersey and will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the right-of-use assets for the office space leases had a balance of $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RleHRyZWdpb246NzEwZTVlMmVjY2NlNGFjYjk1MjhlODc5OGQwZGZiNjFfNDMz_ebd82281-36ca-4880-832c-dfdd278da010">2.1</ix:nonFraction> million, which is included in other assets in the condensed consolidated balance sheet. Current and non-current liabilities relating to the leases were $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-5" name="us-gaap:ShortTermLeaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RleHRyZWdpb246NzEwZTVlMmVjY2NlNGFjYjk1MjhlODc5OGQwZGZiNjFfNTgw_a6f6960d-b399-40f5-82dc-38c52594e93d">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="-5" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RleHRyZWdpb246NzEwZTVlMmVjY2NlNGFjYjk1MjhlODc5OGQwZGZiNjFfNTg3_f7915e79-17ba-4940-8cfa-780487c8861d">1.1</ix:nonFraction> million, respectively, which are included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheet, respectively.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at March&#160;31, 2022:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:80.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMi0xLTEtMS0yMzU5Ng_954c1ec0-07c6-4999-960d-b15e899b5c63">874</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMy0xLTEtMS0yMzU5Ng_57dbc04f-b443-46ac-a27b-b3ce70342494">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfNC0xLTEtMS0yMzU5Ng_fc90de0f-0fa5-4f36-a709-9f9e90bf3c4f">544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfNS0xLTEtMS0yMzU5Ng_9fe2a35a-a1ca-4f54-a63a-02d3facbcc3a">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfNi0xLTEtMS0yMzU5Ng_5afb25ba-f13a-4b97-81f5-cc6361783418">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfOC0xLTEtMS0yMzU5Ng_c1348d76-6cf1-415c-a588-15953b15e551">2,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfOS0xLTEtMS0yMzU5Ng_3bb31536-1baf-4b17-a5d7-1b986067f896">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMTAtMS0xLTEtMjM1OTY_23d633f0-5c29-4a94-9e0b-c9f9835f3431">2,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMTEtMS0xLTEtMjM1OTY_c415e4c1-d0ee-4100-90f1-a8808fecf3d8">940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331" decimals="INF" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMTItMS0xLTEtMjM1OTY_0b3366a2-b033-4f14-8447-69817d2d3af7">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_55"></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181NS9mcmFnOmQwNjM4MTE4MjUyODQzMzU5ZWQxMTUzMzE1N2E2M2Y3L3RleHRyZWdpb246ZDA2MzgxMTgyNTI4NDMzNTllZDExNTMzMTU3YTYzZjdfMjgyNw_03c0d66d-7152-4291-bde1-855bd3ad1334" continuedAt="i3450446ab1ed4a18908172fc99f07f54" escape="true">Collaboration and License Agreements</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3450446ab1ed4a18908172fc99f07f54" continuedAt="i615a4f9bac7c48859fa1d04e9e18c8b2">&#160;</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i615a4f9bac7c48859fa1d04e9e18c8b2">Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331" name="lxrx:OtherCapitalAgreementsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfOTc4_cb0253b6-e8e8-40af-b42a-919915e0a9ef" continuedAt="id541c1579fbc4baaad6de948346b6c60" escape="true">Other Capital Agreements</ix:nonNumeric></span></div><ix:continuation id="id541c1579fbc4baaad6de948346b6c60" continuedAt="ibd4a9c875fb0468cab26ef24293b88f9"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock. In January 2021, Lexicon sold <ix:nonFraction unitRef="shares" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="0" name="lxrx:SharesSoldInJanuary2021ATMOffering" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNTM3_f9ca20bb-9010-4e98-b91a-624bb15c2422">2,000,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="shares" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="3" name="lxrx:SharePriceInJanuary2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNTgx_491d5ca5-2c33-4bda-b9ed-3de449631b7e">8.463</ix:nonFraction> per share pursuant to the Sales Agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331" decimals="-5" name="lxrx:ProceedsFromJanuary2021ATMOffering" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNjU2_54d7108e-4c89-466e-b7b7-dcda144b8d0e">16.4</ix:nonFraction>&#160;million. The net proceeds are reflected as issuances of common stock in the accompanying condensed consolidated financial statements. </span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibd4a9c875fb0468cab26ef24293b88f9">In August and September 2021, Lexicon sold an aggregate of <ix:nonFraction unitRef="shares" contextRef="if5e01daa001c4e169e255a6c6475516d_D20210701-20210930" decimals="0" name="lxrx:SharesSoldInSeptember2021ATMOfferring" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNzIw_7108be0c-65d4-4151-af41-5add8b6487f7">4,176,953</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction unitRef="usd" contextRef="if5e01daa001c4e169e255a6c6475516d_D20210701-20210930" decimals="3" name="lxrx:SharePriceInSeptember2021ATMOfferring" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNzY0_99cf3156-fbf0-4229-bf2d-b2bddd066af0">4.732</ix:nonFraction> per share pursuant to the Sales Agreement, resulting in net proceeds of $<ix:nonFraction unitRef="usd" contextRef="if5e01daa001c4e169e255a6c6475516d_D20210701-20210930" decimals="6" name="lxrx:ProceedsFromSeptember2021ATMOffering" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfODQw_877f4e71-cb2e-4deb-b98b-59e3f61dc8df">19.1</ix:nonFraction> million.</ix:continuation>  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_67"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a biopharmaceutical company with a mission of pioneering medicines that transform patients&#8217; lives.  We are devoting most of our resources to the research, development and preparation for commercialization of our most advanced drug candidates:</span></div><div><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. We have reported positive results from two Phase 3 clinical trials evaluating the effect of sotagliflozin on long-term outcomes related to cardiovascular death and heart failure in approximately 10,500 and 1,200 patients, respectively. We are now preparing a resubmission of our application for regulatory approval to market sotagliflozin in the United States for heart failure after voluntarily withdrawing our initial application to correct a technical issue with the initial submission.</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have reported positive results from three Phase 3 clinical trials evaluating the effect of sotagliflozin on type 1 diabetes in approximately 800, 800 and 1,400 patients, respectively. The U.S. Food and Drug Administration, or FDA, issued a complete response letter regarding our application for regulatory approval to market sotagliflozin for type 1 diabetes in the United States. At our request, the FDA has issued a public Notice of Opportunity for Hearing on whether there are grounds for denying approval of our application and the hearing process is ongoing. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. We have reported results from two Phase 1 clinical trials of LX9211 and are now conducting a Phase 2 clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase 2 clinical trial of LX9211 in post-herpetic neuralgia. LX9211 has received Fast Track designation from the FDA for development in diabetic peripheral neuropathic pain.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are conducting preclinical research and development and preparing to conduct clinical development of compounds from a number of additional drug programs originating from our internal drug discovery efforts.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> LX9211 originated from our collaborative neuroscience drug discovery efforts with Bristol-Myers Squibb, and sotagliflozin and compounds from a number of additional drug programs originated from our own internal drug discovery efforts. Those efforts were driven by a systematic, target biology-driven approach in which we used gene knockout technologies and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. We have identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are working both independently and through collaborations and strategic alliances with third parties to capitalize on our drug target discoveries and drug discovery and development programs. We seek to retain exclusive or co-exclusive rights to the benefits of certain drug discovery and development programs by developing and commercializing drug candidates from those programs internally, particularly in the United States for indications treated by specialist physicians. We seek to collaborate with other pharmaceutical and biotechnology companies with respect to drug discovery or the development and commercialization of certain of our drug candidates, particularly with respect to commercialization in territories outside the United States or commercialization in the United States for indications treated by primary care physicians, or when the collaboration may otherwise provide us with access to expertise and resources that we do not possess internally or are complementary to our own.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have derived substantially all of our revenues from strategic collaborations and other research and development collaborations and technology licenses, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020. To date, we have generated a substantial portion of our revenues from a limited number of sources.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results and, in particular, our ability to generate additional revenues are dependent on many factors, including the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses and our receipt of milestones, royalties and other payments under such arrangements; and general and industry-specific economic conditions which may affect research, development and commercialization expenditures.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to secure future revenue-generating agreements will depend upon our ability to address the needs of our potential future collaborators and licensees, and to negotiate agreements that we believe are in our long-term best interests.  We </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may determine, as we have with certain of our drug candidates, that our interests are better served by retaining rights to our discoveries and advancing our therapeutic programs to a later stage, which could limit our near-term revenues and increase expenses.  Because of these and other factors, our operating results have fluctuated in the past and are likely to do so in the future, and we do not believe that period-to-period comparisons of our operating results are a good indication of our future performance. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant losses and, as of March&#160;31, 2022, we had an accumulated deficit of $1.5&#160;billion. Our losses have resulted principally from costs incurred in research and development, selling, general and administrative costs associated with our operations, and non-cash stock-based compensation expenses associated with stock options and restricted stock units granted to employees and consultants.  Research and development expenses consist primarily of salaries and related personnel costs, external research costs related to our nonclinical and clinical efforts, material costs, facility costs, depreciation on property and equipment, and other expenses related to our drug discovery and development programs. Selling, general and administrative expenses consist primarily of salaries and related expenses for executive, sales and marketing, and administrative personnel, professional fees and other corporate expenses, including information technology, facilities costs and general legal activities.  We expect to continue to incur significant research and development costs in connection with the continuing research and development of our drug candidates. As a result, we will need to generate significantly higher revenues to achieve profitability.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with generally accepted accounting principles requires us to make judgments, estimates and assumptions in the preparation of our condensed consolidated financial statements and accompanying notes.&#160;&#160;Actual results could differ from those estimates.&#160;&#160;We believe there have been no significant changes in our critical accounting policies as discussed in our Annual Report on Form&#160;10-K for the year ended December&#160;31, 2021.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses and dollar and percentage changes as compared to the corresponding period in the prior year are as follows (dollar amounts are presented in millions):</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.637%"><tr><td style="width:1.0%"></td><td style="width:58.491%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.474%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar increase</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of third-party and other services principally related to nonclinical and clinical development activities, salaries and other personnel-related expenses, stock-based compensation expense, and facility and equipment costs.&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Third-party and other services &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Third-party and other services for the three months ended March&#160;31, 2022 increased 32% to $9.5 million, as compared to the corresponding period in 2021 primarily due to increases in professional and consulting fees relating to preparations for the resubmission of our application for regulatory approval to market sotagliflozin in the United States for heart failure. Third-party and other services relate principally to our clinical trial and related development activities, such as nonclinical and clinical studies and contract manufacturing.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Personnel costs for the three months ended March&#160;31, 2022 increased 10% to $3.2 million, as compared to the corresponding period in 2021, primarily due to higher employee salaries and benefit costs as a result of increasing headcount during 2022 in preparation for commercialization of sotagliflozin.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expenses for the three months ended March&#160;31, 2022 decreased 20% to $1.0 million, as compared to the corresponding period in 2021, primarily due to cancellation of unvested share-based awards during 2021.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities and equipment costs for each of the three months ended March&#160;31, 2022 and 2021 were $0.3 million.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for each of the three months ended March&#160;31, 2022 and 2021 were $0.9 million. </span></div><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses and dollar and percentage changes as compared to the corresponding periods in the prior year are as follows (dollar amounts are presented in millions):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.567%"><tr><td style="width:1.0%"></td><td style="width:56.682%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.582%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.304%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dollar increase</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percentage increase</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel costs to support our research and development activities, professional and consulting fees, stock-based compensation expense, and facility and equipment costs.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Personnel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Personnel costs for the three months ended March&#160;31, 2022 increased 5% to $3.3 million, as compared to the corresponding period in 2021, primarily due to higher employee salaries and benefit costs as a result of increasing headcount during 2022 in preparation for commercialization of sotagliflozin.  Salaries, bonuses, employee benefits, payroll taxes, recruiting and relocation costs are included in personnel costs.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Professional and consulting fees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Professional and consulting fees for the three months ended March&#160;31, 2022 decreased 5% to $2.3 million, as compared to the corresponding period in 2021, primarily due to lower legal fees, partially offset by higher marketing and professional fees. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Stock-based compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Stock-based compensation expenses for the three months ended March&#160;31, 2022 increased 11% to $1.7 million, as compared to the corresponding period in 2021.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Facilities and equipment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8211; Facilities and equipment costs for each of the three months ended March&#160;31, 2022 and 2021 were $0.3 million. </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other &#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Other costs for the three months ended March&#160;31, 2022 and 2021 were $0.9 million and $0.8 million, respectively.  </span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss and Net Loss per Common Share</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net loss and Net loss per Common Share.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss was $23.5 million, or $0.16 per share, in the three months ended March&#160;31, 2022 as compared to a net loss of $21.0 million, or $0.15 per share, in the corresponding period in 2021.   </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly operating results have fluctuated in the past and are likely to do so in the future, and we believe that quarter-to-quarter comparisons of our operating results are not a good indication of our future performance.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have financed our operations from inception primarily through sales of common and preferred stock, contract and milestone payments we received under our collaborations and strategic licenses, target validation, database subscription and technology license agreements, product sales, government grants and contracts, and financing under debt and lease arrangements, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.  We have also financed certain of our research and development activities under financing arrangements with Symphony Icon, Inc. In March 2022, we entered into a loan and security agreement with Oxford Finance LLC that provides up to $150 million in borrowing capacity, available in four tranches, under which $25 million has been funded.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, we had $86.5&#160;million in cash, cash equivalents and short-term investments.  As of December&#160;31, 2021, we had $86.7&#160;million in cash, cash equivalents and short-term investments.  We used cash of $23.4&#160;million from operations in the three months ended March&#160;31, 2022.  This consisted primarily of the net loss for the period of $23.5&#160;million and a net decrease in operating liabilities net of assets of $2.9 million, partially offset by non-cash charges of $2.8&#160;million related to stock-based compensation expense. Investing activities used cash of $4.4&#160;million in the three&#160;months ended March&#160;31, 2022, primarily due to net purchases of investments.  Financing activities provided cash of $23.3&#160;million primarily from $24.2 million of net proceeds from the Oxford debt financing during March 2022, which was partially offset by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9 million used to repurchase common stock by retaining shares in substitution of the tax withholding obligations of recipients of restricted stock units granted under our 2017 Equity Incentive Plan with respect to the vesting of such restricted stock units.  </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other commitments.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2019, sotagliflozin was approved in the European Union for use as an adjunct to insulin therapy to improve glycemic control in adults with type 1 diabetes and a body mass index &#8805; </span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 kg/m</span><span style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, who could not achieve adequate glycemic control despite optimal insulin therapy. In March 2022, we filed an application for withdrawal of such approval for business reasons, which request was granted by the European Commission. Upon the achievement of certain European regulatory pricing approvals, we would have been required to make certain royalty payments, totaling $4.5 million, in three equal annual installments of $1.5 million. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facilities.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  In February 2021, we leased a 25,000 square-foot office space in The Woodlands, Texas. The term of the sublease extends from March 1, 2021 through August&#160;31, 2025, and provides for escalating yearly base rent payments starting at $506,000 and increasing to $557,000 in the final year of the lease. </span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2015, our subsidiary Lexicon Pharmaceuticals (New Jersey), Inc. leased a 25,000 square-foot office space in Basking Ridge, New Jersey.  The term of the lease extends from June&#160;1, 2015 through December&#160;31, 2022, and provides for escalating yearly base rent payments starting at $482,000 and increasing to $646,000 in the final year of the lease. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will be substantial and will depend on many factors, including the success of our ongoing nonclinical and clinical development efforts and the ability to obtain necessary regulatory approvals of the drug candidates which are the subject of such efforts; our success in establishing new collaborations and licenses and our receipt of milestones, royalties and other payments under such arrangements; the amount and timing of our research, development and commercialization expenditures; the resources we devote to developing and supporting our products and other factors.&#160;&#160;Our capital requirements will also be affected by any expenditures we make in connection with license agreements and acquisitions of and investments in complementary technologies and businesses.&#160;&#160;We expect to continue to devote substantial capital resources to prepare for the commercialization of sotagliflozin, if approved; successfully complete our nonclinical and clinical development efforts with respect to sotagliflozin, LX9211 and our other drug candidates; and for other general corporate activities.&#160;&#160;We believe that our current unrestricted cash and investment balances and cash and revenues we expect to derive from strategic and other collaborations and other sources will be sufficient to fund our operations for at least the next 12 months.&#160;&#160;During or after this period, if cash generated by operations is insufficient to satisfy our liquidity requirements, we will need to sell additional equity or debt securities or obtain additional credit arrangements.&#160;&#160;Additional financing may not be available on terms acceptable to us or at all. The sale of additional equity or convertible debt securities may result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our board of directors may authorize us to repurchase shares of our common stock.  If and when our board of directors should determine to authorize any such action, it would be on terms and under market conditions that our board of directors determines are in the best interest of us and our stockholders.  Any such actions could deplete significant amounts of our cash resources and/or result in additional dilution to our stockholders.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Disclosure about Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to limited market and credit risk on our cash equivalents which have maturities of three months or less at the time of purchase. We maintain a short-term investment portfolio which consists of U.S. Treasury bills and corporate debt securities that mature three to 12 months from the time of purchase, which we believe are subject to limited market and credit risk. We currently do not hedge interest rate exposure or hold any derivative financial instruments in our investment portfolio.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had approximately $86.5&#160;million in cash and cash equivalents and short-term investments as of March&#160;31, 2022.  We believe that the working capital available to us will be sufficient to meet our cash requirements for at least the next 12&#160;months. We are subject to interest rate sensitivity on our outstanding Oxford Term Loans as they contain a floating rate tied to the 30-day LIBOR rate.  The Oxford Term Loans interest is payable in cash monthly and matures in March 2027, unless earlier repaid in accordance with their terms.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have operated primarily in the United States and substantially all sales to date have been made in U.S. dollars. Accordingly, we have not had any material exposure to foreign currency rate fluctuations.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_76"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Disclosure about Market Risk&#8221; under &#8220;Item 2. Management&#8217;s Discussion and Analysis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Financial Condition and Results of Operations&#8221; for quantitative and qualitative disclosures about market risk.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;Controls and Procedures</span></div><div style="margin-bottom:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) are effective to ensure that the information required to be disclosed by us in the reports we file under the Securities Exchange Act is gathered, analyzed and disclosed with adequate timeliness, accuracy and completeness, based on an evaluation of such controls and procedures as of the end of the period covered by this report. There were no changes in our internal control over financial reporting during the three months ended March&#160;31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Part II -- Other Information&#160;</span></div><div style="text-align:center"><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_85"></div><div style="padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;Legal Proceedings</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are from time to time party to claims and legal proceedings that arise in the normal course of our business and that we believe will not have, individually or in the aggregate, a material adverse effect on our results of operations, financial condition or liquidity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_88"></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risks and uncertainties are important factors that could cause actual results or events to differ materially from those indicated by forward-looking statements.  The factors described below are not the only ones we face and additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Business and Industry</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;We depend heavily on our ability to obtain regulatory approval in the United States for sotagliflozin in heart failure. If we fail to obtain such regulatory approval, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">If approved, we will depend heavily on the commercial success of sotagliflozin in heart failure. If we do not achieve commercial success with sotagliflozin, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;We depend heavily on our ability to obtain positive results from our ongoing Phase 2 clinical trials of LX9211 in diabetic neuropathic pain and post-herpetic neuralgia. If we fail to successfully complete and obtain positive results from such clinical trials, our business will suffer and our stock price will likely decline.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Clinical testing of our drug candidates in humans is an inherently risky and time-consuming process that may fail to demonstrate safety and efficacy, which could result in the delay, limitation or prevention of regulatory approval.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Our drug candidates are subject to a lengthy and uncertain regulatory process that may not result in the necessary regulatory approvals, which could adversely affect our and our collaborators&#8217; ability to commercialize products.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The commercial success of any products that we or our collaborators may develop will depend upon the degree of market acceptance among physicians, patients, health care payers and the medical communit</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">y.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">If we are unable to reestablish an effective sales force, marketing infrastructure and distribution capabilities, we will not be able to successfully commercialize any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">If we are unable to maintain adequate coverage and reimbursement from third-party payers for any products that we or our collaborators may develop, our revenues and prospects for profitability will suffer.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may not be able to manufacture products that we or our collaborators may develop in commercial quantities, which would impair our ability to commercialize such products.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We and our collaborators are subject to extensive and rigorous ongoing regulation relating to any products that we or our collaborators may develop.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We are subject to certain healthcare laws, regulation and enforcement; our failure to comply with those laws could have a material adverse effect on our results of operations and financial condition.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may negatively affect our revenues and prospects for profitability.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;Our competitors may develop products that impair the value of any products that we or our collaborators may develop.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;We face business disruption and related risks resulting from the outbreak of the novel coronavirus, or COVID-19, including delays in the enrollment of ongoing clinical trials and other operational impacts, each of which could have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Risks Related to Our Capital Requirements and Financial Results</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;We will need additional capital in the future and, if it is unavailable, we will be forced to delay, reduce or eliminate our research and development programs. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;If additional capital is not available on reasonable terms, we will be forced to obtain funds, if at all, by entering into financing agreements on unattractive terms.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our operating results have fluctuated and likely will continue to fluctuate, and we believe that period-to-period comparisons of our operating results are not a good indication of our future performance.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;We have substantial indebtedness that may limit cash flow available to invest in the ongoing needs of our business. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">If we do not effectively manage our affirmative and restrictive covenants under the Oxford Term Loans, our financial condition and results of operations could be adversely affected.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We depend on our ability to establish collaborations with pharmaceutical and biotechnology companies for the development and commercialization of our other drug candidates. If we are unable to establish such collaborations, or if pharmaceutical products are not successfully and timely developed and commercialized under such collaborations, our opportunities to generate revenues from our other drug candidates will be greatly reduced.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Conflicts with our collaborators could jeopardize the success of our collaborative agreements and harm our product development efforts</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We rely on third parties to carry out our nonclinical studies and clinical trials, which may harm or delay our research and development efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We lack the capability to manufacture materials for nonclinical studies and clinical trials and commercial supplies for any products which gain regulatory approval. Our reliance on third parties to manufacture our drug candidates may harm or delay our research, development and commercialization efforts.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to adequately protect our intellectual property, third parties may be able to use our products and technologies, which could adversely affect our ability to compete in the market.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may be involved in patent litigation and other disputes regarding intellectual property rights and may require licenses from third parties for our planned nonclinical and clinical development and commercialization activities.&#160;&#160;We may not prevail in any such litigation or other dispute or be able to obtain required licenses.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Data breaches and cyber-attacks could compromise our intellectual property or other sensitive information and cause significant damage to our business, reputational harm and financial loss.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Employees and Facilities</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If we are unable to manage our growth, our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">The loss of key personnel or the inability to attract and retain additional personnel could impair our ability to operate and expand our operations.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our facilities are located near coastal zones, and the occurrence of a hurricane or other disaster could damage our facilities and equipment, which could harm our operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;We have used hazardous chemicals and radioactive and biological substances in our business. Any claims relating to improper handling, storage or disposal of these substances could be time consuming and costly.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business has a substantial risk of product liability and we face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Common Stock</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;&#160;&#160;&#160;&#160;Invus, L.P. and its affiliates own a controlling interest in our outstanding common stock and may have interests which conflict with those of our other stockholders.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;&#160;&#160;&#160;&#160;Invus has additional rights under its stockholders&#8217; agreement relating to the membership of our board of directors and under our certificate of incorporation relating to preemptive and consent rights, which provide Invus with substantial influence over significant corporate matters.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Our stock price may be extremely volatile.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">Future issuances or sales of our common stock, or the perception that such issuances or sales may occur, may depress our stock price.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;padding-left:14.5pt">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional discussion of the risks and uncertainties that affect our business, see &#8220;Item&#160;1A. Risk Factors&#8221; included in our annual report on Form 10-K for the year ended December&#160;31, 2021 as filed with the Securities and Exchange Commission. </span></div><div><span><br/></span></div><div id="i1663458ba3974fd69ad7c84eebd167a7_874"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table provides information about our purchases of shares of our common stock during the three months ended March 31, 2022:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.403%"><tr><td style="width:1.0%"></td><td style="width:26.818%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.661%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.312%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.453%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.010%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number of Shares that May Yet be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1-31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 1-28, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303,201</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.85&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 1-31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:112%">(1) &#160;&#160;&#160;&#160;Represents shares retained by us in satisfaction of the tax withholding obligations of recipients of restricted stock units granted in February 2019, February 2020 and February 2021 under our 2017 Equity Incentive Plan with respect to the vesting of such restricted stock units.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Represents the market price of our common stock on the date of vesting of such restricted stock units, calculated in accordance with the process for determination of fair market value under our 2017 Equity Incentive Plan.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3) &#160;&#160;&#160;&#160;In the future, we may grant additional equity securities under our 2017 Equity Incentive Plan for which the recipient's tax withholding obligations with respect to the grant or vesting of such securities may be satisfied by our retention of a portion of such securities.  Further, for any such equity securities which are subject to vesting conditions, the number of equity securities which we may retain in satisfaction of the recipient's tax withholding obligations may be dependent on the continued employment of such recipient or other performance-based conditions.  Accordingly, we cannot predict with any certainty either the total amount of equity securities or the approximate dollar value of such securities that we may purchase in future years.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;Exhibits</span></div><div style="padding-left:72pt;text-indent:-72pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:10.223%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.782%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:81.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*&#8224;10.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh101oxfordloanandsecurit.htm">Oxford Loan and Security Agreement, dated March 17, 2022, with Oxford Finance, LLC</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh311certificationofprinc.htm">Certification of Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*31.2</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh312certificationofprinc.htm">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*32.1</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exh321certificationofprinc.htm">Certification of Principal Executive and Principal Financial Officers Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension  Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:0.1%"></td><td style="width:1.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In accordance with Item 601(b)(2)(ii) of Regulation S-K, certain information (indicated by &#8220;[**]&#8221;) has been excluded from this exhibit because it is both not material and would likely cause competitive harm to the Company if publicly disclosed.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><div id="i1663458ba3974fd69ad7c84eebd167a7_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Signatures</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.811%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.694%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Lexicon Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 5, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exh101oxfordloanandsecurit.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id6dac2a1831142bca7d799655adab40e_33"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exhibit 10.1</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;**&#93; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Certain information has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LOAN AND SECURITY AGREEMENT</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> LOAN AND SECURITY AGREEMENT</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (as the same may from time to time be amended, modified, supplemented or restated, this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) dated as of March 17, 2022 (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA  22314 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Oxford</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), as collateral agent (in such capacity, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), the Lenders listed on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender and OXFORD FINANCE CREDIT FUND III, LP, by its manager Oxford Finance Advisors, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Credit Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;&#59; each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), LEXICON PHARMACEUTICALS, INC. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) and LEXICON PHARMACEUTICALS (NEW JERSEY), INC. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lex-NJ</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), each a Delaware corporation with offices located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, TX  77381 (Parent and Lex-NJ, individually and collectively, jointly and severally, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), provides the terms on which the Lenders shall lend to Borrower and Borrower shall repay the Lenders.  The parties agree as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">ACCOUNTING AND OTHER TERMS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;Accounting terms not defined in this Agreement shall be construed in accordance with GAAP.  Calculations and determinations must be made in accordance with GAAP.  Capitalized terms not otherwise defined in this Agreement shall have the meanings set forth in Section 13.  All other terms contained in this Agreement, unless otherwise indicated, shall have the meaning provided by the Code to the extent such terms are defined therein.  All references to &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; or &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are United States Dollars, unless otherwise noted.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">LOANS AND TERMS OF PAYMENT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.1&#160;&#160;&#160;&#160;Promise to Pay.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower hereby unconditionally promises to pay each Lender, the outstanding principal amount of all Term Loans advanced to Borrower by such Lender and accrued and unpaid interest thereon and any other amounts due hereunder as and when due in accordance with this Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.2&#160;&#160;&#160;&#160;Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Availability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  (i) Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, to make term loans to Borrower, on the Effective Date, in an aggregate amount of Twenty-Five Million Dollars ($25,000,000.00) according to each Lender&#8217;s Term A Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term A Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term A Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).  After repayment, no Term A Loan may be re&#8209;borrowed.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Second Draw Period, to make term loans to Borrower in an aggregate amount up to Twenty-Five Million Dollars ($25,000,000.00) according to each Lender&#8217;s Term B Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term B Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term B Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).  After repayment, no Term B Loan may be re&#8209;borrowed.</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, the Lenders agree, severally and not jointly, during the Third Draw Period,, to make term loans to Borrower in an aggregate amount up to Fifty Million Dollars ($50,000,000.00) according to each Lender&#8217;s Term C Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term C Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term C Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).  After repayment, no Term C Loan may be re&#8209;borrowed.</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;Subject to the terms and conditions of this Agreement, upon Borrower&#8217;s written request therefor prior to the Amortization Date, the Lenders may agree, in their sole discretion, severally and not jointly, to make term loans to Borrower in an aggregate amount up to Fifty Million Dollars ($50,000,000.00) according to each Lender&#8217;s Term D Loan Commitment as set forth on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hereto (such term loans are hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term D Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;, and collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term D Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;&#59; each Term A Loan, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Term B Loan, Term C Loan or Term D Loan is hereinafter referred to singly as a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; and the</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Term A Loans, Term B Loans, Term C Loans and the Term D Loans are</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">hereinafter referred to collectively as the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).  After repayment, no Term D Loan may be re&#8209;borrowed.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Repayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Borrower shall make monthly payments of interest only commencing on the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) Payment Date following the Funding Date of each Term Loan, and continuing on the Payment Date of each successive month thereafter through and including the Payment Date immediately preceding the Amortization Date.  Commencing on the Amortization Date, and continuing on the Payment Date of each month thereafter, Borrower shall make consecutive equal monthly payments of principal (in accordance with the applicable repayment schedule described in clause (3) below), together with applicable interest, in arrears, to each Lender, as calculated by Collateral Agent (which calculations shall be deemed correct absent manifest error) based upon&#58; (1) the amount of such Lender&#8217;s Term Loan, (2) the effective rate of interest, as determined pursuant to Section 2.3(a), and (3) a repayment amortization schedule equal to (x) twenty-three (23) months, if the Amortization Date is May 1, 2025 or (y) eleven (11) months if the Amortization Date is May 1, 2026, in each case, on the dates and in the amounts set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 2.2(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hereto.  All unpaid principal and accrued and unpaid interest with respect to each Term Loan is due and payable in full on the Maturity Date.  Each Term Loan may only be prepaid in accordance with Sections 2.2(c) and 2.2(d).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Mandatory Prepayments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  If the Term Loans are accelerated following the occurrence of an Event of Default, Borrower shall immediately pay to Lenders, in accordance with each Lender&#8217;s respective Pro Rata Share, an amount equal to the sum of&#58; (i) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (ii) the Final Payment, (iii) the applicable Prepayment Fee, plus (iv) all other Obligations that are due and payable, including Lenders&#8217; Expenses that are due and payable hereunder and interest at the Default Rate with respect to any past due amounts.  Notwithstanding (but without duplication with) the foregoing, on the Maturity Date, if the Final Payment had not previously been paid in full in connection with the prepayment of the Term Loans in full, Borrower shall pay to Collateral Agent, for payment to each Lender in accordance with its respective Pro Rata Share, the Final Payment in respect of the Term Loan(s).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Permitted Prepayment of Term Loans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Borrower shall have the option to prepay all, but not less than all, of the Term Loans advanced by the Lenders under this Agreement, provided Borrower (i) provides written notice to Collateral Agent of its election to prepay the Term Loans at least ten (10) Business Days prior to such prepayment (or such shorter period as may be agreed to by Collateral Agent), and (ii) pays to the Lenders on the date of such prepayment, payable to each Lender in accordance with its respective Pro Rata Share, an amount equal to the sum of (A) all outstanding principal of the Term Loans plus accrued and unpaid interest thereon through the prepayment date, (B) the Final Payment, (C) the applicable Prepayment Fee, plus (D) all other Obligations that are due and payable, including Lenders&#8217; Expenses that are due and payable hereunder and interest at the Default Rate with respect to any past due amounts.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.3</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Payment of Interest on the Credit Extensions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Interest Rate.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Subject to Section 2.3(b), the principal amount outstanding under the Term Loans shall accrue interest at a floating per annum rate equal to the Basic Rate, determined by Collateral Agent on the Funding Date of the applicable Term Loan, which interest shall be payable monthly in arrears in accordance with Sections 2.2(b) and 2.3(e). Interest shall accrue on each Term Loan commencing on, and including, the Funding Date of such Term Loan, and shall accrue on the principal amount outstanding under such Term Loan through and including the day on which such Term Loan is paid in full.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Immediately upon the occurrence and during the continuance of an Event of Default, Obligations shall accrue interest at a floating per annum rate equal to the rate that is otherwise applicable thereto plus &#91;**&#93; (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).  Payment or acceptance of the increased interest rate provided in this Section 2.3(b) is not a permitted alternative to timely payment and shall not constitute a waiver of any Event of Default or otherwise prejudice or limit any rights or remedies of Collateral Agent.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">360&#8209;Day Year</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Interest shall be computed on the basis of a three hundred sixty (360) day year, and the actual number of days elapsed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Reserved</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Payments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Except as otherwise expressly provided herein, all payments by Borrower under the Loan Documents shall be made to Collateral Agent (and Collateral Agent shall then make the payments to the respective Lender to which such payments are owed), at Collateral Agent&#8217;s office in immediately available funds on the date specified herein.  Unless otherwise provided, interest is payable monthly on the Payment Date of each month.  Payments of principal and&#47;or interest received after 12&#58;00 p.m. (Noon) Eastern Standard Time (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">EST</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) are considered received at the opening of business on the next Business Day.  When a payment is due on a day that is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue until paid.  All payments to be made by Borrower hereunder or under any other Loan Document, including payments of principal and interest, and all fees, expenses, indemnities and reimbursements, shall be made without set&#8209;off, recoupment or counterclaim, in lawful money of the United States and in immediately available funds.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.4&#160;&#160;&#160;&#160;Secured Promissory Notes&#59; Register.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The Term Loans shall be evidenced by a Secured Promissory Note or Notes in the form attached as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit D</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hereto (each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Secured Promissory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), and shall be repayable as set forth in this Agreement.  Borrower irrevocably authorizes each Lender to make or cause to be made, on or about the Funding Date of any Term Loan or at the time of receipt of any payment of principal on such Lender&#8217;s Secured Promissory Note, an appropriate notation on such Lender&#8217;s Secured Promissory Note Record reflecting the making of such Term Loan or (as the case may be) the receipt of such payment.  The outstanding amount of each Term Loan set forth on such Lender&#8217;s Secured Promissory Note Record shall be prima facie evidence of the principal amount thereof owing and unpaid to such Lender, but the failure to record, or any error in so recording, any such amount on such Lender&#8217;s Secured Promissory Note Record shall not limit or otherwise affect the obligations of Borrower under any Secured Promissory Note or any other Loan Document to make payments of principal of or interest on any Secured Promissory Note when due.  Upon receipt of an affidavit of an officer of a Lender as to the loss, theft, destruction, or mutilation of its Secured Promissory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrower shall issue, in lieu thereof, a replacement Secured Promissory Note in the same principal amount thereof and of like tenor. Oxford, acting as a non-fiduciary agent of Borrower, shall maintain a register on which it will record the name and address of the Lenders, and the Term Loan Commitments of, and principal amounts (and stated interest) of the Term Loans owing to, each Lender pursuant to the terms hereof from time to time (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).  The entries in the Register shall be conclusive absent manifest error, and Borrower and the Lenders shall treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement.  The Register shall be available for inspection by Borrower and any Lender, at any reasonable time and from time to time upon reasonable prior notice.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.5&#160;&#160;&#160;&#160;Fees.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower shall pay to Collateral Agent&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Good Faith Deposit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Borrower has remitted to Collateral Agent &#91;**&#93; as a good faith deposit, which amount shall be applied towards the facility fee due under Section 2.5(b) hereof on the Effective Date. For the sake of clarity, Borrower shall be responsible for the entire amount of the facility fee payable pursuant to Section 2.5(b) hereof and the Lenders&#8217; Expenses payable under Section 2.5(e).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Facility Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  A non-refundable facility fee of &#91;**&#93; to be shared between the Lenders pursuant to their respective Pro Rata Shares payable on the Funding Date of the Term A Loans&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Final Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The Final Payment, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Prepayment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  The applicable Prepayment Fee, when due hereunder, to be shared between the Lenders in accordance with their respective Pro Rata Shares&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Lenders&#8217; Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  (i) All reasonable and documented out-of-pocket Lenders&#8217; Expenses (including reasonable attorneys&#8217; fees and expenses for documentation and negotiation of this Agreement) incurred through and after the Effective Date (but limited to fees and expenses of one (1) outside counsel for the period through the Effective Date), when due and (ii) all Lenders&#8217; Expenses incurred in connection with the enforcement or protection of the rights of the Lenders under this Agreement or any other Loan Document.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2.6&#160;&#160;&#160;&#160;Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  (a) Payments received by the Lenders from Borrower hereunder will be made free and clear of and without deduction for any and all present or future taxes, levies, imposts, duties, deductions, withholdings, assessments, fees or other charges imposed by any Governmental Authority (including any interest, additions to tax or penalties applicable thereto) except as required by applicable law, regulation or international agreement.  Specifically, however, if at any time any Governmental Authority, applicable law, regulation or international agreement requires Borrower to make any withholding or deduction of any tax other than an Excluded Tax from any such payment or other sum payable hereunder to the Lenders, Borrower hereby covenants and agrees that the amount due from Borrower with respect to such payment or other sum payable hereunder will be increased to the extent necessary to ensure that, after the making of such required withholding or deduction , each Lender receives a net sum equal to the sum which it would have received had no such withholding or deduction been required and Borrower shall pay the full amount withheld or deducted to the relevant Governmental Authority.  Borrower will, upon request, furnish the Lenders with proof reasonably satisfactory to the Lenders indicating that Borrower has made such withholding payment&#59; provided, however, that Borrower need not make any withholding payment if the amount or validity of such withholding payment is contested in good faith by appropriate and timely proceedings and as to which payment in full is bonded or reserved against by Borrower.  The agreements and obligations of Borrower contained in this Section 2.6 shall survive the termination of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)           On the date of this Agreement, each Lender shall deliver to Borrower a complete and properly executed IRS Form W-9 establishing an exemption from U.S. federal backup withholding.  On or prior to the date of any assignment of a Lender&#8217;s rights under Section 12.1 of this Agreement, the assignee shall deliver to Borrower (i) if such assignee is a U.S. Person, a complete and properly executed IRS Form W-9 establishing an exemption from U.S. federal backup withholding or (ii) if such assignee is not a U.S. Person, a complete and properly executed IRS Form W-8BEN-E (or W-8BEN, as applicable), W-8ECI or W-8IMY, as appropriate, or any successor form prescribed by the IRS, certifying that such Non-U.S. Lender is entitled to an exemption or a reduction from U.S. withholding tax on interest and other amounts payable under this Agreement.  Each Lender agrees that if any form or certification it previously delivered expires or becomes obsolete or inaccurate in any respect, it shall update such form or certification or promptly notify Borrower in writing of its legal inability to do so.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)           If any Lender determines, in its sole discretion exercised in good faith, that it has received a refund of any taxes as to which it has been grossed up pursuant to this Section 2.6 (including by the payment of additional amounts pursuant to this Section 2.6), it shall pay to Borrower an amount equal to such refund (but only to the extent of payments made under this Section 2.6 with respect to the taxes giving rise to such refund), net of all out-of-pocket expenses (including taxes) of such Lender and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund).  Borrower, upon the request of such Lender, shall repay to such Lender the amount paid over pursuant to this Section 2.6(c) (plus any penalties, interest or other charges imposed by the relevant Governmental Authority) in the event that such Lender is required to repay such refund to such Governmental Authority.  Notwithstanding anything to the contrary in this Section 2.6(c), in no event will any Lender be required to pay any amount to Borrower pursuant to this Section 2.6(c) the payment of which would place such Lender in a less favorable net after-tax position than such Lender would have been in if the tax subject to gross-up and giving rise to such refund had not been deducted, withheld or otherwise imposed and the payments or additional amounts with respect to such tax had never been paid.  This paragraph shall not be construed to require any Lender to make available its tax returns (or any other information relating to its taxes that it deems confidential) to Borrower or any other Person.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">CONDITIONS OF LOANS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Conditions Precedent to Initial Credit Extension.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Each Lender&#8217;s obligation to make a Term A Loan is subject to the condition precedent that Collateral Agent and each Lender shall consent to or shall have received, in form and substance satisfactory to Collateral Agent and each Lender, such documents, and completion of such other matters, as Collateral Agent and each Lender may reasonably deem necessary or appropriate, including, without limitation&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;duly executed Loan Documents, each duly executed by Borrower and any Subsidiary that is a party thereto, as applicable&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;duly executed original Control Agreements with respect to any Collateral Accounts maintained by Borrower (other than Excluded Accounts)&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;duly executed original Secured Promissory Notes in favor of each Lender according to its Term A Loan Commitment Percentage&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;the certificate(s) for the Shares, if any, together with Assignment(s) Separate from Certificate, if any, duly executed in blank&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;the Operating Documents and good standing certificates of Borrower and its Subsidiaries certified by the Secretary of State (or equivalent agency) of Borrower&#8217;s and such Subsidiaries&#8217; jurisdiction of organization or formation and each jurisdiction in which Borrower and each Subsidiary is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the Effective Date&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(f)&#160;&#160;&#160;&#160;a completed Perfection Certificate for Borrower and each of its Subsidiaries&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(g)&#160;&#160;&#160;&#160;the Annual Projections, for the current calendar year&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(h)&#160;&#160;&#160;&#160;duly executed original officer&#8217;s certificate for Borrower and each Subsidiary that is a party to the Loan Documents, relating to the Operating Documents, corporate authorizations and other matters in a form acceptable to Collateral Agent and the Lenders&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;certified copies, dated as of date no earlier than thirty (30) days prior to the Effective Date, of financing statement searches, as Collateral Agent shall request, accompanied by written evidence (including any UCC termination statements) that the Liens indicated in any such financing statements either constitute Permitted Liens or have been or, in connection with the initial Credit Extension, will be terminated or released&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(j)&#160;&#160;&#160;&#160;reserved&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(k)&#160;&#160;&#160;&#160;reserved&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(l)&#160;&#160;&#160;&#160;a duly executed legal opinion of counsel to Borrower dated as of the Effective Date&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(m)&#160;&#160;&#160;&#160;evidence satisfactory to Collateral Agent and the Lenders that the insurance policies required by Section 6.5 hereof are in full force and effect, together with appropriate evidence showing loss payable and&#47;or additional insured clauses or endorsements in favor of Collateral Agent, for the ratable benefit of the Lenders&#59; and </font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(n)&#160;&#160;&#160;&#160;payment of the fees and Lenders&#8217; Expenses then due and payable as specified in Section 2.5 hereof.</font></div><div style="padding-left:4.5pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3.2&#160;&#160;&#160;&#160;Conditions Precedent to all Credit Extensions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  The obligation of each Lender to make each Credit Extension, including the initial Credit Extension, is subject to the following conditions precedent&#58;</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;receipt by Collateral Agent of an executed Disbursement Letter in the form of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> attached hereto&#59;</font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;the representations and warranties in Section 5 hereof shall be true, accurate and complete in all material respects on the date of the Disbursement Letter and on the Funding Date of each Credit Extension&#59; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof&#59; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date, and no Event of Default shall have occurred and be continuing or result from the Credit Extension.  Each Credit Extension is Borrower&#8217;s representation and warranty on that date that the representations and warranties in Section 5 hereof are true, accurate and complete in all material respects&#59; provided, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof&#59; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;in such Lender&#8217;s sole discretion, there has not been any Material Adverse Change&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;to the extent not delivered at the Effective Date, duly executed original Secured Promissory Notes and Warrants, in number, form and content acceptable to each Lender, and in favor of each Lender according to its Commitment Percentage, with respect to each Credit Extension made by such Lender after the Effective Date&#59; provided that, Warrants issued after the Effective Date, if at all, shall be on substantially the same form as the Warrants issued to the Lenders as of the Effective Date, and shall be issuable for Shares of Borrower&#8217;s common stock equal to (x) one and three-quarters percent (1.75%) of the funded amount of any Term B Loan and (y) seven-eighths of one percent (0.875%) of the funded amount of any Term C Loan, in each case, divided by the Warrant Price (as defined therein)&#59;  and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;payment of the fees and Lenders&#8217; Expenses then due as specified in Section 2.5 hereof.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3.3&#160;&#160;&#160;&#160;Covenant to Deliver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Borrower agrees to deliver to Collateral Agent and the Lenders each item required to be delivered to Collateral Agent under this Agreement as a condition precedent to any Credit Extension.  Borrower expressly agrees that a Credit Extension made prior to the receipt by Collateral Agent or any Lender of any such item shall not constitute a waiver by Collateral Agent or any Lender of Borrower&#8217;s obligation to deliver such item, and any such Credit Extension in the absence of a required item shall be made in each Lender&#8217;s sole discretion.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3.4&#160;&#160;&#160;&#160;Procedures for Borrowing.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Subject to the prior satisfaction of all other applicable conditions to the making of a Term Loan set forth in this Agreement, to obtain a Term Loan (other than the Term A Loans), Borrower shall notify the Lenders (which notice shall be irrevocable) by electronic mail, facsimile, or telephone by 12&#58;00 p.m. (Noon) EST no later than five (5) Business Days prior to the date the Term Loan is to be made (or such shorter period as may be agreed to by Collateral Agent).  Together with any such electronic, facsimile or telephonic notification, Borrower shall deliver to the Lenders by electronic mail or facsimile a completed Disbursement Letter executed by a Responsible Officer or his or her designee.  The Lenders may rely on any telephone notice given by a person whom a Lender reasonably believes is a Responsible Officer or designee.  On the Funding Date, each Lender shall credit and&#47;or transfer (as applicable) to the Designated Deposit Account, an amount equal to its Term Loan Commitment.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">CREATION OF SECURITY INTEREST</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Grant of Security Interest.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the Lenders, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof.  Borrower represents, warrants, and covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that are permitted by the terms of this Agreement to have priority to Collateral Agent&#8217;s Lien.  If Borrower shall acquire a commercial tort claim (as defined in the Code) with value in excess of Two Hundred Fifty Thousand Dollars ($250,000.00), Borrower, shall promptly notify Collateral Agent in a writing signed by Borrower, as the case may be, of the general details thereof (and further details as may be required by Collateral Agent) and grant to Collateral Agent, for the ratable benefit of the Lenders, in such writing a security interest therein and in the proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance reasonably satisfactory to Collateral Agent.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If this Agreement is terminated, Collateral Agent&#8217;s Lien in the Collateral shall continue until the Obligations (other than inchoate indemnity obligations that by their terms are intended to survive the termination of this Agreement) are repaid in full in cash.  Upon payment in full in cash of the Obligations (other than inchoate indemnity obligations that by their terms are intended to survive the termination of this Agreement) and at such time </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as the Lenders&#8217; obligation to make Credit Extensions has terminated, Collateral Agent shall, at the sole cost and expense of Borrower, release its Liens in the Collateral and all rights therein shall revert to Borrower.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.2&#160;&#160;&#160;&#160;Authorization to File Financing Statements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower hereby authorizes Collateral Agent to file financing statements or take any other action required to perfect Collateral Agent&#8217;s security interests in the Collateral, without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent&#8217;s interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of this Agreement, by Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under the Code.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4.3&#160;&#160;&#160;&#160;Pledge of Collateral.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower hereby pledges, assigns and grants to Collateral Agent, for the ratable benefit of the Lenders, a security interest in all the Shares, together with all proceeds and substitutions thereof, all cash, stock and other moneys and property paid thereon, all rights to subscribe for securities declared or granted in connection therewith, and all other cash and noncash proceeds of the foregoing, as security for the performance of the Obligations.  On the Effective Date, or, to the extent not certificated as of the Effective Date, within ten (10) days of the certification of any Shares (or such longer period as may be agreed to by Collateral Agent), the certificate or certificates for the Shares will be delivered to Collateral Agent, accompanied by an instrument of assignment duly executed in blank by Borrower.  To the extent required by the terms and conditions governing the Shares, Borrower shall cause the books of each entity whose Shares are part of the Collateral and any transfer agent to reflect the pledge of the Shares.  Upon the occurrence and during the continuance of an Event of Default hereunder, Collateral Agent may effect the transfer of any securities included in the Collateral (including but not limited to the Shares) into the name of Collateral Agent and cause new (as applicable) certificates representing such securities to be issued in the name of Collateral Agent or its transferee.  Borrower will execute and deliver such documents, and take or cause to be taken such actions, as Collateral Agent may reasonably request to perfect or continue the perfection of Collateral Agent&#8217;s security interest in the Shares.  Unless an Event of Default shall have occurred and be continuing, Borrower shall be entitled to exercise any voting rights with respect to the Shares and to give consents, waivers and ratifications in respect thereof, provided that no vote shall be cast or consent, waiver or ratification given or action taken which would be inconsistent with any of the terms of this Agreement or which would constitute or create any violation of any of such terms.  All such rights to vote and give consents, waivers and ratifications shall terminate upon the occurrence and continuance of an Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">REPRESENTATIONS AND WARRANTIES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrower represents and warrants to Collateral Agent and the Lenders as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Due Organization, Authorization&#58; Power and Authority.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower and each of its Subsidiaries is duly existing and in good standing as a Registered Organization in its jurisdictions of organization or formation and Borrower and each of its Subsidiaries is qualified and licensed to do business and is in good standing in any jurisdiction in which the conduct of its businesses or its ownership of property requires that it be qualified except where the failure to do so could not reasonably be expected to have a Material Adverse Change.  In connection with this Agreement, Borrower and each of its Subsidiaries has delivered to Collateral Agent a completed perfection certificate signed by an officer of Borrower or such Subsidiary (as such certificate and information may be updated pursuant to the terms hereof, each a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; and collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Perfection Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).  Borrower represents and warrants that (a) Borrower and each of its Subsidiaries&#8217; exact legal name is that which is indicated on its respective Perfection Certificate and on the signature page of each Loan Document to which it is a party&#59; (b) Borrower and each of its Subsidiaries is an organization of the type and is organized in the jurisdiction set forth on its respective Perfection Certificate&#59; (c) each Perfection Certificate accurately sets forth each of Borrower&#8217;s and its Subsidiaries&#8217; organizational identification number or accurately states that Borrower or such Subsidiary has none&#59; (d) each Perfection Certificate accurately sets forth Borrower&#8217;s and each of its Subsidiaries&#8217; place of business, or, if more than one, its chief executive office as well as Borrower&#8217;s and each of its Subsidiaries&#8217; mailing address (if different than its chief executive office)&#59; (e) Borrower and each of its Subsidiaries (and each of its respective predecessors) have not, in the past five (5) years, changed its jurisdiction of organization, organizational structure or type, or any organizational number assigned by its jurisdiction&#59; and (f) all other information set forth on the Perfection Certificates pertaining to Borrower and each of its Subsidiaries, is accurate and complete (it being understood and agreed that Borrower and each of its Subsidiaries may from time to time update certain information in the Perfection Certificates (including the information set forth in clause (d) above) after the Effective Date by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">delivering such information to Collateral Agent and to the extent permitted by one or more specific provisions in this Agreement)&#59; such updated Perfection Certificates subject to the review and approval of Collateral Agent.  If Borrower or any of its Subsidiaries is not now a Registered Organization but later becomes one, Borrower shall notify Collateral Agent of such occurrence and provide Collateral Agent with such Person&#8217;s organizational identification number within five (5) Business Days (or such longer period as may be agreed to by Collateral Agent in its sole discretion) of receiving such organizational identification number.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The execution, delivery and performance by Borrower and each of its Subsidiaries of the Loan Documents to which it is a party have been duly authorized, and do not (i) conflict with any of Borrower&#8217;s or such Subsidiaries&#8217; organizational documents, including its respective Operating Documents, (ii) contravene, conflict with, constitute a default under or violate any material Requirement of Law applicable thereto, (iii) contravene, conflict or violate any applicable order, writ, judgment, injunction, decree, determination or award of any Governmental Authority by which Borrower or such Subsidiary, or any of their property or assets may be bound or affected except where such failure could not reasonably be expected to have a Material Adverse Change, (iv) require any action by, filing, registration, or qualification with, or Governmental Approval from, any Governmental Authority (except such Governmental Approvals which have already been obtained and are in full force and effect or are being obtained pursuant to Section 6.1(b)), or (v) constitute an event of default (after giving effect to any applicable grace periods) under any material agreement by which Borrower or any of such Subsidiaries, or their respective properties, is bound. Neither Borrower nor any of its Subsidiaries is in default under any agreement to which it is a party or by which it or any of its assets is bound in which such default could reasonably be expected to have a Material Adverse Change.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Collateral.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrower and each of its Subsidiaries have good title to, have rights in, and the power to transfer each item of the Collateral upon which it purports to grant a Lien under the Loan Documents, if any, free and clear of any and all Liens except Permitted Liens, and as of the Effective Date neither Borrower nor any of its Subsidiaries have any Deposit Accounts, Securities Accounts, Commodity Accounts or other investment accounts other than the Collateral Accounts or the other investment accounts, if any, described in the Perfection Certificates delivered to Collateral Agent in connection herewith with respect of which Borrower or such Subsidiary has given Collateral Agent notice and taken such actions requested by Collateral Agent as are necessary to give Collateral Agent a perfected security interest therein, to the extent such party is otherwise required to grant such security interest pursuant to the terms of this Agreement. The Accounts are bona fide, existing obligations of the Account Debtors.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;On the Effective Date, and except as disclosed on the Perfection Certificate (i) the Collateral is not in the possession of any third-party bailee (such as a warehouse), and (ii)  no such third-party bailee possesses components of the Collateral in excess of One Million Dollars ($1,000,000.00).  None of the components of the Collateral shall be maintained at locations other than as disclosed in the Perfection Certificates on the Effective Date or as permitted pursuant to Section 6.11.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;All Inventory is in all material respects of good and marketable quality, free from material defects.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;Borrower and each of its Subsidiaries is the sole owner of the Intellectual Property each respectively purports to own, free and clear of all Liens other than Permitted Liens.  (i) Each of Borrower&#8217;s and, to the best of Borrower&#8217;s knowledge, its Subsidiaries&#8217; Patents is valid and enforceable and no part of Borrower&#8217;s or its Subsidiaries&#8217; Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (ii) to the best of Borrower&#8217;s knowledge, no claim has been made that any part of the Intellectual Property or any practice by Borrower or its Subsidiaries violates the rights of any third party except to the extent such claim could not reasonably be expected to have a Material Adverse Change.  Except as noted on the Perfection Certificates, neither Borrower nor any of its Subsidiaries is a party to, nor is bound by, any material license or other material agreement with respect to which Borrower or such Subsidiary is the licensee that (i) prohibits or otherwise restricts Borrower or its Subsidiaries from granting a security interest in Borrower&#8217;s or such Subsidiaries&#8217; interest in such material license or material agreement or any other property, or (ii) for which a default under or termination of could interfere with Collateral Agent&#8217;s or any Lender&#8217;s right to sell any Collateral.  Borrower shall provide written notice to Collateral </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agent and each Lender within ten (10) days (or such longer period as may be agreed to by Collateral Agent) of Borrower or any of its Subsidiaries entering into or becoming bound by any license or agreement with respect to which Borrower or any Subsidiary is the licensee (other than over&#8209;the&#8209;counter software that is commercially available to the public).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.3&#160;&#160;&#160;&#160;Litigation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Except as disclosed (i) on the Perfection Certificates, or (ii) in accordance with Section 6.9 hereof, there are no actions, suits, investigations, or proceedings pending or, to the knowledge of the Responsible Officers, threatened in writing by or against Borrower or any of its Subsidiaries involving more than Five Hundred Thousand Dollars (500,000.00).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.4&#160;&#160;&#160;&#160;No Material Deterioration in Financial Condition&#59; Financial Statements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  All consolidated financial statements for Borrower and its Subsidiaries, delivered to Collateral Agent fairly present, in conformity with GAAP, in all material respects the consolidated financial condition of Borrower and its Subsidiaries, and the consolidated results of operations of Borrower and its Subsidiaries.  As of the Effective Date, there has not been any material deterioration in the consolidated financial condition of Borrower and its Subsidiaries since the date of the most recent financial statements submitted to any Lender.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.5&#160;&#160;&#160;&#160;Solvency.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower and Borrower and its Subsidiaries, taken as a whole, are solvent.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.6&#160;&#160;&#160;&#160;Regulatory Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Neither Borrower nor any of its Subsidiaries is an &#8220;investment company&#8221; or a company &#8220;controlled&#8221; by an &#8220;investment company&#8221; under the Investment Company Act of 1940, as amended.  Neither Borrower nor any of its Subsidiaries is engaged as one of its important activities in extending credit for margin stock (under Regulations X, T and U of the Federal Reserve Board of Governors).  Borrower and each of its Subsidiaries has complied in all material respects with the Federal Fair Labor Standards Act.  Neither Borrower nor any of its Subsidiaries is a &#8220;holding company&#8221; or an &#8220;affiliate&#8221; of a &#8220;holding company&#8221; or a &#8220;subsidiary company&#8221; of a &#8220;holding company&#8221; as each term is defined and used in the Public Utility Holding Company Act of 2005.  Neither Borrower nor any of its Subsidiaries has violated any laws, ordinances or rules, the violation of which could reasonably be expected to have a Material Adverse Change.  Neither Borrower&#8217;s nor any of its Subsidiaries&#8217; properties or assets has been used by Borrower or such Subsidiary or, to Borrower&#8217;s knowledge, by previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than in material compliance with applicable laws.  Borrower and each of its Subsidiaries has obtained all consents, approvals and authorizations of, made all declarations or filings with, and given all notices to, all Governmental Authorities that are necessary to continue their respective businesses as currently conducted, except where such failure could not reasonably be expected to have a Material Adverse Change.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">None of Borrower, any of its Subsidiaries, or to their knowledge any of Borrower&#8217;s or its Subsidiaries&#8217; Affiliates or any of their respective agents acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement is (i) in violation of any Anti&#8209;Terrorism Law, (ii) engaging in or conspiring to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding or attempts to violate, any of the prohibitions set forth in any Anti&#8209;Terrorism Law, or (iii) is a Blocked Person.  None of Borrower, any of its Subsidiaries, or to the knowledge of Borrower and any of their Affiliates or agents, acting or benefiting in any capacity in connection with the transactions contemplated by this Agreement, (x) conducts any business or engages in making or receiving any contribution of funds, goods or services to or for the benefit of any Blocked Person, or (y) deals in, or otherwise engages in any transaction relating to, any property or interest in property blocked pursuant to Executive Order No. 13224, any similar executive order or other Anti&#8209;Terrorism Law.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.7&#160;&#160;&#160;&#160;Investments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Neither Borrower nor any of its Subsidiaries owns any stock, shares, partnership interests or other equity securities except for Permitted Investments.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.8</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Tax Returns and Payments&#59; Pension Contributions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower and each of its Subsidiaries has timely filed all required tax returns and reports, and Borrower and each of its Subsidiaries, has timely paid all foreign, federal, and material state, and local taxes, assessments, deposits and contributions owed by Borrower and such Subsidiaries, in all jurisdictions in which Borrower or any such Subsidiary is subject to taxes, including the United States, unless such taxes are being contested in accordance with the following sentence.  Borrower and each of its Subsidiaries, may defer payment of any contested taxes, provided that Borrower or such Subsidiary, (a) in good faith contests its obligation to pay the taxes by appropriate proceedings promptly and diligently instituted and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">conducted, (b) notifies Collateral Agent in writing of the commencement of, and any material development in, the proceedings, and (c) posts bonds or takes any other steps required to prevent the Governmental Authority levying such contested taxes from obtaining a Lien upon any of the Collateral that is other than a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Permitted Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  On the date of this Agreement, neither Borrower nor any of its Subsidiaries is aware of any claims or adjustments proposed for any of Borrower&#8217;s or such Subsidiaries&#8217; prior tax years which could result in additional taxes becoming due and payable by Borrower or its Subsidiaries in excess of Fifty Thousand Dollars ($50,000.00), except to the extent such taxes are being contested in accordance with the immediately preceding sentence. Borrower and each of its Subsidiaries have paid all amounts necessary to fund all present pension, profit sharing and deferred compensation plans in accordance with their terms, and neither Borrower nor any of its Subsidiaries have, withdrawn from participation in, and have not permitted partial or complete termination of, or permitted the occurrence of any other event with respect to, any such plan which, in any such case, could reasonably be expected to result in any liability of Borrower or its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.9&#160;&#160;&#160;&#160;Use of Proceeds.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower shall use the proceeds of the Credit Extensions solely as working capital and to fund its general business requirements in accordance with the provisions of this Agreement, and not for personal, family, household or agricultural purposes.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.10&#160;&#160;&#160;&#160;Shares.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower has full power and authority to create a first lien on the Shares and no disability or contractual obligation exists that would prohibit Borrower from pledging the Shares pursuant to this Agreement.  To Borrower&#8217;s knowledge, there are no subscriptions, warrants, rights of first refusal or other restrictions on transfer relative to, or options exercisable with respect to the Shares.  The Shares have been and will be duly authorized and validly issued, and are fully paid and non&#8209;assessable.  To Borrower&#8217;s knowledge, other than items disclosed as of the Effective Date, the Shares are not the subject of any present or threatened suit, action, arbitration, administrative or other proceeding, and Borrower knows of no reasonable grounds for the institution of any such proceedings.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.11&#160;&#160;&#160;&#160;Full Disclosure.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  No written representation, warranty or other statement of Borrower or any of its Subsidiaries in any certificate or written statement given to Collateral Agent or any Lender, as of the date such representation, warranty, or other statement was made, taken together with all such written certificates and written statements given to Collateral Agent or any Lender, contains any untrue statement of a material fact or omits to state a material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized that the projections and forecasts provided by Borrower in good faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or forecasted results).</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5.12</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Definition of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Knowledge.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;  For purposes of the Loan Documents, whenever a representation or warranty is made to Borrower&#8217;s knowledge or awareness, to the &#8220;best of&#8221; Borrower&#8217;s knowledge, or with a similar qualification, knowledge or awareness means the actual knowledge, after reasonable investigation, of the Responsible Officers.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">AFFIRMATIVE COVENANTS</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrower (except as otherwise indicated) shall, and shall cause each of its Subsidiaries to, do all of the following&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.1&#160;&#160;&#160;&#160;Government Compliance.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Maintain its and all its Subsidiaries&#8217; legal existence and good standing in their respective jurisdictions of organization and maintain qualification in each jurisdiction in which the failure to so qualify could reasonably be expected to have a Material Adverse Change.  Comply with all laws, ordinances and regulations to which Borrower or any of its Subsidiaries is subject, the noncompliance with which could reasonably be expected to have a Material Adverse Change.</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Obtain and keep in full force and effect, all of the material Governmental Approvals necessary for the performance by Borrower and its Subsidiaries of their respective businesses and obligations under </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the Loan Documents and the grant of a security interest to Collateral Agent for the ratable benefit of the Lenders, in all of the Collateral&#59; provided that Borrower and its Subsidiaries shall not be restricted from withdrawing, forfeiting or otherwise ceasing to maintain or pursue any Governmental Approval or right to the extent doing so could not reasonably be expected to have a Material Adverse Change. Borrower shall promptly provide copies to Collateral Agent of any material Governmental Approvals obtained by Borrower or any of its Subsidiaries.</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.2&#160;&#160;&#160;&#160;Financial Statements, Reports, Certificates.</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Parent shall deliver to each Lender&#58; </font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;no later than forty-five (45) days after the last day of each fiscal quarter, a company prepared consolidated and consolidating balance sheet, income statement and cash flow statement covering the consolidated operations of Borrower and its Subsidiaries for such fiscal quarter certified by a Responsible Officer and in a form reasonably acceptable to Collateral Agent&#59; </font></div><div style="text-align:justify;text-indent:112.5pt"><font><br></font></div><div style="text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;no later than ninety (90) days after the last day of Borrower&#8217;s fiscal year or within five (5) days of filing with the SEC, audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion on the financial statements (other than a qualification that results solely from the Maturity Date being less than one year from the date such report is delivered) from an independent certified public accounting firm acceptable to Collateral Agent in its reasonable discretion&#59; </font></div><div style="text-align:justify;text-indent:112.5pt"><font><br></font></div><div style="text-align:justify;text-indent:112.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;no later than forty-five (45) days after the last day of Borrower&#8217;s fiscal year, Borrower&#8217;s annual financial projections for the entire current fiscal year as approved by Borrower&#8217;s Board of Directors, which such annual financial projections shall be set forth in a quarter to quarter format (such annual financial projections as originally delivered to Collateral Agent and the Lenders are referred to herein as the &#8220;Annual Projections&#8221;&#59; provided that, any revisions of the Annual Projections approved by Borrower&#8217;s Board of Directors shall be delivered to Collateral Agent and the Lenders no later than seven (7) days after such approval)&#59; </font></div><div style="text-align:justify;text-indent:112.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;within five (5) days of delivery by Borrower, copies of all material statements, reports and notices made available to Borrower&#8217;s security holders or holders of Subordinated Debt&#59; </font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(v)&#160;&#160;&#160;&#160;&#91;reserved&#93;&#59; </font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(vi)&#160;&#160;&#160;&#160;prompt notice of any material amendments of or other material changes to the capitalization table of Borrower and to the Operating Documents of Borrower or any of its Subsidiaries, together with any copies reflecting such amendments or changes with respect thereto (provided that the Borrower and its Subsidiaries shall be in compliance with this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Section 6.2(a)(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> if such parties provide notice of any such amendments or changes required to be disclosed in accordance with applicable SEC disclosure rules or regulations)&#59;</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(vii)&#160;&#160;&#160;&#160;prompt notice of (A) any material change in the composition of the Intellectual Property and (B) any event that could reasonably be expected to materially and adversely affect the value of the Intellectual Property&#59; </font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(viii)&#160;&#160;&#160;&#160;as soon as available, but no later than forty-five (45) days after the last day of each fiscal quarter, copies of the month end account statements available for months ending during such fiscal quarter for each Collateral Account maintained by Borrower or any Subsidiary, which statements may be provided to Collateral Agent and each Lender by Borrower or directly from the applicable institution(s)&#59; and</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(xi)&#160;&#160;&#160;&#160;other information as reasonably requested by Collateral Agent or any Lender.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Notwithstanding the foregoing, documents required to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically by filing such documents with the SEC and if so delivered, shall be deemed to have been delivered on the date on which Borrower posts such documents, or provides a link thereto, on Borrower&#8217;s website on the internet at Borrower&#8217;s website address.</font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Concurrently with the delivery of the financial statements specified in Section 6.2(a)(i) above but no later than forty-five (45) days after the last day of each fiscal quarter, deliver to each Lender, a duly completed Compliance Certificate signed by a Responsible Officer.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;Keep proper books of record and account in accordance with GAAP in all material respects, in which full, true and correct entries shall be made of all dealings and transactions in relation to its business and activities.  Borrower shall, and shall cause each of its Subsidiaries to, allow, at the sole cost of Borrower, once in any fiscal year unless an Event of Default has occurred and is continuing, Collateral Agent or any Lender, during regular business hours upon reasonable prior notice (provided that no notice shall be required when an Event of Default has occurred and is continuing), to visit and inspect any of its properties, to examine and make abstracts or copies from any of its books and records, and to conduct a</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">collateral audit and analysis of its operations and the Collateral.  Such audits shall be conducted no more often than once every year unless (and more frequently if) an Event of Default has occurred and is continuing.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.3&#160;&#160;&#160;&#160;Inventory&#59; Returns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Keep all unexpired Inventory in good and marketable condition, free from material defects, except for defects arising in the ordinary course of business.  Returns and allowances between Borrower, or any of its Subsidiaries, and their respective Account Debtors shall follow Borrower&#8217;s, or such Subsidiaries&#8217;, customary practices as they exist at the Effective Date.  Borrower must promptly notify Collateral Agent and the Lenders of all returns, recoveries, disputes and claims that involve more than One Million Dollars ($1,000,000.00) individually or in the aggregate in any calendar year.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.4&#160;&#160;&#160;&#160;Taxes&#59; Pensions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Timely file and require each of its Subsidiaries to timely file, all required material tax returns and material reports and timely pay, and require each of its Subsidiaries to timely pay, all material foreign, federal, and state, and local taxes, assessments, deposits and contributions owed by Borrower or its Subsidiaries, except for deferred payment of any taxes contested pursuant to the terms of Section 5.8 hereof, and shall deliver to Lenders, on demand, appropriate certificates attesting to such payments, and pay all amounts necessary to materially fund all present pension, profit sharing and deferred compensation plans in accordance with the terms of such plans.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.5&#160;&#160;&#160;&#160;Insurance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Keep Borrower&#8217;s and its Subsidiaries&#8217; business and the Collateral insured for risks and in amounts standard for companies in Borrower&#8217;s and its Subsidiaries&#8217; industry and location and as Collateral Agent may reasonably request.  Insurance policies shall be in a form, with companies, and in amounts that are reasonably satisfactory to Collateral Agent and Lenders.  All property policies shall have a lender&#8217;s loss payable endorsement showing Collateral Agent as lender loss payee and waive subrogation against Collateral Agent, and all liability policies shall show, or have endorsements showing, Collateral Agent, as additional insured.  The Collateral Agent shall be named as lender loss payee and&#47;or additional insured with respect to any such insurance providing coverage in respect of any Collateral, and each provider of any such insurance shall agree, by endorsement upon the policy or policies issued by it or by independent instruments furnished to the Collateral Agent, that it will give the Collateral Agent at least thirty (30) days prior written notice before any such policy or policies shall be materially altered or canceled (or at least ten (10) days for cancellations resulting from non-payment of policy premiums).  At Collateral Agent&#8217;s request, Borrower shall deliver certified copies of policies and evidence of all premium payments.  Proceeds payable under any policy shall, at Collateral Agent&#8217;s option, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations.  Notwithstanding the foregoing, (a) so long as no Event of Default has occurred and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to Two Million Dollars ($2,000,000.00) with respect to any loss, but not exceeding Two Million Dollars ($2,000,000.00), in the aggregate for all losses under all casualty policies in any one year, toward the replacement or repair of destroyed or damaged property&#59; provided that any such replaced or repaired property (i) shall be of equal or like value as the replaced or repaired Collateral and (ii) shall be deemed Collateral in which Collateral Agent has been granted a first priority security interest, and (b) after the occurrence and during the continuance of an Event of Default, all proceeds payable under such casualty policy shall, at the option of Collateral Agent, be payable to Collateral Agent, for the ratable benefit of the Lenders, on account of the Obligations in such order as Collateral Agent determines in its sole discretion.  If Borrower or any of its Subsidiaries fails to obtain insurance as required under this Section 6.5 or to pay any amount or furnish any required proof of payment to third persons, Collateral Agent and&#47;or any Lender may make, at Borrower&#8217;s expense, all or part of such payment or obtain such insurance policies required in this Section 6.5, and take any action under the policies Collateral Agent or such Lender deems prudent.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.6&#160;&#160;&#160;&#160;Operating Accounts.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Subject to Section 6.6(b), maintain all of Borrower&#8217;s and its Subsidiaries&#8217; Collateral Accounts (other than Excluded Accounts) subject to a Control Agreement in favor of Collateral Agent.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Borrower shall provide Collateral Agent five (5) days&#8217; prior written notice before Borrower or any of its Subsidiaries establishes any Collateral Account (other than Excluded Accounts) at or with any Person other than those subject to Control Agreements in favor of Collateral Agent.  In addition, for each Collateral Account (other than Excluded Accounts) that Borrower or any of its Subsidiaries, at any time maintains, Borrower or such Subsidiary shall cause the applicable bank or financial institution at or with which such Collateral Account is maintained to execute and deliver a Control Agreement or other appropriate instrument with respect to such Collateral Account to perfect Collateral Agent&#8217;s Lien in such Collateral Account in accordance with the terms hereunder prior to the establishment of such Collateral Account, which Control Agreement may not be terminated by Borrower without prior written consent of Collateral Agent.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;Neither Borrower nor any of its Subsidiaries shall maintain any Collateral Accounts except Collateral Accounts maintained in accordance with Sections 6.6(a) and (b).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.7&#160;&#160;&#160;&#160;Protection of Intellectual Property Rights.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower and each of its Subsidiaries shall&#58; (a) use commercially reasonable efforts to protect, defend and maintain the validity and enforceability of its Intellectual Property that is material to Borrower&#8217;s business&#59; (b) promptly advise Collateral Agent in writing of material infringement by a third party of its Intellectual Property&#59; and (c) not allow any Intellectual Property material to Borrower&#8217;s business to be abandoned, forfeited or dedicated to the public without Collateral Agent&#8217;s prior written consent. Within forty-five (45) days after the last day of each fiscal quarter, Borrower shall notify Collateral Agent, to the extent applicable for such fiscal quarter, if it (i) obtained any patent, registered trademark or servicemark, registered copyright, registered mask work, or filed any application for any of the foregoing, whether as owner, licensee or otherwise, or (ii) applied for any patent or the registration of any trademark or servicemark, and, in each case, after written notice thereof to Collateral Agent, Borrower or such Subsidiary shall execute any intellectual property security agreements and other documents and take such other actions as Collateral Agent shall reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in such property.  If Borrower or any of its Subsidiaries decides to register any copyrights or mask works in the United States Copyright Office, Borrower or such Subsidiary shall&#58; (x) provide Collateral Agent and each Lender with at least fifteen (15) days prior written notice of Borrower&#8217;s or such Subsidiary&#8217;s intent to register such copyrights or mask works together with a copy of the application it intends to file with the United States Copyright Office (excluding exhibits thereto)&#59; (y) execute an intellectual property security agreement and such other documents and take such other actions as Collateral Agent may reasonably request in its good faith business judgment to perfect and maintain a first priority perfected security interest in favor of Collateral Agent, for the ratable benefit of the Lenders, in the copyrights or mask works intended to be registered with the United States Copyright Office&#59; and (z) record such intellectual property security agreement with the United States Copyright Office contemporaneously with filing the copyright or mask work application(s) with the United States Copyright Office.  Borrower or such Subsidiary shall promptly provide to Collateral Agent and each Lender evidence of the recording of any intellectual property security agreement necessary for Collateral Agent to perfect and maintain a first priority perfected security interest in such property.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.8&#160;&#160;&#160;&#160;Litigation Cooperation.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Commencing on the Effective Date and continuing through the termination of this Agreement, make available to Collateral Agent and the Lenders, without expense to Collateral Agent or the Lenders, Borrower and each of Borrower&#8217;s officers, employees and agents and Borrower&#8217;s Books, to the extent that Collateral Agent or any Lender may reasonably deem them necessary to prosecute or defend any third&#8209;party suit or proceeding instituted by or against Collateral Agent or any Lender with respect to any Collateral or relating to Borrower.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.9&#160;&#160;&#160;&#160;Notices of Litigation and Default.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower will give prompt written notice to Collateral Agent and the Lenders of any litigation or governmental proceedings pending or threatened (in writing) against Borrower or any of its Subsidiaries, which could reasonably be expected to result in damages or costs to Borrower or any of its Subsidiaries of Five Hundred Thousand Dollars ($500,000.00) or more or which could reasonably be expected to have a Material Adverse Change.  Without limiting or contradicting any other more specific provision of this </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Agreement, promptly (and in any event within three (3) Business Days) upon Borrower becoming aware of the existence of any Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default, Borrower shall give written notice to Collateral Agent and the Lenders of such occurrence, which such notice shall include a reasonably detailed description of such Event of Default or event which, with the giving of notice or passage of time, or both, would constitute an Event of Default.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.10&#160;&#160;&#160;&#160;Financial Covenant.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> As of the last day of each fiscal quarter ending after the date that is &#91;**&#93; after Sotagliflozin FDA Approval, Borrower shall achieve actual trailing &#91;**&#93; net product revenue (excluding any collaboration or royalty revenue) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">NPR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), of at least (x) during the first year following Sotagliflozin FDA Approval, &#91;**&#93; of projected NPR and (y) thereafter, &#91;**&#93; of projected NPR&#59; in each case, as set forth in the projections attached hereto as Annex X&#59; provided that, once Borrower achieves trailing &#91;**&#93; NPR of &#91;**&#93; or greater as of the last day of a fiscal quarter ending after the date that is &#91;**&#93; after Sotagliflozin FDA Approval, Borrower shall, as of the last day of each fiscal quarter thereafter, and in lieu of the requirements otherwise set forth in this Section 6.10, achieve trailing &#91;**&#93; NPR of at least &#91;**&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.11&#160;&#160;&#160;&#160;Landlord Waivers&#59; Bailee Waivers.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  In the event that Borrower or any of its Subsidiaries, after the Effective Date, adds any new offices or business locations, including warehouses, or otherwise store any portion of the Collateral with, or deliver any portion of the Collateral to, a bailee, in each case pursuant to Section 7.2, then Borrower or such Subsidiary shall promptly notify Collateral Agent of such new addition and, in the event that the new location is the chief executive office of the Borrower or such Subsidiary or the Collateral at any such new location is valued in excess of One Million Dollars ($1,000,000.00), in the aggregate, such bailee or landlord, as applicable, shall execute and deliver a bailee waiver or landlord waiver, as applicable, in form and substance reasonably satisfactory to Collateral Agent prior to the addition of any new offices or business locations, or any such storage with or delivery to any such bailee, as the case may be.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.12&#160;&#160;&#160;&#160;Creation&#47;Acquisition of Subsidiaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  In the event Borrower, or any of its Subsidiaries creates or acquires any Subsidiary, Borrower shall promptly notify Collateral Agent and each Lender of the creation or acquisition of such new Subsidiary and take all such action as may be reasonably required by Collateral Agent or any Lender to cause each such Subsidiary to become a co&#8209;Borrower hereunder or to guarantee the Obligations of Borrower under the Loan Documents and, in each case, grant a continuing pledge and security interest in and to the assets of such Subsidiary (substantially as described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hereto)&#59; and Borrower (or its Subsidiary, as applicable) shall grant and pledge to Collateral Agent, for the ratable benefit of the Lenders, a perfected security interest in the Shares of each such newly created Subsidiary&#59; provided, however, that, (a) solely in the circumstance in which Borrower or any Subsidiary creates or acquires a Foreign Subsidiary in an acquisition permitted by Section 7.3 hereof, (i) such Foreign Subsidiary shall not be required to guarantee the Obligations of Borrower under the Loan Documents and grant a continuing pledge and security interest in and to the assets of such Foreign Subsidiary, and (ii) Borrower shall not be required to grant and pledge to Collateral Agent, for the ratable benefit of Lenders, a perfected security interest in more than sixty&#8209;five percent (65.00%) of the Shares of such Foreign Subsidiary, if (A) Borrower demonstrates to the reasonable satisfaction of Collateral Agent that such Foreign Subsidiary providing such guarantee or pledge and security interest or Borrower providing a perfected security interest in more than sixty&#8209;five percent (65.00%) of the Shares would create a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code&#59; (B) no Intellectual Property is held or maintained by such Foreign Subsidiary at any time&#59; and (C) the aggregate value of cash and Cash Equivalents held or maintained by such Foreign Subsidiary does not exceed One Hundred Thousand Dollars ($100,000.00) at any time&#59; and (b) so long as no Event of Default has occurred and is continuing, Borrower shall not be required to pledge any of its ownership in Lion.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6.13&#160;&#160;&#160;&#160;Further Assurances</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Execute any further instruments and take further action as Collateral Agent or any Lender reasonably requests to perfect or continue Collateral Agent&#8217;s Lien in the Collateral or to effect the purposes of this Agreement.</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Deliver to Collateral Agent and Lenders, within five (5) days after the same are sent or received, copies of all material correspondence, reports, documents and other filings with any Governmental</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Authority that could reasonably be expected to have a material adverse effect on any of the Governmental Approvals material to Borrower&#8217;s business or otherwise could reasonably be expected to have a Material Adverse Change.</font></div><div style="padding-left:4.5pt;text-align:justify"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">NEGATIVE COVENANTS</font></div><div style="padding-left:4.5pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrower shall not, and shall not permit any of its Subsidiaries to, do any of the following without the prior written consent of the Required Lenders&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.1&#160;&#160;&#160;&#160;Dispositions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Convey, sell, lease, transfer, assign, or otherwise dispose of (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), or permit any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (a) of Inventory in the ordinary course of business&#59; (b) of worn out or obsolete Equipment&#59; (c) Transfers between Borrower and Subsidiaries that are joined as Borrowers or Guarantors or between Borrower&#8217;s Subsidiaries, subject to limits set forth in Section 7.12&#59; (d) in connection with Permitted Liens, Permitted Investments and Permitted Licenses&#59; and (e) other Transfers of property having a book value not exceeding One Million Dollars ($1,000,000.00) in the aggregate during any fiscal year.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.2&#160;&#160;&#160;&#160;Changes in Business, Management, Ownership, or Business Locations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  (a) Engage in or permit any of its Subsidiaries to engage in any business other than the businesses engaged in by Borrower as of the Effective Date or reasonably related thereto&#59; (b) liquidate or dissolve&#59; or (c) (i) any Key Person shall cease to be actively engaged in the management of Borrower unless written notice thereof is provided to Collateral Agent within five (5) Business Days of such change (provided, that, documents required to be delivered pursuant to the terms hereof (to the extent any such documents are included in materials otherwise filed with the SEC) may be delivered electronically by filing such document with the SEC and if so delivered, shall be deemed to have been delivered on the date on which Borrower posts such documents, or provides a link thereto, on Borrower&#8217;s website on the internet at Borrower&#8217;s website address), or (ii) consummate any transaction or series of related transactions in which the stockholders of Borrower who were not stockholders immediately prior to the first such transaction own more than forty nine percent (49%) of the voting stock of Borrower immediately after giving effect to such transaction or related series of such transactions (other than by the sale of Borrower&#8217;s equity securities in a public offering, a private placement of public equity or to venture capital investors so long as Borrower identifies to Collateral Agent the venture capital investors prior to the closing of the transaction).  Borrower shall not, without at least thirty (30) days&#8217; prior written notice to Collateral Agent (or such shorter period as may be agreed to by Collateral Agent)&#58; (A) enter into any lease or other contractual arrangement for any new offices or business locations, including warehouses (unless such new offices or business locations (i) contain less than One Million Dollars ($1,000,000.00) in assets or property of Borrower or any of its Subsidiaries and (ii) are not Borrower&#8217;s or its Subsidiaries&#8217; chief executive office)&#59; (B) change its jurisdiction of organization, (C) change its organizational structure or type, (D) change its legal name, or (E) change any organizational number (if any) assigned by its jurisdiction of organization.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.3&#160;&#160;&#160;&#160;Mergers or Acquisitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock, shares or property of another Person, other than pursuant to a Permitted Acquisition. A Subsidiary may merge or consolidate into another Subsidiary (provided such surviving Subsidiary is a &#8220;co&#8209;Borrower&#8221; hereunder or has provided a secured Guaranty of Borrower&#8217;s Obligations hereunder) or with (or into) Borrower provided Borrower is the surviving legal entity, and as long as no Event of Default is occurring prior thereto or arises as a result therefrom.  </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.4&#160;&#160;&#160;&#160;Indebtedness.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so, other than Permitted Indebtedness.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.5&#160;&#160;&#160;&#160;Encumbrance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Create, incur, allow, or suffer any Lien on any of its property, or assign or convey any right to receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or permit any Collateral not to be subject to the first priority security interest granted herein (except for Permitted Liens that are permitted by the terms of this Agreement to have priority over Collateral Agent&#8217;s Lien), or enter into any agreement, document, instrument or other arrangement (except with or in favor of Collateral Agent, for the ratable benefit of the Lenders) with any Person which directly or indirectly prohibits or has the effect of prohibiting Borrower, or any of its Subsidiaries, from assigning, mortgaging, pledging, granting a security interest in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or upon, or encumbering any of Borrower&#8217;s or such Subsidiary&#8217;s Intellectual Property, except as is otherwise permitted in Section 7.1 hereof and the definition of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> herein.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.6&#160;&#160;&#160;&#160;Maintenance of Collateral Accounts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Maintain any Collateral Account except pursuant to the terms of Section 6.6 hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.7&#160;&#160;&#160;&#160;Distributions&#59; Investments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (a) Pay any dividends (other than dividends payable solely in capital stock) or make any distribution or payment in respect of or redeem, retire or purchase any capital stock (other than (i) repurchases pursuant to the terms of employee, consultant or director stock purchase or equity incentive plans, employee, consultant or director stock option, restricted stock or restricted stock unit agreements, stockholder rights plans, or similar plans or arrangements, provided such repurchases do not exceed Three Million Dollars ($3,000,000.00) (net of proceeds received from the sale of vested employee stock that has been withheld) in the aggregate per fiscal year and (ii) subject to Section 7.12 hereof, dividends or distributions made by a direct or indirect Subsidiary of Borrower to Borrower or another Subsidiary of Borrower) or (b) directly or indirectly make any Investment other than Permitted Investments, or permit any of its Subsidiaries to do so.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.8&#160;&#160;&#160;&#160;Transactions with Affiliates.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Directly or indirectly enter into or permit to exist any material transaction with any Affiliate of Borrower or any of its Subsidiaries, except for (a) transactions that are in the ordinary course of Borrower&#8217;s or such Subsidiaries&#8217; business, upon fair and reasonable terms that are no less favorable to Borrower or such Subsidiary than would be obtained in an arm&#8217;s length transaction with a non&#8209;affiliated Person, (b) Subordinated Debt or equity investments by Borrower&#8217;s investors in Borrower or its Subsidiaries and (c) transactions among Borrower and its Subsidiaries or among Subsidiaries of Borrower not otherwise prohibited under this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.9&#160;&#160;&#160;&#160;Subordinated Debt.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  (a) Make or permit any payment on any Subordinated Debt, or (b) amend any provision in any document relating to the Subordinated Debt which would increase the amount thereof or adversely affect the subordination thereof to Obligations owed to the Lenders, in each case, except as permitted under the terms of the subordination, intercreditor, or other similar agreement to which such Subordinated Debt is subject.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.10&#160;&#160;&#160;&#160;Compliance.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Become an &#8220;investment company&#8221; or a company controlled by an &#8220;investment company&#8221;, under the Investment Company Act of 1940, as amended, or undertake as one of its important activities extending credit to purchase or carry margin stock (as defined in Regulation U of the Board of Governors of the Federal Reserve System), or use the proceeds of any Credit Extension for that purpose&#59; fail to meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur&#59; fail, or permit any of the Borrower&#8217;s Subsidiaries to fail, to comply with the Federal Fair Labor Standards Act or violate any other law or regulation, if the violation could reasonably be expected to have a Material Adverse Change&#59; withdraw or permit any Subsidiary to withdraw from participation in, permit partial or complete termination of, or permit the occurrence of any other event with respect to, any present pension, profit sharing and deferred compensation plan, in any such case, which could reasonably be expected to result in any material liability of Borrower or any of its Subsidiaries, including any liability to the Pension Benefit Guaranty Corporation or its successors or any other Governmental Authority.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.11&#160;&#160;&#160;&#160;Compliance with Anti&#8209;Terrorism Laws.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Collateral Agent hereby notifies Borrower and each of its Subsidiaries that pursuant to the requirements of Anti&#8209;Terrorism Laws, and Collateral Agent&#8217;s policies and practices, Collateral Agent is required to obtain, verify and record certain information and documentation that identifies Borrower and each of its Subsidiaries and their principals, which information includes the name and address of Borrower and each of its Subsidiaries and their principals and such other information that will allow Collateral Agent to identify such party in accordance with Anti&#8209;Terrorism Laws.  Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries permit any Affiliate controlled by Borrower or any of its Subsidiaries to, directly or indirectly, knowingly enter into any documents, instruments, agreements or contracts with any Person listed on the OFAC Lists.  Borrower and each of its Subsidiaries shall immediately notify Collateral Agent if Borrower or such Subsidiary has knowledge that Borrower, or any Subsidiary or Affiliate of Borrower, is listed on the OFAC Lists or (a) is convicted on, (b) pleads </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">nolo contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to, (c) is indicted on, or (d) is arraigned and held over on charges involving money laundering or predicate crimes to money laundering.  Neither Borrower nor any of its Subsidiaries shall, nor shall Borrower or any of its Subsidiaries, permit any Affiliate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">controlled by Borrower or any of its Subsidiaries to, directly or indirectly, (i) conduct any business or engage in any transaction or dealing with any Blocked Person, including, without limitation, the making or receiving of any contribution of funds, goods or services to or for the benefit of any Blocked Person, (ii) deal in, or otherwise engage in any transaction relating to, any property or interests in property blocked pursuant to Executive Order No. 13224 or any similar executive order or other Anti&#8209;Terrorism Law, or (iii) engage in or conspire to engage in any transaction that evades or avoids, or has the purpose of evading or avoiding, or attempts to violate, any of the prohibitions set forth in Executive Order No. 13224 or other Anti&#8209;Terrorism Law.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7.12&#160;&#160;&#160;&#160;Subsidiary Operations and Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Notwithstanding any other provision of this Agreement to the contrary, cause or permit Lion to engage in any business, maintain cash or other assets, individually or in the aggregate, at any time in excess of Ten Thousand Dollars ($10,000.00), or hold any Intellectual Property.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">EVENTS OF DEFAULT</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any one of the following shall constitute an event of default (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) under this Agreement&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.1&#160;&#160;&#160;&#160;Payment Default.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower fails to (a) make any payment of principal or interest on any Credit Extension on its due date, or (b) pay any other Obligations within three (3) Business Days after such Obligations are due and payable (which three (3) Business Day grace period shall not apply to payments due on the Maturity Date or the date of acceleration pursuant to Section 9.1 (a) hereof).  During the cure period, the failure to cure the payment default is not an Event of Default (but no Credit Extension will be made during the cure period)&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.2&#160;&#160;&#160;&#160;Covenant Default.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Borrower or any of its Subsidiaries fails or neglects to perform any obligation in Sections 6.2 (Financial Statements, Reports, Certificates), 6.4 (Taxes), 6.5 (Insurance), 6.6 (Operating Accounts), 6.7 (Protection of Intellectual Property Rights), 6.9 (Notice of Litigation and Default), 6.10 (Financial Covenant), 6.11 (Landlord Waivers&#59; Bailee Waivers), 6.12 (Creation&#47;Acquisition of Subsidiaries) or 6.13 (Further Assurances) or Borrower violates any covenant in Section 7&#59; or</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Borrower, or any of its Subsidiaries, fails or neglects to perform, keep, or observe any other term, provision, condition, covenant or agreement contained in this Agreement or any Loan Documents, and as to any default (other than those specified in this Section 8) under such other term, provision, condition, covenant or agreement that can be cured, has failed to cure the default within fifteen (15) days after the occurrence thereof&#59; provided, however, that if the default cannot by its nature be cured within the ten (10) day period or cannot after diligent attempts by Borrower be cured within such fifteen (15) day period, and such default is likely to be cured within a reasonable time, then Borrower shall have an additional period (which shall not in any case exceed thirty (30) days) to attempt to cure such default, and within such reasonable time period the failure to cure the default shall not be deemed an Event of Default (but no Credit Extensions shall be made during such cure period).  Grace periods provided under this Section shall not apply, among other things, to financial covenants or any other covenants set forth in subsection (a) above&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.3&#160;&#160;&#160;&#160;Material Adverse Change.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  A Material Adverse Change occurs&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.4&#160;&#160;&#160;&#160;Attachment&#59; Levy&#59; Restraint on Business.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;(i) The service of process seeking to attach, by trustee or similar process, any funds of Borrower or any of its Subsidiaries or of any entity under control of Borrower or its Subsidiaries on deposit with any Lender or any Lender&#8217;s Affiliate or any bank or other institution at which Borrower or any of its Subsidiaries maintains a Collateral Account, or (ii) a notice of lien, levy, or assessment is filed against Borrower or any of its Subsidiaries or their respective assets by any government agency, and the same under subclauses (i) and (ii) hereof are not, within fifteen (15) Business Days after the occurrence thereof, discharged or stayed (whether through the posting of a bond or otherwise)&#59; provided, however, no Credit Extensions shall be made during any fifteen (15) Business Day cure period&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;(i) any material portion of Borrower&#8217;s or any of its Subsidiaries&#8217; assets is attached, seized, levied on, or comes into possession of a trustee or receiver, or (ii) any court order enjoins, restrains, or prevents Borrower or any of its Subsidiaries from conducting any part of its business&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.5&#160;&#160;&#160;&#160;Insolvency.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  (a) Borrower and Borrower and its Subsidiaries, taken as a whole, is or becomes Insolvent&#59; (b) Borrower or any of its Subsidiaries begins an Insolvency Proceeding&#59; or (c) an Insolvency Proceeding is begun against Borrower or any of its Subsidiaries and not dismissed or stayed within forty&#8209;five (45) days (but no Credit Extensions shall be made while Borrower is, or Borrower and its Subsidiaries, taken as a whole are, Insolvent and&#47;or until any such Insolvency Proceeding is dismissed)&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.6&#160;&#160;&#160;&#160;Other Agreements.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  There is an event of default of Borrower or its Subsidiaries (after the expiration of any grace periods) in any agreement to which Borrower or any of its Subsidiaries is a party with a third party or parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of One Million Dollars ($1,000,000.00) or that could reasonably be expected to have a Material Adverse Change&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.7&#160;&#160;&#160;&#160;Judgments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  One or more judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate, of at least One Million Dollars ($1,000,000.00) (not covered by independent third&#8209;party insurance as to which liability has been accepted by such insurance carrier) shall be rendered against Borrower or any of its Subsidiaries and shall remain unsatisfied, unvacated, or unstayed for a period of twenty (20) days after the entry thereof (provided that no Credit Extensions will be made prior to the satisfaction, vacation, or stay of such judgment, order or decree)&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.8&#160;&#160;&#160;&#160;Misrepresentations.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower or any of its Subsidiaries or any Person acting for Borrower or any of its Subsidiaries makes any representation, warranty, or other statement now or later in this Agreement, any Loan Document or in any writing delivered to Collateral Agent and&#47;or Lenders or to induce Collateral Agent and&#47;or the Lenders to enter this Agreement or any Loan Document, and such representation, warranty, or other statement is incorrect in any material respect when made&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.9&#160;&#160;&#160;&#160;Subordinated Debt.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  An event of default of Borrower or its Subsidiaries (after the expiration of any grace periods) occurs under any agreement between Borrower or any of its Subsidiaries and any creditor of Borrower or any of its Subsidiaries that signed a subordination, intercreditor, or other similar agreement with Collateral Agent or the Lenders, or any creditor that has signed such an agreement with Collateral Agent or the Lenders breaches any terms of such agreement&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.10&#160;&#160;&#160;&#160;Guaranty.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  (a) Any Guaranty required to be maintained pursuant to the terms hereof terminates or ceases for any reason to be in full force and effect and a replacement Guaranty is not delivered in accordance with the terms hereof&#59; (b) any Guarantor does not perform any obligation or covenant under any Guaranty&#59; (c) any circumstance described in Sections 8.3, 8.4, 8.5, 8.7, or 8.8 occurs with respect to any Guarantor, or (d) the liquidation, winding up, or termination of existence of any Guarantor&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.11&#160;&#160;&#160;&#160;Governmental Approvals.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Any Governmental Approval shall have been revoked, rescinded, suspended, modified in an adverse manner, or not renewed in the ordinary course for a full term </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> such revocation, rescission, suspension, modification or non&#8209;renewal has resulted in or could reasonably be expected to result in a Material Adverse Change&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.12&#160;&#160;&#160;&#160;Lien Priority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Any Lien created hereunder or by any other Loan Document shall at any time fail to constitute a valid and perfected Lien on any of the Collateral purported to be secured thereby, subject to no prior or equal Lien, other than Permitted Liens which are permitted to have priority in accordance with the terms of this Agreement&#59; provided that such circumstance is not due to Collateral Agent&#8217;s failure to file an appropriate continuation financing statement, amendment financing statement or initial financing statement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8.13&#160;&#160;&#160;&#160;Delisting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. The shares of common stock of Borrower are delisted from NASDAQ Capital Market because of failure to comply with continued listing standards thereof or due to a voluntary delisting which results in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">such shares not being listed on any other nationally recognized stock exchange in the United States having listing standards at least as restrictive as the NASDAQ Capital Market.</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">RIGHTS AND REMEDIES</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9.1&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rights and Remedies.</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Upon the occurrence and during the continuance of an Event of Default, Collateral Agent may, and at the written direction of Required Lenders shall,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">without notice or demand, do any or all of the following&#58; (i) deliver notice of the Event of Default to Borrower, (ii) by notice to Borrower declare all Obligations immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations shall be immediately due and payable without any action by Collateral Agent or the Lenders) or (iii) by notice to Borrower suspend or terminate the obligations, if any, of the Lenders to advance money or extend credit for Borrower&#8217;s benefit under this Agreement or under any other agreement between Borrower and Collateral Agent and&#47;or the Lenders (but if an Event of Default described in Section 8.5 occurs all obligations, if any, of the Lenders to advance money or extend credit for Borrower&#8217;s benefit under this Agreement or under any other agreement between Borrower and Collateral Agent and&#47;or the Lenders shall be immediately terminated without any action by Collateral Agent or the Lenders).</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Without limiting the rights of Collateral Agent and the Lenders set forth in Section 9.1(a) above, upon the occurrence and during the continuance of an Event of Default, Collateral Agent shall have the right, at the written direction of the Required Lenders,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">without notice or demand, to do any or all of the following&#58;</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font><br></font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;foreclose upon and&#47;or sell or otherwise liquidate, the Collateral&#59;</font></div><div style="padding-left:40.5pt;text-align:justify;text-indent:67.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;apply to the Obligations any (a) balances and deposits of Borrower that Collateral Agent or any Lender holds or controls, or (b) any amount held or controlled by Collateral Agent or any Lender owing to or for the credit or the account of Borrower&#59; and&#47;or</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;commence and prosecute an Insolvency Proceeding or consent to Borrower commencing any Insolvency Proceeding.</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;Without limiting the rights of Collateral Agent and the Lenders set forth in Sections 9.1(a) and (b) above, upon the occurrence and during the continuance of an Event of Default, Collateral Agent shall have the right, without notice or demand, to do any or all of the following&#58;</font></div><div style="padding-left:4.5pt;text-align:justify;text-indent:67.5pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;settle or adjust disputes and claims directly with Account Debtors for amounts on terms and in any order that Collateral Agent considers advisable, notify any Person owing Borrower money of Collateral Agent&#8217;s security interest in such funds, and verify the amount of such account&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;make any payments and do any acts it considers necessary or reasonable to protect the Collateral and&#47;or its security interest in the Collateral.  Borrower shall assemble the Collateral if Collateral Agent requests and make it available in a location as Collateral Agent reasonably designates.  Collateral Agent may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest, or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Collateral Agent a license to enter and occupy any of its premises, without charge, to exercise any of Collateral Agent&#8217;s rights or remedies&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;ship, reclaim, recover, store, finish, maintain, repair, prepare for sale, and&#47;or advertise for sale, the Collateral.  Collateral Agent is hereby granted a non&#8209;exclusive, royalty&#8209;free license or other right to use, without charge, Borrower&#8217;s and each of its Subsidiaries&#8217; labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in connection with Collateral Agent&#8217;s exercise of its rights under this Section 9.1, Borrower&#8217;s and each of its </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsidiaries&#8217; rights under all licenses and all franchise agreements inure to Collateral Agent, for the benefit of the Lenders&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;place a &#8220;hold&#8221; on any account maintained with Collateral Agent or the Lenders and&#47;or deliver a notice of exclusive control, any entitlement order, or other directions or instructions pursuant to any Control Agreement or similar agreements providing control of any Collateral&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(v)&#160;&#160;&#160;&#160;demand and receive possession of Borrower&#8217;s Books&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(vi)&#160;&#160;&#160;&#160;appoint a receiver to seize, manage and realize any of the Collateral, and such receiver shall have any right and authority as any competent court will grant or authorize in accordance with any applicable law, including any power or authority to manage the business of Borrower or any of its Subsidiaries&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(vii)&#160;&#160;&#160;&#160;subject to clauses 9.1(a) and (b), exercise all rights and remedies available to Collateral Agent and each Lender under the Loan Documents or at law or equity, including all remedies provided under the Code (including disposal of the Collateral pursuant to the terms thereof).</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Notwithstanding any provision of this Section 9.1 to the contrary, upon the occurrence of any Event of Default, Collateral Agent shall have the right to exercise any and all remedies referenced in this Section 9.1 without the written consent of Required Lenders following the occurrence of an Exigent Circumstance.  As used in the immediately preceding sentence, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Exigent Circumstance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means any event or circumstance that, in the reasonable judgment of Collateral Agent, imminently threatens the ability of Collateral Agent to realize upon all or any material portion of the Collateral, such as, without limitation, fraudulent removal, concealment, or abscondment thereof, destruction or material waste thereof, or failure of Borrower or any of its Subsidiaries after reasonable demand to maintain or reinstate adequate casualty insurance coverage, or which, in the judgment of Collateral Agent, could reasonably be expected to result in a material diminution in value of the Collateral.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9.2&#160;&#160;&#160;&#160;Power of Attorney.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower hereby irrevocably appoints Collateral Agent as its lawful attorney in fact, exercisable upon the occurrence and during the continuance of an Event of Default, to&#58; (a) endorse Borrower&#8217;s or any of its Subsidiaries&#8217; name on any checks or other forms of payment or security&#59; (b) sign Borrower&#8217;s or any of its Subsidiaries&#8217; name on any invoice or bill of lading for any Account or drafts against Account Debtors&#59; (c) settle and adjust disputes and claims about the Accounts directly with Account Debtors, for amounts and on terms Collateral Agent determines reasonable&#59; (d) make, settle, and adjust all claims under Borrower&#8217;s insurance policies&#59; (e) pay, contest or settle any Lien, charge, encumbrance, security interest, and adverse claim in or to the Collateral, or any judgment based thereon, or otherwise take any action to terminate or discharge the same&#59; and (f) transfer the Collateral into the name of Collateral Agent or a third party as the Code or any applicable law permits.  Borrower hereby appoints Collateral Agent as its lawful attorney in fact to sign Borrower&#8217;s or any of its Subsidiaries&#8217; name on any documents necessary to perfect or continue the perfection of Collateral Agent&#8217;s security interest in the Collateral regardless of whether an Event of Default has occurred until all Obligations (other than inchoate indemnity obligations that by their terms are intended to survive the termination of this Agreement) have been satisfied in full and Collateral Agent and the Lenders are under no further obligation to make Credit Extensions hereunder.  Collateral Agent&#8217;s foregoing appointment as Borrower&#8217;s or any of its Subsidiaries&#8217; attorney in fact, and all of Collateral Agent&#8217;s rights and powers, coupled with an interest, are irrevocable until all Obligations (other than inchoate indemnity obligations that by their terms are intended to survive the termination of this Agreement) have been fully repaid and performed and Collateral Agent&#8217;s and the Lenders&#8217; obligation to provide Credit Extensions terminates.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9.3&#160;&#160;&#160;&#160;Protective Payments.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  If Borrower or any of its Subsidiaries fail to obtain the insurance called for by Section 6.5 or fails to pay any premium thereon or fails to pay any other amount which Borrower or any of its Subsidiaries is obligated to pay under this Agreement or any other Loan Document, Collateral Agent may obtain such insurance or make such payment, and all amounts so paid by Collateral Agent are Lenders&#8217; Expenses and immediately due and payable, bearing interest at the Default Rate, and secured by the Collateral.  Collateral Agent will make reasonable efforts to provide Borrower with notice of Collateral Agent obtaining such insurance or making such payment at the time it is obtained or paid or within a reasonable time thereafter.  No such payments by Collateral Agent are deemed an agreement to make similar payments in the future or Collateral Agent&#8217;s waiver of any Event of Default.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9.4&#160;&#160;&#160;&#160;Application of Payments and Proceeds.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Notwithstanding anything to the contrary contained in this Agreement, upon the occurrence and during the continuance of an Event of Default, (a) Borrower irrevocably waives the right to direct the application of any and all payments at any time or times thereafter received by Collateral Agent from or on behalf of Borrower or any of its Subsidiaries of all or any part of the Obligations, and, as between Borrower on the one hand and Collateral Agent and Lenders on the other, Collateral Agent shall have the continuing and exclusive right to apply and to reapply any and all payments received against the Obligations in such manner as Collateral Agent may deem advisable notwithstanding any previous application by Collateral Agent, and (b) the proceeds of any sale of, or other realization upon all or any part of the Collateral shall be applied&#58; first, to the Lenders&#8217; Expenses&#59; second, to accrued and unpaid interest on the Obligations (including any interest which, but for the provisions of the United States Bankruptcy Code, would have accrued on such amounts)&#59; third, to the principal amount of the Obligations outstanding&#59; and fourth, to any other indebtedness or obligations of Borrower owing to Collateral Agent or any Lender under the Loan Documents.  Any balance remaining shall be delivered to Borrower or to whoever may be lawfully entitled to receive such balance or as a court of competent jurisdiction may direct.  In carrying out the foregoing, (x) amounts received shall be applied in the numerical order provided until exhausted prior to the application to the next succeeding category, and (y) each of the Persons entitled to receive a payment in any particular category shall receive an amount equal to its pro rata share of amounts available to be applied pursuant thereto for such category.  Any reference in this Agreement to an allocation between or sharing by the Lenders of any right, interest or obligation &#8220;ratably,&#8221; &#8220;proportionally&#8221; or in similar terms shall refer to Pro Rata Share unless expressly provided otherwise.  Collateral Agent, or if applicable, each Lender, shall promptly remit to the other Lenders such sums as may be necessary to ensure the ratable repayment of each Lender&#8217;s portion of any Term Loan and the ratable distribution of interest, fees and reimbursements paid or made by Borrower.  Notwithstanding the foregoing, a Lender receiving a scheduled payment shall not be responsible for determining whether the other Lenders also received their scheduled payment on such date&#59; provided, however, if it is later determined that a Lender received more than its ratable share of scheduled payments made on any date or dates, then such Lender shall remit to Collateral Agent or other Lenders such sums as may be necessary to ensure the ratable payment of such scheduled payments, as instructed by Collateral Agent.  If any payment or distribution of any kind or character, whether in cash, properties or securities, shall be received by a Lender in excess of its ratable share, then the portion of such payment or distribution in excess of such Lender&#8217;s ratable share shall be received by such Lender in trust for and shall be promptly paid over to the other Lender for application to the payments of amounts due on the other Lenders&#8217; claims.  To the extent any payment for the account of Borrower is required to be returned as a voidable transfer or otherwise, the Lenders shall contribute to one another as is necessary to ensure that such return of payment is on a pro rata basis.  If any Lender shall obtain possession of any Collateral, it shall hold such Collateral for itself and as agent and bailee for Collateral Agent and other Lenders for purposes of perfecting Collateral Agent&#8217;s security interest therein.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9.5&#160;&#160;&#160;&#160;Liability for Collateral.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  So long as Collateral Agent and the Lenders comply with reasonable banking practices regarding the safekeeping of the Collateral in the possession or under the control of Collateral Agent and the Lenders, Collateral Agent and the Lenders shall not be liable or responsible for&#58; (a) the safekeeping of the Collateral&#59; (b) any loss or damage to the Collateral&#59; (c) any diminution in the value of the Collateral&#59; or (d) any act or default of any carrier, warehouseman, bailee, or other Person.  Borrower bears all risk of loss, damage or destruction of the Collateral.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9.6&#160;&#160;&#160;&#160;No Waiver&#59; Remedies Cumulative.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Failure by Collateral Agent or any Lender, at any time or times, to require strict performance by Borrower of any provision of this Agreement or any other Loan Document shall not waive, affect, or diminish any right of Collateral Agent or any Lender thereafter to demand strict performance and compliance herewith or therewith.  No waiver hereunder shall be effective unless signed by Collateral Agent and the Required Lenders and then is only effective for the specific instance and purpose for which it is given.  The rights and remedies of Collateral Agent and the Lenders under this Agreement and the other Loan Documents are cumulative.  Collateral Agent and the Lenders have all rights and remedies provided under the Code, any applicable law, by law, or in equity.  The exercise by Collateral Agent or any Lender of one right or remedy is not an election, and Collateral Agent&#8217;s or any Lender&#8217;s waiver of any Event of Default is not a continuing waiver.  Collateral Agent&#8217;s or any Lender&#8217;s delay in exercising any remedy is not a waiver, election, or acquiescence.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9.7&#160;&#160;&#160;&#160;Demand Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower waives, to the fullest extent permitted by law, demand, notice of default or dishonor, notice of payment and nonpayment, notice of any default, nonpayment at maturity, release, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Collateral Agent or any Lender on which Borrower or any Subsidiary is liable.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">NOTICES</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All notices, consents, requests, approvals, demands, or other communication (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Communication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) by any party to this Agreement or any other Loan Document must be in writing and shall be deemed to have been validly served, given, or delivered&#58; (a) upon the earlier of actual receipt and three (3) Business Days after deposit in the U.S. mail, first class, registered or certified mail return receipt requested, with proper postage prepaid&#59; (b) upon transmission, when sent by facsimile or electronic mail transmission&#59; (c) one (1) Business Day after deposit with a reputable overnight courier with all charges prepaid&#59; or (d) when delivered, if hand delivered by messenger, all of which shall be addressed to the party to be notified and sent to the address, facsimile number, or email address indicated below.  Any of Collateral Agent, Lender or Borrower may change its mailing address, facsimile number, or email address by giving the other party written notice thereof in accordance with the terms of this Section 10.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:67.948%"><tr><td style="width:1.0%"></td><td style="width:32.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.938%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If to Borrower&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c&#47;o LEXICON PHARMACEUTICALS, INC.<br>2445 Technology Forest Blvd., 11th Floor<br>The Woodlands, TX 77381<br>Attn&#58; General Counsel<br>Fax&#58; &#91;**&#93;<br>Email&#58; &#91;**&#93;</font></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with a copy (which shall not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Vinson &#38; Elkins<br>845 Texas Avenue, Suite 4700<br>Houston, TX 77002<br>Attn&#58; Guy Gribov<br>Fax&#58; &#91;**&#93;<br>Email&#58; &#91;**&#93;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If to Collateral Agent&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC<br>115 South Union Street, Suite 300<br>Alexandria, VA 22314<br>Attention&#58; Legal Department<br>Fax&#58; &#91;**&#93;<br>Email&#58; &#91;**&#93;</font></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If to Credit Fund&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Oxford Finance Credit Fund III, LP, by its manager Oxford Finance Advisors, LLC<br>115 South Union Street, Suite 300<br>Alexandria, VA 22314<br>Attention&#58; Legal Department<br>Fax&#58; &#91;**&#93;<br>Email&#58; &#91;**&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with a copy (which shall not constitute notice) to&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Barnes &#38; Thornburg LLP<br>655 W. Broadway, Suite 1300<br>San Diego, California 92101<br>Attn&#58; Troy Zander<br>Email&#58; &#91;**&#93;</font></td></tr></table></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">New York law governs the Loan Documents without regard to principles of conflicts of law.  Borrower, Lenders and Collateral Agent each submit to the exclusive jurisdiction of the State and Federal courts in the City of New York, Borough of Manhattan.  NOTWITHSTANDING THE FOREGOING, COLLATERAL AGENT AND THE </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LENDERS SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION WHICH COLLATERAL AGENT AND THE LENDERS (IN ACCORDANCE WITH THE PROVISIONS OF SECTION 9.1) DEEM NECESSARY OR APPROPRIATE TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE COLLATERAL AGENT&#8217;S AND THE LENDERS&#8217; RIGHTS AGAINST BORROWER OR ITS PROPERTY.  Borrower expressly submits and consents in advance to such jurisdiction in any action or suit commenced in any such court, and Borrower hereby waives any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents to the granting of such legal or equitable relief as is deemed appropriate by such court.  Borrower hereby waives personal service of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and other process may be made by registered or certified mail addressed to Borrower at the address set forth in, or subsequently provided by Borrower in accordance with, Section 10 of this Agreement and that service so made shall be deemed completed upon the earlier to occur of Borrower&#8217;s actual receipt thereof or three (3) days after deposit in the U.S. mails, first class, registered or certified mail return receipt requested, proper postage prepaid.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, BORROWER, COLLATERAL AGENT, AND THE LENDERS EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR EACH PARTY TO ENTER INTO THIS AGREEMENT.  EACH PARTY HAS REVIEWED THIS WAIVER WITH ITS COUNSEL.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">GENERAL PROVISIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> This Agreement binds and is for the benefit of the successors and permitted assigns of each party.  Borrower may not transfer, pledge or assign this Agreement or any rights or obligations under it without Collateral Agent&#8217;s and each Lender&#8217;s prior written consent (which may be granted or withheld in Collateral Agent&#8217;s and each Lender&#8217;s discretion, subject to Section 12.6).  The Lenders have the right, without the consent of or notice to Borrower, to sell, transfer, assign, pledge, negotiate, or grant participation in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(any </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">such sale, transfer, assignment, negotiation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or grant of a participation, a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;Lender Transfer&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> all or any part of, or any interest in, the Lenders&#8217; obligations, rights, and benefits under this Agreement and the other Loan Documents&#59;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, that any such Lender Transfer (other than a transfer, pledge, sale or assignment to an Eligible Assignee) of its obligations, rights, and benefits under this Agreement and the other Loan Documents shall require the prior written consent of the Required Lenders (such approved assignee, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Approved Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower and Collateral Agent shall be entitled to continue to deal solely and directly with such Lender in connection with the interests so assigned until Collateral Agent shall have received and accepted an effective assignment agreement in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee or Approved Lender as Collateral Agent reasonably shall require.  Notwithstanding anything to the contrary contained herein, so long as no Event of Default has occurred and is continuing, no Lender Transfer (other than a Lender Transfer (i) in respect of the Warrants or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ii) in connection with (x) assignments by a Lender due to a forced divestiture at the request of any regulatory agency&#59; or (y) upon the occurrence of a default, event of default or similar occurrence with respect to a Lender&#8217;s own financing or securitization transactions) shall be permitted, without Borrower&#8217;s consent, to any Person which is an Affiliate or Subsidiary of Borrower, a direct competitor of Borrower or a vulture hedge fund, each as determined by Collateral Agent in its reasonable discretion.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.2&#160;&#160;&#160;&#160;Indemnification.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower agrees to indemnify, defend and hold Collateral Agent and the Lenders and their respective directors, officers, employees, agents, attorneys, or any other Person affiliated with or representing Collateral Agent or the Lenders (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) harmless against&#58;  (a) all obligations, demands, claims, and liabilities (collectively, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) asserted by any other party in connection with, related to, following, or arising from, out of or under, the transactions contemplated by the Loan Documents&#59; and (b) all losses or Lenders&#8217; Expenses incurred, or paid by Indemnified Person in connection with, related to, following, or arising from, out of or under, the transactions contemplated by the Loan Documents between Collateral Agent, and&#47;or the Lenders and Borrower (including reasonable and documented out-of-pocket attorneys&#8217; fees and expenses), except for Claims and&#47;or losses directly caused by such Indemnified Person&#8217;s  gross negligence or willful misconduct or Claims between or among Indemnified Persons.  Borrower hereby further indemnifies, defends and holds each </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indemnified Person harmless from and against any and all liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements of any kind or nature whatsoever (including the fees and disbursements of counsel for such Indemnified Person) in connection with any investigative, response, remedial, administrative or judicial matter or proceeding, whether or not such Indemnified Person shall be designated a party thereto and including any such proceeding initiated by or on behalf of Borrower, and the reasonable expenses of investigation by engineers, environmental consultants and similar technical personnel and any commission, fee or compensation claimed by any broker (other than any broker retained by Collateral Agent or Lenders) asserting any right to payment for the transactions contemplated hereby which may be imposed on, incurred by or asserted against such Indemnified Person as a result of or in connection with the transactions contemplated hereby and the use or intended use of the proceeds of the loan proceeds except for liabilities, obligations, losses, damages, penalties, actions, judgments, suits, claims, costs, expenses and disbursements directly caused by such Indemnified Person&#8217;s gross negligence or willful misconduct or Claims between or among Indemnified Persons.  This Section 12.2 shall not apply with respect to taxes.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.3&#160;&#160;&#160;&#160;Time of Essence.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Time is of the essence for the performance of all Obligations in this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.4&#160;&#160;&#160;&#160;Severability of Provisions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Each provision of this Agreement is severable from every other provision in determining the enforceability of any provision.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.5&#160;&#160;&#160;&#160;Correction of Loan Documents.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Collateral Agent and the Lenders may correct patent errors and fill in any blanks in this Agreement and the other Loan Documents consistent with the agreement of the parties so long as Collateral Agent provides Borrower with written notice of such correction and allows Borrower at least ten (10) days to object to such correction.  In the event of such objection, such correction shall not be made except by an amendment signed by both Collateral Agent and Borrower.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.6&#160;&#160;&#160;&#160;Amendments in Writing&#59; Integration.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  (a) No amendment, modification, termination or waiver of any provision of this Agreement or any other Loan Document, no approval or consent thereunder, or any consent to any departure by Borrower or any of its Subsidiaries therefrom, shall in any event be effective unless the same shall be in writing and signed by Borrower, Collateral Agent and the Required Lenders provided that&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;no such amendment, waiver or other modification that would have the effect of increasing or reducing a Lender&#8217;s Term Loan Commitment or Commitment Percentage shall be effective as to such Lender without such Lender&#8217;s written consent&#59;</font></div><div style="text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;no such amendment, waiver or modification that would affect the rights and duties of Collateral Agent shall be effective without Collateral Agent&#8217;s written consent or signature&#59;</font></div><div style="text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;no such amendment, waiver or other modification shall, unless signed by all the Lenders directly affected thereby, (A) reduce the principal of, rate of interest on or any fees with respect to any Term Loan or forgive any principal, interest (other than default interest) or fees (other than late charges) with respect to any Term Loan (B) postpone the date fixed for, or waive, any payment of principal of any Term Loan or of interest on any Term Loan (other than default interest) or any fees provided for hereunder (other than late charges or for any termination of any commitment)&#59; (C) change the definition of the term &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Required Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; or the percentage of Lenders which shall be required for the Lenders to take any action hereunder&#59; (D) release all or substantially all of any material portion of the Collateral, authorize Borrower to sell or otherwise dispose of all or substantially all or any material portion of the Collateral or release any Guarantor of all or any portion of the Obligations or its guaranty obligations with respect thereto, except, in each case with respect to this clause (D), as otherwise may be expressly permitted under this Agreement or the other Loan Documents (including in connection with any disposition permitted hereunder)&#59; (E) amend, waive or otherwise modify this Section 12.6 or the definitions of the terms used in this Section 12.6 insofar as the definitions affect the substance of this Section 12.6&#59; (F) consent to the assignment, delegation or other transfer by Borrower of any of its rights and obligations under any Loan Document or release Borrower of its payment obligations under any Loan Document, except, in each case with respect to this clause (F), pursuant to a merger or consolidation permitted pursuant to this Agreement&#59; (G) amend any of the provisions of Section 9.4 or amend any of the definitions of Pro Rata Share, Term Loan Commitment, Commitment Percentage or that provide for the Lenders to receive their Pro Rata Shares of any fees, payments, setoffs or proceeds of Collateral </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">hereunder&#59; (H) subordinate the Liens granted in favor of Collateral Agent securing the Obligations&#59; or (I) amend any of the provisions of Section 12.10.  It is hereby understood and agreed that all Lenders shall be deemed directly affected by an amendment, waiver or other modification of the type described in the preceding clauses (C), (D), (E), (F), (G) and (H) of the preceding sentence&#59; and</font></div><div style="text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="text-align:justify;text-indent:103.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;the provisions of the foregoing clauses (i), (ii) and (iii) are subject to the provisions of any interlender or agency agreement among the Lenders and Collateral Agent pursuant to which any Lender may agree to give its consent in connection with any amendment, waiver or modification of the Loan Documents only in the event of the unanimous agreement of all Lenders.</font></div><div style="text-align:justify;text-indent:103.5pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Other than as expressly provided for in Section 12.6(a)(i)&#8209;(iii), Collateral Agent may, if requested by the Required Lenders, from time to time designate covenants in this Agreement less restrictive by notification to a representative of Borrower.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;This Agreement and the Loan Documents represent the entire agreement about this subject matter and supersede prior negotiations or agreements.  All prior agreements, understandings, representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.7&#160;&#160;&#160;&#160;Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  This Agreement may be executed in any number of counterparts and by different parties on separate counterparts, each of which, when executed and delivered, is an original, and all taken together, constitute one Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.8&#160;&#160;&#160;&#160;Survival.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  All covenants, representations and warranties made in this Agreement continue in full force and effect until this Agreement has terminated pursuant to its terms and all Obligations (other than inchoate indemnity obligations and any other obligations which, by their terms, are to survive the termination of this Agreement) have been satisfied.  The obligation of Borrower in Section 12.2 to indemnify each Lender and Collateral Agent, as well as the confidentiality provisions in Section 12.9 below, shall survive until the statute of limitations with respect to such claim or cause of action shall have run.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.9&#160;&#160;&#160;&#160;Confidentiality.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  In handling any information of Borrower and its Subsidiaries, the Lenders and Collateral Agent shall exercise the same degree of care that it exercises for their own proprietary information and maintain such information confidential, but disclosure of information may be made&#58; (a) subject to the terms and conditions of this Agreement, to the Lenders&#8217; and Collateral Agent&#8217;s Subsidiaries or Affiliates, or in connection with a Lender&#8217;s own financing or securitization transactions and upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction&#59; (b) to prospective transferees (other than those identified in (a) above) or purchasers of any interest in the Credit Extensions (provided, however, the Lenders and Collateral Agent shall, except upon the occurrence and during the continuance of an Event of Default, obtain such prospective transferee&#8217;s or purchaser&#8217;s agreement to the terms of this provision or to similar confidentiality terms)&#59; (c) as required by law, regulation, subpoena, or other order&#59; (d) to Lenders&#8217; or Collateral Agent&#8217;s regulators or as otherwise required in connection with an examination or audit&#59; (e) as Collateral Agent reasonably considers appropriate in exercising remedies under the Loan Documents&#59; and (f) to third party service providers of the Lenders and&#47;or Collateral Agent so long as such service providers have executed a confidentiality agreement with the Lenders and Collateral Agent with terms no less restrictive than those contained herein.  Confidential information does not include information that either&#58; (i) is in the public domain or in the Lenders&#8217; and&#47;or Collateral Agent&#8217;s possession when disclosed to the Lenders and&#47;or Collateral Agent, or becomes part of the public domain after disclosure to the Lenders and&#47;or Collateral Agent&#59; or (ii) is disclosed to the Lenders and&#47;or Collateral Agent by a third party, if the Lenders and&#47;or Collateral Agent does not know that the third party is prohibited from disclosing the information.  Collateral Agent and the Lenders may use confidential information for any purpose relating to the administration of this Agreement, including, without limitation, for the development of client databases, reporting purposes, and market analysis.  The provisions of the immediately preceding sentence shall survive the termination of this Agreement.  The agreements provided under this Section 12.9 supersede all prior agreements, understanding, representations, warranties, and negotiations between the parties about the subject matter of this Section 12.9.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.10&#160;&#160;&#160;&#160;Public Announcement.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Notwithstanding anything else herein to the contrary, Borrower hereby agrees that Collateral Agent and each Lender may, at any time after the announcement of the transaction by Borrower, make a public announcement of the transactions contemplated by this Agreement, and may publicize the same on its company website, in marketing materials, newspapers and other publications, and otherwise, and in connection therewith may use Borrower&#8217;s name, tradenames, logos, and any information related to the transactions to the extent such information is not confidential.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.11&#160;&#160;&#160;&#160;Right of Set Off.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  Borrower hereby grants to Collateral Agent and to each Lender, a lien, security interest and right of set off as security for all Obligations to Collateral Agent and each Lender hereunder, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the possession, custody, safekeeping or control of Collateral Agent or the Lenders or any entity under the control of Collateral Agent or the Lenders (including an Affiliate of Collateral Agent) or in transit to any of them.  At any time after the occurrence and during the continuance of an Event of Default, without demand or notice, Collateral Agent or the Lenders may set off the same or any part thereof and apply the same to any liability or obligation of Borrower even though unmatured and regardless of the adequacy of any other collateral securing the Obligations.  ANY AND ALL RIGHTS TO REQUIRE COLLATERAL AGENT TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS, PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF BORROWER ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.12&#160;&#160;&#160;&#160;Cooperation of Borrower.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  If necessary, Borrower agrees to (i) execute any documents (including new Secured Promissory Notes) reasonably required to effectuate and acknowledge each assignment of a Term Loan Commitment or Loan to an assignee in accordance with Section 12.1, (ii) make Borrower&#8217;s management available to meet with Collateral Agent and prospective participants and assignees of Term Loan Commitments or Credit Extensions (which meetings shall be conducted during normal business hours and upon reasonable prior written notice no more often than twice every twelve (12) months unless an Event of Default has occurred and is continuing), and (iii) assist Collateral Agent or the Lenders in the preparation of information relating to the financial affairs of Borrower as any prospective participant or assignee of a Term Loan Commitment or Term Loan reasonably may request.  Subject to the provisions of Section 12.9, Borrower authorizes each Lender to disclose to any prospective participant or assignee of a Term Loan Commitment, any and all information in such Lender&#8217;s possession concerning Borrower and its financial affairs which has been delivered to such Lender by or on behalf of Borrower pursuant to this Agreement, or which has been delivered to such Lender by or on behalf of Borrower in connection with such Lender&#8217;s credit evaluation of Borrower prior to entering into this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">12.13&#160;&#160;&#160;&#160;Borrower Liability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Either Borrower may, acting singly, request Credit Extensions hereunder.  Each Borrower hereby appoints the other as agent for the other for all purposes hereunder, including with respect to requesting Credit Extensions hereunder.  Each Borrower hereunder shall be jointly and severally obligated to repay all Credit Extensions made hereunder, regardless of which Borrower actually receives said Credit Extension, as if each Borrower hereunder directly received all Credit Extensions.  Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable law, and (b) any right to require Collateral Agent or any Lender to&#58; (i) proceed against any Borrower or any other person&#59; (ii) proceed against or exhaust any security&#59; or (iii) pursue any other remedy.  Collateral Agent and or any Lender may exercise or not exercise any right or remedy it has against any Borrower or any security it holds (including the right to foreclose by judicial or non&#8209;judicial sale) without affecting any Borrower&#8217;s liability.  Notwithstanding any other provision of this Agreement or other related document, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Collateral Agent and the Lenders under this Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise and all rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Agreement or otherwise.  Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section shall be null and void.  If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust for Collateral Agent and the Lenders and such payment shall be promptly delivered to Collateral Agent for application to the Obligations, whether matured or unmatured.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">DEFINITIONS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">13.1&#160;&#160;&#160;&#160;Definitions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  As used in this Agreement, the following terms have the following meanings&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any &#8220;account&#8221; as defined in the Code with such additions to such term as may hereafter be made, and includes, without limitation, all accounts receivable and other sums owing to Borrower.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Account Debtor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any &#8220;account debtor&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; of any Person is a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by or is under common control with the Person, and each of that Person&#8217;s senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person&#8217;s managers and members.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in the preamble hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amortization Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is May 1, 2025&#59; provided that, as long as Borrower remains in compliance with the financial covenant in Section 6.10 at all times prior to May 1, 2025 (tested as of the then most recently ended fiscal quarter), Borrower shall have the option to notify Collateral Agent, in writing no later than five (5) Business Days prior thereto, of Borrower&#8217;s election to extend the Amortization Date, in which case, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Amortization Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; shall mean May 1, 2026.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Annual Projections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 6.2(a).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Anti&#8209;Terrorism Laws</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are any laws relating to terrorism or money laundering, including Executive Order No. 13224 (effective September 24, 2001), the USA PATRIOT Act, the laws comprising or implementing the Bank Secrecy Act, and the laws administered by OFAC.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Approved Fund</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any (a) Person, investment company, fund, securitization vehicle or conduit that is (or will be) engaged in making, purchasing, holding or otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its business and that is administered or managed by (i) a Lender, (ii) an Affiliate of a Lender, or (iii) a Person (other than a natural person) or an Affiliate of a Person (other than a natural person) that administers or manages a Lender, or (b) any Person (other than a natural person) which temporarily warehouses loans, or provides financing or securitizations, in each case, for any Lender or any entity described in the preceding clause (a).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Approved Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 12.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Basic Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is the per annum rate of interest (based on a year of three hundred sixty (360) days) equal to the greater of (i) eight and one-hundredth percent (8.01%) and (ii) the sum of (a) the greater of (x) the thirty (30) day U.S. LIBOR rate reported in the </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Wall Street Journal</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> on the last Business Day of the month that immediately precedes the month in which the interest will accrue, and (y) eleven one-hundredths of one percent (0.11%), plus (b) seven and ninety one-hundredths percent (7.90%).  Notwithstanding anything to the contrary herein or in any other Loan Document, upon the occurrence of a LIBOR Transition Event, Collateral Agent may, upon reasonable notice to Borrower, amend this Agreement to replace the Basic Rate with a LIBOR Replacement Rate. Any such amendment with respect to a LIBOR Transition Event will become effective at 5&#58;00 p.m. EST on the third Business Day after Collateral Agent and Borrower have agreed to such amendment.  Any determination, decision or election that may be made by Collateral Agent pursuant hereto will be conclusive and binding absent manifest error and may be made in Collateral Agent&#8217;s sole discretion and without consent from any other party.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Blocked Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">is any Person&#58;  (a) listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (b) a Person owned or controlled by, or acting for or on behalf of, any Person that is listed in the annex to, or is otherwise subject to the provisions of, Executive Order No. 13224, (c) a Person with which any Lender is prohibited from dealing or otherwise engaging in any transaction by any Anti&#8209;Terrorism Law, (d) a Person that commits, threatens or conspires to commit or supports &#8220;terrorism&#8221; as defined in Executive Order </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No. 13224, or (e) a Person that is named a &#8220;specially designated national&#8221; or &#8220;blocked person&#8221; on the most current list published by OFAC or other similar list.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in the preamble hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Borrower&#8217;s Books</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are Borrower&#8217;s or any of its Subsidiaries&#8217; books and records including ledgers, federal, and state tax returns, records regarding Borrower&#8217;s or its Subsidiaries&#8217; assets or liabilities, the Collateral, business operations or financial condition, and all computer programs or storage or any equipment containing such information.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Business Day</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any day that is not a Saturday, Sunday or a day on which Collateral Agent is closed.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Cash Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are (a) marketable direct obligations issued or unconditionally guaranteed by the United States or any agency or any State thereof having maturities of not more than one (1) year from the date of acquisition&#59; (b) commercial paper maturing no more than one (1) year after its creation and having the highest rating from either Standard &#38; Poor&#8217;s Ratings Group or Moody&#8217;s Investors Service, Inc., (c) certificates of deposit maturing no more than one (1) year after issue provided that the account in which any such certificate of deposit is maintained is subject to a Control Agreement in favor of Collateral Agent and (d) money market funds of which at least ninety-five percent (95.00%) of the assets constitute Cash Equivalents of the kinds described in clauses (a) through (c) of this definition.  For the avoidance of doubt, the direct purchase by Borrower or any of its Subsidiaries of any Auction Rate Securities, or purchasing participations in, or entering into any type of swap or other derivative transaction, or otherwise holding or engaging in any ownership interest in any type of Auction Rate Security by Borrower or any of its Subsidiaries shall be conclusively determined by the Lenders as an ineligible Cash Equivalent, and any such transaction shall expressly violate each other provision of this Agreement governing Permitted Investments.  Notwithstanding the foregoing, Cash Equivalents does not include and Borrower, and each of its Subsidiaries, are prohibited from purchasing, purchasing participations in, entering into any type of swap or other equivalent derivative transaction, or otherwise holding or engaging in any ownership interest in any type of debt instrument, including, without limitation, any corporate or municipal bonds with a long&#8209;term nominal maturity for which the interest rate is reset through a Dutch auction and more commonly referred to as an</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">auction rate security (each, an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Auction Rate Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are defined in Section 12.2.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is the Uniform Commercial Code, as the same may, from time to time, be enacted and in effect in the State of New York&#59; provided, that, to the extent that the Code is used to define any term herein or in any Loan Document and such term is defined differently in different Articles or Divisions of the Code, the definition of such term contained in Article or Division 9 shall govern&#59; provided further, that in the event that, by reason of mandatory provisions of law, any or all of the attachment, perfection, or priority of, or remedies with respect to, Collateral Agent&#8217;s Lien on any Collateral is governed by the Uniform Commercial Code in effect in a jurisdiction other than the State of New York, the term &#8220;Code&#8221; shall mean the Uniform Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions thereof relating to such attachment, perfection, priority, or remedies and for purposes of definitions relating to such provisions.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Collateral</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any and all properties, rights and assets of Borrower described on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Collateral Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any Deposit Account, Securities Account, or Commodity Account, or any other bank account maintained by Borrower or any Subsidiary at any time.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is, Oxford, not in its individual capacity, but solely in its capacity as agent on behalf of and for the benefit of the Lenders.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commitment Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is set forth in </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, as amended from time to time.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commodity Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any &#8220;commodity account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Communication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 10.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Compliance Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is that certain certificate in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit C</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Contingent Obligation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is, for any Person, any direct or indirect liability, contingent or not, of that Person for (a) any indebtedness, capital lease, letter of credit or other obligation of the type listed in this definition directly or indirectly guaranteed, endorsed, co&#8209;made, discounted or sold with recourse by that Person, or for which that Person is directly or indirectly liable&#59; (b) any obligations for undrawn letters of credit for the account of that Person&#59; and (c) all obligations from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest rates, currency exchange rates or commodity prices&#59; but &#8220;Contingent Obligation&#8221; does not include endorsements in the ordinary course of business.  The amount of a Contingent Obligation is the stated or determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good faith&#59; but the amount may not exceed the maximum of the obligations under any guarantee or other support arrangement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Control Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any control agreement entered into among the depository institution at which Borrower or any of its Subsidiaries maintains a Deposit Account or the securities intermediary or commodity intermediary at which Borrower or any of its Subsidiaries maintains a Securities Account or a Commodity Account, Borrower and such Subsidiary, and Collateral Agent pursuant to which Collateral Agent obtains control (within the meaning of the Code) for the benefit of the Lenders over such Deposit Account, Securities Account, or Commodity Account.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Copyrights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are any and all copyright rights, copyright applications, copyright registrations and like protections in each work or authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Credit Extension</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any Term Loan or any other extension of credit by Collateral Agent or Lenders for Borrower&#8217;s benefit.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Default Rate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 2.3(b).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Deposit Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any &#8220;deposit account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Designated Deposit Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is Borrower&#8217;s deposit account, account number &#91;**&#93;, maintained with &#91;**&#93;.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Disbursement Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is that certain form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">dollars</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; and &#8220;$&#8221; each mean lawful money of the United States.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in the preamble of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Eligible Assignee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is (i) a Lender, (ii) an Affiliate of a Lender, (iii) an Approved Fund and (iv) any commercial bank, savings and loan association or savings bank or any other entity which is an &#8220;accredited investor&#8221; (as defined in Regulation D under the Securities Act of 1933, as amended) and which extends credit or buys loans as one of its businesses, including insurance companies, mutual funds, lease financing companies and commercial finance companies, in each case, which either (A) has a rating of BBB or higher from Standard &#38; Poor&#8217;s Rating Group and a rating of Baa2 or higher from Moody&#8217;s Investors Service, Inc. at the date that it becomes a Lender or (B) has total assets in excess of Five Billion Dollars ($5,000,000,000.00), and in each case of clauses (i) through (iv), which, through its applicable lending office, is capable of lending to Borrower without the imposition of any withholding or similar taxes&#59; provided that notwithstanding the foregoing, &#8220;Eligible Assignee&#8221; shall not include, unless an Event of Default has occurred and is continuing, (i) Borrower or any of Borrower&#8217;s Affiliates or Subsidiaries or (ii) a direct competitor of Borrower or a vulture hedge fund, each as determined by Collateral Agent.  Notwithstanding the foregoing, (x) in connection with assignments by a Lender due to a forced divestiture at the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">request of any regulatory agency, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party and (y) in connection with a Lender&#8217;s own financing or securitization transactions, the restrictions set forth herein shall not apply and Eligible Assignee shall mean any Person or party providing such financing or formed to undertake such securitization transaction and any transferee of such Person or party upon the occurrence of a default, event of default or similar occurrence with respect to such financing or securitization transaction&#59; provided that no such sale, transfer, pledge or assignment under this clause (y) shall release such Lender from any of its obligations hereunder or substitute any such Person or party for such Lender as a party hereto until Collateral Agent shall have received and accepted an effective assignment agreement from such Person or party in form satisfactory to Collateral Agent executed, delivered and fully completed by the applicable parties thereto, and shall have received such other information regarding such Eligible Assignee as Collateral Agent reasonably shall require.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Equipment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is all &#8220;equipment&#8221; as defined in the Code with such additions to such term as may hereafter be made, and includes without limitation all machinery, fixtures, goods, vehicles (including motor vehicles and trailers), and any interest in any of the foregoing.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ERISA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is the Employee Retirement Income Security Act of 1974, as amended, and its regulations.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Excluded Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means deposit accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of Borrower&#8217;s, or any of its Subsidiaries&#8217;, employees and identified to Collateral Agent by Borrower as such in the Perfection Certificates and (y) cash collateral accounts with respect to Indebtedness permitted pursuant to clause (h) of the definition of Permitted Indebtedness.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Excluded Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means any of the following taxes imposed on or with respect to a Lender or required to be withheld or deducted from a payment to a Lender, (a) taxes imposed on or measured by net income (however denominated), franchise taxes, and branch profits taxes, in each case, (i) imposed as a result of such Lender being organized under the laws of, or having its principal office or, in the case of any Lender, its applicable lending office located in, the jurisdiction imposing such tax (or any political subdivision thereof) or (ii) that are Other Connection Taxes, (b) U.S. federal withholding taxes imposed on amounts payable to or for the account of such Lender with respect to an applicable interest in a Term Loan or Term Loan Commitment pursuant to a law in effect on the date on which (i) such Lender acquires such interest in the Term Loan or Term Loan Commitment or (ii) such Lender changes its lending office, except in each case to the extent that, pursuant to Section 2.6, amounts with respect to such taxes were payable either to such Lender's assignor immediately before such Lender became a party hereto or to such Lender immediately before it changed its lending office, (c)  taxes attributable to such Lender&#8217;s failure to comply with Section 2.6(b) and (d) any withholding taxes imposed under FATCA.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Event of Default</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 8.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">FATCA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means Sections 1471 through 1474 of the Internal Revenue Code, as of the date of this Agreement (or any amended or successor version that is substantively comparable and not materially more onerous to comply with), any current or future regulations or official interpretations thereof, any agreements entered into pursuant to Section 1471(b)(1) of the Code and any fiscal or regulatory legislation, rules or practices adopted pursuant to any intergovernmental agreement, treaty or convention among Governmental Authorities and implementing such Sections of the Internal Revenue Code.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">FDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means the U.S. Food and Drug Administration or any successor thereto.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Federal Reserve Bank of New York&#8217;s Website</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means the website of the Federal Reserve Bank of New York at http&#58;&#47;&#47;www.newyorkfed.org, or any successor source.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Final Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is a payment (in addition to and not a substitution for the regular monthly payments of principal plus accrued interest) due on the earliest to occur of (a) the Maturity Date, or (b) the acceleration of any Term Loan, or (c) the prepayment of a Term Loan pursuant to Section 2.2(c) or (d), equal to the original principal amount of such Term Loan multiplied by the Final Payment Percentage, payable to Lenders in accordance with their respective Pro Rata Shares. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Final Payment Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is six percent (6.00%)&#59; provided that, if the Amortization Date is May 1, 2026, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Final Payment Percentage</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; shall mean seven percent (7.00%).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Foreign Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is a Subsidiary that is not an entity organized under the laws of the United States or any territory thereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Foreign Subsidiary Holding Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means any Subsidiary substantially all of whose assets consist of outstanding capital stock, membership units or other securities owned or held of record and&#47;or Indebtedness of one or more Subsidiaries that are &#8220;controlled foreign corporations&#8221; within the meaning of Section 957 of the Internal Revenue Code.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Funding Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any date on which a Credit Extension is made to or on account of Borrower which shall be a Business Day.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">GAAP</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is generally accepted accounting principles set forth in the opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other Person as may be approved by a significant segment of the accounting profession in the United States, which are applicable to the circumstances as of the date of determination.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">General Intangibles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are all &#8220;general intangibles&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation, all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, any patents, trademarks, service marks and, to the extent permitted under applicable law, any applications therefor, whether registered or not, any trade secret rights, including any rights to unpatented inventions, payment intangibles, royalties, contract rights, goodwill, franchise agreements, purchase orders, customer lists, route lists, telephone numbers, domain names, claims, income and other tax refunds, security and other deposits, options to purchase or sell real or personal property, rights in all litigation presently or hereafter pending (whether in contract, tort or otherwise), insurance policies (including without limitation key man, property damage, and business interruption insurance), payments of insurance and rights to payment of any kind.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Governmental Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any consent, authorization, approval, order, license, franchise, permit, certificate, accreditation, registration, filing or notice, of, issued by, from or to, or other act by or in respect of, any Governmental Authority.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Governmental Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any nation or government, any state or other political subdivision thereof, any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative, judicial, taxing, regulatory or administrative functions of or pertaining to government, any securities exchange and any self&#8209;regulatory organization.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Guarantor</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any Person providing a Guaranty in favor of Collateral Agent&#59; provided, that, so long as no Event of Default has occurred and is continuing, Lion shall be excluded from the definition of Guarantor and any requirements hereunder or under any other Loan Documents to become a Guarantor.  As of the Effective Date there are no Guarantors.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Guaranty</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any guarantee of all or any part of the Obligations, as the same may from time to time be amended, restated, modified or otherwise supplemented.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is (a) indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations, and (d) Contingent Obligations.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Indemnified Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 12.2.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Insolvency Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Insolvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means not Solvent.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Intellectual Property</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means all of Borrower&#8217;s or any Subsidiaries&#8217; right, title and interest in and to the following&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;its Copyrights, Trademarks and Patents&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know&#8209;how, operating manuals&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;any and all source code&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;any and all design rights which may be available to Borrower&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;any and all claims for damages by way of past, present and future infringement of any of the foregoing, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the Intellectual Property rights identified above&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(f)&#160;&#160;&#160;&#160;all amendments, renewals and extensions of any of the Copyrights, Trademarks or Patents.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Internal Revenue Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means the Internal Revenue Code of 1986, as amended from time to time.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Inventory</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is all &#8220;inventory&#8221; as defined in the Code in effect on the date hereof with such additions to such term as may hereafter be made, and includes without limitation all merchandise, raw materials, parts, supplies, packing and shipping materials, work in process and finished products, including without limitation such inventory as is temporarily out of any Person&#8217;s custody or possession or in transit and including any returned goods and any documents of title representing any of the above.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Investment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any beneficial ownership interest in any Person (including stock, partnership interest or other securities), and any loan, advance or capital contribution to any Person.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">IP Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is that certain Intellectual Property Security Agreement entered into by and between Borrower and Collateral Agent dated as of the Effective Date, as such may be amended from time to time.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">IRS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means the Internal Revenue Service.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Key Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is each of Borrower&#8217;s (i) Chief Executive Officer, who is Lonnel Coats as of the Effective Date, (ii) Chief Financial Officer, who is Jeffrey L. Wade as of the Effective Date and (iii) Chief Medical Officer, who is Craig B. Granowitz, M.D., Ph.D. as of the Effective Date.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any one of the Lenders.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are the Persons identified on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hereto and each assignee that becomes a party to this Agreement pursuant to Section 12.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lenders&#8217; Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are all audit fees and expenses, costs, and expenses (including reasonable and documented out-of-pocket attorneys&#8217; fees and expenses, as well as appraisal fees, fees incurred on account of lien searches, inspection fees, and filing fees) for preparing, amending, negotiating, administering, defending and enforcing the Loan Documents (including, without limitation, those incurred in connection with appeals or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Insolvency Proceedings) or otherwise incurred by Collateral Agent and&#47;or the Lenders in connection with the Loan Documents.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;LIBOR Replacement Rate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means the sum of&#58; (a) the alternate benchmark rate (which may include SOFR) that has been selected by Collateral Agent in consultation with Borrower giving due consideration to (i) any selection or recommendation of a replacement rate or the mechanism for determining such a rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a rate of interest as a replacement to the LIBOR rate for U.S. dollar-denominated syndicated credit facilities and (b) the LIBOR Replacement Spread</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">provided that, if the LIBOR Replacement Rate as so determined would be less than zero, the LIBOR Replacement Rate will be deemed to be zero for the purposes of this Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;LIBOR Replacement Spread&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means, with respect to any replacement of the Basic Rate, the spread adjustment, or method for calculating or determining such spread adjustment, (which may be a positive or negative value or zero) that has been selected by Collateral Agent in consultation with Borrower giving due consideration to (i) any selection or recommendation of a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of the LIBOR rate by the Relevant Governmental Body or (ii) any evolving or then-prevailing market convention for determining a spread adjustment, or method for calculating or determining such spread adjustment, for the replacement of the LIBOR rate for U.S. dollar-denominated syndicated credit facilities at such time.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;LIBOR Transition Event&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means the occurrence of one or more of the following events with respect to the LIBOR rate&#58; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)    a public statement or publication of information by or on behalf of the administrator of the LIBOR rate announcing that such administrator has ceased or will cease to provide the LIBOR rate, permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide the LIBOR rate&#59; </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(2)   a public statement or publication of information by the regulatory supervisor for the administrator of the LIBOR rate, the U.S. Federal Reserve System, an insolvency official with jurisdiction over the administrator for the LIBOR rate, a resolution authority with jurisdiction over the administrator for the LIBOR rate or a court or an entity with similar insolvency or resolution authority over the administrator for the LIBOR rate, which states that the administrator of the LIBOR rate has ceased or will cease to provide the LIBOR rate permanently or indefinitely, provided that, at the time of such statement or publication, there is no successor administrator that will continue to provide the LIBOR rate&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(3)   a public statement or publication of information by the regulatory supervisor for the administrator of the LIBOR rate announcing that the LIBOR rate is no longer representative. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lien</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is a claim, mortgage, deed of trust, levy, charge, pledge, security interest, or other encumbrance of any kind, whether voluntarily incurred or arising by operation of law or otherwise against any property.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means Lion Acquisition Corporation, a Delaware corporation and a wholly-owned Subsidiary of Parent.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are, collectively, this Agreement, the Warrants, the Perfection Certificates, each Compliance Certificate, each Disbursement Letter, the IP Agreement, the Post Closing Letter, any subordination agreements, any note, or notes or guaranties executed by Borrower or any other Person, and any other present or future agreement entered into by Borrower, any Guarantor or any other Person for the benefit of the Lenders and Collateral Agent in connection with this Agreement&#59; all as amended, restated, or otherwise modified.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Material Adverse Change</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is (a) a material impairment in the perfection or priority of Collateral Agent&#8217;s Lien in the Collateral or in the value of such Collateral&#59; (b) a material adverse change in the business, operations or condition (financial or otherwise) or prospects of Borrower or any Subsidiary&#59; or (c) a material impairment of the prospect of repayment of any portion of the Obligations that are then due and payable&#59; provided, that, Borrower&#8217;s </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">withdrawal, forfeiture or other loss of the existing regulatory approval for the use of Sotagliflozin in the European Union </font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">as an adjunct to insulin therapy to improve blood sugar (glycemic) control in adults with type 1 diabetes mellitus and a body mass index &#8805; 27 kg&#47;m</font><font style="color:#333333;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">2</font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, who could not achieve adequate glycemic control despite optimal insulin therapy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> for the treatment of type 1 diabetes shall not constitute a Material Adverse Change.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Maturity Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is March 1, 2027.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">NDA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means a new drug application in the United States for authorization to market a product, as defined in the applicable laws and regulations and submitted to the FDA.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Obligations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are all of Borrower&#8217;s obligations to pay when due any debts, principal, interest, Lenders&#8217; Expenses, the Prepayment Fee, the Final Payment, and other amounts Borrower owes the Lenders now or later, in each case, connection with, related to, following, or arising from, out of or under, this Agreement or, the other Loan Documents (other than the Warrants), or otherwise, and including interest accruing after Insolvency Proceedings begin (whether or not allowed) and debts, liabilities, or obligations of Borrower assigned to the Lenders and&#47;or Collateral Agent, and the performance of Borrower&#8217;s duties under the Loan Documents (other than the Warrants).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OFAC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is the U.S. Department of Treasury Office of Foreign Assets Control.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OFAC Lists</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are, collectively, the Specially Designated Nationals and Blocked Persons List maintained by OFAC pursuant to Executive Order No. 13224, 66 Fed. Reg. 49079 (Sept. 25, 2001) and&#47;or any other list of terrorists or other restricted Persons maintained pursuant to any of the rules and regulations of OFAC or pursuant to any other applicable Executive Orders.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Operating Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are, for any Person, such Person&#8217;s formation documents, as certified by the Secretary of State (or equivalent agency) of such Person&#8217;s jurisdiction of organization on a date that is no earlier than thirty (30) days prior to the Effective Date, and, (a) if such Person is a corporation, its bylaws in current form, (b) if such Person is a limited liability company, its limited liability company agreement (or similar agreement), and (c) if such Person is a partnership, its partnership agreement (or similar agreement), each of the foregoing with all current amendments or modifications thereto.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other Connection Taxes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means, with respect to any Lender, taxes imposed as a result of a present or former connection between such Lender and the jurisdiction imposing such tax (other than connections arising from such Lender having executed, delivered, become a party to, performed its obligations under, received payments under, received or perfected a security interest under, engaged in any other transaction pursuant to or enforced this Agreement, or sold or assigned an interest in any Term Loan or this Agreement).</font></div><div style="text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in the preamble hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Patents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means all patents, patent applications and like protections including without limitation improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is the first (1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">) calendar day of each calendar month, commencing on April 1, 2022.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Perfection Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Perfection Certificates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 5.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Permitted Acquisition</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means an acquisition pursuant to which Borrower acquires a Person or an ownership interest in a Person through the issuance of Borrower&#8217;s capital stock, so long as (i) the number of shares or the voting power of Borrower&#8217;s capital stock issued with respect to any one Peron is less than twenty percent (20%) of the total shares or voting power of Borrower&#8217;s capital stock outstanding before the issuance and (ii) the cash consideration for the Permitted Acquisition shall not exceed Five Million Dollars ($5,000,000.00) in the aggregate, to the extent that  each of the following conditions shall have been satisfied&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;immediately prior to, and after giving effect thereto, no Event of Default shall have occurred and be continuing or would result therefrom&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;all transactions in connection therewith shall be consummated, in all material respects, in accordance with applicable law&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;such acquired Person or assets shall be in the same line of business as is conducted by Borrower as of the Effective Date (or a line of business reasonably related thereto)&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;such acquisition shall not cause the focus or locations of Borrower&#8217;s and its Subsidiaries&#8217; operations (when taken as a whole) to be located outside of the United States&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;in the case of the purchase or other acquisition of Shares, all of the Shares acquired or otherwise issued by such Person or any newly formed Subsidiary in connection with such acquisition shall be  wholly owned by Borrower or a Subsidiary&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(f)&#160;&#160;&#160;&#160;in connection with such acquisition, neither Borrower nor any of its Subsidiaries (including for this purpose, the target of the acquisition) shall acquire or be subject to any Indebtedness or Liens that are not otherwise permitted hereunder&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(g)         &#91;reserved&#93;&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(h)&#160;&#160;&#160;&#160;Borrower shall have delivered to the Collateral Agent and Lenders at least five (5) Business Days (or such shorter period as may be acceptable to Collateral Agent and Lenders) prior to such proposed acquisition (i) a copy of the purchase agreement related to the proposed acquisition (and any related documents reasonably requested by the Collateral Agent and Lenders), (ii) a general description of the acquired assets or acquired business line or unit or division and the competitive position of such business line or unit or division within the industry, (iii) the sources and uses of funds to finance the proposed acquisition, and (iv) to the extent available, quarterly and annual audited financial statements of the Person whose Shares or assets are being acquired for the twelve (12) month period immediately prior to such proposed acquisition&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;such Permitted Acquisition shall only involve assets located in the United States&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(j)&#160;&#160;&#160;&#160;Collateral Agent and the Lenders have received a certificate from a Responsible Officer together with Board approved projections certifying and setting forth in reasonable detail that Borrower has enough cash on hand to pay its projected expenses and all debt service when due for a period of twelve (12) months after the consummation of such transaction (after giving effect to such transaction)&#59; and</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(k)&#160;&#160;&#160;&#160;such Permitted Acquisition shall be consensual and shall have been approved by the target&#8217;s board of directors.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Notwithstanding anything to the contrary contained herein, in order for any acquisition of Shares or assets of another Person to constitute a Permitted Acquisition, Borrower must comply with all of the following&#58; (a) within five (5) Business Days of the closing of such Permitted Acquisition, the applicable Borrower (or Subsidiary) making such Permitted Acquisition and the target shall have executed such documents and taken such actions as may be required under Section 6.12&#59; (b) the applicable Borrower shall have delivered to Collateral Agent and Lenders, in form and substance satisfactory to the Collateral Agent and Lenders and sufficiently in advance (and in any case no later than five (5) Business Days prior to such Permitted Acquisition), such other financial information, financial analysis, documentation or other information relating to such Permitted Acquisition and the pro forma certifications required by clause (c) below, in each case, as Collateral Agent and Lenders shall reasonably request&#59; (c) on or prior to the  date of such Permitted Acquisition, the Collateral Agent and Lenders shall have received, in form and substance reasonably satisfactory to the Collateral Agent and Lenders, a certificate of the chief financial officer of Borrower certifying compliance with the requirements contained in this definition of &#8220;Permitted Acquisition&#8221; and with the other terms of the Loan Documents (before and after giving effect to such Permitted Acquisition)&#59; and (d) Borrower shall provide to the Collateral Agent and Lenders as soon as available but in any event not later than five (5) Business Days after the execution thereof, a copy of the executed purchase agreement or similar agreement with respect to any such acquisition.&#8221;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Permitted Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Borrower&#8217;s Indebtedness to the Lenders and Collateral Agent under this Agreement and the other Loan Documents&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Indebtedness existing on the Effective Date and disclosed on the Perfection Certificate(s)&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;Subordinated Debt&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;unsecured Indebtedness to trade creditors incurred in the ordinary course of business&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;Indebtedness consisting of capitalized lease obligations and purchase money Indebtedness, in each case incurred by Borrower or any of its Subsidiaries solely to finance the acquisition, repair, improvement or construction of fixed or capital assets of such person, provided that (i) the aggregate outstanding principal amount of all such Indebtedness does not exceed One Million Dollars ($1,000,000.00)  at any time and (ii) the principal amount of such Indebtedness does not exceed the lower of the cost or fair market value of the property so acquired or built or of such repairs or improvements financed with such Indebtedness (each measured at the time of such acquisition, repair, improvement or construction is made)&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(f)&#160;&#160;&#160;&#160;Indebtedness incurred as a result of endorsing negotiable instruments received in the ordinary course of Borrower&#8217;s business&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(g)&#160;&#160;&#160;&#160;extensions, refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (e) above, provided that the principal amount thereof is not increased or the terms thereof are not modified to impose materially more burdensome terms upon Borrower, or its Subsidiary, as the case may be&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(h)&#160;&#160;&#160;&#160;Indebtedness of Borrower or any of its Subsidiaries with respect to corporate credit cards in an aggregate outstanding amount not to exceed One Million Dollars ($1,000,000.00) at any given time&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;Indebtedness relating to insurance premium financing arrangements, including relating to Borrower&#8217;s directors and officers policy in the ordinary course of business&#59; and </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(j)&#160;&#160;&#160;&#160;other Indebtedness not to exceed One Million Dollars ($1,000,000.00) in the aggregate at any one time outstanding.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Permitted Investments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Investments disclosed on the Perfection Certificate(s) and existing on the Effective Date&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;(i) Investments consisting of cash and Cash Equivalents held in Borrower&#8217;s Collateral Accounts that are maintained in accordance with Section 6.6 of this Agreement, and (ii) any other Investments permitted by Borrower&#8217;s investment policy, as amended from time to time, provided that such investment policy (and any such amendment thereto) has been approved in writing by Collateral Agent&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;Investments consisting of the endorsement of negotiable instruments for deposit or collection or similar transactions in the ordinary course of Borrower&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;Investments consisting of deposit accounts in which Collateral Agent has a perfected security interest&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;Investments in connection with Transfers permitted by Section 7.1&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(f)&#160;&#160;&#160;&#160;Investments consisting of (i) travel advances and employee relocation loans and other employee loans and advances in the ordinary course of business, and (ii) loans to employees, officers or directors </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">relating to the purchase of equity securities of Borrower or its Subsidiaries pursuant to employee stock purchase plans or agreements approved by Borrower&#8217;s Board of Directors not to exceed One Million Dollars ($1,000,000.00) in the aggregate for (i) and (ii) in any fiscal year&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(g)&#160;&#160;&#160;&#160;Investments (including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of business&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(h)&#160;&#160;&#160;&#160;Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and suppliers who are not Affiliates, in the ordinary course of business&#59; provided that this paragraph (h) shall not apply to Investments of Borrower in any Subsidiary&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;non-cash Investments in joint ventures or strategic alliances in the ordinary course of Borrower&#8217;s business consisting of the non&#8209;exclusive licensing of technology, the development of technology or the providing of technical support&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(j)&#160;&#160;&#160;&#160;Investments consisting of Permitted Acquisitions or Permitted Licenses&#59; </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(k)&#160;&#160;&#160;&#160;Investments by Borrower (i) in direct or indirect Subsidiaries, other than Lion, so long as Borrower and any such Subsidiary are in compliance with the requirements (and subject to the limitations) set forth in Section 6.12 and (ii) in Lion so long as such investments to do not exceed Ten Thousand Dollars ($10,000.00) in the aggregate in any fiscal year and so long as Borrower and&#47;or Lion, as applicable, are in compliance with the requirements (and subject to the limitations) set forth in Section 6.12 and Section 7.12&#59; and </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(l)&#160;&#160;&#160;&#160;other Investments not exceeding One Million Dollars ($1,000,000.00) in the aggregate in any given year&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, no Investment otherwise permitted by this </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">clause (k)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> shall be permitted to be made if any Event of Default has occurred and is continuing or would result therefrom.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Permitted Licenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are (A) licenses of over-the-counter software that is commercially available to the public, and (B) non-exclusive and exclusive licenses for the use of the Intellectual Property of Borrower or any of its Subsidiaries entered into in the ordinary course of business, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, that, with respect to each such license described in clause (B), (i) no Event of Default has occurred or is continuing at the time of such license&#59; (ii) the license constitutes an arms&#8217; length transaction, the terms of which, on their face, do not provide for a sale or assignment of any Intellectual Property and do not restrict the ability of Borrower or any of its Subsidiaries, as applicable, to pledge, grant a security interest in or lien on, or assign or otherwise Transfer any Intellectual Property&#59; (iii) in the case of any exclusive licenses, (x) Borrower delivers ten (10) days&#8217; prior written notice and a brief summary of the terms of the proposed license to Collateral Agent and the Lenders and delivers to Collateral Agent and the Lenders copies of the final executed licensing documents in connection with the exclusive license promptly upon consummation thereof, and (y) any such license could not result in a legal transfer of title of the licensed property but may be exclusive in respects other than territory and may be exclusive as to territory only as to discrete geographical areas outside of the United States&#59; and (iv) all upfront payments, royalties, milestone payments or other proceeds arising from the licensing agreement that are payable to Borrower or any of its Subsidiaries are paid to a Deposit Account that is governed by a Control Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Permitted Liens</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)&#160;&#160;&#160;&#160;Liens existing on the Effective Date and disclosed on the Perfection Certificates or  arising under this Agreement and the other Loan Documents&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)&#160;&#160;&#160;&#160;Liens for taxes, fees, assessments or other government charges or levies, either (i) not due and payable or (ii) being contested in good faith and for which Borrower maintains adequate reserves on its Books&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)&#160;&#160;&#160;&#160;liens securing Indebtedness permitted under clause (e) of the definition of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Permitted Indebtedness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">,&#8221; provided that (i) such liens exist prior to the acquisition of, or attach substantially simultaneous with, or within twenty (20) days after the, acquisition, lease, repair, improvement or construction of, such property </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">financed or leased by such Indebtedness and (ii) such liens do not extend to any property of Borrower other than the property (and proceeds thereof) acquired, leased or built, or the improvements or repairs, financed by such Indebtedness&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)&#160;&#160;&#160;&#160;Liens of materialmen, mechanics, carriers, warehousemen, suppliers, or other Persons that are possessory in nature arising in the ordinary course of business so long as such Liens attach only to Inventory, securing liabilities in the aggregate amount not to exceed Five Hundred Thousand Dollars ($500,000.00), and which are not delinquent or remain payable without penalty or which are being contested in good faith and by appropriate proceedings which proceedings have the effect of preventing the forfeiture or sale of the property subject thereto&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)&#160;&#160;&#160;&#160;Liens to secure payment of workers&#8217; compensation, employment insurance, old&#8209;age pensions, social security and other like obligations incurred in the ordinary course of business (other than Liens imposed by ERISA)&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(f)&#160;&#160;&#160;&#160;Liens incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) through (c), </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">but</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> any extension, renewal or replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness may not increase&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(g)&#160;&#160;&#160;&#160;leases or subleases of real property granted in the ordinary course of Borrower&#8217;s business (or, if referring to another Person, in the ordinary course of such Person&#8217;s business), and leases, subleases, non&#8209;exclusive licenses or sublicenses of personal property (other than Intellectual Property) granted in the ordinary course of Borrower&#8217;s business (or, if referring to another Person, in the ordinary course of such Person&#8217;s business), if the leases, subleases, licenses and sublicenses do not prohibit granting Collateral Agent or any Lender a security interest therein&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(h)&#160;&#160;&#160;&#160;banker&#8217;s liens, rights of setoff and Liens in favor of financial institutions incurred in the ordinary course of business arising in connection with Borrower&#8217;s deposit accounts or securities accounts held at such institutions solely to secure payment of fees and similar costs and expenses and provided such accounts are maintained in compliance with Section 6.6(b) hereof&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;Liens arising from judgments (or appeal or other surety bonds relating to such judgments), decrees or attachments in circumstances not constituting an Event of Default under Section 8.4 or 8.7&#59;</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(j)&#160;&#160;&#160;&#160;Liens consisting of Permitted Licenses&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(k)&#160;&#160;&#160;&#160;Liens solely on cash collateral pledged to secure Indebtedness in respect of corporate credit cards permitted pursuant to clause (d) of the definition of Permitted Indebtedness&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(l)&#160;&#160;&#160;&#160;deposits to secure the performance of leases entered into in the ordinary course of business and not representing an obligation for borrowed money so long as each such deposit is made at the commencement of a lease or its renewal when there is no underlying default under such lease&#59; </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(m)&#160;&#160;&#160;&#160;Liens granted in the ordinary course of business securing the financing of insurance premiums&#59; and </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(n)&#160;&#160;&#160;&#160;other Liens securing Indebtedness or other obligations permitted hereunder, in an aggregate amount at any time outstanding not to exceed One Million Dollars ($1,000,000.00).</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Post-Closing Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is that certain Post Closing Letter dated as of the Effective Date by and between Collateral Agent and Borrower.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Prepayment Fee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is, with respect to any Term Loan subject to prepayment prior to the Maturity Date, whether by mandatory or voluntary prepayment, acceleration or otherwise, an additional fee payable to the Lenders in amount equal to&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(i)&#160;&#160;&#160;&#160;for a prepayment made on or after the Funding Date of such Term Loan through and including the first anniversary of the Funding Date of such Term Loan, &#91;**&#93; of the principal amount of such Term Loan being prepaid&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(ii)&#160;&#160;&#160;&#160;for a prepayment made after the date which is after the first anniversary of the Funding Date of such Term Loan through and including the second anniversary of the Funding Date of such Term Loan, &#91;**&#93; of the principal amount of such Term Loan being prepaid&#59;</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iii)&#160;&#160;&#160;&#160;for a prepayment made after the date which is after the second anniversary of the Funding Date of such Term Loan through and including the third anniversary of the Funding Date of such Term Loan, &#91;**&#93; of the principal amount of such Term Loan being prepaid&#59; and</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(iv)&#160;&#160;&#160;&#160;for a prepayment made after the third anniversary of the Funding Date of such Term Loan or on the Maturity Date, no Prepayment Fee shall be applicable.</font></div><div style="text-align:justify;text-indent:108pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Pro Rata Share</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is, as of any date of determination, with respect to each Lender, a percentage (expressed as a decimal, rounded to the ninth decimal place) determined by dividing the outstanding principal amount of Term Loans held by such Lender by the aggregate outstanding principal amount of all Term Loans.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Register</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 2.4.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Registered Organization</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any &#8220;registered organization&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;Relevant Governmental Body&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">means the Federal Reserve Board and&#47;or the Federal Reserve Bank of New York, or a committee officially endorsed or convened by the Federal Reserve Board and&#47;or the Federal Reserve Bank of New York or any successor thereto. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Required Lenders</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means (i) for so long as all of the Persons that are Lenders on the Effective Date (each an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Original Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) have not assigned or transferred any of their interests in their Term Loan, Lenders holding one hundred percent (100%) of the aggregate outstanding principal balance of the Term Loan, or (ii) at any time from and after any Original Lender has assigned or transferred any interest in its Term Loan, Lenders holding at least sixty six percent (66%) of the aggregate outstanding principal balance of the Term Loan and, in respect of this clause (ii), (A) each Original Lender that has not assigned or transferred any portion of its Term Loan, (B) each assignee or transferee of an Original Lender&#8217;s interest in the Term Loan, but only to the extent that such assignee or transferee is an Affiliate or Approved Fund of such Original Lender, and (C) any Person providing financing to any Person described in clauses (A) and (B) above&#59; provided, however, that this clause (C) shall only apply upon the occurrence of a default, event of default or similar occurrence with respect to such financing.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Requirement of Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is as to any Person, the organizational or governing documents of such Person, and any law (statutory or common), treaty, rule or regulation or determination of an arbitrator or a court or other Governmental Authority, in each case applicable to or binding upon such Person or any of its property or to which such Person or any of its property is subject.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Responsible Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any of the President, Chief Executive Officer, or Chief Financial Officer of Borrower acting alone.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SEC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means the Securities and Exchange Commission.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Second Draw Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is the period commencing on the date Borrower achieves the Sotagliflozin NDA Milestone and ending on the earliest of (i) thirty (30) days thereafter&#59; (ii) August 31, 2022&#59; and (iii) the occurrence </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of an Event of Default&#59; provided, however, that the Second Draw Period shall not commence if on the date of the occurrence of the Sotagliflozin NDA Milestone an Event of Default has occurred and is continuing.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Secured Promissory Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 2.4.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Secured Promissory Note Record</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is a record maintained by each Lender with respect to the outstanding Obligations owed by Borrower to Lender and credits made thereto.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Securities Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is any &#8220;securities account&#8221; as defined in the Code with such additions to such term as may hereafter be made.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is one hundred percent (100%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by Borrower or Borrower&#8217;s Subsidiary, in any Subsidiary&#59; provided that, in the event Borrower demonstrates to Collateral Agent&#8217;s reasonable satisfaction, that a pledge of more than sixty-five percent (65%) of the Shares of such Subsidiary which is a Foreign Subsidiary, creates (or will create, immediately after (and as a result of) giving effect to such pledge) a present and existing adverse tax consequence to Borrower under the U.S. Internal Revenue Code, &#8220;Shares&#8221; shall mean sixty&#8209;five percent (65%) of the issued and outstanding capital stock, membership units or other securities owned or held of record by Borrower or its Subsidiary in such Foreign Subsidiary. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#8220;SOFR&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with respect to any day means the secured overnight financing rate published for such day by the Federal Reserve Bank of New York, as the administrator of the benchmark, (or a successor administrator) on the Federal Reserve Bank of New York&#8217;s Website.  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Solvent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is, with respect to any Person&#58; the fair salable value of such Person&#8217;s consolidated assets (including goodwill minus disposition costs) exceeds the fair value of such Person&#8217;s liabilities&#59; such Person is not left with unreasonably small capital after the transactions in this Agreement&#59; and such Person is able to pay its debts (including trade debts) as they mature.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Sotagliflozin NDA Milestone</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means the FDA&#8217;s acceptance of Borrower&#8217;s planned resubmission of the Sotagliflozin NDA for an indication that is no narrower in scope than to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with Type-2 diabetes with either worsening heart failure or additional risk factors for heart failure irrespective of left ventricular ejection fraction (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Heart Failure Indication</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;)&#59; written evidence of which must be provided to, reviewed and approved in writing by Collateral Agent.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Sotagliflozin FDA Approval</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means the FDA&#8217;s approval of the Sotagliflozin NDA for an indication that is no narrower in scope than the Heart Failure Indication&#59; written evidence of which must be provided to, reviewed and approved in writing by Collateral Agent.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Subordinated Debt</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is indebtedness incurred by Borrower or any of its Subsidiaries subordinated to all Indebtedness of Borrower and&#47;or its Subsidiaries to the Lenders (pursuant to a subordination, intercreditor, or other similar agreement in form and substance satisfactory to Collateral Agent and the Lenders entered into between Collateral Agent, Borrower, and&#47;or any of its Subsidiaries, and the other creditor), on terms acceptable to Collateral Agent and the Lenders.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is, with respect to any Person, any Person of which more than fifty percent (50%) of the voting stock or other equity interests (in the case of Persons other than corporations) is owned or controlled, directly or indirectly, by such Person or through one or more intermediaries.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term A Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 2.2(a)(i) hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term B Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 2.2(a)(ii) hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term C Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 2.2(a)(iii) hereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term D Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 2.2(a)(iv) hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 2.2(a)(iv) hereof.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loan Commitment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is, for any Lender, the obligation of such Lender to make a Term Loan, up to the principal amount shown on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Schedule 1.1</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loan Commitments</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means the aggregate amount of such commitments of all Lenders.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Third Draw Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is the period commencing on the date of Sotagliflozin FDA Approval and ending on the earliest of (i) sixty (60) days thereafter&#59; (ii) June 30, 2023&#59; and (iii) the occurrence of an Event of Default&#59; provided, however, that the Second Draw Period shall not commence if on the date of the occurrence of Sotagliflozin FDA Approval an Event of Default has occurred and is continuing.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Trademarks</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Borrower connected with and symbolized by such trademarks.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; is defined in Section 7.1.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">U.S. Person</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means any Person that is a &#8220;United States Person&#8221; as defined in Section 7701(a)(30) of the Internal Revenue Code.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; are those certain Warrants to Purchase Stock dated as of the Effective Date, or any date thereafter, issued by Borrower in favor of each Lender or such Lender&#8217;s Affiliates&#59; provided that any Warrants issued after the Effective Date shall be on substantially the same form as the Warrants issued as of the Effective Date.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">IN WITNESS WHEREOF</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the parties hereto have caused this Agreement to be executed as of the Effective Date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS (NEW JERSEY), INC.<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58;<br>Name&#58; Jeffrey L. Wade<br>Title&#58; President and Chief Financial Officer<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"><br></font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS, INC.</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By _________________________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58; Jeffrey L. Wade</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58; President and Chief Financial Officer</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS (NEW JERSEY), INC.<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58; ________________________________<br>Name&#58; Jeffrey L. Wade<br>Title&#58; President and Chief Financial Officer<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br></font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Signature Page to Loan and Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93; </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Signatures Continued, Next Page</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">COLLATERAL AGENT&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By _______________________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Senior Vice President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LENDER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By _______________________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; Senior Vice President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">LENDER&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">OXFORD FINANCE CREDIT FUND III, LP</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By&#58; Oxford Finance Advisors, LLC, its manager</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">____________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; Colette H. Featherly</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Its&#58; Senior Vice President</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Signature Page to Loan and Security Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SCHEDULE 1.1  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Lenders and Commitments</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term A Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lender</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loan Commitment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$21,250,000.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">85.00%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OXFORD FINANCE CREDIT FUND III, LP</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$3,750,000.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">15.00%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$25,000,000.00</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">100.00%</font></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term B Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lender</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loan Commitment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$25,000,000.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100.00%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$25,000,000.00</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">100.00%</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term C Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lender</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loan Commitment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$50,000,000.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100.00%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$50,000,000.00</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">100.00%</font></td></tr></table></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term D Loans</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lender</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loan Commitment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$50,000,000.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">100.00%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$50,000,000.00</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">100.00%</font></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Aggregate (all Term Loans)</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lender</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Term Loan Commitment</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Commitment Percentage</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$146,250,000.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">97.50%</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OXFORD FINANCE CREDIT FUND III, LP</font></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$3,750,000.00</font></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.50%</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TOTAL</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$150,000,000.00</font></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">100.00%</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT A  </font></div><div style="padding-right:-2.25pt;text-align:center"><font><br></font></div><div style="padding-right:-2.25pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Description of Collateral</font></div><div style="padding-right:-2.25pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Collateral consists of all of Borrower&#8217;s right, title and interest in and to the following personal property&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All goods, Accounts (including health&#8209;care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (including all Intellectual Property), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All Borrower&#8217;s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT B </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Form of Disbursement Letter</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;see attached&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DISBURSEMENT LETTER</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 17, 2022</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The undersigned, being the duly elected and acting </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                             </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of LEXICON PHARMACEUTICALS, INC., a Delaware corporation with offices located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, TX  77381 (for itself and each Borrower identified in the Loan Agreement (as defined below), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), does hereby certify to </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">OXFORD FINANCE LLC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Oxford</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; and &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), as collateral agent on behalf of the Lenders from time to time party to (and as defined in) the Loan Agreement (as defined below&#59; the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Collateral Agent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) in connection with that certain Loan and Security Agreement dated as of March 17, 2022, by and among Borrower, Collateral Agent and the Lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;&#59; with other capitalized terms used below having the meanings ascribed thereto in the Loan Agreement) that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.             The representations and warranties made by Borrower in Section 5 of the Loan Agreement and in the other Loan Documents are true and correct in all material respects as of the date hereof&#59; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof&#59; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.             No event or condition has occurred constitutes an Event of Default under the Loan Agreement or any other Loan Document.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.             Borrower is in compliance with the covenants and requirements contained in Sections 4, 6 and 7 of the Loan Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.             All conditions referred to in Section 3 of the Loan Agreement to the making of the Loan to be made on or about the date hereof have been satisfied or waived by Collateral Agent.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.             No Material Adverse Change has occurred.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6.             The undersigned is a Responsible Officer.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#91;Balance of Page Intentionally Left Blank&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">7.&#160;&#160;&#160;&#160;The proceeds of the Term &#91;A&#93;&#91;B&#93;&#91;C&#93; Loan shall be disbursed as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:71.627%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.173%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Disbursement from Oxford&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:12.6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Loan Amount</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$25,000,000.00</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:24.6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Plus&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:24.6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8209;&#8209;Deposit Received</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$&#91;**&#93;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:24.6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Less&#58;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:24.6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8209;&#8209;Facility Fee</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">($&#91;**&#93;)</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;text-indent:24.6pt;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8209;&#8209;Lender&#8217;s Legal Fees</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">($_________)</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">*</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">TOTAL TERM &#91;A&#93;&#91;B&#93;&#91;C&#93; LOAN NET PROCEEDS FROM LENDERS</font></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">$_______________</font></td></tr></table></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8.&#160;&#160;&#160;&#160;The Term &#91;A&#93;&#91;B&#93;&#91;C&#93; Loan shall amortize in accordance with the Amortization Table attached hereto.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9.&#160;&#160;&#160;&#160;The aggregate net proceeds of the Term Loans shall be transferred to the Designated Deposit Account as follows&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.615%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:68.597%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Account Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bank Name&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Bank Address&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;**&#93;<br>&#91;**&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Account Number&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;**&#93;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ABA Number&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;**&#93;</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#91;Balance of Page Intentionally Left Blank&#93;</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_____________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">* Legal fees and costs are through the Effective Date.  Post&#8209;closing legal fees and costs, payable after the Effective Date, to be invoiced and paid post&#8209;closing.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Dated as of the date first set forth above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">BORROWER&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS, INC.,<br>for itself and on behalf of each Borrower</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By ________________________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; _____________________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Title&#58; ______________________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">COLLATERAL AGENT&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC, as Collateral Agent on behalf of the Lenders</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">By ________________________________</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Name&#58; Colette H. Featherly</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Its&#58; Senior Vice President</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Signature Page to Disbursement Letter</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">AMORTIZATION TABLE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Term &#91;A&#93;&#91;B&#93;&#91;C&#93; Loan)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;**&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT C  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Compliance Certificate</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.264%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TO&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">OXFORD FINANCE LLC, as Collateral Agent and Lender <br>OXFORD FINANCE CREDIT FUND III, LP, as Lender</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FROM&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS, INC., <br>for itself and on behalf of each Borrower</font></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The undersigned authorized officer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Officer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) of LEXICON PHARMACEUTICALS, INC. (for itself and on behalf of each Borrower party to the Loan Agreement (as defined below), &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;), hereby certifies that in accordance with the terms and conditions of the Loan and Security Agreement by and among Borrower, Collateral Agent, and the Lenders from time to time party thereto (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#59;&#8221; capitalized terms used but not otherwise defined herein shall have the meanings given them in the Loan Agreement),</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a)           Borrower is in complete compliance for the period ending _______________ with all required covenants except as noted below&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(b)           There are no Events of Default, except as noted below&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(c)           Except as noted below, all representations and warranties of Borrower stated in the Loan Documents are true and correct in all material respects on this date and for the period described in (a), above&#59; provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that already are qualified or modified by materiality in the text thereof&#59; and provided, further that those representations and warranties expressly referring to a specific date shall be true, accurate and complete in all material respects as of such date.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)           Borrower, and each of Borrower&#8217;s Subsidiaries, has timely filed all required tax returns and reports, Borrower, and each of Borrower&#8217;s Subsidiaries, has timely paid all foreign, federal, state, and local taxes, assessments, deposits and contributions owed by Borrower, or Subsidiary, except as otherwise permitted pursuant to the terms of Section 5.8 of the Loan Agreement&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(e)           No Liens have been levied or claims made against Borrower or any of its Subsidiaries relating to unpaid employee payroll or benefits of which Borrower has not previously provided written notification to Collateral Agent and the Lenders.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Attached are the required documents, if any, supporting our certification(s).  The Officer, on behalf of Borrower, further certifies that the attached financial statements are prepared in accordance with Generally Accepted Accounting Principles (GAAP) and are consistently applied from one period to the next except as explained in an accompanying letter or footnotes and except, in the case of unaudited financial statements, for the absence of footnotes and subject to year&#8209;end audit adjustments as to the interim financial statements.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Please indicate compliance status since the last Compliance Certificate by circling Yes, No, or N&#47;A under &#8220;Complies&#8221; column.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Reporting Covenant</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Requirement</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Actual</font></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complies</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Financial statements</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quarterly within 45 days</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Annual (CPA Audited) <br>statements</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Within 90 days after FYE</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Annual Financial Projections&#47;Budget (prepared on a monthly basis)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Annually (within 45 days of FYE), and when revised</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.601%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.502%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A&#47;R &#38; A&#47;P agings</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If applicable</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">5)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">8&#8209;K, 10&#8209;K and 10&#8209;Q Filings</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If applicable, within 5 days of filing</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">6)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compliance Certificate</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Quarterly within 45 days</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">7)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IP Report</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">When required</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">8)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total amount of Borrower&#8217;s cash and cash equivalents at the last day of the measurement period</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">9)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Total amount of Borrower&#8217;s Subsidiaries&#8217; cash and cash equivalents at the last day of the measurement period</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">N&#47;A</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Deposit and Securities Accounts</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">(Please list all accounts&#59; attach separate sheet if additional space needed)</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.209%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Institution Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Account Number</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">New Account&#63;</font></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Account Control Agreement in place&#63;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">1)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Financial Covenants</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.163%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.321%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Covenant</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Requirement</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Actual</font></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Compliance</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Minimum Net Product Revenue<br>(trailing &#91;**&#93; or (if applicable) &#91;**&#93;)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">See Section 6.10&#59; Annex X</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Other Matters</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.707%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.427%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">1)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Have there been any changes in management since the last Compliance Certificate&#63;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">2)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Have there been any transfers&#47;sales&#47;disposals&#47;retirement of Collateral or IP prohibited by the Loan Agreement&#63;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td></tr><tr style="height:16pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">3)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Have there been any new or pending claims or causes of action against Borrower that involve more than Five Hundred Thousand Dollars ($500,000.00)&#63;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">4)</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Have there been any material amendments of or other material changes to the capitalization table of Borrower and to the Operating Documents of Borrower or any of its Subsidiaries&#63; If yes, provide copies of any such amendments or changes with this Compliance Certificate.</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Yes</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">No</font></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Exceptions</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Please explain any exceptions with respect to the certification above&#58; (If no exceptions exist, state &#8220;No exceptions.&#8221;  Attach separate sheet if additional space needed.)</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS, INC., </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for itself and on behalf of each Borrower</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By  _________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">                                            </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;  _______________________</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Date&#58;  _______________________</font></div><div><font><br></font></div><div><font><br></font></div><div style="padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LENDER USE ONLY</font></div><div style="padding-left:252pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Received by&#58; ____________________  Date&#58; ______</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Verified by&#58; ____________________    Date&#58; ______</font></div><div style="padding-left:216pt;text-indent:36pt"><font><br></font></div><div style="padding-left:216pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Compliance Status&#58; &#160;&#160;&#160;&#160;Yes &#160;&#160;&#160;&#160;No</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">ANNEX X</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(Projected Net Product Revenue)  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;**&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT D</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Form of Secured Promissory Note</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;see attached&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">THIS NOTE IS BEING ISSUED WITH ORIGINAL ISSUE DISCOUNT FOR UNITED STATES FEDERAL INCOME TAX PURPOSES.  FOR INFORMATION REGARDING THE ISSUE PRICE, THE TOTAL AMOUNT OF ORIGINAL ISSUE DISCOUNT, THE ISSUE DATE, AND THE YIELD TO MATURITY OF THE NOTE, PLEASE CONTACT BRIAN CRUM, GENERAL COUNSEL, FAX&#58;  (281) 863-8010, EMAIL&#58; BCRUM&#64;LEXPHARMA.COM</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SECURED PROMISSORY NOTE </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(Term A Loan)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$&#91;10,000,000.00&#93;&#91;11,250,000.00&#93;&#91;3,750,000.00&#93;                                                                        Dated&#58;  March 17, 2022</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">FOR VALUE RECEIVED, the undersigned, LEXICON PHARMACEUTICALS, INC. and LEXICON PHARMACEUTICALS (NEW JERSEY), INC., each a Delaware corporation with offices located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, TX  77381 (individually and collectively, jointly and severally, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Borrower</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) HEREBY PROMISES TO PAY to &#91;OXFORD FINANCE LLC&#93;&#91; OXFORD FINANCE CREDIT FUND III, LP&#93; or its registered assigns (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Lender</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;) the principal amount of &#91;TEN MILLION DOLLARS ($10,000,000.00)&#93;&#91;ELEVEN MILLION TWO HUNDRED FIFTY THOUSAND DOLLARS ($11,250,000.00)&#93;&#91;THREE MILLION SEVEN HUNDRED FIFTY THOUSAND DOLLARS ($3,750,000.00)&#93; or such lesser amount as shall equal the outstanding principal balance of the Term A Loan made to Borrower by Lender, plus interest on the aggregate unpaid principal amount of such Term A Loan, at the rates and in accordance with the terms of the Loan and Security Agreement dated March 17, 2022 by and among Borrower, Lender, Oxford Finance LLC, as Collateral Agent, and the other Lenders from time to time party thereto (as amended, restated, supplemented or otherwise modified from time to time, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Loan Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).  If not sooner paid, the entire principal amount and all accrued and unpaid interest hereunder shall be due and payable on the Maturity Date as set forth in the Loan Agreement.  Any capitalized term not otherwise defined herein shall have the meaning attributed to such term in the Loan Agreement.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Principal, interest and all other amounts due with respect to the Term A Loan, are payable in lawful money of the United States of America to Lender as set forth in the Loan Agreement and this Secured Promissory Note (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Note</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8221;).  The principal amount of this Note and the interest rate applicable thereto, and all payments made with respect thereto, shall be recorded by Lender and, prior to any transfer hereof, endorsed on the grid attached hereto which is part of this Note.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Loan Agreement, among other things, (a) provides for the making of a secured Term A Loan by Lender to Borrower, and (b) contains provisions for acceleration of the maturity hereof upon the happening of certain stated events.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Note may not be prepaid except as set forth in Section 2.2 (c) and Section 2.2(d) of the Loan Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Note and the obligation of Borrower to repay the unpaid principal amount of the Term A Loan, interest on the Term A Loan and all other amounts due Lender under the Loan Agreement is secured under the Loan Agreement.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Presentment for payment, demand, notice of protest and all other demands and notices of any kind in connection with the execution, delivery, performance and enforcement of this Note are hereby waived.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrower shall pay all reasonable fees and expenses, including, without limitation, reasonable attorneys&#8217; fees and costs, incurred by Lender in the enforcement or attempt to enforce any of Borrower&#8217;s obligations hereunder not performed when due.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This Note shall be governed by, and construed and interpreted in accordance with, the internal laws of the State of New York.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The ownership of an interest in this Note shall be registered in the Register.  Notwithstanding anything else in this Note to the contrary, the right to the principal of, and stated interest on, this Note may be transferred only if the transfer is registered in the Register the transferee is identified as the owner of an interest in the obligation.  </font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Borrower shall be entitled to treat the registered holder of this Note (as recorded on such record of ownership) as the owner in fact thereof for all purposes and shall not be bound to recognize any equitable or other claim to or interest in this Note on the part of any other person or entity.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">&#91;Balance of Page Intentionally Left Blank&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">IN WITNESS WHEREOF, Borrower has caused this Note to be duly executed by one of its officers thereunto duly authorized on the date hereof.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.055%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BORROWER&#58;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS, INC.</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By _____________________________________</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Name&#58;  __________________________________</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Title&#58;  ___________________________________<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS (NEW JERSEY), INC.<br></font><font style="font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">By&#58; <br>Name&#58;  __________________________________<br>Title&#58;  ___________________________________</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LOAN INTEREST RATE AND PAYMENTS OF PRINCIPAL</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.878%"><tr><td style="width:1.0%"></td><td style="width:19.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.862%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.159%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Date</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Principal Amount</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Interest Rate</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Scheduled Payment </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Amount</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Notation By</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">CORPORATE BORROWING CERTIFICATE</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BORROWER&#58;  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS, INC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DATE&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 17, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LENDER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58;  &#160;&#160;&#160;&#160;OXFORD FINANCE LLC, as Collateral Agent and Lender</font></div><div style="padding-left:36pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">OXFORD FINANCE CREDIT FUND III, LP, as Lender</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I hereby certify as follows, as of the date set forth above&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">1.             I am the Secretary, Assistant Secretary or other officer of Borrower.  My title is as set forth below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2.             Borrower&#8217;s exact legal name is set forth above.  Borrower is a corporation existing under the laws of the State of Delaware.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3.             Attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, respectively, are true, correct and complete copies of (i) Borrower&#8217;s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above&#59; and (ii) Borrower&#8217;s Bylaws.  Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">4.             The following resolutions were duly and validly adopted by Borrower&#8217;s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action).  Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them until each Lender receives written notice of revocation from Borrower.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">any one </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 16.75pt;text-align:center;text-indent:31.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Signature</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized to Add or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Remove Signatories</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">any one</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that such individuals may, on behalf of Borrower&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Borrow Money</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Borrow money from the Lenders.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Execute Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Execute any loan documents any Lender requires. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Grant Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Grant Collateral Agent a security interest in any of Borrower&#8217;s assets.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Negotiate Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Issue Warrants</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Issue warrants for Borrower&#8217;s capital stock.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Further Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower&#8217;s right to a jury trial) they believe to be necessary to effectuate such resolutions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RESOLVED FURTHER,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.             The persons listed above are Borrower&#8217;s officers or employees with their titles and signatures shown next to their names.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LEXICON PHARMACEUTICALS, INC.</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">By&#58;  _____________________________________________</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name&#58;  ___________________________________________</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title&#58;  ____________________________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I, the __________________________ of Borrower, hereby certify as to paragraphs 1 through 5 above, as </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                          &#91;print title&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the date set forth above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">By&#58;  _____________________________________________</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name&#58;  ___________________________________________</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title&#58;  ____________________________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Signature Page to Corporate Borrowing Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT A </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Certificate of Incorporation (including amendments)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;see attached&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT B  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Bylaws</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;see attached&#93;</font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CORPORATE BORROWING CERTIFICATE</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">BORROWER&#58;  &#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEXICON PHARMACEUTICALS, INC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;DATE&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">March 17, 2022</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">LENDER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#58;  &#160;&#160;&#160;&#160;OXFORD FINANCE LLC, as Collateral Agent and Lender</font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I hereby certify as follows, as of the date set forth above&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.&#160;&#160;&#160;&#160;I am the Secretary, Assistant Secretary or other officer of Borrower.  My title is as set forth below.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">2.&#160;&#160;&#160;&#160;Borrower&#8217;s exact legal name is set forth above.  Borrower is a corporation existing under the laws of the State of Delaware.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.&#160;&#160;&#160;&#160;Attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, respectively, are true, correct and complete copies of (i) Borrower&#8217;s Certificate of Incorporation (including amendments), as filed with the Secretary of State of the state in which Borrower is incorporated as set forth in paragraph 2 above&#59; and (ii) Borrower&#8217;s Bylaws.  Neither such Certificate of Incorporation nor such Bylaws have been amended, annulled, rescinded, revoked or supplemented, and such Certificate of Incorporation and such Bylaws remain in full force and effect as of the date hereof.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.&#160;&#160;&#160;&#160;The following resolutions were duly and validly adopted by Borrower&#8217;s Board of Directors at a duly held meeting of such directors (or pursuant to a unanimous written consent or other authorized corporate action).  Such resolutions are in full force and effect as of the date hereof and have not been in any way modified, repealed, rescinded, amended or revoked, and the Lenders may rely on them until each Lender receives written notice of revocation from Borrower.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RESOLVED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">any one </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the following officers or employees of Borrower, whose names, titles and signatures are below, may act on behalf of Borrower&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.669%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.412%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.746%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 16.75pt;text-align:center;text-indent:31.5pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Signature</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Authorized to Add or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Remove Signatories</font></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_______________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">______________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">_____________________</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:400;line-height:100%">&#9633;</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">any one</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of the persons designated above with a checked box beside his or her name may, from time to time, add or remove any individuals to and from the above list of persons authorized to act on behalf of Borrower.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RESOLVED FURTHER, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that such individuals may, on behalf of Borrower&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Borrow Money</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Borrow money from the Lenders.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Execute Loan Documents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Execute any loan documents any Lender requires. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Grant Security</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Grant Collateral Agent a security interest in any of Borrower&#8217;s assets.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Negotiate Items</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Negotiate or discount all drafts, trade acceptances, promissory notes, or other indebtedness in which Borrower has an interest and receive cash or otherwise use the proceeds.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Further Acts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.  Designate other individuals to request advances, pay fees and costs and execute other documents or agreements (including documents or agreement that waive Borrower&#8217;s right to a jury trial) they believe to be necessary to effectuate such resolutions.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">RESOLVED FURTHER,</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> that all acts authorized by the above resolutions and any prior acts relating thereto are ratified.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Balance of Page Intentionally Left Blank</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">5.             The persons listed above are Borrower&#8217;s officers or employees with their titles and signatures shown next to their names.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LEXICON PHARMACEUTICALS, (NEW JERSEY) INC.</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">By&#58;  _____________________________________________</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name&#58;  ___________________________________________</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title&#58;  ____________________________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">*** If the Secretary, Assistant Secretary or other certifying officer executing above is designated by the resolutions set forth in paragraph 4 as one of the authorized signing officers, this Certificate must also be signed by a second authorized officer or director of Borrower.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">I, the __________________________ of Borrower, hereby certify as to paragraphs 1 through 5 above, as </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">                          &#91;print title&#93;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">of the date set forth above.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">By&#58;  _____________________________________________</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Name&#58;  ___________________________________________</font></div><div style="text-align:justify;text-indent:216pt"><font><br></font></div><div style="text-align:justify;text-indent:216pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Title&#58;  ____________________________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Signature Page to Corporate Borrowing Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT A  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Certificate of Incorporation (including amendments)</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;see attached&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT B  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Bylaws</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#91;see attached&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">DEBTOR&#58;   &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;LEXICON PHARMACEUTICALS, INC. AND     </font></div><div style="padding-left:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">LEXICON PHARMACEUTICALS (NEW JERSEY), INC.  </font></div><div style="padding-left:108pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">SECURED PARTY&#58; &#160;&#160;&#160;&#160;OXFORD FINANCE LLC, as Collateral Agent</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">EXHIBIT A TO UCC FINANCING STATEMENT  </font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%;text-decoration:underline">Description of Collateral</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Collateral consists of all of Debtor&#8217;s right, title and interest in and to the following personal property&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All goods, Accounts (including health&#8209;care receivables), Equipment, Inventory, contract rights or rights to payment of money, leases, license agreements, franchise agreements, General Intangibles (including all Intellectual Property), commercial tort claims, documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts and other Collateral Accounts, all certificates of deposit, fixtures, letters of credit rights (whether or not the letter of credit is evidenced by a writing), securities, and all other investment property, supporting obligations, and financial assets, whether now owned or hereafter acquired, wherever located&#59; and</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">All Borrower&#8217;s Books relating to the foregoing, and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div><font><br></font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Capitalized terms used but not defined herein have the meanings ascribed in the Uniform Commercial Code in effect in the State of New York as in effect from time to time (the &#8220;Code&#8221;) or, if not defined in the Code, then in the Loan and Security Agreement by and between Debtor, Secured Party and the other Lenders party thereto (as modified, amended and&#47;or restated from time to time). </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">DMS 22024654.13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>exh311certificationofprinc.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id6d09853430a4fe79337e1b8a9453a7a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Lonnel Coats, certify that&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022 </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:46.599%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.201%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>exh312certificationofprinc.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8671077f51354047915bf6ab40750c80_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:10pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:10pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Jeffrey L. Wade, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q of Lexicon Pharmaceuticals, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;  </font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; May&#160;5, 2022 </font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:51.023%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>exh321certificationofprinc.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i88bd54f3cf74483192e0b8fc39e836ca_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350, as adopted), Lonnel Coats, Principal Executive Officer of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221;), and Jeffrey L. Wade, Principal Financial Officer of Lexicon, each hereby certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">Lexicon's Quarterly Report on Form 10-Q for the period ended March&#160;31, 2022, and to which this Certification is attached as Exhibit 32.1 (the &#8220;Periodic Report&#8221;), fully complies with the requirements of section 13(a) or section 15(d) of the Securities Exchange Act of 1934, and </font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:28.5pt">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of Lexicon. </font></div><div style="margin-bottom:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the undersigned have set their hands hereto as of the 5th day of May, 2022.</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.432%"><tr><td style="width:1.0%"></td><td style="width:7.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.833%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lonnel Coats</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:56.286%"><tr><td style="width:1.0%"></td><td style="width:8.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jeffrey L. Wade</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">President and Chief Financial Officer</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"> </font></div></td></tr></table></div><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>lxrx-20220331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d7a1dbc6-b99b-4a1d-848b-92cec6605016,g:574c9470-43fb-4b26-864a-707e5ed846fe-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lxrx="http://www.lexpharma.com/20220331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.lexpharma.com/20220331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lxrx-20220331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation">
        <link:definition>0001001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited">
        <link:definition>1001002 - Statement - Consolidated Balance Sheets-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals">
        <link:definition>1002003 - Statement - Consolidated Balance Sheets Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited">
        <link:definition>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossParentheticals" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals">
        <link:definition>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
        <link:definition>1006007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNotes" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables">
        <link:definition>2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
        <link:definition>2404401 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
        <link:definition>2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails">
        <link:definition>2408405 - Disclosure - Summary of Significant Accounting Policies Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RecentAccountingPronouncementsLevel1Notes" roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes">
        <link:definition>2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestments" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments">
        <link:definition>2110103 - Disclosure - Cash and Cash Equivalents and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsTables" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables">
        <link:definition>2311302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails1" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1">
        <link:definition>2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandCashEquivalentsandInvestmentsDetails2" roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2">
        <link:definition>2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.lexpharma.com/role/FairValueMeasurements">
        <link:definition>2114104 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables">
        <link:definition>2315303 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1">
        <link:definition>2416408 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligations" roleURI="http://www.lexpharma.com/role/DebtObligations">
        <link:definition>2117105 - Disclosure - Debt Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsTables" roleURI="http://www.lexpharma.com/role/DebtObligationsTables">
        <link:definition>2318304 - Disclosure - Debt Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtObligationsDetails" roleURI="http://www.lexpharma.com/role/DebtObligationsDetails">
        <link:definition>2419409 - Disclosure - Debt Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies">
        <link:definition>2120106 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails">
        <link:definition>2421410 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements">
        <link:definition>2122107 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>2323305 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsDetails" roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails">
        <link:definition>2424411 - Disclosure - Collaboration and License Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreements" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements">
        <link:definition>2125108 - Disclosure - Other Capital Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherCapitalAgreementsDetails" roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails">
        <link:definition>2426412 - Disclosure - Other Capital Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="lxrx_TermLoanAInterestExpense" abstract="false" name="TermLoanAInterestExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ProceedsFromNov2020ATMOffering" abstract="false" name="ProceedsFromNov2020ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_GainOnSaleOfNonFinancialAssets" abstract="false" name="GainOnSaleOfNonFinancialAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" abstract="true" name="ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SharesSoldInJanuary2021ATMOffering" abstract="false" name="SharesSoldInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeRemainingNotes" abstract="false" name="ConvertibleDebtExchangeRemainingNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedResearchAndDevelopmentServicesCurrent" abstract="false" name="AccruedResearchAndDevelopmentServicesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanANetCashReceipt" abstract="false" name="TermLoanANetCashReceipt" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberCashPortion" abstract="false" name="ConvertibleDebtExchangeSeptemberCashPortion" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_InitialRecognitionOfRightOfUseAsset" abstract="false" name="InitialRecognitionOfRightOfUseAsset" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanA" abstract="false" name="TermLoanA" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanDWarrant" abstract="false" name="TermLoanDWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" abstract="false" name="IpsenRevenueAllocatedtoDevelopmentDeliverable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_FairValueMeasurementsAbstract" abstract="true" name="FairValueMeasurementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_Lxrx_Sanofiterminationcashpayment" abstract="false" name="Lxrx_Sanofiterminationcashpayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SettlementPaymentFromTermination" abstract="false" name="SettlementPaymentFromTermination" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInNov2020ATMOffering" abstract="false" name="SharesSoldInNov2020ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_A2026OxfordPrincipalPayments" abstract="false" name="A2026OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesLineItems" abstract="true" name="AccruedLiabilitiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_TermLoanAFinalPayment" abstract="false" name="TermLoanAFinalPayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OtherCapitalAgreementsTextBlock" abstract="false" name="OtherCapitalAgreementsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" abstract="false" name="StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAWarrantsNumber" abstract="false" name="TermLoanAWarrantsNumber" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_IpsenMilestonePaymentReceived" abstract="false" name="IpsenMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_A2025OxfordPrincipalPayments" abstract="false" name="A2025OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ConsolidatedBalanceSheetsAbstract" abstract="true" name="ConsolidatedBalanceSheetsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfOperationsAbstract" abstract="true" name="ConsolidatedStatementsOfOperationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ProceedsFromSeptember2021ATMOffering" abstract="false" name="ProceedsFromSeptember2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SummaryOfSignificantAccountingPoliciesAbstract" abstract="true" name="SummaryOfSignificantAccountingPoliciesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_FinalPaymentWithExtention" abstract="false" name="FinalPaymentWithExtention" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_AccruedInterestOnConvertible" abstract="false" name="AccruedInterestOnConvertible" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanD" abstract="false" name="TermLoanD" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SanofiDisputedCosts" abstract="false" name="SanofiDisputedCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedCompensationAndBenefitsCurrent" abstract="false" name="AccruedCompensationAndBenefitsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Netproductrevenue" abstract="false" name="Netproductrevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Sellinggeneralandadministrativeexpenses" abstract="false" name="Sellinggeneralandadministrativeexpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeSeptemberSharePayment" abstract="false" name="ConvertibleDebtExchangeSeptemberSharePayment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" abstract="false" name="ConvertibleDebtExchangeTotalPrincipalAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ProceedsFromJanuary2021ATMOffering" abstract="false" name="ProceedsFromJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" abstract="false" name="Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_DebtObligationsAbstract" abstract="true" name="DebtObligationsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesDomain" abstract="true" name="AccruedLiabilitiesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="lxrx_TermLoanB" abstract="false" name="TermLoanB" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesAxis" abstract="true" name="AccruedLiabilitiesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_TermLoanABWarrant" abstract="false" name="TermLoanABWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_AccruedLiabilitiesTable" abstract="true" name="AccruedLiabilitiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_A2027OxfordPrincipalPayments" abstract="false" name="A2027OxfordPrincipalPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_IpsenMilestonePayment" abstract="false" name="IpsenMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanC" abstract="false" name="TermLoanC" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_OxfordLoanFacility" abstract="false" name="OxfordLoanFacility" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanADebtDiscount" abstract="false" name="TermLoanADebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" abstract="true" name="ConsolidatedStatementsOfStockholdersEquityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_IpsenMaximumSalesMilestones" abstract="false" name="IpsenMaximumSalesMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanCWarrant" abstract="false" name="TermLoanCWarrant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchangeShares" abstract="false" name="FutureConvertibleDebtExchangeShares" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SharePriceInSeptember2021ATMOfferring" abstract="false" name="SharePriceInSeptember2021ATMOfferring" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanAWarrantExercisePrice" abstract="false" name="TermLoanAWarrantExercisePrice" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="lxrx_OxfordFacilityFee" abstract="false" name="OxfordFacilityFee" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="lxrx_FutureConvertibleDebtExchange" abstract="false" name="FutureConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharePriceInNovember20ATMOffering" abstract="false" name="SharePriceInNovember20ATMOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ConvDebtInstrumentInterestRateStatedPercentage" abstract="false" name="ConvDebtInstrumentInterestRateStatedPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_IpsenRevenueRecognized" abstract="false" name="IpsenRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_LiabilitiesAssumedByTerSera" abstract="false" name="LiabilitiesAssumedByTerSera" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_TermLoanADebtIssuanceCosts" abstract="false" name="TermLoanADebtIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_FinalPaymentWithNoExtention" abstract="false" name="FinalPaymentWithNoExtention" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_Lxrx_sanofiInitialCashPayment" abstract="false" name="Lxrx_sanofiInitialCashPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_ATMOfferingTotal" abstract="false" name="ATMOfferingTotal" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" abstract="true" name="CashAndCashEquivalentsAndInvestmentsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_IpsenTotalPayments" abstract="false" name="IpsenTotalPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_LexiconIncrementalBorrowingRate" abstract="false" name="LexiconIncrementalBorrowingRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="lxrx_RecentAccountingPronouncementsAbstract" abstract="true" name="RecentAccountingPronouncementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="lxrx_SanofiRevenueRecognized" abstract="false" name="SanofiRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_SharesSoldInSeptember2021ATMOfferring" abstract="false" name="SharesSoldInSeptember2021ATMOfferring" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_SharePriceInJanuary2021ATMOffering" abstract="false" name="SharePriceInJanuary2021ATMOffering" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="lxrx_ConvertibleDebtExchange" abstract="false" name="ConvertibleDebtExchange" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="lxrx_PrincipalAmountOfConvertibleNotes" abstract="false" name="PrincipalAmountOfConvertibleNotes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>lxrx-20220331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d7a1dbc6-b99b-4a1d-848b-92cec6605016,g:574c9470-43fb-4b26-864a-707e5ed846fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7083fef1-1382-4bb1-ad56-afda5532cb02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_664f89d0-2742-4768-ac28-10475acec200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7083fef1-1382-4bb1-ad56-afda5532cb02" xlink:to="loc_us-gaap_LiabilitiesCurrent_664f89d0-2742-4768-ac28-10475acec200" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_93ddccc5-6b1a-47d8-9ccd-2d4f2b7668a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7083fef1-1382-4bb1-ad56-afda5532cb02" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_93ddccc5-6b1a-47d8-9ccd-2d4f2b7668a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d1a0d37b-22ff-4cbd-85d1-9ef18820d5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_60a334f9-8716-40d4-8d5e-69ab0e8a594b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1a0d37b-22ff-4cbd-85d1-9ef18820d5c3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_60a334f9-8716-40d4-8d5e-69ab0e8a594b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_78dfcd4e-30d5-4e96-9a6f-f95c4e64db86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1a0d37b-22ff-4cbd-85d1-9ef18820d5c3" xlink:to="loc_us-gaap_ShortTermInvestments_78dfcd4e-30d5-4e96-9a6f-f95c4e64db86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d52c505d-836c-45c0-9b48-baa173f6ccc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1a0d37b-22ff-4cbd-85d1-9ef18820d5c3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d52c505d-836c-45c0-9b48-baa173f6ccc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_2d23cef5-740e-4b49-9689-2deb00951f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_d1a0d37b-22ff-4cbd-85d1-9ef18820d5c3" xlink:to="loc_us-gaap_OtherAssetsCurrent_2d23cef5-740e-4b49-9689-2deb00951f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b7180f0a-2fbe-4711-ae93-37c9fc8230e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_411b3026-1f60-4970-a900-20396c2e6780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b7180f0a-2fbe-4711-ae93-37c9fc8230e6" xlink:to="loc_us-gaap_AssetsCurrent_411b3026-1f60-4970-a900-20396c2e6780" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6cfff256-00db-4ea0-a781-adaf9a9959a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b7180f0a-2fbe-4711-ae93-37c9fc8230e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6cfff256-00db-4ea0-a781-adaf9a9959a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_42b4550f-f45e-40f9-b6b0-66367bcbfd38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b7180f0a-2fbe-4711-ae93-37c9fc8230e6" xlink:to="loc_us-gaap_Goodwill_42b4550f-f45e-40f9-b6b0-66367bcbfd38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b1f91b63-ba5a-4f36-9595-41916bf43cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_b7180f0a-2fbe-4711-ae93-37c9fc8230e6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b1f91b63-ba5a-4f36-9595-41916bf43cda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_88a6fb47-be0c-45bf-80da-c01c5ddedf28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_2f104fa2-042f-4ef1-8b9b-31d888a88e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_88a6fb47-be0c-45bf-80da-c01c5ddedf28" xlink:to="loc_us-gaap_Liabilities_2f104fa2-042f-4ef1-8b9b-31d888a88e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4620280a-c764-4f77-8255-b5817f8ec41d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_88a6fb47-be0c-45bf-80da-c01c5ddedf28" xlink:to="loc_us-gaap_StockholdersEquity_4620280a-c764-4f77-8255-b5817f8ec41d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1973fd96-ad50-405e-a111-7ac65fdd1682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_1062a631-8ece-4e17-b4b4-0a9040a741e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1973fd96-ad50-405e-a111-7ac65fdd1682" xlink:to="loc_us-gaap_AccountsPayableCurrent_1062a631-8ece-4e17-b4b4-0a9040a741e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e0a72eb2-aecd-4e0c-9755-6e667096efa6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1973fd96-ad50-405e-a111-7ac65fdd1682" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e0a72eb2-aecd-4e0c-9755-6e667096efa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_dde9c558-4e9e-4311-9249-5d462f195cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1973fd96-ad50-405e-a111-7ac65fdd1682" xlink:to="loc_us-gaap_LongTermDebtCurrent_dde9c558-4e9e-4311-9249-5d462f195cc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cde7b13c-95f0-498a-9828-4076f3fc32b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_33f6adc0-f902-4c3b-8375-b369272bc34f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde7b13c-95f0-498a-9828-4076f3fc32b5" xlink:to="loc_us-gaap_PreferredStockValue_33f6adc0-f902-4c3b-8375-b369272bc34f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b3b85909-9706-4f2a-b89c-cda05179d607" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde7b13c-95f0-498a-9828-4076f3fc32b5" xlink:to="loc_us-gaap_CommonStockValue_b3b85909-9706-4f2a-b89c-cda05179d607" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_0c820eb2-5c58-4861-aa23-7e8c196b8c54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde7b13c-95f0-498a-9828-4076f3fc32b5" xlink:to="loc_us-gaap_AdditionalPaidInCapital_0c820eb2-5c58-4861-aa23-7e8c196b8c54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_068f3366-a201-48e9-868b-2d9d389e666f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde7b13c-95f0-498a-9828-4076f3fc32b5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_068f3366-a201-48e9-868b-2d9d389e666f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7ccaf97f-43a0-49c5-bc0c-ec8ee5c245ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde7b13c-95f0-498a-9828-4076f3fc32b5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7ccaf97f-43a0-49c5-bc0c-ec8ee5c245ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_efaeca55-5711-4ee6-bb72-d95939ce0d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cde7b13c-95f0-498a-9828-4076f3fc32b5" xlink:to="loc_us-gaap_TreasuryStockValue_efaeca55-5711-4ee6-bb72-d95939ce0d10" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cb5af682-f008-4198-bd52-a1713bba25d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1c6cd9b4-408e-4417-8afd-ce8a27839120" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cb5af682-f008-4198-bd52-a1713bba25d3" xlink:to="loc_us-gaap_NetIncomeLoss_1c6cd9b4-408e-4417-8afd-ce8a27839120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_77b813ab-4275-4a08-89b4-560ef52c58c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_cb5af682-f008-4198-bd52-a1713bba25d3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_77b813ab-4275-4a08-89b4-560ef52c58c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_dec1cbe1-ba00-41c8-9b62-352897c527b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_b3fe8a8f-078b-4cb2-854e-a896b1ecd583" xlink:href="lxrx-20220331.xsd#lxrx_Netproductrevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_dec1cbe1-ba00-41c8-9b62-352897c527b4" xlink:to="loc_lxrx_Netproductrevenue_b3fe8a8f-078b-4cb2-854e-a896b1ecd583" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4b24999f-10d8-4cc8-a599-4c878e6f0d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_dec1cbe1-ba00-41c8-9b62-352897c527b4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4b24999f-10d8-4cc8-a599-4c878e6f0d6e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_e89d5db3-b1f1-4cfd-9b4f-9a6e19176ba9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_dec1cbe1-ba00-41c8-9b62-352897c527b4" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_e89d5db3-b1f1-4cfd-9b4f-9a6e19176ba9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c0f3d678-e6a9-4900-b48f-3bd9340f9463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_527feda2-f83d-4182-8c76-74b33573a5b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c0f3d678-e6a9-4900-b48f-3bd9340f9463" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_527feda2-f83d-4182-8c76-74b33573a5b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f4ab31f3-7b73-446d-a008-9eb0c77f312c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c0f3d678-e6a9-4900-b48f-3bd9340f9463" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f4ab31f3-7b73-446d-a008-9eb0c77f312c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_ddc05e99-bb23-411d-aabe-6c90b6103498" xlink:href="lxrx-20220331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c0f3d678-e6a9-4900-b48f-3bd9340f9463" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_ddc05e99-bb23-411d-aabe-6c90b6103498" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f469de3f-935f-43f3-a823-6e3bf4400523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_c0f3d678-e6a9-4900-b48f-3bd9340f9463" xlink:to="loc_us-gaap_AssetImpairmentCharges_f469de3f-935f-43f3-a823-6e3bf4400523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_d895b62b-62ba-4f28-8faa-1e4553b3f558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_20d9957f-27da-40ba-b971-806182f3f956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d895b62b-62ba-4f28-8faa-1e4553b3f558" xlink:to="loc_us-gaap_Revenues_20d9957f-27da-40ba-b971-806182f3f956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_347b9eaf-088b-461c-a1d5-e868cc35862b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d895b62b-62ba-4f28-8faa-1e4553b3f558" xlink:to="loc_us-gaap_OperatingExpenses_347b9eaf-088b-461c-a1d5-e868cc35862b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_c10ed2bb-f267-4a15-b40b-c436ffa4dc6a" xlink:href="lxrx-20220331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_d895b62b-62ba-4f28-8faa-1e4553b3f558" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_c10ed2bb-f267-4a15-b40b-c436ffa4dc6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_e09239a6-bc3e-46fd-9a1f-02a46d3e9d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_ShareBasedCompensation_e09239a6-bc3e-46fd-9a1f-02a46d3e9d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88701a97-0683-4e9b-85cd-6a3126b05622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_88701a97-0683-4e9b-85cd-6a3126b05622" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5fbf4565-cb2a-4c22-b1ea-c8e3321a0471" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5fbf4565-cb2a-4c22-b1ea-c8e3321a0471" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_2c0e563d-25a0-42e3-9b0a-940aec8c1fdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_AssetImpairmentCharges_2c0e563d-25a0-42e3-9b0a-940aec8c1fdb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_173506c4-e680-497c-9c18-7ec715b01b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_173506c4-e680-497c-9c18-7ec715b01b7b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74ac69c9-c0ed-4c22-a39e-13e54d1bfba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_NetIncomeLoss_74ac69c9-c0ed-4c22-a39e-13e54d1bfba3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7a7a3be8-a636-4242-a4fc-f15ca8156253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_7a7a3be8-a636-4242-a4fc-f15ca8156253" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_81da7a62-cb37-4028-8bbe-fb6130080dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_81da7a62-cb37-4028-8bbe-fb6130080dc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_08cd61bf-8436-48d1-b05e-c0782ba1f906" xlink:href="lxrx-20220331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_08cd61bf-8436-48d1-b05e-c0782ba1f906" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_61dde1b9-d01a-47a0-8e40-5648d2071d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_61dde1b9-d01a-47a0-8e40-5648d2071d3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_39fa332b-5ebc-458f-aa05-f3fe7b3894b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_39fa332b-5ebc-458f-aa05-f3fe7b3894b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9d2b12ee-0f3a-4306-9bcd-b13410d1a121" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_abc5d28c-b414-4f80-a951-370f76739f9d" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9d2b12ee-0f3a-4306-9bcd-b13410d1a121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_a9be37f2-e6a7-4788-8c7c-53d6e8ac0083" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2c6f394-6903-4a65-ae5b-957c3a72db35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_a9be37f2-e6a7-4788-8c7c-53d6e8ac0083" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2c6f394-6903-4a65-ae5b-957c3a72db35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3ae5c56e-fd27-4698-939c-75655c5eb61d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_a9be37f2-e6a7-4788-8c7c-53d6e8ac0083" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_3ae5c56e-fd27-4698-939c-75655c5eb61d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66470242-d24f-41dd-a03c-5a55cfb60b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_a9be37f2-e6a7-4788-8c7c-53d6e8ac0083" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_66470242-d24f-41dd-a03c-5a55cfb60b66" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e745636d-87b5-4589-a107-83b07690185b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9d11218b-68f3-410e-ade4-be52a61001ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e745636d-87b5-4589-a107-83b07690185b" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9d11218b-68f3-410e-ade4-be52a61001ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_e87af397-3b3f-4df8-b0f3-ca781b20398c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e745636d-87b5-4589-a107-83b07690185b" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_e87af397-3b3f-4df8-b0f3-ca781b20398c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5827f8bc-5cdc-44cd-b832-c26503275a36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e745636d-87b5-4589-a107-83b07690185b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_5827f8bc-5cdc-44cd-b832-c26503275a36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af011757-fd11-4c9d-af3e-b6408296752a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e7c89326-fa9b-412a-a8ad-9f881ce4be58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af011757-fd11-4c9d-af3e-b6408296752a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e7c89326-fa9b-412a-a8ad-9f881ce4be58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_07f7bb58-ed55-4cd5-ad34-7ce5e3e12e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af011757-fd11-4c9d-af3e-b6408296752a" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_07f7bb58-ed55-4cd5-ad34-7ce5e3e12e1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_dd091750-6790-4e63-b607-fcc51c835132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af011757-fd11-4c9d-af3e-b6408296752a" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_dd091750-6790-4e63-b607-fcc51c835132" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_bfaeab72-57a4-41bf-9730-52198a13e6ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_af011757-fd11-4c9d-af3e-b6408296752a" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_bfaeab72-57a4-41bf-9730-52198a13e6ba" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>lxrx-20220331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d7a1dbc6-b99b-4a1d-848b-92cec6605016,g:574c9470-43fb-4b26-864a-707e5ed846fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended" id="i131b698b16bf44d3ab8d08daf8ce9bd0_ConsolidatedBalanceSheetsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be8c5c1c-d462-4882-9c16-b6277cf7f17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be8c5c1c-d462-4882-9c16-b6277cf7f17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a75891f3-42d6-49b5-9481-9b3c63dd844e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_ShortTermInvestments_a75891f3-42d6-49b5-9481-9b3c63dd844e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8f09bbe6-bf91-4cfe-9ba2-705309f7b26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8f09bbe6-bf91-4cfe-9ba2-705309f7b26e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_cdda71b5-d9a6-40c0-af3c-db070f054a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_OtherAssetsCurrent_cdda71b5-d9a6-40c0-af3c-db070f054a70" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1c42005f-20ed-4ba8-b9ee-cc5de17cd66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_AssetsCurrent_1c42005f-20ed-4ba8-b9ee-cc5de17cd66f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13658cc0-d0e1-4457-9428-050deb83fde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13658cc0-d0e1-4457-9428-050deb83fde9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ecad2be9-634a-474b-917b-0975ce68f488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_Goodwill_ecad2be9-634a-474b-917b-0975ce68f488" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3052cba8-4e67-4839-a79f-fd3251472394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3052cba8-4e67-4839-a79f-fd3251472394" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_89c590fc-f18f-4ac0-99b2-581b401f0d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_Assets_89c590fc-f18f-4ac0-99b2-581b401f0d2a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8c664979-dd1d-4fb5-a822-f40a97c6eaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_AccountsPayableCurrent_8c664979-dd1d-4fb5-a822-f40a97c6eaaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a2585f6e-022d-473e-b086-fb5ec23c7a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a2585f6e-022d-473e-b086-fb5ec23c7a81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ddb17f36-6558-4e89-a967-9860679490de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_LongTermDebtCurrent_ddb17f36-6558-4e89-a967-9860679490de" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb2491ee-0db0-4581-bbe7-cad41ed9cee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_LiabilitiesCurrent_bb2491ee-0db0-4581-bbe7-cad41ed9cee5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_ed05a67d-9f89-48e5-95c9-07e782547cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_SecuredLongTermDebt_ed05a67d-9f89-48e5-95c9-07e782547cf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6ff997ca-f93e-4508-a2ae-de2f717bdec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6ff997ca-f93e-4508-a2ae-de2f717bdec9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_77e4297a-fda5-44f4-a31b-5f1bd7b69d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_Liabilities_77e4297a-fda5-44f4-a31b-5f1bd7b69d5e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a24cdab7-4d54-4c76-b088-77ecb067e436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a24cdab7-4d54-4c76-b088-77ecb067e436" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d4ad3c06-28b0-42c9-b157-d6617da01485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_PreferredStockValue_d4ad3c06-28b0-42c9-b157-d6617da01485" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dcdc507d-12a1-4501-8455-a3135d758e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_CommonStockValue_dcdc507d-12a1-4501-8455-a3135d758e67" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_252b5326-ab20-40c6-8ff9-40bae5c8b024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_252b5326-ab20-40c6-8ff9-40bae5c8b024" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e81ea4ba-f6e7-4331-8131-2f76f0cac2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e81ea4ba-f6e7-4331-8131-2f76f0cac2a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3b5aab7d-5ba2-4b3f-9d55-1677b9e1fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3b5aab7d-5ba2-4b3f-9d55-1677b9e1fc6e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_331223e6-0f71-49a5-80dc-b10ad1998a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_TreasuryStockValue_331223e6-0f71-49a5-80dc-b10ad1998a80" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_86ee3276-37a3-4832-88ac-c505628f5af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_StockholdersEquity_86ee3276-37a3-4832-88ac-c505628f5af8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5123fe3a-dfd5-4b9b-9ef9-ee4dcfca98c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5123fe3a-dfd5-4b9b-9ef9-ee4dcfca98c9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_da8e51cf-8ff0-4d65-b67b-12a0e22dc25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_da8e51cf-8ff0-4d65-b67b-12a0e22dc25f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_94681189-2994-4908-aafe-cf77096b28b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_StatementTable_94681189-2994-4908-aafe-cf77096b28b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3076b390-7713-481b-81bc-fedfdde7520b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_94681189-2994-4908-aafe-cf77096b28b1" xlink:to="loc_srt_StatementScenarioAxis_3076b390-7713-481b-81bc-fedfdde7520b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3076b390-7713-481b-81bc-fedfdde7520b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_3076b390-7713-481b-81bc-fedfdde7520b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3076b390-7713-481b-81bc-fedfdde7520b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e9781744-37fb-4d5c-b906-a205eb941b99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_3076b390-7713-481b-81bc-fedfdde7520b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e9781744-37fb-4d5c-b906-a205eb941b99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5bd24985-1655-4f2e-8742-53709c18c986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_94681189-2994-4908-aafe-cf77096b28b1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5bd24985-1655-4f2e-8742-53709c18c986" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5bd24985-1655-4f2e-8742-53709c18c986_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5bd24985-1655-4f2e-8742-53709c18c986" xlink:to="loc_us-gaap_ClassOfStockDomain_5bd24985-1655-4f2e-8742-53709c18c986_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_359703c5-25bf-450f-b52d-e6c53f4b3b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5bd24985-1655-4f2e-8742-53709c18c986" xlink:to="loc_us-gaap_ClassOfStockDomain_359703c5-25bf-450f-b52d-e6c53f4b3b2e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended" id="i526b31f9104c44e899f0d60bee591500_ConsolidatedStatementsofComprehensiveLossUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_8533762a-46d1-45e8-ab66-bf79774ad189" xlink:href="lxrx-20220331.xsd#lxrx_Netproductrevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:to="loc_lxrx_Netproductrevenue_8533762a-46d1-45e8-ab66-bf79774ad189" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_facfc56b-32ee-4283-9a20-9880c59c1da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_facfc56b-32ee-4283-9a20-9880c59c1da2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_8630f8e4-c3c6-484c-a96b-985213e36181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_8630f8e4-c3c6-484c-a96b-985213e36181" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5c2ce5bb-84aa-4683-a3d4-3d634aa15f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:to="loc_us-gaap_Revenues_5c2ce5bb-84aa-4683-a3d4-3d634aa15f38" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_74f4b260-6736-49d4-9be3-7e8646d42eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_74f4b260-6736-49d4-9be3-7e8646d42eef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4e3e57bc-ec51-40da-90f3-10897cd34144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4e3e57bc-ec51-40da-90f3-10897cd34144" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_4d6b3e2e-ddaa-4fa0-8a99-4517bff95b55" xlink:href="lxrx-20220331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_4d6b3e2e-ddaa-4fa0-8a99-4517bff95b55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1eefce58-923c-47a5-a611-b7f092b639e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_us-gaap_AssetImpairmentCharges_1eefce58-923c-47a5-a611-b7f092b639e0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_579994b0-b39c-4fa8-a0c4-9d4505363448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_us-gaap_OperatingExpenses_579994b0-b39c-4fa8-a0c4-9d4505363448" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_c40f8382-b9fc-44a2-9e06-c1c7da2d2232" xlink:href="lxrx-20220331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_c40f8382-b9fc-44a2-9e06-c1c7da2d2232" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ecc0e02-326c-4cfa-a394-18700bc74233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ecc0e02-326c-4cfa-a394-18700bc74233" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_375c2c47-d3a6-44c8-84c9-49f110d6774e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_375c2c47-d3a6-44c8-84c9-49f110d6774e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5efa8113-3293-4539-81c1-d1b195a58015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_InterestExpense_5efa8113-3293-4539-81c1-d1b195a58015" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f2828741-30da-4c20-9898-e8beeaabdef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f2828741-30da-4c20-9898-e8beeaabdef6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d8842575-15f7-47cb-86c5-cae4a1748339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_NetIncomeLoss_d8842575-15f7-47cb-86c5-cae4a1748339" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3a9d9b16-ca69-48eb-8926-393137983c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_EarningsPerShareBasic_3a9d9b16-ca69-48eb-8926-393137983c12" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_13267599-ca36-4621-ae40-7c56bfc647d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_13267599-ca36-4621-ae40-7c56bfc647d5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10c7144f-88ef-4de6-a49e-12a1b036e5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10c7144f-88ef-4de6-a49e-12a1b036e5c3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2eac7b8e-e27d-4e47-99aa-07f33320c181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2eac7b8e-e27d-4e47-99aa-07f33320c181" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d0d466d9-4ec6-4c4c-9532-b8dfdf92cc92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d0d466d9-4ec6-4c4c-9532-b8dfdf92cc92" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b49e25c-ea90-402c-b2bf-c43aaee9d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b49e25c-ea90-402c-b2bf-c43aaee9d02b" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_4dd4e42f-5098-4309-a49b-e73f4e3b1b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_4dd4e42f-5098-4309-a49b-e73f4e3b1b17" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_a845f2fc-ad06-40f8-892c-c6cfbfcc3d16" xlink:href="lxrx-20220331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_4dd4e42f-5098-4309-a49b-e73f4e3b1b17" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_a845f2fc-ad06-40f8-892c-c6cfbfcc3d16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_5300ac20-3204-4228-8dda-1783010f29cb" xlink:href="lxrx-20220331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_4dd4e42f-5098-4309-a49b-e73f4e3b1b17" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_5300ac20-3204-4228-8dda-1783010f29cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_475ab1ab-b456-4ae8-8a65-04c05313bd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_StatementTable_475ab1ab-b456-4ae8-8a65-04c05313bd47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_de069c95-859e-4486-a10f-c91eee0266ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_475ab1ab-b456-4ae8-8a65-04c05313bd47" xlink:to="loc_srt_StatementScenarioAxis_de069c95-859e-4486-a10f-c91eee0266ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_de069c95-859e-4486-a10f-c91eee0266ac_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_de069c95-859e-4486-a10f-c91eee0266ac" xlink:to="loc_srt_ScenarioUnspecifiedDomain_de069c95-859e-4486-a10f-c91eee0266ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a4459ebb-999e-403a-89cf-f47904871bfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_de069c95-859e-4486-a10f-c91eee0266ac" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a4459ebb-999e-403a-89cf-f47904871bfa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended" id="ifec0b6cd26e94d4abb6b4909e3d8d499_ConsolidatedStatementsofStockholdersEquityDeficitUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fb6ef8ba-e9ca-4aa2-bb04-96a189faaa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_CommonStockSharesIssued_fb6ef8ba-e9ca-4aa2-bb04-96a189faaa09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6446601d-e7c6-41ab-a9f5-ca1839b1ee04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6446601d-e7c6-41ab-a9f5-ca1839b1ee04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_940f14b0-e667-4cb3-891c-2b4ef5091474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_940f14b0-e667-4cb3-891c-2b4ef5091474" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_98820f62-1b2b-4ecf-8dcb-b25cbcd3c90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_98820f62-1b2b-4ecf-8dcb-b25cbcd3c90e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_540a4619-e46b-4532-b214-f147db33f1da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_540a4619-e46b-4532-b214-f147db33f1da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_01f856ce-1072-4442-ba04-4a7987a5d826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_01f856ce-1072-4442-ba04-4a7987a5d826" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_487dcf01-fec1-4af2-9c83-77785b31dcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_487dcf01-fec1-4af2-9c83-77785b31dcab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d422ca00-cb40-4ae4-aa1c-b9f63c488026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_NetIncomeLoss_d422ca00-cb40-4ae4-aa1c-b9f63c488026" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4f820c49-48cd-473d-910f-d201da65a8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4f820c49-48cd-473d-910f-d201da65a8d1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d998d36f-2294-4a76-a1c0-9e96af09dcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d998d36f-2294-4a76-a1c0-9e96af09dcc9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fbac95aa-5c59-443e-8d73-74f435f17ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00c20377-e134-4dac-b13d-31957ce64520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_01f7b188-9a41-43b5-8cd8-3e6d2a547a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_01f7b188-9a41-43b5-8cd8-3e6d2a547a0e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6d2b49ff-f8a6-43bb-bc4a-e8a48fd295b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6d2b49ff-f8a6-43bb-bc4a-e8a48fd295b6" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b3112b0a-abad-4ae6-b3b5-0b06ee1ca988" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:to="loc_srt_StatementScenarioAxis_b3112b0a-abad-4ae6-b3b5-0b06ee1ca988" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_b3112b0a-abad-4ae6-b3b5-0b06ee1ca988_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_b3112b0a-abad-4ae6-b3b5-0b06ee1ca988" xlink:to="loc_srt_ScenarioUnspecifiedDomain_b3112b0a-abad-4ae6-b3b5-0b06ee1ca988_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_be5006fb-a124-4d72-8c51-bdb024cd745d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_b3112b0a-abad-4ae6-b3b5-0b06ee1ca988" xlink:to="loc_srt_ScenarioUnspecifiedDomain_be5006fb-a124-4d72-8c51-bdb024cd745d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_480655e7-b995-4dcc-8cbd-c96a66c0821a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_480655e7-b995-4dcc-8cbd-c96a66c0821a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_480655e7-b995-4dcc-8cbd-c96a66c0821a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_480655e7-b995-4dcc-8cbd-c96a66c0821a" xlink:to="loc_us-gaap_EquityComponentDomain_480655e7-b995-4dcc-8cbd-c96a66c0821a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_480655e7-b995-4dcc-8cbd-c96a66c0821a" xlink:to="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a909cee6-86de-49e2-a518-903a2ec4e933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_CommonStockMember_a909cee6-86de-49e2-a518-903a2ec4e933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_435c9513-55e8-4ec9-85eb-b1622eb153db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_435c9513-55e8-4ec9-85eb-b1622eb153db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4d3fea55-7996-467e-92f8-b4022763b2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_RetainedEarningsMember_4d3fea55-7996-467e-92f8-b4022763b2b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77a20ed4-7f40-4b2c-afbc-e63571996e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77a20ed4-7f40-4b2c-afbc-e63571996e06" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_35e4cde0-5bc9-4dbd-a52e-07db55a5f693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_TreasuryStockMember_35e4cde0-5bc9-4dbd-a52e-07db55a5f693" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0aa0be0d-8753-4992-bf0d-dc01e7934c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0aa0be0d-8753-4992-bf0d-dc01e7934c47" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0aa0be0d-8753-4992-bf0d-dc01e7934c47_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0aa0be0d-8753-4992-bf0d-dc01e7934c47" xlink:to="loc_us-gaap_ClassOfStockDomain_0aa0be0d-8753-4992-bf0d-dc01e7934c47_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5fe621ba-7d35-4bb5-8f6d-d6d6cfeb938d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0aa0be0d-8753-4992-bf0d-dc01e7934c47" xlink:to="loc_us-gaap_ClassOfStockDomain_5fe621ba-7d35-4bb5-8f6d-d6d6cfeb938d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended" id="iec0cda98464f404b9d6af9e56ff90c5b_SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_4f9c98db-4aa6-49be-a38f-bb510e3e3c62" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_4f9c98db-4aa6-49be-a38f-bb510e3e3c62" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_0ae10043-e4d9-431b-aadf-1d63cfd20e1e" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_0ae10043-e4d9-431b-aadf-1d63cfd20e1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_75e067a3-4ae8-425c-86ef-f3d7083de145" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_75e067a3-4ae8-425c-86ef-f3d7083de145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_13c478c4-94a5-4301-9477-04f5392f227a" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_13c478c4-94a5-4301-9477-04f5392f227a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_661fbea8-c5ce-402a-96ba-e878ea8a6396" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_661fbea8-c5ce-402a-96ba-e878ea8a6396" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_9a77e731-c1aa-4930-82e1-f4ffe1a948b5" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_9a77e731-c1aa-4930-82e1-f4ffe1a948b5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_fe999f3a-d5b4-4145-931d-2faaeeac7e2b" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_fe999f3a-d5b4-4145-931d-2faaeeac7e2b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_455d7479-bd2d-4080-8421-7aa23d16378d" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_455d7479-bd2d-4080-8421-7aa23d16378d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7c2efc6c-8ca4-410e-ab25-20f72baa0d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_PlanNameAxis_7c2efc6c-8ca4-410e-ab25-20f72baa0d39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7c2efc6c-8ca4-410e-ab25-20f72baa0d39_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7c2efc6c-8ca4-410e-ab25-20f72baa0d39" xlink:to="loc_us-gaap_PlanNameDomain_7c2efc6c-8ca4-410e-ab25-20f72baa0d39_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_430c6fca-5487-4d03-a26b-86981dfea0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7c2efc6c-8ca4-410e-ab25-20f72baa0d39" xlink:to="loc_us-gaap_PlanNameDomain_430c6fca-5487-4d03-a26b-86981dfea0ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_1f098d5e-92b4-4b7f-b84c-11d679c7a480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_AwardDateAxis_1f098d5e-92b4-4b7f-b84c-11d679c7a480" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_1f098d5e-92b4-4b7f-b84c-11d679c7a480_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_1f098d5e-92b4-4b7f-b84c-11d679c7a480" xlink:to="loc_us-gaap_AwardDateDomain_1f098d5e-92b4-4b7f-b84c-11d679c7a480_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_31e29570-898b-41ec-a531-659b87786067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_1f098d5e-92b4-4b7f-b84c-11d679c7a480" xlink:to="loc_us-gaap_AwardDateDomain_31e29570-898b-41ec-a531-659b87786067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aa578f1a-59f0-49a7-89ec-4f65dab91556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_AwardTypeAxis_aa578f1a-59f0-49a7-89ec-4f65dab91556" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa578f1a-59f0-49a7-89ec-4f65dab91556_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_aa578f1a-59f0-49a7-89ec-4f65dab91556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_aa578f1a-59f0-49a7-89ec-4f65dab91556_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8b81787-5c21-4693-a33d-d5d5ff8fda38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_aa578f1a-59f0-49a7-89ec-4f65dab91556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8b81787-5c21-4693-a33d-d5d5ff8fda38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_bdf24d68-ff52-476b-afc1-d1d0f00da4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8b81787-5c21-4693-a33d-d5d5ff8fda38" xlink:to="loc_us-gaap_StockOptionMember_bdf24d68-ff52-476b-afc1-d1d0f00da4ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_927ea0e6-17f0-40d7-8674-bd0e8e7956f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_927ea0e6-17f0-40d7-8674-bd0e8e7956f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_927ea0e6-17f0-40d7-8674-bd0e8e7956f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_927ea0e6-17f0-40d7-8674-bd0e8e7956f6" xlink:to="loc_us-gaap_ClassOfStockDomain_927ea0e6-17f0-40d7-8674-bd0e8e7956f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd5b7c33-ed77-4049-971f-9d3bb336381b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_927ea0e6-17f0-40d7-8674-bd0e8e7956f6" xlink:to="loc_us-gaap_ClassOfStockDomain_cd5b7c33-ed77-4049-971f-9d3bb336381b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c44b6874-7bdf-4b7f-85bd-c0c010ab3d91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_srt_RangeAxis_c44b6874-7bdf-4b7f-85bd-c0c010ab3d91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c44b6874-7bdf-4b7f-85bd-c0c010ab3d91_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c44b6874-7bdf-4b7f-85bd-c0c010ab3d91" xlink:to="loc_srt_RangeMember_c44b6874-7bdf-4b7f-85bd-c0c010ab3d91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b6174a4-7c29-4f24-841c-94c0231e4eea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c44b6874-7bdf-4b7f-85bd-c0c010ab3d91" xlink:to="loc_srt_RangeMember_9b6174a4-7c29-4f24-841c-94c0231e4eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7c1c69fa-ca85-4e63-a8d1-0419630540bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_VestingAxis_7c1c69fa-ca85-4e63-a8d1-0419630540bb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_7c1c69fa-ca85-4e63-a8d1-0419630540bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_7c1c69fa-ca85-4e63-a8d1-0419630540bb" xlink:to="loc_us-gaap_VestingDomain_7c1c69fa-ca85-4e63-a8d1-0419630540bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_361383e7-0f51-4bcb-b88b-ccc52a53d40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_7c1c69fa-ca85-4e63-a8d1-0419630540bb" xlink:to="loc_us-gaap_VestingDomain_361383e7-0f51-4bcb-b88b-ccc52a53d40a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended" id="i0fa65ac5d5b94e349ffdc1d788699a9d_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0685701d-1848-42cd-826b-309245675883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0685701d-1848-42cd-826b-309245675883" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8cc55ed5-7ae7-4108-87ee-cd2acf049f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8cc55ed5-7ae7-4108-87ee-cd2acf049f24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_13fe9d43-3ae9-4023-8e27-2dd274ec7def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_13fe9d43-3ae9-4023-8e27-2dd274ec7def" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee1cfc58-cad4-49a4-91c5-c214723b65a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee1cfc58-cad4-49a4-91c5-c214723b65a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3c6c0e62-a0d9-4701-9da1-ca44d6d88d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3c6c0e62-a0d9-4701-9da1-ca44d6d88d7d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3b147f11-c412-42c8-8e2e-e2125f83fac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3b147f11-c412-42c8-8e2e-e2125f83fac3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_10f829a5-84e8-405f-8afe-a89b96db4c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_10f829a5-84e8-405f-8afe-a89b96db4c8d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3f46636e-b233-4738-a633-b16013daaed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3f46636e-b233-4738-a633-b16013daaed9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2035866e-411e-445e-9b9d-49cb7c8b6920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2035866e-411e-445e-9b9d-49cb7c8b6920" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_51a90c9d-fc5c-4b26-8739-6a213e52a857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_51a90c9d-fc5c-4b26-8739-6a213e52a857" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_129830a5-cb7b-41bb-91a2-de2be46587c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_129830a5-cb7b-41bb-91a2-de2be46587c7" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1b72b407-fc53-49e2-955e-2fd2969202ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1b72b407-fc53-49e2-955e-2fd2969202ce" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b5a0f98-58a7-4980-8dab-cdd45c36c800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b5a0f98-58a7-4980-8dab-cdd45c36c800" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8034d329-5d0b-4623-8dd8-9c3867160513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8034d329-5d0b-4623-8dd8-9c3867160513" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f9a01827-c85d-4bd2-8ab9-224e6cbe5e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f9a01827-c85d-4bd2-8ab9-224e6cbe5e84" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f23bafe0-a7b7-48f3-bb94-8e00f36a160b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f23bafe0-a7b7-48f3-bb94-8e00f36a160b" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3083bab1-b09e-4672-8c7d-291f785196e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3083bab1-b09e-4672-8c7d-291f785196e5" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_500331a8-d2c8-4c27-a061-577d990ba7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_500331a8-d2c8-4c27-a061-577d990ba7f5" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ef92d857-0706-4b0c-be2b-4c97fb862570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ef92d857-0706-4b0c-be2b-4c97fb862570" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2e992110-6f9c-4f6f-83db-09cbce8da1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2e992110-6f9c-4f6f-83db-09cbce8da1de" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47a8518f-ddc4-4fd1-9a7a-812ed6d73cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_PlanNameAxis_47a8518f-ddc4-4fd1-9a7a-812ed6d73cbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_47a8518f-ddc4-4fd1-9a7a-812ed6d73cbc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_47a8518f-ddc4-4fd1-9a7a-812ed6d73cbc" xlink:to="loc_us-gaap_PlanNameDomain_47a8518f-ddc4-4fd1-9a7a-812ed6d73cbc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aac39b03-a217-4806-8f8e-2ef768d83983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_47a8518f-ddc4-4fd1-9a7a-812ed6d73cbc" xlink:to="loc_us-gaap_PlanNameDomain_aac39b03-a217-4806-8f8e-2ef768d83983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_1ec18c4d-6279-4ffe-819a-2ef4170d68f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_AwardDateAxis_1ec18c4d-6279-4ffe-819a-2ef4170d68f5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_1ec18c4d-6279-4ffe-819a-2ef4170d68f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardDateAxis_1ec18c4d-6279-4ffe-819a-2ef4170d68f5" xlink:to="loc_us-gaap_AwardDateDomain_1ec18c4d-6279-4ffe-819a-2ef4170d68f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_c2dbce4d-049f-4b7d-976b-2c028f929ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardDateAxis_1ec18c4d-6279-4ffe-819a-2ef4170d68f5" xlink:to="loc_us-gaap_AwardDateDomain_c2dbce4d-049f-4b7d-976b-2c028f929ba6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_87b668bc-f31d-423c-a4ba-969bdb43c095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_AwardTypeAxis_87b668bc-f31d-423c-a4ba-969bdb43c095" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87b668bc-f31d-423c-a4ba-969bdb43c095_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_87b668bc-f31d-423c-a4ba-969bdb43c095" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_87b668bc-f31d-423c-a4ba-969bdb43c095_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9dd2b8a-b3d9-417d-87ad-d77b9ec456ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_87b668bc-f31d-423c-a4ba-969bdb43c095" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9dd2b8a-b3d9-417d-87ad-d77b9ec456ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_423d55ab-7a4d-4b8a-9039-d5191b67c502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9dd2b8a-b3d9-417d-87ad-d77b9ec456ec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_423d55ab-7a4d-4b8a-9039-d5191b67c502" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d78738e6-fcf9-48d6-9c9a-151f29016a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9dd2b8a-b3d9-417d-87ad-d77b9ec456ec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d78738e6-fcf9-48d6-9c9a-151f29016a23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_114e6954-3727-4af2-9d30-b6268ff7c64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_StatementClassOfStockAxis_114e6954-3727-4af2-9d30-b6268ff7c64e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_114e6954-3727-4af2-9d30-b6268ff7c64e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_114e6954-3727-4af2-9d30-b6268ff7c64e" xlink:to="loc_us-gaap_ClassOfStockDomain_114e6954-3727-4af2-9d30-b6268ff7c64e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3fa41c13-d879-4519-b348-7c0f75fbdd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_114e6954-3727-4af2-9d30-b6268ff7c64e" xlink:to="loc_us-gaap_ClassOfStockDomain_3fa41c13-d879-4519-b348-7c0f75fbdd10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1e30c42-a2bd-4f92-ae55-cef6042abdc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_srt_RangeAxis_d1e30c42-a2bd-4f92-ae55-cef6042abdc1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1e30c42-a2bd-4f92-ae55-cef6042abdc1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d1e30c42-a2bd-4f92-ae55-cef6042abdc1" xlink:to="loc_srt_RangeMember_d1e30c42-a2bd-4f92-ae55-cef6042abdc1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_846a43d3-ecb8-4da5-b430-507330fb53d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d1e30c42-a2bd-4f92-ae55-cef6042abdc1" xlink:to="loc_srt_RangeMember_846a43d3-ecb8-4da5-b430-507330fb53d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c9d3a966-5568-4f11-8b12-c4c5a6d40aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_VestingAxis_c9d3a966-5568-4f11-8b12-c4c5a6d40aa5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_c9d3a966-5568-4f11-8b12-c4c5a6d40aa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_c9d3a966-5568-4f11-8b12-c4c5a6d40aa5" xlink:to="loc_us-gaap_VestingDomain_c9d3a966-5568-4f11-8b12-c4c5a6d40aa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_afa204b4-1165-4cc8-b610-99672d0ba4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_c9d3a966-5568-4f11-8b12-c4c5a6d40aa5" xlink:to="loc_us-gaap_VestingDomain_afa204b4-1165-4cc8-b610-99672d0ba4d3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended" id="i5852bc0337724ad191113ee7f49e5929_SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0e1a828-35cb-4731-bdb7-e79425d7c851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0e1a828-35cb-4731-bdb7-e79425d7c851" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_08f26e1e-23a1-442b-93e6-a74066e56d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:to="loc_us-gaap_PlanNameAxis_08f26e1e-23a1-442b-93e6-a74066e56d63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_08f26e1e-23a1-442b-93e6-a74066e56d63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_08f26e1e-23a1-442b-93e6-a74066e56d63" xlink:to="loc_us-gaap_PlanNameDomain_08f26e1e-23a1-442b-93e6-a74066e56d63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ac7cdd0a-5384-4024-b5f0-dafc087643d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_08f26e1e-23a1-442b-93e6-a74066e56d63" xlink:to="loc_us-gaap_PlanNameDomain_ac7cdd0a-5384-4024-b5f0-dafc087643d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e3da09e-2cc8-4ee3-89ea-443973916018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:to="loc_us-gaap_AwardTypeAxis_6e3da09e-2cc8-4ee3-89ea-443973916018" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e3da09e-2cc8-4ee3-89ea-443973916018_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6e3da09e-2cc8-4ee3-89ea-443973916018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e3da09e-2cc8-4ee3-89ea-443973916018_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b527b055-4c3f-4243-ad33-74fc71dd308e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6e3da09e-2cc8-4ee3-89ea-443973916018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b527b055-4c3f-4243-ad33-74fc71dd308e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46683ebc-649e-4149-8e4d-ee35d56400d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46683ebc-649e-4149-8e4d-ee35d56400d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_46683ebc-649e-4149-8e4d-ee35d56400d9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46683ebc-649e-4149-8e4d-ee35d56400d9" xlink:to="loc_us-gaap_ClassOfStockDomain_46683ebc-649e-4149-8e4d-ee35d56400d9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2cdf752e-6a29-458b-8204-72c4e2e4d461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46683ebc-649e-4149-8e4d-ee35d56400d9" xlink:to="loc_us-gaap_ClassOfStockDomain_2cdf752e-6a29-458b-8204-72c4e2e4d461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae8aadda-c00a-4442-9cad-b7f94cf97d33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:to="loc_srt_RangeAxis_ae8aadda-c00a-4442-9cad-b7f94cf97d33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ae8aadda-c00a-4442-9cad-b7f94cf97d33_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ae8aadda-c00a-4442-9cad-b7f94cf97d33" xlink:to="loc_srt_RangeMember_ae8aadda-c00a-4442-9cad-b7f94cf97d33_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c22b918d-f854-4d11-bfb5-ddae5a7059f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ae8aadda-c00a-4442-9cad-b7f94cf97d33" xlink:to="loc_srt_RangeMember_c22b918d-f854-4d11-bfb5-ddae5a7059f7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended" id="i026fb58261e54ac8a880df6c2343b4e0_SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_0186965c-a915-4b6e-8de6-91dcb0f36091" xlink:href="lxrx-20220331.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_0186965c-a915-4b6e-8de6-91dcb0f36091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_1ce8ba3a-dc30-4ac7-9854-9e4678f318f0" xlink:href="lxrx-20220331.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_1ce8ba3a-dc30-4ac7-9854-9e4678f318f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f4e522b-4f77-41cf-89ca-6b2d635f337f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f4e522b-4f77-41cf-89ca-6b2d635f337f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da1dd3d6-77d6-435a-a9ce-d5f39ccaa42d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da1dd3d6-77d6-435a-a9ce-d5f39ccaa42d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_4c18fb7d-3e83-4bff-9667-0a5c90b0e23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_4c18fb7d-3e83-4bff-9667-0a5c90b0e23f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_6a3d6a6a-9fd2-4bf6-ab81-a0f2bb3f9180" xlink:href="lxrx-20220331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_6a3d6a6a-9fd2-4bf6-ab81-a0f2bb3f9180" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_6cd6a5f4-cb20-4342-967e-14fd8f09797b" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_lxrx_AccruedLiabilitiesTable_6cd6a5f4-cb20-4342-967e-14fd8f09797b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_325b933e-1f4b-4625-b53b-f4503a8947e2" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_lxrx_AccruedLiabilitiesTable_6cd6a5f4-cb20-4342-967e-14fd8f09797b" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_325b933e-1f4b-4625-b53b-f4503a8947e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_325b933e-1f4b-4625-b53b-f4503a8947e2_default" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_325b933e-1f4b-4625-b53b-f4503a8947e2" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_325b933e-1f4b-4625-b53b-f4503a8947e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_12042a1c-8a48-4a99-883e-d8107601e534" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_325b933e-1f4b-4625-b53b-f4503a8947e2" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_12042a1c-8a48-4a99-883e-d8107601e534" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended" id="if7352d92d22947a1936f6bd44aaeffe5_CashandCashEquivalentsandInvestmentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1113dba9-1570-43e3-9e0c-79d1039fff54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1113dba9-1570-43e3-9e0c-79d1039fff54" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fdb989a9-6f4e-4a33-a382-76287a981043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fdb989a9-6f4e-4a33-a382-76287a981043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c3d1187-456d-4013-9330-fa4a48c62f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c3d1187-456d-4013-9330-fa4a48c62f53" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_ab43b0ba-af38-4b54-8986-89ffe144d44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_ab43b0ba-af38-4b54-8986-89ffe144d44b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1f57d511-37cc-4f42-8175-72ce4c340794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1f57d511-37cc-4f42-8175-72ce4c340794" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_72badf5e-0f73-465f-893e-8149c8b12564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1f57d511-37cc-4f42-8175-72ce4c340794" xlink:to="loc_us-gaap_InvestmentTypeAxis_72badf5e-0f73-465f-893e-8149c8b12564" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_72badf5e-0f73-465f-893e-8149c8b12564_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_72badf5e-0f73-465f-893e-8149c8b12564" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_72badf5e-0f73-465f-893e-8149c8b12564_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_72badf5e-0f73-465f-893e-8149c8b12564" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_38324f0e-15dd-41c7-b339-eaf3a4c3b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_CashMember_38324f0e-15dd-41c7-b339-eaf3a4c3b3f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_df5857a6-5796-490e-86d9-21c0c8a0ec04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_df5857a6-5796-490e-86d9-21c0c8a0ec04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_ef46b6cf-e605-4725-8e65-309254038572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_ef46b6cf-e605-4725-8e65-309254038572" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_49375fd4-ad23-4778-84b1-75fed7477aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_InvestmentsMember_49375fd4-ad23-4778-84b1-75fed7477aa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1b7938d7-fb32-4363-82b3-2c629a9ec828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1b7938d7-fb32-4363-82b3-2c629a9ec828" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended" id="i77e6ef49084848538c9d1ceb3d1f1fbe_CashandCashEquivalentsandInvestmentsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ab0e524-17b4-4d79-8fb7-2146accad830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_8d1e12c4-52eb-41e6-a861-b3f5cb82cc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ab0e524-17b4-4d79-8fb7-2146accad830" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_8d1e12c4-52eb-41e6-a861-b3f5cb82cc5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_14472011-1ac3-4541-9004-c30f3e787e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ab0e524-17b4-4d79-8fb7-2146accad830" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_14472011-1ac3-4541-9004-c30f3e787e5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_c5e485d4-58e0-4b7f-8586-d7d33ea507f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_14472011-1ac3-4541-9004-c30f3e787e5e" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_c5e485d4-58e0-4b7f-8586-d7d33ea507f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_c5e485d4-58e0-4b7f-8586-d7d33ea507f1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_c5e485d4-58e0-4b7f-8586-d7d33ea507f1" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_c5e485d4-58e0-4b7f-8586-d7d33ea507f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_b0a516e3-5d9d-4c6d-8e7d-56a6a26c153b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_c5e485d4-58e0-4b7f-8586-d7d33ea507f1" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_b0a516e3-5d9d-4c6d-8e7d-56a6a26c153b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20220331.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i858660a848e241f6a39dffcb8cfca787_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3be943a6-b802-4eab-9147-f7c81dec0b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3be943a6-b802-4eab-9147-f7c81dec0b2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_ed25ff8e-b8f1-41b9-ae24-715323d82955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:to="loc_us-gaap_AvailableForSaleSecurities_ed25ff8e-b8f1-41b9-ae24-715323d82955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_48c46b97-2e42-4d1b-a80b-9ddccd25c0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_48c46b97-2e42-4d1b-a80b-9ddccd25c0f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_44a2a72f-8694-4579-8323-ee74a075357f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_44a2a72f-8694-4579-8323-ee74a075357f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50e9f8b8-5945-4656-ae3c-612f7c3fbe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_44a2a72f-8694-4579-8323-ee74a075357f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50e9f8b8-5945-4656-ae3c-612f7c3fbe8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e9f8b8-5945-4656-ae3c-612f7c3fbe8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50e9f8b8-5945-4656-ae3c-612f7c3fbe8f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e9f8b8-5945-4656-ae3c-612f7c3fbe8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50e9f8b8-5945-4656-ae3c-612f7c3fbe8f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_44a28d89-ce9e-4119-99c0-c39c3f02c8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_44a28d89-ce9e-4119-99c0-c39c3f02c8f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2c2a72ca-c132-4cd9-9a73-a2a81823a440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2c2a72ca-c132-4cd9-9a73-a2a81823a440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f4e0f480-0723-476c-95ca-a8391eef6ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f4e0f480-0723-476c-95ca-a8391eef6ebf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#DebtObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended" id="i893c6eacd5b7486e95613b9a2978c3fc_DebtObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_a36ac973-107a-43e7-b6c0-bbdb5f92f142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_a36ac973-107a-43e7-b6c0-bbdb5f92f142" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_0e1c8cee-170d-4a28-9ebc-8e1c7edf3a5c" xlink:href="lxrx-20220331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_0e1c8cee-170d-4a28-9ebc-8e1c7edf3a5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_31def85d-fe11-4ae6-9897-98f9e9f6dd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_31def85d-fe11-4ae6-9897-98f9e9f6dd51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4b332b7b-75c2-4b0f-a44f-d3b0f59f63e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4b332b7b-75c2-4b0f-a44f-d3b0f59f63e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_21a0dcb1-c3d3-421a-90e3-8c493106997a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentFairValue_21a0dcb1-c3d3-421a-90e3-8c493106997a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_59d1b145-8281-478a-a997-9bdbf3c417e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_CommonStockSharesIssued_59d1b145-8281-478a-a997-9bdbf3c417e3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_432a815e-702a-4158-b476-01711666d337" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchange_432a815e-702a-4158-b476-01711666d337" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_1c906100-fa80-4f7a-be1d-34c53d0ad8f8" xlink:href="lxrx-20220331.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_AccruedInterestOnConvertible_1c906100-fa80-4f7a-be1d-34c53d0ad8f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_1e14ec7e-9061-46d0-8b82-1c70a9802400" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_1e14ec7e-9061-46d0-8b82-1c70a9802400" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_c8d64b66-c73f-462c-ab2a-2eb80a5bd0a8" xlink:href="lxrx-20220331.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_c8d64b66-c73f-462c-ab2a-2eb80a5bd0a8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_a6175540-c005-4e52-b999-cf0d0baf29b3" xlink:href="lxrx-20220331.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_a6175540-c005-4e52-b999-cf0d0baf29b3" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_87cff41a-286b-45dc-b630-ffcd8ffb5269" xlink:href="lxrx-20220331.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_87cff41a-286b-45dc-b630-ffcd8ffb5269" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_113ec275-6e57-4593-8c78-2d898e402a64" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_113ec275-6e57-4593-8c78-2d898e402a64" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_b03095e6-bdf4-4788-8355-887cdd12118e" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_b03095e6-bdf4-4788-8355-887cdd12118e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_f1dbea30-a64e-46df-b909-edb50bdcf4c1" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_f1dbea30-a64e-46df-b909-edb50bdcf4c1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6d2bf017-deab-4818-9c6a-db1b274d30bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6d2bf017-deab-4818-9c6a-db1b274d30bb" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_964db592-7f74-4013-bd2e-009a102f3bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LongTermDebt_964db592-7f74-4013-bd2e-009a102f3bfc" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_a2577024-7b90-4327-9dfa-fd183443d41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LongTermDebtTerm_a2577024-7b90-4327-9dfa-fd183443d41f" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7e107a41-e449-4d72-8977-424154cb96aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7e107a41-e449-4d72-8977-424154cb96aa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_e75b7acd-b173-4784-a81e-4e9d9b3081d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_e75b7acd-b173-4784-a81e-4e9d9b3081d2" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB_b787b308-28ba-494d-8d88-9802d7d3d9ad" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanB"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanB_b787b308-28ba-494d-8d88-9802d7d3d9ad" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC_6650ebea-9b94-4dae-82b7-198bfa6dafb9" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanC"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanC_6650ebea-9b94-4dae-82b7-198bfa6dafb9" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD_ab6283d3-f56f-453a-8a89-d04e5db48490" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanD_ab6283d3-f56f-453a-8a89-d04e5db48490" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility_efcd0d73-8570-4e43-a8e7-86b86182b8fb" xlink:href="lxrx-20220331.xsd#lxrx_OxfordLoanFacility"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_OxfordLoanFacility_efcd0d73-8570-4e43-a8e7-86b86182b8fb" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA_9d6b888e-2ebc-4d3e-8e1d-003400da9bdf" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanA_9d6b888e-2ebc-4d3e-8e1d-003400da9bdf" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant_a2ea0038-6495-4bff-88cc-1becef54f73b" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanABWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanABWarrant_a2ea0038-6495-4bff-88cc-1becef54f73b" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant_ca291914-d619-4fbb-8616-d303edd68e49" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanCWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanCWarrant_ca291914-d619-4fbb-8616-d303edd68e49" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant_c8259764-fce0-46e2-832c-f48fa421c9b8" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanDWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanDWarrant_c8259764-fce0-46e2-832c-f48fa421c9b8" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber_326f14a4-5829-4a13-80a5-20a79de24a07" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanAWarrantsNumber_326f14a4-5829-4a13-80a5-20a79de24a07" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice_9ae6e47f-07c2-49d6-b7b7-275c2160f44b" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanAWarrantExercisePrice_9ae6e47f-07c2-49d6-b7b7-275c2160f44b" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b4f6733e-6e25-47a4-9824-b0f79c68952b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b4f6733e-6e25-47a4-9824-b0f79c68952b" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_3cf143e4-ff02-495a-989a-0f58c3aa3574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_3cf143e4-ff02-495a-989a-0f58c3aa3574" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2cdab534-5cfe-41bc-9720-299c6fe54f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2cdab534-5cfe-41bc-9720-299c6fe54f18" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_a6e9dbe5-f082-4b6c-9dc3-1cd68279411e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_a6e9dbe5-f082-4b6c-9dc3-1cd68279411e" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate_cd8ab508-415f-44ed-b3b1-2c592861fb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_SubordinatedBorrowingInterestRate_cd8ab508-415f-44ed-b3b1-2c592861fb63" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention_11469a2b-99c4-4165-84d6-e6a526cb7855" xlink:href="lxrx-20220331.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_FinalPaymentWithNoExtention_11469a2b-99c4-4165-84d6-e6a526cb7855" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention_205cf900-8c8f-4667-89b8-45722e371a20" xlink:href="lxrx-20220331.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_FinalPaymentWithExtention_205cf900-8c8f-4667-89b8-45722e371a20" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment_0e198172-7d6f-47ff-887c-1996fa218ca7" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanAFinalPayment_0e198172-7d6f-47ff-887c-1996fa218ca7" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt_25c84132-e983-4fab-8ed6-4c4c4e3679bd" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanANetCashReceipt_25c84132-e983-4fab-8ed6-4c4c4e3679bd" xlink:type="arc" order="38"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts_12ef71f0-946d-47e5-a56d-89c5b53a5f06" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanADebtIssuanceCosts_12ef71f0-946d-47e5-a56d-89c5b53a5f06" xlink:type="arc" order="39"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee_3d6b3358-7373-49d3-a65a-136e233079be" xlink:href="lxrx-20220331.xsd#lxrx_OxfordFacilityFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_OxfordFacilityFee_3d6b3358-7373-49d3-a65a-136e233079be" xlink:type="arc" order="40"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount_989cfeba-4be5-4dac-837a-cc1b0c0ca0f3" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanADebtDiscount_989cfeba-4be5-4dac-837a-cc1b0c0ca0f3" xlink:type="arc" order="41"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAInterestExpense_88b3ef44-9629-4bab-9a6b-0e257d02ffc3" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanAInterestExpense_88b3ef44-9629-4bab-9a6b-0e257d02ffc3" xlink:type="arc" order="42"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPayments_129fdbc1-ae2e-493a-b7bc-53d71080e802" xlink:href="lxrx-20220331.xsd#lxrx_A2025OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_A2025OxfordPrincipalPayments_129fdbc1-ae2e-493a-b7bc-53d71080e802" xlink:type="arc" order="43"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments_b824b24b-efac-4ed4-b462-5bc3d3bd2e81" xlink:href="lxrx-20220331.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_A2026OxfordPrincipalPayments_b824b24b-efac-4ed4-b462-5bc3d3bd2e81" xlink:type="arc" order="44"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments_6a819ebf-3f4b-40b8-9d0d-443d590c98d3" xlink:href="lxrx-20220331.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_A2027OxfordPrincipalPayments_6a819ebf-3f4b-40b8-9d0d-443d590c98d3" xlink:type="arc" order="45"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ef073502-9ee2-4d7b-a973-691b26392203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentTable_ef073502-9ee2-4d7b-a973-691b26392203" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="ifab9d36fcf60423eabbf60fca752e898_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_cd593513-25aa-4b50-96a8-91f415e855dc" xlink:href="lxrx-20220331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_cd593513-25aa-4b50-96a8-91f415e855dc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_240da60e-bf68-4afa-995c-9060550daa69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_240da60e-bf68-4afa-995c-9060550daa69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b55b6225-4d41-4820-917d-67b1727b5e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b55b6225-4d41-4820-917d-67b1727b5e2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3cd39274-e136-4167-9336-3c2013e62274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3cd39274-e136-4167-9336-3c2013e62274" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0686253d-7559-4b30-9783-2a0dd6d4c3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0686253d-7559-4b30-9783-2a0dd6d4c3df" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_646e103b-c3cc-42a4-8263-cb84b8ec7e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_646e103b-c3cc-42a4-8263-cb84b8ec7e5d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e24e6088-6008-4dbf-941b-4a562adab670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e24e6088-6008-4dbf-941b-4a562adab670" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8482c250-8db8-4381-a98d-0aefe794bc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8482c250-8db8-4381-a98d-0aefe794bc3c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_45b32275-86b8-47fe-9288-d6277c3e8a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_45b32275-86b8-47fe-9288-d6277c3e8a15" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5892f5f0-2019-4bf3-ac4a-83b879c28b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_OperatingLeaseLiability_5892f5f0-2019-4bf3-ac4a-83b879c28b91" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_cc2fd39e-20dc-4274-a393-abb3a6605db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_cc2fd39e-20dc-4274-a393-abb3a6605db0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c181b43-c927-4827-9aea-3fd3d8da7cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c181b43-c927-4827-9aea-3fd3d8da7cdf" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts_e99bff22-73a1-4680-96f1-bc56d6c0e3d2" xlink:href="lxrx-20220331.xsd#lxrx_SanofiDisputedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_lxrx_SanofiDisputedCosts_e99bff22-73a1-4680-96f1-bc56d6c0e3d2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_8d45f3fb-32b6-4731-82b0-ef1660105643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_OtherCommitmentsTable_8d45f3fb-32b6-4731-82b0-ef1660105643" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3e202ac4-f676-49be-925b-19a7d5457c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_8d45f3fb-32b6-4731-82b0-ef1660105643" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3e202ac4-f676-49be-925b-19a7d5457c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_3e202ac4-f676-49be-925b-19a7d5457c4e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3e202ac4-f676-49be-925b-19a7d5457c4e" xlink:to="loc_us-gaap_ReceivableTypeDomain_3e202ac4-f676-49be-925b-19a7d5457c4e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a6a85fb3-5108-43c4-a97b-44588355301e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3e202ac4-f676-49be-925b-19a7d5457c4e" xlink:to="loc_us-gaap_ReceivableTypeDomain_a6a85fb3-5108-43c4-a97b-44588355301e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3e31bb71-12b2-4f9b-a456-26f2ac3e34cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_a6a85fb3-5108-43c4-a97b-44588355301e" xlink:to="loc_us-gaap_AccountsReceivableMember_3e31bb71-12b2-4f9b-a456-26f2ac3e34cb" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>lxrx-20220331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d7a1dbc6-b99b-4a1d-848b-92cec6605016,g:574c9470-43fb-4b26-864a-707e5ed846fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_TreasuryStockShares_47e00f61-c9da-486d-b0c4-4fad8fd981e0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_83634e56-5fbc-4ab1-875d-97e9aeb00bb1_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchange" xlink:to="lab_lxrx_ConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b8a296ce-dd76-46b7-b032-6e8b0c03a042_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c311667-2ecd-4156-937f-254d5af322a9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b8df3acd-be5a-4d31-b4d6-dc791ef40326_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_5659c375-9008-4c0a-ab98-4a066f09f85e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_c3c09947-261e-4449-b834-6a990b9b5deb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_891d5405-f193-4594-a5c6-2a02d73e0dcb_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchangeShares_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Convertible debt exchange shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:href="lxrx-20220331.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchangeShares" xlink:to="lab_lxrx_FutureConvertibleDebtExchangeShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_c64a73d6-2efa-4e20-8f37-bb28907c6dbc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_2a9ff3d8-7881-4635-b114-0fb4e38a33d2_terseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_acbe7239-7d2d-4ab6-9595-406d3aa395a2_negatedTerseLabel_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_label_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:label id="lab_lxrx_GainOnSaleOfNonFinancialAssets_documentation_en-US" xlink:label="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of non-financial assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:href="lxrx-20220331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_GainOnSaleOfNonFinancialAssets" xlink:to="lab_lxrx_GainOnSaleOfNonFinancialAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_6b5aa09a-512b-45bb-8d32-c488a42952eb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_DebtObligationsAbstract_ecc97da3-4b27-4317-883d-f2058b688969_terseLabel_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_label_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:label id="lab_lxrx_DebtObligationsAbstract_documentation_en-US" xlink:label="lab_lxrx_DebtObligationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Obligations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract" xlink:href="lxrx-20220331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_DebtObligationsAbstract" xlink:to="lab_lxrx_DebtObligationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_48ad9603-fe71-4ad1-8d07-09cab56f7d2e_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales (including finite-lived intangible asset amortization)</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_37695add-2aea-44f7-adb9-3ecf8494a197_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cd25fff0-85bd-43e3-af7b-d035073439a7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_8ac75da5-2430-4da9-b5a8-45f9a8c883cd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_9cecda4d-a12f-4d4f-a8be-f4c7ffadcb01_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation and amortization, property and equipment</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_b1f65d4b-ad09-44fd-82e3-0753dfde4c77_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_6526300d-7b74-4915-be61-871eacce4ce0_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ff170765-c165-4195-b36b-bc530eda03df_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_a7291422-541a-43fe-aaad-f65df62156df_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_85d8ce9a-8ca8-48bc-9bbb-84a74b7c32ee_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_04646642-1d44-4868-aa39-5d2aa8eb08b2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_9cd0aca6-e329-41ce-963a-49dafcd5ed80_terseLabel_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_label_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:label id="lab_lxrx_LiabilitiesAssumedByTerSera_documentation_en-US" xlink:label="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed by TerSera</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:href="lxrx-20220331.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LiabilitiesAssumedByTerSera" xlink:to="lab_lxrx_LiabilitiesAssumedByTerSera" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2812235a-4014-44f0-969f-927c66debbb8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 225,000 shares authorized; 150,082 and 150,082 shares issued, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_333d83ac-124c-4f63-8b23-ace29e0f1c96_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Lease Commitment, Amount</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCommitmentAmount" xlink:to="lab_us-gaap_ShortTermLeaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_8e233f14-19ae-4434-8f58-d83acbc4b485_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_77d70781-bbd5-4e28-bc2b-f982c6603669_terseLabel_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_label_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithNoExtention_documentation_en-US" xlink:label="lab_lxrx_FinalPaymentWithNoExtention" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with no extention</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention" xlink:href="lxrx-20220331.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalPaymentWithNoExtention" xlink:to="lab_lxrx_FinalPaymentWithNoExtention" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_84c2ba94-7072-4553-baa5-c750ac5831f2_terseLabel_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_label_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:label id="lab_lxrx_FairValueMeasurementsAbstract_documentation_en-US" xlink:label="lab_lxrx_FairValueMeasurementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract" xlink:href="lxrx-20220331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FairValueMeasurementsAbstract" xlink:to="lab_lxrx_FairValueMeasurementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_3a8a650e-c2e2-493d-a6dd-92fe830d6316_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_e43ca0bb-c2aa-4456-b5d6-1c20975bd3f5_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_55abb138-1902-46e8-8a19-13e00eb329bc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_9dd34ee0-5d06-47d0-85a5-7fa4c3caad78_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_288fcb85-9fc9-4e84-8ef2-b93e52e2fc6a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_bab7c8a4-6168-4988-99ce-bba416e259c1_terseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1481b8bc-ff83-49a8-802f-ce5ff0c274b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_9f375722-95b1-4a20-8805-32db78c80e29_terseLabel_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative, including stock-based compensation of $1,740, and $1,565, respectively</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_label_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_lxrx_Sellinggeneralandadministrativeexpenses_documentation_en-US" xlink:label="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:href="lxrx-20220331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Sellinggeneralandadministrativeexpenses" xlink:to="lab_lxrx_Sellinggeneralandadministrativeexpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_70e4fcc9-55b3-4042-b7a2-adfd7ff7d83a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_60827379-3e69-4d68-924c-4145db5ac046_terseLabel_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_label_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current</link:label>
    <link:label id="lab_lxrx_AccruedCompensationAndBenefitsCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits current - due within 1 year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:href="lxrx-20220331.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:to="lab_lxrx_AccruedCompensationAndBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_78d01bfc-e3c6-4ac6-87dc-4e4964bdc464_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_d5bc0e1a-ed2e-471e-b8f4-9369be15b27c_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:href="lxrx-20220331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanDWarrant_419eb1ad-b0bd-442e-a3f7-7ed321bb75d9_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanDWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanDWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanDWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanDWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanDWarrant" xlink:to="lab_lxrx_TermLoanDWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9d1b895b-9136-4ffb-8bd2-cfe17d9c0e88_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_19f9cd6b-ff47-4f0f-8957-08860672dfb1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_b6caefbb-f00e-488f-90bf-5281288743ca_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_7ad2c019-68cc-46d9-8af2-e515a75fbc3c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1fe82e07-ae4f-4851-a71f-6bc35ce68e9b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_b864ae65-c04c-4ad7-847d-98be15abbd7c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_40843b7c-f914-4b3b-a3a6-563252394eea_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_fe7cc964-ddba-4e9e-b25c-6601d75e9808_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_label_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Maximum Sales Milestones</link:label>
    <link:label id="lab_lxrx_IpsenMaximumSalesMilestones_documentation_en-US" xlink:label="lab_lxrx_IpsenMaximumSalesMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones" xlink:href="lxrx-20220331.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMaximumSalesMilestones" xlink:to="lab_lxrx_IpsenMaximumSalesMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_819bf0b9-4e82-4c45-ab18-3fce25794d1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f8808e1e-91f1-4fab-97df-6e4bb8c3e521_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_092d5aae-751a-434b-a8a5-2518e7c9a58c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_de22cd77-bdfe-4887-a43d-c8821abfba66_terseLabel_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_label_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:label id="lab_lxrx_FutureConvertibleDebtExchange_documentation_en-US" xlink:label="lab_lxrx_FutureConvertibleDebtExchange" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">future convertible debt exchange</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange" xlink:href="lxrx-20220331.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FutureConvertibleDebtExchange" xlink:to="lab_lxrx_FutureConvertibleDebtExchange" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_022eea41-c920-42b7-a4c3-9613ce2eba5d_terseLabel_en-US" xlink:label="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of Asset and Liability for Lease of Acquiree</link:label>
    <link:label id="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognition of Asset and Liability for Lease of Acquiree [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:to="lab_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_492b8004-e01b-4b7c-b25e-0e0f9a5dea8c_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Axis]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesAxis_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesAxis" xlink:to="lab_lxrx_AccruedLiabilitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_e00a5202-c02a-4e5b-9249-5f43867871fa_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - Total Principal Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:to="lab_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_9924e735-8129-4077-9ca1-c5d1f25dec0b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_0611503d-0504-48e6-9804-97f23e7ef585_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_f3453cf9-f44e-447e-9740-2aa64563523f_terseLabel_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments2</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2027OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2027OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments" xlink:href="lxrx-20220331.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2027OxfordPrincipalPayments" xlink:to="lab_lxrx_A2027OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3069b6f1-0f48-4e94-8400-4da7acf35311_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_09f95810-8ac8-440d-9c6a-916337a92ebc_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eecde50-ea33-43d5-a0b6-32f661f66176_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_1f3cfe43-cb82-4039-9d85-2599b80a6ca8_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_a7332d69-6b61-47c8-a2fc-7d6581f599f6_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement, Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_a2bda1e1-870c-40e3-ac12-5a8f51f44c56_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a07a8ab1-b27b-4542-aac7-aad3ab1ae4d2_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_9a7f022f-2c85-4ce7-842d-122c148ad59a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a8310ac1-febe-43eb-a8ad-a5fa8629612e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_2164c5ac-cdbf-4b3b-b83d-82ac2da412d5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_268dfb67-43eb-4325-b7f4-1f10cac3c58e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_542ac976-80c3-4637-bb0c-6c079f8429c5_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_3abc9ad1-183f-4562-89e7-459f5f922c03_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c3654e9f-a8e8-42b8-89e2-193f3bb64360_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_a48168db-f58c-4391-8e74-865a03e9fabe_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_d7d48ca7-a50f-4b4b-ae41-ac19a25b5e13_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_732840c5-4ae2-4faa-81a8-287e9698d1e1_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_73ae6157-124d-44ae-9ba7-924f0ee781d0_terseLabel_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_label_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:label id="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_documentation_en-US" xlink:label="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:href="lxrx-20220331.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:to="lab_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_ef60262f-5088-4e49-8ce9-45836e43938b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_84c08622-483b-47de-a78d-206522c5a436_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Domain]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesDomain_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesDomain" xlink:to="lab_lxrx_AccruedLiabilitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_91a3654a-beb9-4754-96ab-0d6f58ea3b17_terseLabel_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with research and development expense</link:label>
    <link:label id="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense included in research and development expense.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:href="lxrx-20220331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:to="lab_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_a1ba80ad-dff9-4f26-921c-0cf594b9d159_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_215dd1fa-8800-49ac-9d50-313295863fff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_f911d030-fbd1-4b39-bb3d-d609707706ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOfferring_404bb292-360c-48cc-b830-1e82a0785362_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOfferring_label_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharePriceInSeptember2021ATMOfferring_documentation_en-US" xlink:label="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price in September 2021 ATM Offerring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:href="lxrx-20220331.xsd#lxrx_SharePriceInSeptember2021ATMOfferring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:to="lab_lxrx_SharePriceInSeptember2021ATMOfferring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f22e936d-83d6-4f37-8499-cf00ecdd1c39_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_5d7e95ea-cdb4-4144-a799-68755a04965e_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_77e0a127-1de7-4d45-9f5c-ef70dd9f1fb5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_d4698066-dc54-44ec-a36c-f5e726be7fae_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_9a0cad86-c15b-4d57-a464-56a03e3b80a3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2c698711-3af2-4214-a31f-8575dd50149a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net of accumulated depreciation and amortization of $4,962 and $4,853, respectively</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_04a63475-a2f2-4c63-8ba8-92f1d7d77449_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_0e9853c0-4e76-4c8b-acd2-cf44fe9a1d29_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of debt borrowings, net of fees</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_877a7e1c-68b5-413c-8a1b-66052afc3090_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_label_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Recognized</link:label>
    <link:label id="lab_lxrx_IpsenRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized" xlink:href="lxrx-20220331.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueRecognized" xlink:to="lab_lxrx_IpsenRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_d57b2b87-fb55-4bf6-a98f-abc671f4f3b2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePayment_2f1d80a6-f078-42b7-bdc3-f4f9896ded56_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePayment_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment" xlink:href="lxrx-20220331.xsd#lxrx_IpsenMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePayment" xlink:to="lab_lxrx_IpsenMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_65bcb9b7-b909-438f-975c-65816e968d12_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 488 and 1,165 shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPayments_f79b16f8-365a-40f6-a065-948b49352d7e_terseLabel_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2025OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2025OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPayments" xlink:href="lxrx-20220331.xsd#lxrx_A2025OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2025OxfordPrincipalPayments" xlink:to="lab_lxrx_A2025OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3618187b-aab5-4b1d-8f22-cc3b628abe59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_8abf8c95-ee1f-49d1-bb05-7f0660320bb3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e18aaa96-6493-4fa5-91f6-4215bdc0edcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ae2c6d59-7eec-4b71-a4b5-319d875cc240_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8ed8010e-3b35-43a8-ab38-de44b4e5a003_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_f5619688-f35a-4e33-ae99-efc784093933_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8bacaa40-f615-41a8-9b28-79aacdb33e83_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_2c198cb3-c2bd-4a5b-8b14-6b5fb2a7e69c_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_237cd5f5-5beb-4355-b225-c4ea07753ceb_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_label_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:label id="lab_lxrx_TermLoanAFinalPayment_documentation_en-US" xlink:label="lab_lxrx_TermLoanAFinalPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Final Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAFinalPayment" xlink:to="lab_lxrx_TermLoanAFinalPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_91849c24-3b9c-4c26-be24-eea48a0d0bf8_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_83fc38f7-7ca2-46bf-8eb3-06366daaee33_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_a0baeb9e-72f3-4b60-9afe-7a91f2c82c56_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease) (Deprecated 2022)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f8a746dc-87b0-4ca8-a29f-562873dfb373_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_e99e5d28-e1f2-44d8-adbc-13e584a5f528_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f842901f-a866-4e9b-a692-eb83fba7aa5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_1e9db810-27d5-4cbb-bf5b-95523aa0272f_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b2bc06fa-521f-4f33-8638-54c0d65abe2c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c2c2fa5a-b94e-4b46-a072-81603b2d5d2a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_1b8e768a-75f0-47c1-99b6-86e2f8a694fa_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_d1365c14-ff3c-40fd-a990-fa346e197f66_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Fair Value of Amount Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:to="lab_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e90a7727-d7c1-4a26-a585-b0e3f8dd776e_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7acc361c-ee12-466e-8bc1-2ea0629f0ba7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_daa55392-05a5-4687-8dc5-f533ad137a26_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_94ea3801-684e-45b9-81cd-0d50e76bf110_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_2bfcdc0a-1560-4397-9c27-48a5bb9840c5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_c9a0be25-8863-44cd-a406-d7c363ec65f8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOfferring_46254dd1-ddf6-4603-8e20-299e8773173b_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOfferring_label_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM Offerring</link:label>
    <link:label id="lab_lxrx_SharesSoldInSeptember2021ATMOfferring_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in September 2021 ATM Offerring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:href="lxrx-20220331.xsd#lxrx_SharesSoldInSeptember2021ATMOfferring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:to="lab_lxrx_SharesSoldInSeptember2021ATMOfferring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_26f2d4b8-925c-4ab9-a89c-d55a0c6db80b_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_5c5d69c7-f356-47a1-9cd5-f11cd28c138a_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_31368076-9995-4555-9276-897d990a8fb5_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:href="lxrx-20220331.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharePriceInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_46be9087-79d1-474b-8c37-877380e0c732_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_b32418e7-51e4-4331-b26d-26ed62854e2e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_3310b9ba-fa92-4cd1-97aa-ae4565248003_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_bae4b30c-8223-4e17-a336-5cbe2b3a62aa_terseLabel_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:label id="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_label_en-US" xlink:label="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of Stock and Warrants for Services or Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:to="lab_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_9ee142f9-0ed8-48bf-9e84-1d37b411792e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_56393ea3-a901-4204-b582-a8714cbc99cd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_39f0ce13-560a-48e7-8198-8d379a24a967_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_fe042a6a-bc9b-4fc5-adcb-eb737eb0dc2b_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_c79d16a5-fd14-4d5d-a874-e5d8a594c993_terseLabel_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_label_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:label id="lab_lxrx_SettlementPaymentFromTermination_documentation_en-US" xlink:label="lab_lxrx_SettlementPaymentFromTermination" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Payment from Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination" xlink:href="lxrx-20220331.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SettlementPaymentFromTermination" xlink:to="lab_lxrx_SettlementPaymentFromTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_61c4b6d2-9a85-44ab-8b2d-bb99492c029e_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanABWarrant_592ed554-59a0-4bf0-9d21-08f098b6dd94_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanABWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanABWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanABWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A&amp;B Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanABWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanABWarrant" xlink:to="lab_lxrx_TermLoanABWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_df5a693e-c175-4146-bea1-c615987a682d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_c143a35f-76da-48eb-952a-8ad893df6fdc_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_label_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:label id="lab_lxrx_TermLoanANetCashReceipt_documentation_en-US" xlink:label="lab_lxrx_TermLoanANetCashReceipt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Net Cash Receipt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanANetCashReceipt" xlink:to="lab_lxrx_TermLoanANetCashReceipt" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_eefc8793-9ee7-4ea6-9bbd-050456420dc9_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from January 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:href="lxrx-20220331.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_4882393c-80fc-4de4-bde6-12bb46bb5d6f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f6a7560c-e8da-4239-bc51-87760b409db4_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_fef104ac-2a86-49a9-8bee-044f1c144fe2_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_5e612abe-07a3-40a1-8432-963af8df5e3a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubordinatedBorrowingInterestRate_38230da2-cebb-478a-8771-9f2a3641b523_terseLabel_en-US" xlink:label="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated Borrowing, Interest Rate</link:label>
    <link:label id="lab_us-gaap_SubordinatedBorrowingInterestRate_label_en-US" xlink:label="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subordinated Borrowing, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubordinatedBorrowingInterestRate" xlink:to="lab_us-gaap_SubordinatedBorrowingInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_d2609291-d79e-4e38-96c4-c1f44d29dd42_terseLabel_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_label_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:label id="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_documentation_en-US" xlink:label="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense associated with selling, general and administrative expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:href="lxrx-20220331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:to="lab_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6a5238b6-4f59-4da1-a616-ba07b6e86704_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_250aacbe-2905-460e-9982-7958075ed87a_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_58293590-7f87-47a3-897d-ab592fcf79e5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_1c0fd168-110b-450d-bed6-a16bb33cb74b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_420723c8-bfe0-4005-b04c-c1c5dc919dbd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_2af21cd2-a067-4f34-8d26-24ee0ee91761_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedBalanceSheetsAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Balance Sheets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:href="lxrx-20220331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:to="lab_lxrx_ConsolidatedBalanceSheetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3b1816a7-35b0-4cb7-8bb4-396564f55c33_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_f7eac36c-8096-481b-a459-9ad0805b52d2_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_4e9cc11b-aff2-4851-baf7-4f9adc112bb2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_f6592c40-364f-49ba-a1a6-316f2f839d03_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInJanuary2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in January 2021 ATM offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:href="lxrx-20220331.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:to="lab_lxrx_SharesSoldInJanuary2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_b589b62a-966c-444d-9db4-76854175833a_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_3dfb65c1-adff-4814-ab87-faa3ad6687f6_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury Securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_46b0b3ad-6860-4d7a-86bf-f4323c96d6c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_369417c8-3369-424c-861e-ad2c01786a9e_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_36dfef9f-a170-4c0a-a69f-322c38e0e5a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_512cd4bd-26a1-45ac-a0f4-76f332ebefc0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_b73b4192-ea58-4238-838c-c909ccb6d023_terseLabel_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_label_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:label id="lab_lxrx_LexiconIncrementalBorrowingRate_documentation_en-US" xlink:label="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lexicon incremental borrowing rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate" xlink:href="lxrx-20220331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_LexiconIncrementalBorrowingRate" xlink:to="lab_lxrx_LexiconIncrementalBorrowingRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_d61e0cc9-6971-41f9-ae83-62925f48811c_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeRemainingNotes_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange Remaining Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:to="lab_lxrx_ConvertibleDebtExchangeRemainingNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_0e4f176d-9094-49a6-8817-944af594e10a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ef1fdc07-60dc-4035-8be3-eb170fa6cc12_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenTotalPayments_6793db28-6e4c-4d0c-8b13-766e8d0b2b06_terseLabel_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_label_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Total Payments</link:label>
    <link:label id="lab_lxrx_IpsenTotalPayments_documentation_en-US" xlink:label="lab_lxrx_IpsenTotalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments" xlink:href="lxrx-20220331.xsd#lxrx_IpsenTotalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenTotalPayments" xlink:to="lab_lxrx_IpsenTotalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_93813878-69ea-41f6-868e-1218e52b20da_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_798f5f94-48dd-41a1-b507-782537fbd19c_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange - September share payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberSharePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e2384f5f-ebef-4be1-a88e-85e7170a0888_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_f87c094d-5cc7-4168-be0d-c6cacbcf2166_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_952d2f2b-b244-4abd-9442-6b89ff55d444_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_97fa3786-ecb6-4319-b765-6242a585dc1f_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_70409d5a-00e1-460d-bb7b-c0087b28d73b_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Short-term Investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_f7573983-e799-4a97-834c-eaa523320a7d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9875479a-a307-4942-bf89-609f07aecde9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net loss per common share, Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2efd4705-469d-4029-bcd3-46db1266b02b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_202a104c-fa1c-4063-87b8-2f18ce4ba609_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_aef773dc-5b81-4a10-890c-414a8b4a8507_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_959d6aa6-a3b6-4546-a729-19c3c5f2356f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_346ffd80-011b-496f-bf8d-ea2b48a6f508_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_656f8d44-0962-44c2-96cd-229ba90142f6_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_label_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantsNumber_documentation_en-US" xlink:label="lab_lxrx_TermLoanAWarrantsNumber" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrants Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAWarrantsNumber" xlink:to="lab_lxrx_TermLoanAWarrantsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_45d1fa8c-9de5-47d3-94e4-d8e76ab3a899_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7d806a45-01fc-43cc-a961-c3e0e27b8cfa_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f5e81134-8723-4ffb-a0a9-b205c4a1a38e_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_82cae4f8-9040-44e2-8fb3-ca9f0d14a68d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_63edc137-45f3-4ee6-923f-77ab9cf150a7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under Equity Incentive Plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_0a0958f8-8c11-4bc3-8ef1-c0fbccacb5c3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_1ba9ed4d-e736-4e0f-8da0-b9e9a5fcc4a4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanD_91200c18-986d-4836-85a8-05fed9b5cf1f_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:label id="lab_lxrx_TermLoanD_label_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:label id="lab_lxrx_TermLoanD_documentation_en-US" xlink:label="lab_lxrx_TermLoanD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan D</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanD" xlink:to="lab_lxrx_TermLoanD" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_107d8ef9-313f-42c8-adaf-06dc76d1fe97_terseLabel_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_label_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements [Text Block]</link:label>
    <link:label id="lab_lxrx_OtherCapitalAgreementsTextBlock_documentation_en-US" xlink:label="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Capital Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:href="lxrx-20220331.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OtherCapitalAgreementsTextBlock" xlink:to="lab_lxrx_OtherCapitalAgreementsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanC_8bc3239e-2509-4a0f-9235-29c434e8e76c_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:label id="lab_lxrx_TermLoanC_label_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:label id="lab_lxrx_TermLoanC_documentation_en-US" xlink:label="lab_lxrx_TermLoanC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanC"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanC" xlink:to="lab_lxrx_TermLoanC" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ba7cb8f9-a5fb-4e3d-be33-4e80cf0900f7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanB_c0ac3c6b-1619-482a-8aca-c1e8e1fedcd4_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_lxrx_TermLoanB_label_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:label id="lab_lxrx_TermLoanB_documentation_en-US" xlink:label="lab_lxrx_TermLoanB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanB"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanB" xlink:to="lab_lxrx_TermLoanB" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_76507f5b-57ae-4c34-a80b-508f7ce142cb_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanA_6cb6b0fe-dc79-48f3-80e7-ca43fae6489f_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_lxrx_TermLoanA_label_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:label id="lab_lxrx_TermLoanA_documentation_en-US" xlink:label="lab_lxrx_TermLoanA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanA" xlink:to="lab_lxrx_TermLoanA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTerm_397f9b7d-0fd6-4875-9fe5-e4a8bbf4fbba_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Term</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTerm_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTerm" xlink:to="lab_us-gaap_LongTermDebtTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b0f2d82f-f346-4cc5-877a-f098c3aa6393_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_671a1200-764c-48bd-8593-552265c851d7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_da6481c1-18de-46a8-8ae0-b3f875e80050_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_665b6906-a5f2-457e-ad98-135cea040516_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, value</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_edaf213e-2118-4e1f-88b4-4087b71a4188_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_a90c22c5-b41f-44f6-bdd7-37aeab21e646_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_35d99c4f-b9f7-4b3d-8014-6a0da28ab396_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:to="lab_us-gaap_DebtInstrumentConvertibleConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_39448e23-d315-44d9-9cc5-63ac0247eaa9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_c416c1d6-d967-4f9f-b74b-62418d5d111f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_b5d93e65-8e87-40ed-a3d7-e1a04fb163fc_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e63aeadc-f376-4107-924c-83006f7473b2_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateAxis_fee7f70a-ea57-48e1-aba0-835438f52d25_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardDateAxis_label_en-US" xlink:label="lab_us-gaap_AwardDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateAxis" xlink:to="lab_us-gaap_AwardDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c49441ac-36fe-41e3-8380-172cb92d0acc_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_c6bd1a31-3a1d-4aa4-934d-bc39668404a8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d8c4acb4-ae4c-4dba-b56c-ddb9a377b277_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_e7cf5413-0afa-4ce3-9abd-92093257c092_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The expected term assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9129d8f7-bb36-4593-a2d7-5561bd456ec0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development, including stock-based compensation of $1,032, and $1,286, respectively</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_70a34095-6aad-49de-bcb2-b699b81a6c56_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_label_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_Sanofiterminationcashpayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:href="lxrx-20220331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:to="lab_lxrx_Lxrx_Sanofiterminationcashpayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_2424f314-5f41-44ee-8a70-434242e86d80_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:label id="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_label_en-US" xlink:label="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_cc93ae1f-baf2-403f-9a57-6571f5413c80_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_575e505f-33d5-4483-81ef-618896a8e436_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_41df3f2b-be43-4234-be64-d7c8b5910f2b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_2816ca9b-d27a-4475-a66c-891c31db50fb_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_03de9767-0695-46bd-b264-357614c78463_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_22bdc3e8-c125-434b-81e6-295126b9076d_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Income Statement Elements [Abstract]</link:label>
    <link:label id="lab_us-gaap_SupplementalIncomeStatementElementsAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Income Statement Elements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:to="lab_us-gaap_SupplementalIncomeStatementElementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ecd81a1f-280c-4668-ac18-463b53ee23d2_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_b26947f6-0fe0-45c2-9d37-d509b0759902_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c19f9720-623b-42e5-8c9a-82bc5bf7bf88_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_beb9e3c3-0eca-4fd9-9531-09fdede7d016_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_a6b4a85f-84ab-42ad-b756-321af7308af9_terseLabel_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_label_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:label id="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_documentation_en-US" xlink:label="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt exchange- September cash portion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:to="lab_lxrx_ConvertibleDebtExchangeSeptemberCashPortion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_61792f4d-047c-41ef-97bb-3753b4f99f20_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_ea924960-4bad-452d-bd6b-39c9b83a4916_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_dc93037e-0dda-4299-9d49-1cbd8be0bc9a_terseLabel_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_label_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Revenue Allocated to Development Deliverable</link:label>
    <link:label id="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_documentation_en-US" xlink:label="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:href="lxrx-20220331.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:to="lab_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockOptionMember_29f7444d-c261-4696-a96f-df07ca1f2e3a_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_label_en-US" xlink:label="lab_us-gaap_StockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember" xlink:to="lab_us-gaap_StockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_09f253cb-3138-43f5-a7b7-65aa22267dd3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_a7a66e89-e977-42bc-a8b3-b4302f790c0b_terseLabel_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_label_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:label id="lab_lxrx_PrincipalAmountOfConvertibleNotes_documentation_en-US" xlink:label="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">principal amount of convertible notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:href="lxrx-20220331.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_PrincipalAmountOfConvertibleNotes" xlink:to="lab_lxrx_PrincipalAmountOfConvertibleNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_f9aae514-709e-47e2-a36e-be8348b0a222_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_eda6ddf9-bcc1-48a3-8604-061de3e48ddb_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromSeptember2021ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from September 2021 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:href="lxrx-20220331.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:to="lab_lxrx_ProceedsFromSeptember2021ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e939a8a6-cea1-4229-91de-71c9fc853f0c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_26ac8f4c-b301-440a-80c3-ebc38b8577e5_terseLabel_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_label_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:label id="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent_documentation_en-US" xlink:label="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development services current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:href="lxrx-20220331.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:to="lab_lxrx_AccruedResearchAndDevelopmentServicesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_6e49ab68-047b-4406-a882-01a558278b65_terseLabel_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharesSoldInNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares sold in Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:href="lxrx-20220331.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharesSoldInNov2020ATMOffering" xlink:to="lab_lxrx_SharesSoldInNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_21c0abe4-667a-4c20-8328-f500bf781b58_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2d560c41-7713-4b7a-baff-ff496175a0be_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_c9418ed5-41b8-4e49-9c78-006f19e4d165_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_466cbd09-d8fa-48b3-bfc6-0e32d669532e_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesTable_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued liabilities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesTable" xlink:to="lab_lxrx_AccruedLiabilitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_94ec670f-4521-41f4-9c01-0a9732512456_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:label id="lab_us-gaap_SecuredLongTermDebt_label_en-US" xlink:label="lab_us-gaap_SecuredLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Secured Long-Term Debt, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredLongTermDebt" xlink:to="lab_us-gaap_SecuredLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6282b9b9-d4b9-4837-9336-13fa1fa8e9d3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_30005dc1-ad2d-4db7-af4e-311a48e6f978_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_db539dad-1316-43f3-9b91-f4ed728dfb89_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share, Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_6d6e0562-83a3-4b22-b2fa-7653294a1a9d_terseLabel_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_label_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:label id="lab_lxrx_A2026OxfordPrincipalPayments_documentation_en-US" xlink:label="lab_lxrx_A2026OxfordPrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026 Oxford Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments" xlink:href="lxrx-20220331.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_A2026OxfordPrincipalPayments" xlink:to="lab_lxrx_A2026OxfordPrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanCWarrant_a365c435-179c-4d08-9579-aa61b663e4a9_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanCWarrant_label_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:label id="lab_lxrx_TermLoanCWarrant_documentation_en-US" xlink:label="lab_lxrx_TermLoanCWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan C Warrant %</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanCWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanCWarrant" xlink:to="lab_lxrx_TermLoanCWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ebd1b076-a338-4279-9936-aec44ed48d42_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_4a66a7a1-59f6-4a97-b359-cbb78da53c54_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_48d8d52d-8a9b-418d-b289-f7c87851b18d_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_label_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:label id="lab_lxrx_TermLoanADebtIssuanceCosts_documentation_en-US" xlink:label="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanADebtIssuanceCosts" xlink:to="lab_lxrx_TermLoanADebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_85117758-a9d6-4102-99d7-42b04ef3474d_terseLabel_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_label_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:label id="lab_lxrx_RecentAccountingPronouncementsAbstract_documentation_en-US" xlink:label="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:href="lxrx-20220331.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract" xlink:to="lab_lxrx_RecentAccountingPronouncementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_dff6e4ee-4914-42e6-be06-9911fc4f5bcd_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_738c8f6e-1e31-4cad-b0a7-904e37f4edf0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_91fd9fa6-f190-48ab-bbb1-bcb390ee6a90_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_3376db46-fe12-4a65-9418-1e60ecaca0df_terseLabel_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_label_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Milestone Payment Received</link:label>
    <link:label id="lab_lxrx_IpsenMilestonePaymentReceived_documentation_en-US" xlink:label="lab_lxrx_IpsenMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived" xlink:href="lxrx-20220331.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_IpsenMilestonePaymentReceived" xlink:to="lab_lxrx_IpsenMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_d2d5456d-95fb-4c65-9d62-5986d0e38693_terseLabel_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_lxrx_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:href="lxrx-20220331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_lxrx_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_812d0a45-8c28-4dcd-bb56-f690d25e791e_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_150b0c43-e029-4833-9f11-e6590b05fafb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5b37be7a-889f-40cd-ab80-8469378ad996_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholder's equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_b07aaa72-9ce2-4338-a90c-3ab88fbcf95e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_7f62d81a-61ef-4fe0-adc5-97e194181868_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_d3a91a38-a5cd-4ebd-a2b3-268d72a7ecf9_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsMember_1531ada7-5a91-4e16-8cab-b8a13fc7a866_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Cash and Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsMember_label_en-US" xlink:label="lab_us-gaap_InvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsMember" xlink:to="lab_us-gaap_InvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordLoanFacility_92a4bfde-90f5-4834-b213-cf7c585a4782_terseLabel_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:label id="lab_lxrx_OxfordLoanFacility_label_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:label id="lab_lxrx_OxfordLoanFacility_documentation_en-US" xlink:label="lab_lxrx_OxfordLoanFacility" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility" xlink:href="lxrx-20220331.xsd#lxrx_OxfordLoanFacility"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordLoanFacility" xlink:to="lab_lxrx_OxfordLoanFacility" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_b13d03c2-8d2b-4cbb-b77f-677251713c12_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a64b1367-5bcb-4d18-8de2-fe0c809d83a1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_d9ea1b39-1c83-49da-9d14-5d3eeaf81de9_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_label_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:label id="lab_lxrx_TermLoanADebtDiscount_documentation_en-US" xlink:label="lab_lxrx_TermLoanADebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanADebtDiscount" xlink:to="lab_lxrx_TermLoanADebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_26cf4507-d509-46b1-975e-815a1bc07aff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_4f542d60-3f1e-4b89-a4c8-98f3757ce9c3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_ad67b0a4-2088-47a1-a102-faeeb5f0e2c0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt and Lease Obligation</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_72783d5a-045b-4f66-a7ad-e5fe3d959ff7_terseLabel_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_label_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:label id="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_documentation_en-US" xlink:label="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:href="lxrx-20220331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:to="lab_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_b26c2e7a-61fc-40cf-8a09-a1456855f2a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_588420ac-e768-412b-a31a-f2b0c479e0c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardDateDomain_eb8c086e-5164-4ab1-876c-56a6129f6839_terseLabel_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:label id="lab_us-gaap_AwardDateDomain_label_en-US" xlink:label="lab_us-gaap_AwardDateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Date [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardDateDomain" xlink:to="lab_us-gaap_AwardDateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_3dc93026-c0ff-44df-af65-e36114533894_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9b63d4b9-6119-4d39-b482-9d3f2906ce67_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_OxfordFacilityFee_680b7789-13ac-4109-9a91-4b756115a048_terseLabel_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:label id="lab_lxrx_OxfordFacilityFee_label_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:label id="lab_lxrx_OxfordFacilityFee_documentation_en-US" xlink:label="lab_lxrx_OxfordFacilityFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oxford Facility Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee" xlink:href="lxrx-20220331.xsd#lxrx_OxfordFacilityFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_OxfordFacilityFee" xlink:to="lab_lxrx_OxfordFacilityFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_cfa2b9c2-ada4-4f82-93c5-02ecdbf57f66_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_35b37d56-bffc-4205-89d1-47db7562c65e_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_69ec7955-d7d6-4f3a-8108-2c5c887a17c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents and investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_133e0097-2f29-4be8-a02e-dbc1d52e467c_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_6fac42ee-de45-4077-be28-07f0379660bb_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_828a12d2-2ac8-4efa-8b4d-190b542324b4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_03f40a70-ddd3-4ef4-ba0e-56a5e21b653f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_e4b7043b-4427-4f45-ac24-b8824ced9f06_terseLabel_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_label_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:label id="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_documentation_en-US" xlink:label="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:href="lxrx-20220331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:to="lab_lxrx_SummaryOfSignificantAccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_b594e2e6-c088-4a5b-985f-9ba85d71c166_terseLabel_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_label_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:label id="lab_lxrx_InitialRecognitionOfRightOfUseAsset_documentation_en-US" xlink:label="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial recognition of right of use asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:href="lxrx-20220331.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:to="lab_lxrx_InitialRecognitionOfRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_0d3e8ab9-5aec-4edc-bc32-a0da7a74454a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_ce02265a-816a-45dc-9248-60af43780c2c_terseLabel_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage</link:label>
    <link:label id="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_documentation_en-US" xlink:label="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:href="lxrx-20220331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:to="lab_lxrx_ConvDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_edcbf738-1985-43a6-9a05-7025d4796991_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeAxis_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeAxis" xlink:to="lab_us-gaap_TradingActivityByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3b853267-7bad-40b2-ad55-85ababbffcb9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_ef1a023e-14d3-4d34-ae61-37c56a15162b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_b9e1b03a-0208-4fc0-bca5-ad217a518bcf_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiDisputedCosts_ca1d80fd-2f32-4b0a-87b4-208b5f42b6d9_terseLabel_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:label id="lab_lxrx_SanofiDisputedCosts_label_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:label id="lab_lxrx_SanofiDisputedCosts_documentation_en-US" xlink:label="lab_lxrx_SanofiDisputedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Disputed Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts" xlink:href="lxrx-20220331.xsd#lxrx_SanofiDisputedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiDisputedCosts" xlink:to="lab_lxrx_SanofiDisputedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b09771b0-e1d3-418e-82e3-afbb7ae6c902_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_d7e27480-5942-4c19-94fc-da0a9f6a4daf_terseLabel_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_label_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:label id="lab_lxrx_Lxrx_sanofiInitialCashPayment_documentation_en-US" xlink:label="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">lxrx_sanofi initial cash payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:href="lxrx-20220331.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Lxrx_sanofiInitialCashPayment" xlink:to="lab_lxrx_Lxrx_sanofiInitialCashPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_846bd658-9206-4c53-935e-c554e21579f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_08f8915f-04a8-4638-a371-6cf1b9962348_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_f631c20a-d4be-4437-a537-51ad795f8057_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e158b4dd-ae59-4ba5-b449-a934c7c8908a_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_ee9c0684-8bc3-4c75-acc4-30d1a89874ed_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:to="lab_us-gaap_DebtInstrumentInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_bc81dfdd-0a0a-4eae-a273-4fd854c1979e_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_5cfae0ad-896f-420c-93f2-1a778d22cf45_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_3f6f278b-d5c9-4237-9d32-ef4336600df7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_6e0c1333-45a1-438b-aefb-3191d6097b0a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3e34ef5f-cda0-475a-bf00-ec434e88b482_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2e7873cd-5287-49f8-8882-12bdc239e628_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_ccf8f35c-3aaa-44aa-bdf9-91b4e51fddc0_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_482a59af-c97a-47fe-8d14-14de6c48262e_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_b23438d9-2e23-4eaa-b2a8-cd3342770b88_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_40060636-f286-420a-b27e-fb35ba33426b_terseLabel_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_label_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:label id="lab_lxrx_SharePriceInNovember20ATMOffering_documentation_en-US" xlink:label="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price in November 20 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:href="lxrx-20220331.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SharePriceInNovember20ATMOffering" xlink:to="lab_lxrx_SharePriceInNovember20ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ATMOfferingTotal_cdb1b602-3a1a-4a8f-80fe-10fc1eb03f22_terseLabel_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_label_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:label id="lab_lxrx_ATMOfferingTotal_documentation_en-US" xlink:label="lab_lxrx_ATMOfferingTotal" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Offering Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal" xlink:href="lxrx-20220331.xsd#lxrx_ATMOfferingTotal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ATMOfferingTotal" xlink:to="lab_lxrx_ATMOfferingTotal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_66dadba5-9b4d-407f-b1eb-dd394c759b6f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c1bbfe01-af02-4e5e-bc7e-ee0467524e1b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d4e527e9-42f9-4e83-be20-10f6fde3671b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_09b4864e-d2a2-4cb6-a971-441fc0ce41b6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Inputs, Disclosure</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementInputsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_Netproductrevenue_4b8f49f2-b493-4147-9069-085fd53b543c_terseLabel_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_label_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_lxrx_Netproductrevenue_documentation_en-US" xlink:label="lab_lxrx_Netproductrevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue" xlink:href="lxrx-20220331.xsd#lxrx_Netproductrevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_Netproductrevenue" xlink:to="lab_lxrx_Netproductrevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_63163f4b-9aa1-4743-aa2d-3c94a0cefddf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1f8e3030-62ae-4466-bc2a-870646a02988_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_489d708d-a452-4e6c-a286-18b776d46065_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAInterestExpense_fd75c659-696e-4214-b562-834053ef9780_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Interest Expense</link:label>
    <link:label id="lab_lxrx_TermLoanAInterestExpense_label_en-US" xlink:label="lab_lxrx_TermLoanAInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Interest Expense</link:label>
    <link:label id="lab_lxrx_TermLoanAInterestExpense_documentation_en-US" xlink:label="lab_lxrx_TermLoanAInterestExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAInterestExpense" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAInterestExpense" xlink:to="lab_lxrx_TermLoanAInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_a850bed1-8d18-4fff-96b8-49d9560e7345_terseLabel_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_label_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:label id="lab_lxrx_AccruedInterestOnConvertible_documentation_en-US" xlink:label="lab_lxrx_AccruedInterestOnConvertible" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">accrued interest on convertible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible" xlink:href="lxrx-20220331.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedInterestOnConvertible" xlink:to="lab_lxrx_AccruedInterestOnConvertible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_ebcf1859-52f0-4b9a-a531-161e5f97366c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_2a65ca6c-2310-46c4-a6af-9b48d2f8bb74_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_3ae576f9-4529-4045-8274-39aabc943af9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_bfeb6cca-83d1-427d-a0f3-9419137250d8_terseLabel_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_label_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sanofi Revenue Recognized</link:label>
    <link:label id="lab_lxrx_SanofiRevenueRecognized_documentation_en-US" xlink:label="lab_lxrx_SanofiRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized" xlink:href="lxrx-20220331.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_SanofiRevenueRecognized" xlink:to="lab_lxrx_SanofiRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0abfd3e2-1899-4f65-9dc3-805f06941f00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_19c52132-7b23-4621-afaf-dec7ae640b5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_c1a53278-e2d8-48f3-98c6-7f75149c8820_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_e4756419-f63f-4cdf-b3b5-fabb56ae765e_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_010c4714-7641-4229-95ed-75cc5f5727c6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_804db6f9-4054-4989-a0cb-a37715da4935_terseLabel_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_label_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_lxrx_AccruedLiabilitiesLineItems_documentation_en-US" xlink:label="lab_lxrx_AccruedLiabilitiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems" xlink:to="lab_lxrx_AccruedLiabilitiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_130c0fc8-cb9b-4238-8c0c-9fe40a83c3cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_1bc53110-1b7a-4c36-ac4e-c375caefa39e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_910565c5-120b-442d-9511-b3ef7766d9da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_c6b31601-a442-419b-a2b9-60578f720785_terseLabel_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_label_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:label id="lab_lxrx_ProceedsFromNov2020ATMOffering_documentation_en-US" xlink:label="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Nov 2020 ATM Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:href="lxrx-20220331.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ProceedsFromNov2020ATMOffering" xlink:to="lab_lxrx_ProceedsFromNov2020ATMOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_e357f7c2-b290-47e9-87d2-e86e6c2561bc_terseLabel_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_label_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:label id="lab_lxrx_FinalPaymentWithExtention_documentation_en-US" xlink:label="lab_lxrx_FinalPaymentWithExtention" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final Payment % with extention</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention" xlink:href="lxrx-20220331.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_FinalPaymentWithExtention" xlink:to="lab_lxrx_FinalPaymentWithExtention" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_2eec711f-bc73-476a-9a5d-884dc24941c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_8ca9b8cf-8527-4bf0-9176-db39c76041a3_terseLabel_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_label_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</link:label>
    <link:label id="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_documentation_en-US" xlink:label="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:to="lab_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_4ada46ec-1ae5-48e7-bf8d-efbde28c39e3_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ae871c23-a501-40cc-a765-df17758242bb_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_2b72557c-95d4-4081-8614-3da5cdf0d78c_terseLabel_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:label id="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_documentation_en-US" xlink:label="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Statements of Stockholders&#8217; Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:href="lxrx-20220331.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:to="lab_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b2dcb76d-9fcd-49be-b46d-3388fb34460c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_8842e5b5-e4ce-4b44-8027-ed1fba25b6db_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_f57d1749-ac26-4382-be73-06c15e7d07f4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_17c56c26-cabc-4cc3-9406-be25a183b789_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_91c7a789-b21c-44bd-9a8c-c849f8cde1aa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2c6b9eb8-31d2-42ff-b600-f92832907d6a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_5db32dd9-f984-4555-8afd-0388fe0f26de_terseLabel_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:label id="lab_us-gaap_TradingActivityByTypeDomain_label_en-US" xlink:label="lab_us-gaap_TradingActivityByTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Activity, by Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradingActivityByTypeDomain" xlink:to="lab_us-gaap_TradingActivityByTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b0b922c1-41fc-47f2-b3be-b43282833367_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase) decrease in prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_caa22815-6c8b-4792-8e52-18fea35991c4_terseLabel_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_label_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:label id="lab_lxrx_TermLoanAWarrantExercisePrice_documentation_en-US" xlink:label="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan A Warrant Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_lxrx_TermLoanAWarrantExercisePrice" xlink:to="lab_lxrx_TermLoanAWarrantExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4504a579-b2f1-40ab-9546-e5e99ae38a39_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>lxrx-20220331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:d7a1dbc6-b99b-4a1d-848b-92cec6605016,g:574c9470-43fb-4b26-864a-707e5ed846fe-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="lxrx-20220331.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b27ff3e4-43f9-4545-a886-b0e4eb5436ed" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_DocumentType_b27ff3e4-43f9-4545-a886-b0e4eb5436ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_e95f2d72-0e43-4669-b23a-ea36a567fd08" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_e95f2d72-0e43-4669-b23a-ea36a567fd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_4ff6e0a9-567a-48c2-ac56-d9bb9c1a6206" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_DocumentQuarterlyReport_4ff6e0a9-567a-48c2-ac56-d9bb9c1a6206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_1c4352a0-93ec-484b-ac19-59df48eeae7b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_DocumentPeriodEndDate_1c4352a0-93ec-484b-ac19-59df48eeae7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5ef4e661-5262-4f69-a2d3-091334753809" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_DocumentTransitionReport_5ef4e661-5262-4f69-a2d3-091334753809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9ff7f1da-45c0-4510-bc70-3e8e390f7e03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_AmendmentFlag_9ff7f1da-45c0-4510-bc70-3e8e390f7e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_0f76f308-9f78-4308-bb63-9b0adca9c4ec" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_DocumentFiscalYearFocus_0f76f308-9f78-4308-bb63-9b0adca9c4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_f2bbb912-ecb7-457b-a094-36d4a8b33f57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_CurrentFiscalYearEndDate_f2bbb912-ecb7-457b-a094-36d4a8b33f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_061ec5aa-8ae7-4c16-aad1-a936b1795e7c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityFileNumber_061ec5aa-8ae7-4c16-aad1-a936b1795e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_b641936d-61d8-4a76-8e3f-96e813094df1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityRegistrantName_b641936d-61d8-4a76-8e3f-96e813094df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_1ab414d0-76bb-4333-bb04-401f21b18d9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityCentralIndexKey_1ab414d0-76bb-4333-bb04-401f21b18d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4fd22ddb-086b-4029-9090-72628eb6c5ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4fd22ddb-086b-4029-9090-72628eb6c5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1acf2a0b-91ae-47a0-8fd7-2a89e097f8d1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityTaxIdentificationNumber_1acf2a0b-91ae-47a0-8fd7-2a89e097f8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cee19ab7-c835-4c52-829b-267fee186b8a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityAddressAddressLine1_cee19ab7-c835-4c52-829b-267fee186b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_d064a11b-1e17-4506-8bc4-240a201f793b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityAddressAddressLine2_d064a11b-1e17-4506-8bc4-240a201f793b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_2ac11165-cf40-47d2-bb36-d1aa1d43eddb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityAddressCityOrTown_2ac11165-cf40-47d2-bb36-d1aa1d43eddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_86722663-d920-43d1-8195-898eed17277a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityAddressStateOrProvince_86722663-d920-43d1-8195-898eed17277a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bf4e5afa-f741-49a0-abfb-5bccb9adfd0c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityAddressPostalZipCode_bf4e5afa-f741-49a0-abfb-5bccb9adfd0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f3c0212d-dfaa-4ea0-821c-6a54dce5c0e0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_CityAreaCode_f3c0212d-dfaa-4ea0-821c-6a54dce5c0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1580be99-66a7-4c06-ab04-da6198081329" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_LocalPhoneNumber_1580be99-66a7-4c06-ab04-da6198081329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_2b6188a1-8709-40da-bb41-f92f14d49a3b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_Security12bTitle_2b6188a1-8709-40da-bb41-f92f14d49a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_e253a7b2-1781-4203-947e-19c4ccd78f31" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_TradingSymbol_e253a7b2-1781-4203-947e-19c4ccd78f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_b1d29267-491e-45f4-a68a-1a1086bf25e9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_SecurityExchangeName_b1d29267-491e-45f4-a68a-1a1086bf25e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_40277acf-d2ca-4e4a-ab6a-3cbe0297682e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityCurrentReportingStatus_40277acf-d2ca-4e4a-ab6a-3cbe0297682e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a19af7bb-4f2a-4da7-9b1f-d1cb3d2025be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityInteractiveDataCurrent_a19af7bb-4f2a-4da7-9b1f-d1cb3d2025be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_c56a5886-e240-4b31-9676-92163043aa7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityFilerCategory_c56a5886-e240-4b31-9676-92163043aa7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7d629b6b-6a0b-4a33-9114-0047eccfa1c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntitySmallBusiness_7d629b6b-6a0b-4a33-9114-0047eccfa1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c0a4e535-c1cb-48e1-8fd5-efd34f458a2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityEmergingGrowthCompany_c0a4e535-c1cb-48e1-8fd5-efd34f458a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_577267fe-32a0-422f-85f6-0ac352bf4953" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityShellCompany_577267fe-32a0-422f-85f6-0ac352bf4953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_4a2a1170-ec9c-4fd6-89e0-56d498cda1bb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_4db3a1dc-bd46-4886-9dd6-d59f95f5f6e4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_4a2a1170-ec9c-4fd6-89e0-56d498cda1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_3ac187cd-ccbe-44b6-9057-2ba3c434dddf" xlink:href="lxrx-20220331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_94681189-2994-4908-aafe-cf77096b28b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_3ac187cd-ccbe-44b6-9057-2ba3c434dddf" xlink:to="loc_us-gaap_StatementTable_94681189-2994-4908-aafe-cf77096b28b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_3076b390-7713-481b-81bc-fedfdde7520b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94681189-2994-4908-aafe-cf77096b28b1" xlink:to="loc_srt_StatementScenarioAxis_3076b390-7713-481b-81bc-fedfdde7520b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_e9781744-37fb-4d5c-b906-a205eb941b99" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_3076b390-7713-481b-81bc-fedfdde7520b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_e9781744-37fb-4d5c-b906-a205eb941b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5bd24985-1655-4f2e-8742-53709c18c986" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94681189-2994-4908-aafe-cf77096b28b1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5bd24985-1655-4f2e-8742-53709c18c986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_359703c5-25bf-450f-b52d-e6c53f4b3b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5bd24985-1655-4f2e-8742-53709c18c986" xlink:to="loc_us-gaap_ClassOfStockDomain_359703c5-25bf-450f-b52d-e6c53f4b3b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94681189-2994-4908-aafe-cf77096b28b1" xlink:to="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be8c5c1c-d462-4882-9c16-b6277cf7f17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_be8c5c1c-d462-4882-9c16-b6277cf7f17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a75891f3-42d6-49b5-9481-9b3c63dd844e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_ShortTermInvestments_a75891f3-42d6-49b5-9481-9b3c63dd844e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8f09bbe6-bf91-4cfe-9ba2-705309f7b26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8f09bbe6-bf91-4cfe-9ba2-705309f7b26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_cdda71b5-d9a6-40c0-af3c-db070f054a70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_OtherAssetsCurrent_cdda71b5-d9a6-40c0-af3c-db070f054a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1c42005f-20ed-4ba8-b9ee-cc5de17cd66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_07fba6d3-01f8-4265-aa3c-33b86378255a" xlink:to="loc_us-gaap_AssetsCurrent_1c42005f-20ed-4ba8-b9ee-cc5de17cd66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_13658cc0-d0e1-4457-9428-050deb83fde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_13658cc0-d0e1-4457-9428-050deb83fde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ecad2be9-634a-474b-917b-0975ce68f488" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_Goodwill_ecad2be9-634a-474b-917b-0975ce68f488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3052cba8-4e67-4839-a79f-fd3251472394" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3052cba8-4e67-4839-a79f-fd3251472394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_89c590fc-f18f-4ac0-99b2-581b401f0d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_Assets_89c590fc-f18f-4ac0-99b2-581b401f0d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_8c664979-dd1d-4fb5-a822-f40a97c6eaaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_AccountsPayableCurrent_8c664979-dd1d-4fb5-a822-f40a97c6eaaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a2585f6e-022d-473e-b086-fb5ec23c7a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a2585f6e-022d-473e-b086-fb5ec23c7a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_ddb17f36-6558-4e89-a967-9860679490de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_LongTermDebtCurrent_ddb17f36-6558-4e89-a967-9860679490de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb2491ee-0db0-4581-bbe7-cad41ed9cee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_LiabilitiesCurrent_bb2491ee-0db0-4581-bbe7-cad41ed9cee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredLongTermDebt_ed05a67d-9f89-48e5-95c9-07e782547cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SecuredLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8fcf2301-c183-4253-bd3e-f2b1445adb6d" xlink:to="loc_us-gaap_SecuredLongTermDebt_ed05a67d-9f89-48e5-95c9-07e782547cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_6ff997ca-f93e-4508-a2ae-de2f717bdec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_6ff997ca-f93e-4508-a2ae-de2f717bdec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_77e4297a-fda5-44f4-a31b-5f1bd7b69d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_Liabilities_77e4297a-fda5-44f4-a31b-5f1bd7b69d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a24cdab7-4d54-4c76-b088-77ecb067e436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a24cdab7-4d54-4c76-b088-77ecb067e436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_d4ad3c06-28b0-42c9-b157-d6617da01485" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_PreferredStockValue_d4ad3c06-28b0-42c9-b157-d6617da01485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dcdc507d-12a1-4501-8455-a3135d758e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_CommonStockValue_dcdc507d-12a1-4501-8455-a3135d758e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_252b5326-ab20-40c6-8ff9-40bae5c8b024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_AdditionalPaidInCapital_252b5326-ab20-40c6-8ff9-40bae5c8b024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e81ea4ba-f6e7-4331-8131-2f76f0cac2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_e81ea4ba-f6e7-4331-8131-2f76f0cac2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3b5aab7d-5ba2-4b3f-9d55-1677b9e1fc6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3b5aab7d-5ba2-4b3f-9d55-1677b9e1fc6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_331223e6-0f71-49a5-80dc-b10ad1998a80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_TreasuryStockValue_331223e6-0f71-49a5-80dc-b10ad1998a80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_86ee3276-37a3-4832-88ac-c505628f5af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0c9244fb-c7e5-454d-8cac-41b25c6b2fe1" xlink:to="loc_us-gaap_StockholdersEquity_86ee3276-37a3-4832-88ac-c505628f5af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_5123fe3a-dfd5-4b9b-9ef9-ee4dcfca98c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_5123fe3a-dfd5-4b9b-9ef9-ee4dcfca98c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_da8e51cf-8ff0-4d65-b67b-12a0e22dc25f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ad88b288-73aa-4600-992b-977f9cde7393" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_da8e51cf-8ff0-4d65-b67b-12a0e22dc25f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:href="lxrx-20220331.xsd#lxrx_ConsolidatedBalanceSheetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4204a38b-85c8-4e2b-8ba8-9ea3f4583dd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4204a38b-85c8-4e2b-8ba8-9ea3f4583dd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_43e9c7d5-7951-4f45-a2ae-e3647cc747eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_43e9c7d5-7951-4f45-a2ae-e3647cc747eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_53d7ebe9-1ad0-4774-938f-bfdb040fe372" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_53d7ebe9-1ad0-4774-938f-bfdb040fe372" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_422bab5a-07c2-4719-a7b1-a0fbeb3f0a7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_422bab5a-07c2-4719-a7b1-a0fbeb3f0a7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_0960ed7a-8dcd-4831-821d-ef78e456e5ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_0960ed7a-8dcd-4831-821d-ef78e456e5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1713d66f-ac44-4566-9719-854eaa62c8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1713d66f-ac44-4566-9719-854eaa62c8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_aa940c79-ca9c-48a2-b249-376dc094f61c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_aa940c79-ca9c-48a2-b249-376dc094f61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a6ff1e72-c2c2-4cbe-bc9f-1d437f9928e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:to="loc_us-gaap_CommonStockSharesIssued_a6ff1e72-c2c2-4cbe-bc9f-1d437f9928e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_a7448a40-a8c1-4d34-a0b1-8b9a881250f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedBalanceSheetsAbstract_8b145a77-1392-47fa-8884-601c40fed60c" xlink:to="loc_us-gaap_TreasuryStockShares_a7448a40-a8c1-4d34-a0b1-8b9a881250f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedStatementsofComprehensiveLossUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_ca64e0f5-936a-4f43-92b8-9eca8c1d75ce" xlink:href="lxrx-20220331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_475ab1ab-b456-4ae8-8a65-04c05313bd47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_ca64e0f5-936a-4f43-92b8-9eca8c1d75ce" xlink:to="loc_us-gaap_StatementTable_475ab1ab-b456-4ae8-8a65-04c05313bd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_de069c95-859e-4486-a10f-c91eee0266ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_475ab1ab-b456-4ae8-8a65-04c05313bd47" xlink:to="loc_srt_StatementScenarioAxis_de069c95-859e-4486-a10f-c91eee0266ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a4459ebb-999e-403a-89cf-f47904871bfa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_de069c95-859e-4486-a10f-c91eee0266ac" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a4459ebb-999e-403a-89cf-f47904871bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_475ab1ab-b456-4ae8-8a65-04c05313bd47" xlink:to="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Netproductrevenue_8533762a-46d1-45e8-ab66-bf79774ad189" xlink:href="lxrx-20220331.xsd#lxrx_Netproductrevenue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:to="loc_lxrx_Netproductrevenue_8533762a-46d1-45e8-ab66-bf79774ad189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_facfc56b-32ee-4283-9a20-9880c59c1da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_facfc56b-32ee-4283-9a20-9880c59c1da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_8630f8e4-c3c6-484c-a96b-985213e36181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RoyaltyIncomeNonoperating"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_8630f8e4-c3c6-484c-a96b-985213e36181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5c2ce5bb-84aa-4683-a3d4-3d634aa15f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c250a00d-af20-44de-a4fd-e6e93d0b3b3a" xlink:to="loc_us-gaap_Revenues_5c2ce5bb-84aa-4683-a3d4-3d634aa15f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_74f4b260-6736-49d4-9be3-7e8646d42eef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_74f4b260-6736-49d4-9be3-7e8646d42eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4e3e57bc-ec51-40da-90f3-10897cd34144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4e3e57bc-ec51-40da-90f3-10897cd34144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Sellinggeneralandadministrativeexpenses_4d6b3e2e-ddaa-4fa0-8a99-4517bff95b55" xlink:href="lxrx-20220331.xsd#lxrx_Sellinggeneralandadministrativeexpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_lxrx_Sellinggeneralandadministrativeexpenses_4d6b3e2e-ddaa-4fa0-8a99-4517bff95b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1eefce58-923c-47a5-a611-b7f092b639e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_us-gaap_AssetImpairmentCharges_1eefce58-923c-47a5-a611-b7f092b639e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_579994b0-b39c-4fa8-a0c4-9d4505363448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5ed3a7c1-b422-4d42-88ff-afecf77207ac" xlink:to="loc_us-gaap_OperatingExpenses_579994b0-b39c-4fa8-a0c4-9d4505363448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_c40f8382-b9fc-44a2-9e06-c1c7da2d2232" xlink:href="lxrx-20220331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_c40f8382-b9fc-44a2-9e06-c1c7da2d2232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7ecc0e02-326c-4cfa-a394-18700bc74233" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_OperatingIncomeLoss_7ecc0e02-326c-4cfa-a394-18700bc74233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_375c2c47-d3a6-44c8-84c9-49f110d6774e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_375c2c47-d3a6-44c8-84c9-49f110d6774e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_5efa8113-3293-4539-81c1-d1b195a58015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_InterestExpense_5efa8113-3293-4539-81c1-d1b195a58015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f2828741-30da-4c20-9898-e8beeaabdef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f2828741-30da-4c20-9898-e8beeaabdef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d8842575-15f7-47cb-86c5-cae4a1748339" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_NetIncomeLoss_d8842575-15f7-47cb-86c5-cae4a1748339" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3a9d9b16-ca69-48eb-8926-393137983c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_EarningsPerShareBasic_3a9d9b16-ca69-48eb-8926-393137983c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_13267599-ca36-4621-ae40-7c56bfc647d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_EarningsPerShareDiluted_13267599-ca36-4621-ae40-7c56bfc647d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10c7144f-88ef-4de6-a49e-12a1b036e5c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10c7144f-88ef-4de6-a49e-12a1b036e5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2eac7b8e-e27d-4e47-99aa-07f33320c181" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2eac7b8e-e27d-4e47-99aa-07f33320c181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d0d466d9-4ec6-4c4c-9532-b8dfdf92cc92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d0d466d9-4ec6-4c4c-9532-b8dfdf92cc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b49e25c-ea90-402c-b2bf-c43aaee9d02b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5b49e25c-ea90-402c-b2bf-c43aaee9d02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_4dd4e42f-5098-4309-a49b-e73f4e3b1b17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalIncomeStatementElementsAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3c233e95-92ee-40ce-b88b-77b0bf5719c5" xlink:to="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_4dd4e42f-5098-4309-a49b-e73f4e3b1b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_a845f2fc-ad06-40f8-892c-c6cfbfcc3d16" xlink:href="lxrx-20220331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_4dd4e42f-5098-4309-a49b-e73f4e3b1b17" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_a845f2fc-ad06-40f8-892c-c6cfbfcc3d16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_5300ac20-3204-4228-8dda-1783010f29cb" xlink:href="lxrx-20220331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalIncomeStatementElementsAbstract_4dd4e42f-5098-4309-a49b-e73f4e3b1b17" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_5300ac20-3204-4228-8dda-1783010f29cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedStatementsofComprehensiveLossParentheticals"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_17696569-a1f6-4038-8fa9-7e430f212a42" xlink:href="lxrx-20220331.xsd#lxrx_ConsolidatedStatementsOfOperationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_8d7bf33d-5aa0-4e9a-ba4a-41a7cb3d5eb9" xlink:href="lxrx-20220331.xsd#lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_17696569-a1f6-4038-8fa9-7e430f212a42" xlink:to="loc_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense_8d7bf33d-5aa0-4e9a-ba4a-41a7cb3d5eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_5832e884-9285-482d-b72d-e8d5f441853a" xlink:href="lxrx-20220331.xsd#lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfOperationsAbstract_17696569-a1f6-4038-8fa9-7e430f212a42" xlink:to="loc_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense_5832e884-9285-482d-b72d-e8d5f441853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_98309269-0ee6-4048-8efa-2fb49747ece5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_98309269-0ee6-4048-8efa-2fb49747ece5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_77bb6814-ea7f-4f83-9fd3-0ec5287df0e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_NetIncomeLoss_77bb6814-ea7f-4f83-9fd3-0ec5287df0e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3cd31b94-bb46-465a-8855-84cc808dc981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3cd31b94-bb46-465a-8855-84cc808dc981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_5df9eeeb-c18c-4c7e-9398-e8c863b0549e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3cd31b94-bb46-465a-8855-84cc808dc981" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_5df9eeeb-c18c-4c7e-9398-e8c863b0549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_188ce53d-4479-4c13-885c-bb2446f57a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3cd31b94-bb46-465a-8855-84cc808dc981" xlink:to="loc_us-gaap_ShareBasedCompensation_188ce53d-4479-4c13-885c-bb2446f57a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c38d274f-9da7-4b09-ad17-0d525f32996e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3cd31b94-bb46-465a-8855-84cc808dc981" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_c38d274f-9da7-4b09-ad17-0d525f32996e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_GainOnSaleOfNonFinancialAssets_1a424f9a-d6c5-4bde-a9c2-bfb5a2f46a54" xlink:href="lxrx-20220331.xsd#lxrx_GainOnSaleOfNonFinancialAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3cd31b94-bb46-465a-8855-84cc808dc981" xlink:to="loc_lxrx_GainOnSaleOfNonFinancialAssets_1a424f9a-d6c5-4bde-a9c2-bfb5a2f46a54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9fc909b5-6b57-4caf-bd10-d642788ca71a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3cd31b94-bb46-465a-8855-84cc808dc981" xlink:to="loc_us-gaap_AssetImpairmentCharges_9fc909b5-6b57-4caf-bd10-d642788ca71a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_789e5b97-fd61-4823-b438-dd846463d651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3cd31b94-bb46-465a-8855-84cc808dc981" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_789e5b97-fd61-4823-b438-dd846463d651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f53adf-3c19-48ff-a723-a283a6bc3465" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3cd31b94-bb46-465a-8855-84cc808dc981" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f53adf-3c19-48ff-a723-a283a6bc3465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_99776b80-e3f6-4bf0-b017-7f92dbcac9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f53adf-3c19-48ff-a723-a283a6bc3465" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_99776b80-e3f6-4bf0-b017-7f92dbcac9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_3a58cf5e-c358-4c0e-b2b9-db2160c45f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f53adf-3c19-48ff-a723-a283a6bc3465" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_3a58cf5e-c358-4c0e-b2b9-db2160c45f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ae54d5ad-ec08-4d94-9c41-72968553be6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f53adf-3c19-48ff-a723-a283a6bc3465" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ae54d5ad-ec08-4d94-9c41-72968553be6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c0ddd40b-e08b-41f1-b74b-cc9a6f10ea62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f53adf-3c19-48ff-a723-a283a6bc3465" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_c0ddd40b-e08b-41f1-b74b-cc9a6f10ea62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76bdeaec-de9a-4639-9290-f996a205d4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_34f53adf-3c19-48ff-a723-a283a6bc3465" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_76bdeaec-de9a-4639-9290-f996a205d4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_52e27313-c1df-41f6-869d-e32664d16dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_52e27313-c1df-41f6-869d-e32664d16dc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6c668a82-f7f8-4b8f-99a3-85e7b32dd51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_6c668a82-f7f8-4b8f-99a3-85e7b32dd51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e4cf417-9494-4d85-a502-bb96b90b402a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9e4cf417-9494-4d85-a502-bb96b90b402a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_4fe5115f-7334-4e6d-8eca-0942372c9c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_InterestPaidNet_4fe5115f-7334-4e6d-8eca-0942372c9c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset_9d0b5026-3fcd-42a4-b31e-e2faaeece315" xlink:href="lxrx-20220331.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_lxrx_InitialRecognitionOfRightOfUseAsset_9d0b5026-3fcd-42a4-b31e-e2faaeece315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_8ce8e44a-7215-4100-ada8-f0300fa5fb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims_8ce8e44a-7215-4100-ada8-f0300fa5fb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2b9220b3-5cff-44af-95c1-08cdd358570b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2b9220b3-5cff-44af-95c1-08cdd358570b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_92023b0e-5926-4b71-850c-2a143eab858a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_92023b0e-5926-4b71-850c-2a143eab858a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_83d9852a-bc3e-45aa-a05c-85737ee365d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_BusinessExitCosts1_83d9852a-bc3e-45aa-a05c-85737ee365d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ffb55dfe-33f0-4864-80f7-087abc6bae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_67f8372b-48ee-46c9-95f7-0f850b56cc6b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_ffb55dfe-33f0-4864-80f7-087abc6bae5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65f9cac9-422c-4c4c-8ec4-d597cce21354" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_98309269-0ee6-4048-8efa-2fb49747ece5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65f9cac9-422c-4c4c-8ec4-d597cce21354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5c14101e-a2ab-48d2-8398-f4dfc8caf490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65f9cac9-422c-4c4c-8ec4-d597cce21354" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5c14101e-a2ab-48d2-8398-f4dfc8caf490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_61f22b14-db94-45e9-9c74-8f99c4b546a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65f9cac9-422c-4c4c-8ec4-d597cce21354" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_61f22b14-db94-45e9-9c74-8f99c4b546a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_069ac153-6cbc-42e5-b6c2-be4a483d78b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65f9cac9-422c-4c4c-8ec4-d597cce21354" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_069ac153-6cbc-42e5-b6c2-be4a483d78b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_257f2c3a-9b25-499d-9c0b-dc7740f64df2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65f9cac9-422c-4c4c-8ec4-d597cce21354" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_257f2c3a-9b25-499d-9c0b-dc7740f64df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7cfdbe4-e9cc-4948-acba-c83cb50f1f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_65f9cac9-422c-4c4c-8ec4-d597cce21354" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b7cfdbe4-e9cc-4948-acba-c83cb50f1f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_555fcba4-5907-4adb-824a-aedb8c6736e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_98309269-0ee6-4048-8efa-2fb49747ece5" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_555fcba4-5907-4adb-824a-aedb8c6736e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2b8ef006-6160-47be-9237-c0aeb1b2c68e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_555fcba4-5907-4adb-824a-aedb8c6736e8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_2b8ef006-6160-47be-9237-c0aeb1b2c68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7ab49b8e-101a-4904-9ba9-2f4956104b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_555fcba4-5907-4adb-824a-aedb8c6736e8" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_7ab49b8e-101a-4904-9ba9-2f4956104b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_af9b453a-6559-4a73-a387-a90898aabe16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_555fcba4-5907-4adb-824a-aedb8c6736e8" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_af9b453a-6559-4a73-a387-a90898aabe16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2e4d18f6-e33c-4444-ba6f-131e020c0efd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_555fcba4-5907-4adb-824a-aedb8c6736e8" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_2e4d18f6-e33c-4444-ba6f-131e020c0efd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a2c8c7e-3446-4994-8448-b6ee445dcf24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_555fcba4-5907-4adb-824a-aedb8c6736e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_6a2c8c7e-3446-4994-8448-b6ee445dcf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_4cbf2e91-9eae-4521-98a8-c3f7c212b81d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_98309269-0ee6-4048-8efa-2fb49747ece5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_4cbf2e91-9eae-4521-98a8-c3f7c212b81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3e7b1373-c98b-47ea-82c4-d1e574d3705c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_98309269-0ee6-4048-8efa-2fb49747ece5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3e7b1373-c98b-47ea-82c4-d1e574d3705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_53c172f7-7e2d-4814-b251-2c07d99f653b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_98309269-0ee6-4048-8efa-2fb49747ece5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_53c172f7-7e2d-4814-b251-2c07d99f653b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_44a26da4-dc61-4abd-94e6-8adf8b85be24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_98309269-0ee6-4048-8efa-2fb49747ece5" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_44a26da4-dc61-4abd-94e6-8adf8b85be24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_1de17026-7029-438f-acd1-70e4c38d1150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_44a26da4-dc61-4abd-94e6-8adf8b85be24" xlink:to="loc_us-gaap_InterestPaidNet_1de17026-7029-438f-acd1-70e4c38d1150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_InitialRecognitionOfRightOfUseAsset_e9dcf921-f238-44ee-a2ec-5c03f6a9cd35" xlink:href="lxrx-20220331.xsd#lxrx_InitialRecognitionOfRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_44a26da4-dc61-4abd-94e6-8adf8b85be24" xlink:to="loc_lxrx_InitialRecognitionOfRightOfUseAsset_e9dcf921-f238-44ee-a2ec-5c03f6a9cd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LiabilitiesAssumedByTerSera_582c031b-516f-4093-bb1b-cc835494927e" xlink:href="lxrx-20220331.xsd#lxrx_LiabilitiesAssumedByTerSera"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_44a26da4-dc61-4abd-94e6-8adf8b85be24" xlink:to="loc_lxrx_LiabilitiesAssumedByTerSera_582c031b-516f-4093-bb1b-cc835494927e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a4a4cf54-c9d1-4c00-ad4a-1b54c470f9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_44a26da4-dc61-4abd-94e6-8adf8b85be24" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_a4a4cf54-c9d1-4c00-ad4a-1b54c470f9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="simple" xlink:href="lxrx-20220331.xsd#ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_4f3b730c-93fc-4650-87ee-fcd5df40d198" xlink:href="lxrx-20220331.xsd#lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract_4f3b730c-93fc-4650-87ee-fcd5df40d198" xlink:to="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_b3112b0a-abad-4ae6-b3b5-0b06ee1ca988" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:to="loc_srt_StatementScenarioAxis_b3112b0a-abad-4ae6-b3b5-0b06ee1ca988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_be5006fb-a124-4d72-8c51-bdb024cd745d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_b3112b0a-abad-4ae6-b3b5-0b06ee1ca988" xlink:to="loc_srt_ScenarioUnspecifiedDomain_be5006fb-a124-4d72-8c51-bdb024cd745d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_480655e7-b995-4dcc-8cbd-c96a66c0821a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_480655e7-b995-4dcc-8cbd-c96a66c0821a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_480655e7-b995-4dcc-8cbd-c96a66c0821a" xlink:to="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_a909cee6-86de-49e2-a518-903a2ec4e933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_CommonStockMember_a909cee6-86de-49e2-a518-903a2ec4e933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_435c9513-55e8-4ec9-85eb-b1622eb153db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_435c9513-55e8-4ec9-85eb-b1622eb153db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_4d3fea55-7996-467e-92f8-b4022763b2b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_RetainedEarningsMember_4d3fea55-7996-467e-92f8-b4022763b2b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77a20ed4-7f40-4b2c-afbc-e63571996e06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_77a20ed4-7f40-4b2c-afbc-e63571996e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_35e4cde0-5bc9-4dbd-a52e-07db55a5f693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_928a0ea1-e211-4b1f-a7e1-55e8892e0a3b" xlink:to="loc_us-gaap_TreasuryStockMember_35e4cde0-5bc9-4dbd-a52e-07db55a5f693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0aa0be0d-8753-4992-bf0d-dc01e7934c47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0aa0be0d-8753-4992-bf0d-dc01e7934c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5fe621ba-7d35-4bb5-8f6d-d6d6cfeb938d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0aa0be0d-8753-4992-bf0d-dc01e7934c47" xlink:to="loc_us-gaap_ClassOfStockDomain_5fe621ba-7d35-4bb5-8f6d-d6d6cfeb938d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_beaa98e7-be01-4fe4-955d-ba1e0af2d43b" xlink:to="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fb6ef8ba-e9ca-4aa2-bb04-96a189faaa09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_CommonStockSharesIssued_fb6ef8ba-e9ca-4aa2-bb04-96a189faaa09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6446601d-e7c6-41ab-a9f5-ca1839b1ee04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6446601d-e7c6-41ab-a9f5-ca1839b1ee04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_940f14b0-e667-4cb3-891c-2b4ef5091474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_940f14b0-e667-4cb3-891c-2b4ef5091474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_98820f62-1b2b-4ecf-8dcb-b25cbcd3c90e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_98820f62-1b2b-4ecf-8dcb-b25cbcd3c90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_540a4619-e46b-4532-b214-f147db33f1da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_540a4619-e46b-4532-b214-f147db33f1da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_01f856ce-1072-4442-ba04-4a7987a5d826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_01f856ce-1072-4442-ba04-4a7987a5d826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_487dcf01-fec1-4af2-9c83-77785b31dcab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_487dcf01-fec1-4af2-9c83-77785b31dcab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d422ca00-cb40-4ae4-aa1c-b9f63c488026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_NetIncomeLoss_d422ca00-cb40-4ae4-aa1c-b9f63c488026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4f820c49-48cd-473d-910f-d201da65a8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4f820c49-48cd-473d-910f-d201da65a8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d998d36f-2294-4a76-a1c0-9e96af09dcc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_d998d36f-2294-4a76-a1c0-9e96af09dcc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_fbac95aa-5c59-443e-8d73-74f435f17ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_CommonStockSharesIssued_fbac95aa-5c59-443e-8d73-74f435f17ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00c20377-e134-4dac-b13d-31957ce64520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_00c20377-e134-4dac-b13d-31957ce64520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_01f7b188-9a41-43b5-8cd8-3e6d2a547a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_01f7b188-9a41-43b5-8cd8-3e6d2a547a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6d2b49ff-f8a6-43bb-bc4a-e8a48fd295b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ab7e7f95-3b4a-461b-9783-d28c9910ced1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6d2b49ff-f8a6-43bb-bc4a-e8a48fd295b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesNotes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_f2c272bd-3b38-43a6-8612-503dc9f60895" xlink:href="lxrx-20220331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_aa25be70-08aa-4e6c-afa2-bf74269859b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_f2c272bd-3b38-43a6-8612-503dc9f60895" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_aa25be70-08aa-4e6c-afa2-bf74269859b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:href="lxrx-20220331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_569aa316-60d8-467a-89e8-5d9f9876a399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_569aa316-60d8-467a-89e8-5d9f9876a399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_da9230d4-3ca6-4eec-9a6b-40244ba1ca82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:to="loc_us-gaap_UseOfEstimates_da9230d4-3ca6-4eec-9a6b-40244ba1ca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e0a9a97f-1e59-45ee-8ce3-d8a40f023a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_e0a9a97f-1e59-45ee-8ce3-d8a40f023a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_24324638-173d-4429-85d9-83f39a9c9aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_24324638-173d-4429-85d9-83f39a9c9aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_68c1dc8d-0bd7-412e-9bef-9ba62054c9e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_68c1dc8d-0bd7-412e-9bef-9ba62054c9e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c649c455-fa87-4fb8-8c88-76396a481eba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_c649c455-fa87-4fb8-8c88-76396a481eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_128f24e9-bab1-470b-b3fa-e22bf2391388" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_128f24e9-bab1-470b-b3fa-e22bf2391388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_ada373c8-c927-49fb-b88b-c79220e2b7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_ada373c8-c927-49fb-b88b-c79220e2b7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_a55ae699-6933-4abe-a719-be0465fbf631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_7eaff330-376c-466c-b4e2-96468fad5c78" xlink:to="loc_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock_a55ae699-6933-4abe-a719-be0465fbf631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_fb4401b9-cd29-4bed-a6f4-e4e903efb4f5" xlink:href="lxrx-20220331.xsd#lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_14155a85-0a3e-4063-bca8-9db0eec3eace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_fb4401b9-cd29-4bed-a6f4-e4e903efb4f5" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_14155a85-0a3e-4063-bca8-9db0eec3eace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f65d60b6-44a7-4687-af9c-b82942060dee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_fb4401b9-cd29-4bed-a6f4-e4e903efb4f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_f65d60b6-44a7-4687-af9c-b82942060dee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_727dc153-8a0d-495c-9d54-2f6e8540d144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_fb4401b9-cd29-4bed-a6f4-e4e903efb4f5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_727dc153-8a0d-495c-9d54-2f6e8540d144" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_15917214-d9e8-4e61-8a3b-59cbaec4edcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract_fb4401b9-cd29-4bed-a6f4-e4e903efb4f5" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_15917214-d9e8-4e61-8a3b-59cbaec4edcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_9d35ac99-f755-4d87-8d68-bf3ad78ee4fc" xlink:href="lxrx-20220331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_9d35ac99-f755-4d87-8d68-bf3ad78ee4fc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7c2efc6c-8ca4-410e-ab25-20f72baa0d39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_PlanNameAxis_7c2efc6c-8ca4-410e-ab25-20f72baa0d39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_430c6fca-5487-4d03-a26b-86981dfea0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7c2efc6c-8ca4-410e-ab25-20f72baa0d39" xlink:to="loc_us-gaap_PlanNameDomain_430c6fca-5487-4d03-a26b-86981dfea0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_1f098d5e-92b4-4b7f-b84c-11d679c7a480" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_AwardDateAxis_1f098d5e-92b4-4b7f-b84c-11d679c7a480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_31e29570-898b-41ec-a531-659b87786067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_1f098d5e-92b4-4b7f-b84c-11d679c7a480" xlink:to="loc_us-gaap_AwardDateDomain_31e29570-898b-41ec-a531-659b87786067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_aa578f1a-59f0-49a7-89ec-4f65dab91556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_AwardTypeAxis_aa578f1a-59f0-49a7-89ec-4f65dab91556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8b81787-5c21-4693-a33d-d5d5ff8fda38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_aa578f1a-59f0-49a7-89ec-4f65dab91556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8b81787-5c21-4693-a33d-d5d5ff8fda38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockOptionMember_bdf24d68-ff52-476b-afc1-d1d0f00da4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d8b81787-5c21-4693-a33d-d5d5ff8fda38" xlink:to="loc_us-gaap_StockOptionMember_bdf24d68-ff52-476b-afc1-d1d0f00da4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_927ea0e6-17f0-40d7-8674-bd0e8e7956f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_927ea0e6-17f0-40d7-8674-bd0e8e7956f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_cd5b7c33-ed77-4049-971f-9d3bb336381b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_927ea0e6-17f0-40d7-8674-bd0e8e7956f6" xlink:to="loc_us-gaap_ClassOfStockDomain_cd5b7c33-ed77-4049-971f-9d3bb336381b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c44b6874-7bdf-4b7f-85bd-c0c010ab3d91" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_srt_RangeAxis_c44b6874-7bdf-4b7f-85bd-c0c010ab3d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9b6174a4-7c29-4f24-841c-94c0231e4eea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c44b6874-7bdf-4b7f-85bd-c0c010ab3d91" xlink:to="loc_srt_RangeMember_9b6174a4-7c29-4f24-841c-94c0231e4eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_7c1c69fa-ca85-4e63-a8d1-0419630540bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_VestingAxis_7c1c69fa-ca85-4e63-a8d1-0419630540bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_361383e7-0f51-4bcb-b88b-ccc52a53d40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_7c1c69fa-ca85-4e63-a8d1-0419630540bb" xlink:to="loc_us-gaap_VestingDomain_361383e7-0f51-4bcb-b88b-ccc52a53d40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9fd762fc-0c28-4371-a658-50eed30ab2a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_4f9c98db-4aa6-49be-a38f-bb510e3e3c62" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees_4f9c98db-4aa6-49be-a38f-bb510e3e3c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_0ae10043-e4d9-431b-aadf-1d63cfd20e1e" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee_0ae10043-e4d9-431b-aadf-1d63cfd20e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_75e067a3-4ae8-425c-86ef-f3d7083de145" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees_75e067a3-4ae8-425c-86ef-f3d7083de145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_13c478c4-94a5-4301-9477-04f5392f227a" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees_13c478c4-94a5-4301-9477-04f5392f227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_661fbea8-c5ce-402a-96ba-e878ea8a6396" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors_661fbea8-c5ce-402a-96ba-e878ea8a6396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_9a77e731-c1aa-4930-82e1-f4ffe1a948b5" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors_9a77e731-c1aa-4930-82e1-f4ffe1a948b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_fe999f3a-d5b4-4145-931d-2faaeeac7e2b" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors_fe999f3a-d5b4-4145-931d-2faaeeac7e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_455d7479-bd2d-4080-8421-7aa23d16378d" xlink:href="lxrx-20220331.xsd#lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_02d0cfaa-d930-4588-8ecb-62aa0d0cfb4b" xlink:to="loc_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors_455d7479-bd2d-4080-8421-7aa23d16378d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_43a47e47-1310-4a6b-b5d2-f314d39cd94d" xlink:href="lxrx-20220331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_43a47e47-1310-4a6b-b5d2-f314d39cd94d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_47a8518f-ddc4-4fd1-9a7a-812ed6d73cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_PlanNameAxis_47a8518f-ddc4-4fd1-9a7a-812ed6d73cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_aac39b03-a217-4806-8f8e-2ef768d83983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_47a8518f-ddc4-4fd1-9a7a-812ed6d73cbc" xlink:to="loc_us-gaap_PlanNameDomain_aac39b03-a217-4806-8f8e-2ef768d83983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateAxis_1ec18c4d-6279-4ffe-819a-2ef4170d68f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_AwardDateAxis_1ec18c4d-6279-4ffe-819a-2ef4170d68f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardDateDomain_c2dbce4d-049f-4b7d-976b-2c028f929ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardDateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardDateAxis_1ec18c4d-6279-4ffe-819a-2ef4170d68f5" xlink:to="loc_us-gaap_AwardDateDomain_c2dbce4d-049f-4b7d-976b-2c028f929ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_87b668bc-f31d-423c-a4ba-969bdb43c095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_AwardTypeAxis_87b668bc-f31d-423c-a4ba-969bdb43c095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9dd2b8a-b3d9-417d-87ad-d77b9ec456ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_87b668bc-f31d-423c-a4ba-969bdb43c095" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9dd2b8a-b3d9-417d-87ad-d77b9ec456ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_423d55ab-7a4d-4b8a-9039-d5191b67c502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9dd2b8a-b3d9-417d-87ad-d77b9ec456ec" xlink:to="loc_us-gaap_EmployeeStockOptionMember_423d55ab-7a4d-4b8a-9039-d5191b67c502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_d78738e6-fcf9-48d6-9c9a-151f29016a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_e9dd2b8a-b3d9-417d-87ad-d77b9ec456ec" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_d78738e6-fcf9-48d6-9c9a-151f29016a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_114e6954-3727-4af2-9d30-b6268ff7c64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_StatementClassOfStockAxis_114e6954-3727-4af2-9d30-b6268ff7c64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3fa41c13-d879-4519-b348-7c0f75fbdd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_114e6954-3727-4af2-9d30-b6268ff7c64e" xlink:to="loc_us-gaap_ClassOfStockDomain_3fa41c13-d879-4519-b348-7c0f75fbdd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d1e30c42-a2bd-4f92-ae55-cef6042abdc1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_srt_RangeAxis_d1e30c42-a2bd-4f92-ae55-cef6042abdc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_846a43d3-ecb8-4da5-b430-507330fb53d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d1e30c42-a2bd-4f92-ae55-cef6042abdc1" xlink:to="loc_srt_RangeMember_846a43d3-ecb8-4da5-b430-507330fb53d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_c9d3a966-5568-4f11-8b12-c4c5a6d40aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_VestingAxis_c9d3a966-5568-4f11-8b12-c4c5a6d40aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_afa204b4-1165-4cc8-b610-99672d0ba4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_c9d3a966-5568-4f11-8b12-c4c5a6d40aa5" xlink:to="loc_us-gaap_VestingDomain_afa204b4-1165-4cc8-b610-99672d0ba4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6536fbac-7651-4b46-8458-26f32d6d9818" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0685701d-1848-42cd-826b-309245675883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0685701d-1848-42cd-826b-309245675883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8cc55ed5-7ae7-4108-87ee-cd2acf049f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8cc55ed5-7ae7-4108-87ee-cd2acf049f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_13fe9d43-3ae9-4023-8e27-2dd274ec7def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_13fe9d43-3ae9-4023-8e27-2dd274ec7def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee1cfc58-cad4-49a4-91c5-c214723b65a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ee1cfc58-cad4-49a4-91c5-c214723b65a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3c6c0e62-a0d9-4701-9da1-ca44d6d88d7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_3c6c0e62-a0d9-4701-9da1-ca44d6d88d7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3b147f11-c412-42c8-8e2e-e2125f83fac3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3b147f11-c412-42c8-8e2e-e2125f83fac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_10f829a5-84e8-405f-8afe-a89b96db4c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_10f829a5-84e8-405f-8afe-a89b96db4c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3f46636e-b233-4738-a633-b16013daaed9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_3f46636e-b233-4738-a633-b16013daaed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2035866e-411e-445e-9b9d-49cb7c8b6920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2035866e-411e-445e-9b9d-49cb7c8b6920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_51a90c9d-fc5c-4b26-8739-6a213e52a857" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_51a90c9d-fc5c-4b26-8739-6a213e52a857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_129830a5-cb7b-41bb-91a2-de2be46587c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_129830a5-cb7b-41bb-91a2-de2be46587c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1b72b407-fc53-49e2-955e-2fd2969202ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1b72b407-fc53-49e2-955e-2fd2969202ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b5a0f98-58a7-4980-8dab-cdd45c36c800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0b5a0f98-58a7-4980-8dab-cdd45c36c800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8034d329-5d0b-4623-8dd8-9c3867160513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8034d329-5d0b-4623-8dd8-9c3867160513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f9a01827-c85d-4bd2-8ab9-224e6cbe5e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_f9a01827-c85d-4bd2-8ab9-224e6cbe5e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f23bafe0-a7b7-48f3-bb94-8e00f36a160b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f23bafe0-a7b7-48f3-bb94-8e00f36a160b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3083bab1-b09e-4672-8c7d-291f785196e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_3083bab1-b09e-4672-8c7d-291f785196e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_500331a8-d2c8-4c27-a061-577d990ba7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_500331a8-d2c8-4c27-a061-577d990ba7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ef92d857-0706-4b0c-be2b-4c97fb862570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_ef92d857-0706-4b0c-be2b-4c97fb862570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2e992110-6f9c-4f6f-83db-09cbce8da1de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6577627b-dded-4aa0-a85d-e45d5a7cec2a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2e992110-6f9c-4f6f-83db-09cbce8da1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_bbc8fbed-1e3b-4321-8068-5487b311db8d" xlink:href="lxrx-20220331.xsd#lxrx_SummaryOfSignificantAccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_SummaryOfSignificantAccountingPoliciesAbstract_bbc8fbed-1e3b-4321-8068-5487b311db8d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_08f26e1e-23a1-442b-93e6-a74066e56d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:to="loc_us-gaap_PlanNameAxis_08f26e1e-23a1-442b-93e6-a74066e56d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_ac7cdd0a-5384-4024-b5f0-dafc087643d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_08f26e1e-23a1-442b-93e6-a74066e56d63" xlink:to="loc_us-gaap_PlanNameDomain_ac7cdd0a-5384-4024-b5f0-dafc087643d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e3da09e-2cc8-4ee3-89ea-443973916018" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:to="loc_us-gaap_AwardTypeAxis_6e3da09e-2cc8-4ee3-89ea-443973916018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b527b055-4c3f-4243-ad33-74fc71dd308e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6e3da09e-2cc8-4ee3-89ea-443973916018" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b527b055-4c3f-4243-ad33-74fc71dd308e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46683ebc-649e-4149-8e4d-ee35d56400d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46683ebc-649e-4149-8e4d-ee35d56400d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2cdf752e-6a29-458b-8204-72c4e2e4d461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46683ebc-649e-4149-8e4d-ee35d56400d9" xlink:to="loc_us-gaap_ClassOfStockDomain_2cdf752e-6a29-458b-8204-72c4e2e4d461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ae8aadda-c00a-4442-9cad-b7f94cf97d33" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:to="loc_srt_RangeAxis_ae8aadda-c00a-4442-9cad-b7f94cf97d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c22b918d-f854-4d11-bfb5-ddae5a7059f7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ae8aadda-c00a-4442-9cad-b7f94cf97d33" xlink:to="loc_srt_RangeMember_c22b918d-f854-4d11-bfb5-ddae5a7059f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0e1a828-35cb-4731-bdb7-e79425d7c851" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_753f7ed1-5679-4b53-9e5e-94be818ea518" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_d0e1a828-35cb-4731-bdb7-e79425d7c851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f826f303-85e9-4f0e-9da8-1978ec94eaed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesTable_6cd6a5f4-cb20-4342-967e-14fd8f09797b" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f826f303-85e9-4f0e-9da8-1978ec94eaed" xlink:to="loc_lxrx_AccruedLiabilitiesTable_6cd6a5f4-cb20-4342-967e-14fd8f09797b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesAxis_325b933e-1f4b-4625-b53b-f4503a8947e2" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_6cd6a5f4-cb20-4342-967e-14fd8f09797b" xlink:to="loc_lxrx_AccruedLiabilitiesAxis_325b933e-1f4b-4625-b53b-f4503a8947e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesDomain_12042a1c-8a48-4a99-883e-d8107601e534" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesAxis_325b933e-1f4b-4625-b53b-f4503a8947e2" xlink:to="loc_lxrx_AccruedLiabilitiesDomain_12042a1c-8a48-4a99-883e-d8107601e534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:href="lxrx-20220331.xsd#lxrx_AccruedLiabilitiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesTable_6cd6a5f4-cb20-4342-967e-14fd8f09797b" xlink:to="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_0186965c-a915-4b6e-8de6-91dcb0f36091" xlink:href="lxrx-20220331.xsd#lxrx_AccruedResearchAndDevelopmentServicesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_lxrx_AccruedResearchAndDevelopmentServicesCurrent_0186965c-a915-4b6e-8de6-91dcb0f36091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedCompensationAndBenefitsCurrent_1ce8ba3a-dc30-4ac7-9854-9e4678f318f0" xlink:href="lxrx-20220331.xsd#lxrx_AccruedCompensationAndBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_lxrx_AccruedCompensationAndBenefitsCurrent_1ce8ba3a-dc30-4ac7-9854-9e4678f318f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f4e522b-4f77-41cf-89ca-6b2d635f337f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9f4e522b-4f77-41cf-89ca-6b2d635f337f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da1dd3d6-77d6-435a-a9ce-d5f39ccaa42d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_da1dd3d6-77d6-435a-a9ce-d5f39ccaa42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_4c18fb7d-3e83-4bff-9667-0a5c90b0e23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent_4c18fb7d-3e83-4bff-9667-0a5c90b0e23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_LexiconIncrementalBorrowingRate_6a3d6a6a-9fd2-4bf6-ab81-a0f2bb3f9180" xlink:href="lxrx-20220331.xsd#lxrx_LexiconIncrementalBorrowingRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_AccruedLiabilitiesLineItems_cc781e6f-7130-4fc2-96cc-51452544d855" xlink:to="loc_lxrx_LexiconIncrementalBorrowingRate_6a3d6a6a-9fd2-4bf6-ab81-a0f2bb3f9180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ad075d51-09a6-4d90-8918-eebf313e8f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_46d65689-f9b9-43fa-b4d0-35a5f6528433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ad075d51-09a6-4d90-8918-eebf313e8f57" xlink:to="loc_us-gaap_AssetImpairmentCharges_46d65689-f9b9-43fa-b4d0-35a5f6528433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="simple" xlink:href="lxrx-20220331.xsd#RecentAccountingPronouncementsLevel1Notes"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_RecentAccountingPronouncementsAbstract_08c6ebc5-93ad-4bb0-b1df-6125b42b11f7" xlink:href="lxrx-20220331.xsd#lxrx_RecentAccountingPronouncementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cc1c9bd9-7cd2-4535-93f3-69590261ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_RecentAccountingPronouncementsAbstract_08c6ebc5-93ad-4bb0-b1df-6125b42b11f7" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_cc1c9bd9-7cd2-4535-93f3-69590261ccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CashandCashEquivalentsandInvestments"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_81ee441c-0290-4cf4-8832-054cd242f4a2" xlink:href="lxrx-20220331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_ad8c1c08-c08d-4b24-84ab-8d699648dac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_81ee441c-0290-4cf4-8832-054cd242f4a2" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_ad8c1c08-c08d-4b24-84ab-8d699648dac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CashandCashEquivalentsandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_903ec31d-b446-46d4-be8c-6f27c6c7e985" xlink:href="lxrx-20220331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5b6e8f0e-6499-4812-a8bf-5dde27b43630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_903ec31d-b446-46d4-be8c-6f27c6c7e985" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_5b6e8f0e-6499-4812-a8bf-5dde27b43630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CashandCashEquivalentsandInvestmentsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_eed6596c-00fb-4bd4-8286-401c33ec56d0" xlink:href="lxrx-20220331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_1f57d511-37cc-4f42-8175-72ce4c340794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_eed6596c-00fb-4bd4-8286-401c33ec56d0" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_1f57d511-37cc-4f42-8175-72ce4c340794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_72badf5e-0f73-465f-893e-8149c8b12564" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1f57d511-37cc-4f42-8175-72ce4c340794" xlink:to="loc_us-gaap_InvestmentTypeAxis_72badf5e-0f73-465f-893e-8149c8b12564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_72badf5e-0f73-465f-893e-8149c8b12564" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_38324f0e-15dd-41c7-b339-eaf3a4c3b3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_CashMember_38324f0e-15dd-41c7-b339-eaf3a4c3b3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_df5857a6-5796-490e-86d9-21c0c8a0ec04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_df5857a6-5796-490e-86d9-21c0c8a0ec04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_ef46b6cf-e605-4725-8e65-309254038572" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_ef46b6cf-e605-4725-8e65-309254038572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsMember_49375fd4-ad23-4778-84b1-75fed7477aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_InvestmentsMember_49375fd4-ad23-4778-84b1-75fed7477aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_1b7938d7-fb32-4363-82b3-2c629a9ec828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_fbbfbbfd-a816-4354-9f2d-0843833a7c5a" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_1b7938d7-fb32-4363-82b3-2c629a9ec828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_1f57d511-37cc-4f42-8175-72ce4c340794" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1113dba9-1570-43e3-9e0c-79d1039fff54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAmortizedCost_1113dba9-1570-43e3-9e0c-79d1039fff54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fdb989a9-6f4e-4a33-a382-76287a981043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_fdb989a9-6f4e-4a33-a382-76287a981043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c3d1187-456d-4013-9330-fa4a48c62f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8c3d1187-456d-4013-9330-fa4a48c62f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_ab43b0ba-af38-4b54-8986-89ffe144d44b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b8dde253-c8d2-4a3e-b4a6-9e2a651ee3aa" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_ab43b0ba-af38-4b54-8986-89ffe144d44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CashandCashEquivalentsandInvestmentsDetails2"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_26e02abb-2411-4685-8ae0-e1865bbc8737" xlink:href="lxrx-20220331.xsd#lxrx_CashAndCashEquivalentsAndInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsTable_14472011-1ac3-4541-9004-c30f3e787e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract_26e02abb-2411-4685-8ae0-e1865bbc8737" xlink:to="loc_us-gaap_ScheduleOfInvestmentsTable_14472011-1ac3-4541-9004-c30f3e787e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeAxis_c5e485d4-58e0-4b7f-8586-d7d33ea507f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_14472011-1ac3-4541-9004-c30f3e787e5e" xlink:to="loc_us-gaap_TradingActivityByTypeAxis_c5e485d4-58e0-4b7f-8586-d7d33ea507f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradingActivityByTypeDomain_b0a516e3-5d9d-4c6d-8e7d-56a6a26c153b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradingActivityByTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TradingActivityByTypeAxis_c5e485d4-58e0-4b7f-8586-d7d33ea507f1" xlink:to="loc_us-gaap_TradingActivityByTypeDomain_b0a516e3-5d9d-4c6d-8e7d-56a6a26c153b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ab0e524-17b4-4d79-8fb7-2146accad830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInvestmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsTable_14472011-1ac3-4541-9004-c30f3e787e5e" xlink:to="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ab0e524-17b4-4d79-8fb7-2146accad830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_8d1e12c4-52eb-41e6-a861-b3f5cb82cc5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentsLineItems_2ab0e524-17b4-4d79-8fb7-2146accad830" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_8d1e12c4-52eb-41e6-a861-b3f5cb82cc5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="lxrx-20220331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_a960325f-8a37-489e-9735-22b809db1131" xlink:href="lxrx-20220331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_698e111d-e23e-460a-ac3c-41b05f0e6007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementInputsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_a960325f-8a37-489e-9735-22b809db1131" xlink:to="loc_us-gaap_FairValueMeasurementInputsDisclosureTextBlock_698e111d-e23e-460a-ac3c-41b05f0e6007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="lxrx-20220331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_b579bf7f-4625-4bbc-ae9f-3dd0af49e217" xlink:href="lxrx-20220331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_bf2872b8-3a84-4cc2-b870-dc0854512f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_b579bf7f-4625-4bbc-ae9f-3dd0af49e217" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_bf2872b8-3a84-4cc2-b870-dc0854512f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="lxrx-20220331.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FairValueMeasurementsAbstract_4407ba43-f3f9-4c3d-a14d-b9feb53b03bf" xlink:href="lxrx-20220331.xsd#lxrx_FairValueMeasurementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_44a2a72f-8694-4579-8323-ee74a075357f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_FairValueMeasurementsAbstract_4407ba43-f3f9-4c3d-a14d-b9feb53b03bf" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_44a2a72f-8694-4579-8323-ee74a075357f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50e9f8b8-5945-4656-ae3c-612f7c3fbe8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_44a2a72f-8694-4579-8323-ee74a075357f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50e9f8b8-5945-4656-ae3c-612f7c3fbe8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_50e9f8b8-5945-4656-ae3c-612f7c3fbe8f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_44a28d89-ce9e-4119-99c0-c39c3f02c8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_44a28d89-ce9e-4119-99c0-c39c3f02c8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_2c2a72ca-c132-4cd9-9a73-a2a81823a440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_2c2a72ca-c132-4cd9-9a73-a2a81823a440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f4e0f480-0723-476c-95ca-a8391eef6ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ea15efa1-8993-40a5-8ff7-56c8c79e9854" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f4e0f480-0723-476c-95ca-a8391eef6ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_44a2a72f-8694-4579-8323-ee74a075357f" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3be943a6-b802-4eab-9147-f7c81dec0b2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_3be943a6-b802-4eab-9147-f7c81dec0b2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecurities_ed25ff8e-b8f1-41b9-ae24-715323d82955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:to="loc_us-gaap_AvailableForSaleSecurities_ed25ff8e-b8f1-41b9-ae24-715323d82955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_48c46b97-2e42-4d1b-a80b-9ddccd25c0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b3a3d05c-2d57-4e6f-99ac-7b591bd96a7b" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_48c46b97-2e42-4d1b-a80b-9ddccd25c0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligations" xlink:type="simple" xlink:href="lxrx-20220331.xsd#DebtObligations"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_2d07a8d9-5ac1-42fa-ab5c-11405903ee5b" xlink:href="lxrx-20220331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_46ca9102-3cba-4818-8e7e-135c7151dfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_2d07a8d9-5ac1-42fa-ab5c-11405903ee5b" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_46ca9102-3cba-4818-8e7e-135c7151dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="simple" xlink:href="lxrx-20220331.xsd#DebtObligationsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#DebtObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/DebtObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_DebtObligationsAbstract_206dcc2a-520b-430d-9814-b28dd4cba863" xlink:href="lxrx-20220331.xsd#lxrx_DebtObligationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ef073502-9ee2-4d7b-a973-691b26392203" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_DebtObligationsAbstract_206dcc2a-520b-430d-9814-b28dd4cba863" xlink:to="loc_us-gaap_DebtInstrumentTable_ef073502-9ee2-4d7b-a973-691b26392203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ef073502-9ee2-4d7b-a973-691b26392203" xlink:to="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_a36ac973-107a-43e7-b6c0-bbdb5f92f142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_a36ac973-107a-43e7-b6c0-bbdb5f92f142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_0e1c8cee-170d-4a28-9ebc-8e1c7edf3a5c" xlink:href="lxrx-20220331.xsd#lxrx_ConvDebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvDebtInstrumentInterestRateStatedPercentage_0e1c8cee-170d-4a28-9ebc-8e1c7edf3a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_31def85d-fe11-4ae6-9897-98f9e9f6dd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionRatio1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionRatio1_31def85d-fe11-4ae6-9897-98f9e9f6dd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4b332b7b-75c2-4b0f-a44f-d3b0f59f63e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleConversionPrice1_4b332b7b-75c2-4b0f-a44f-d3b0f59f63e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_21a0dcb1-c3d3-421a-90e3-8c493106997a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentFairValue_21a0dcb1-c3d3-421a-90e3-8c493106997a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_59d1b145-8281-478a-a997-9bdbf3c417e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_CommonStockSharesIssued_59d1b145-8281-478a-a997-9bdbf3c417e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchange_432a815e-702a-4158-b476-01711666d337" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchange"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchange_432a815e-702a-4158-b476-01711666d337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_AccruedInterestOnConvertible_1c906100-fa80-4f7a-be1d-34c53d0ad8f8" xlink:href="lxrx-20220331.xsd#lxrx_AccruedInterestOnConvertible"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_AccruedInterestOnConvertible_1c906100-fa80-4f7a-be1d-34c53d0ad8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_1e14ec7e-9061-46d0-8b82-1c70a9802400" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeRemainingNotes"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchangeRemainingNotes_1e14ec7e-9061-46d0-8b82-1c70a9802400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchangeShares_c8d64b66-c73f-462c-ab2a-2eb80a5bd0a8" xlink:href="lxrx-20220331.xsd#lxrx_FutureConvertibleDebtExchangeShares"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_FutureConvertibleDebtExchangeShares_c8d64b66-c73f-462c-ab2a-2eb80a5bd0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FutureConvertibleDebtExchange_a6175540-c005-4e52-b999-cf0d0baf29b3" xlink:href="lxrx-20220331.xsd#lxrx_FutureConvertibleDebtExchange"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_FutureConvertibleDebtExchange_a6175540-c005-4e52-b999-cf0d0baf29b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_PrincipalAmountOfConvertibleNotes_87cff41a-286b-45dc-b630-ffcd8ffb5269" xlink:href="lxrx-20220331.xsd#lxrx_PrincipalAmountOfConvertibleNotes"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_PrincipalAmountOfConvertibleNotes_87cff41a-286b-45dc-b630-ffcd8ffb5269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_113ec275-6e57-4593-8c78-2d898e402a64" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeTotalPrincipalAmount"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount_113ec275-6e57-4593-8c78-2d898e402a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_b03095e6-bdf4-4788-8355-887cdd12118e" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeSeptemberCashPortion"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberCashPortion_b03095e6-bdf4-4788-8355-887cdd12118e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_f1dbea30-a64e-46df-b909-edb50bdcf4c1" xlink:href="lxrx-20220331.xsd#lxrx_ConvertibleDebtExchangeSeptemberSharePayment"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_ConvertibleDebtExchangeSeptemberSharePayment_f1dbea30-a64e-46df-b909-edb50bdcf4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_6d2bf017-deab-4818-9c6a-db1b274d30bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_6d2bf017-deab-4818-9c6a-db1b274d30bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_964db592-7f74-4013-bd2e-009a102f3bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LongTermDebt_964db592-7f74-4013-bd2e-009a102f3bfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTerm_a2577024-7b90-4327-9dfa-fd183443d41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTerm"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LongTermDebtTerm_a2577024-7b90-4327-9dfa-fd183443d41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7e107a41-e449-4d72-8977-424154cb96aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7e107a41-e449-4d72-8977-424154cb96aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_e75b7acd-b173-4784-a81e-4e9d9b3081d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding_e75b7acd-b173-4784-a81e-4e9d9b3081d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanB_b787b308-28ba-494d-8d88-9802d7d3d9ad" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanB"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanB_b787b308-28ba-494d-8d88-9802d7d3d9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanC_6650ebea-9b94-4dae-82b7-198bfa6dafb9" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanC"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanC_6650ebea-9b94-4dae-82b7-198bfa6dafb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanD_ab6283d3-f56f-453a-8a89-d04e5db48490" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanD"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanD_ab6283d3-f56f-453a-8a89-d04e5db48490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordLoanFacility_efcd0d73-8570-4e43-a8e7-86b86182b8fb" xlink:href="lxrx-20220331.xsd#lxrx_OxfordLoanFacility"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_OxfordLoanFacility_efcd0d73-8570-4e43-a8e7-86b86182b8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanA_9d6b888e-2ebc-4d3e-8e1d-003400da9bdf" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanA"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanA_9d6b888e-2ebc-4d3e-8e1d-003400da9bdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanABWarrant_a2ea0038-6495-4bff-88cc-1becef54f73b" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanABWarrant"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanABWarrant_a2ea0038-6495-4bff-88cc-1becef54f73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanCWarrant_ca291914-d619-4fbb-8616-d303edd68e49" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanCWarrant"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanCWarrant_ca291914-d619-4fbb-8616-d303edd68e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanDWarrant_c8259764-fce0-46e2-832c-f48fa421c9b8" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanDWarrant"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanDWarrant_c8259764-fce0-46e2-832c-f48fa421c9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantsNumber_326f14a4-5829-4a13-80a5-20a79de24a07" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAWarrantsNumber"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanAWarrantsNumber_326f14a4-5829-4a13-80a5-20a79de24a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAWarrantExercisePrice_9ae6e47f-07c2-49d6-b7b7-275c2160f44b" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAWarrantExercisePrice"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanAWarrantExercisePrice_9ae6e47f-07c2-49d6-b7b7-275c2160f44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b4f6733e-6e25-47a4-9824-b0f79c68952b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_b4f6733e-6e25-47a4-9824-b0f79c68952b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_3cf143e4-ff02-495a-989a-0f58c3aa3574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateDuringPeriod"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateDuringPeriod_3cf143e4-ff02-495a-989a-0f58c3aa3574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2cdab534-5cfe-41bc-9720-299c6fe54f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2cdab534-5cfe-41bc-9720-299c6fe54f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_a6e9dbe5-f082-4b6c-9dc3-1cd68279411e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_a6e9dbe5-f082-4b6c-9dc3-1cd68279411e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubordinatedBorrowingInterestRate_cd8ab508-415f-44ed-b3b1-2c592861fb63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubordinatedBorrowingInterestRate"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_us-gaap_SubordinatedBorrowingInterestRate_cd8ab508-415f-44ed-b3b1-2c592861fb63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithNoExtention_11469a2b-99c4-4165-84d6-e6a526cb7855" xlink:href="lxrx-20220331.xsd#lxrx_FinalPaymentWithNoExtention"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_FinalPaymentWithNoExtention_11469a2b-99c4-4165-84d6-e6a526cb7855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_FinalPaymentWithExtention_205cf900-8c8f-4667-89b8-45722e371a20" xlink:href="lxrx-20220331.xsd#lxrx_FinalPaymentWithExtention"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_FinalPaymentWithExtention_205cf900-8c8f-4667-89b8-45722e371a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAFinalPayment_0e198172-7d6f-47ff-887c-1996fa218ca7" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAFinalPayment"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanAFinalPayment_0e198172-7d6f-47ff-887c-1996fa218ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanANetCashReceipt_25c84132-e983-4fab-8ed6-4c4c4e3679bd" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanANetCashReceipt"/>
    <link:presentationArc order="39" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanANetCashReceipt_25c84132-e983-4fab-8ed6-4c4c4e3679bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtIssuanceCosts_12ef71f0-946d-47e5-a56d-89c5b53a5f06" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanADebtIssuanceCosts"/>
    <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanADebtIssuanceCosts_12ef71f0-946d-47e5-a56d-89c5b53a5f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OxfordFacilityFee_3d6b3358-7373-49d3-a65a-136e233079be" xlink:href="lxrx-20220331.xsd#lxrx_OxfordFacilityFee"/>
    <link:presentationArc order="41" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_OxfordFacilityFee_3d6b3358-7373-49d3-a65a-136e233079be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanADebtDiscount_989cfeba-4be5-4dac-837a-cc1b0c0ca0f3" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanADebtDiscount"/>
    <link:presentationArc order="42" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanADebtDiscount_989cfeba-4be5-4dac-837a-cc1b0c0ca0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_TermLoanAInterestExpense_88b3ef44-9629-4bab-9a6b-0e257d02ffc3" xlink:href="lxrx-20220331.xsd#lxrx_TermLoanAInterestExpense"/>
    <link:presentationArc order="43" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_TermLoanAInterestExpense_88b3ef44-9629-4bab-9a6b-0e257d02ffc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2025OxfordPrincipalPayments_129fdbc1-ae2e-493a-b7bc-53d71080e802" xlink:href="lxrx-20220331.xsd#lxrx_A2025OxfordPrincipalPayments"/>
    <link:presentationArc order="44" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_A2025OxfordPrincipalPayments_129fdbc1-ae2e-493a-b7bc-53d71080e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2026OxfordPrincipalPayments_b824b24b-efac-4ed4-b462-5bc3d3bd2e81" xlink:href="lxrx-20220331.xsd#lxrx_A2026OxfordPrincipalPayments"/>
    <link:presentationArc order="45" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_A2026OxfordPrincipalPayments_b824b24b-efac-4ed4-b462-5bc3d3bd2e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_A2027OxfordPrincipalPayments_6a819ebf-3f4b-40b8-9d0d-443d590c98d3" xlink:href="lxrx-20220331.xsd#lxrx_A2027OxfordPrincipalPayments"/>
    <link:presentationArc order="46" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_091127fe-aade-4d4f-8f0b-2fe902751d8e" xlink:to="loc_lxrx_A2027OxfordPrincipalPayments_6a819ebf-3f4b-40b8-9d0d-443d590c98d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41f51e69-5f3f-4d0c-9917-f375c3069c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_40d643fc-429b-4fb7-9d45-be13d8436947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_41f51e69-5f3f-4d0c-9917-f375c3069c8b" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_40d643fc-429b-4fb7-9d45-be13d8436947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce4462ba-2f65-4c9d-aaf1-d1a41e2cc01a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_974d40c2-6e69-4f74-a9ca-02d3c8d21831" xlink:href="lxrx-20220331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce4462ba-2f65-4c9d-aaf1-d1a41e2cc01a" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_974d40c2-6e69-4f74-a9ca-02d3c8d21831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_8d45f3fb-32b6-4731-82b0-ef1660105643" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ce4462ba-2f65-4c9d-aaf1-d1a41e2cc01a" xlink:to="loc_us-gaap_OtherCommitmentsTable_8d45f3fb-32b6-4731-82b0-ef1660105643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3e202ac4-f676-49be-925b-19a7d5457c4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8d45f3fb-32b6-4731-82b0-ef1660105643" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3e202ac4-f676-49be-925b-19a7d5457c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_a6a85fb3-5108-43c4-a97b-44588355301e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_3e202ac4-f676-49be-925b-19a7d5457c4e" xlink:to="loc_us-gaap_ReceivableTypeDomain_a6a85fb3-5108-43c4-a97b-44588355301e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_3e31bb71-12b2-4f9b-a456-26f2ac3e34cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_a6a85fb3-5108-43c4-a97b-44588355301e" xlink:to="loc_us-gaap_AccountsReceivableMember_3e31bb71-12b2-4f9b-a456-26f2ac3e34cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_8d45f3fb-32b6-4731-82b0-ef1660105643" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_cd593513-25aa-4b50-96a8-91f415e855dc" xlink:href="lxrx-20220331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_cd593513-25aa-4b50-96a8-91f415e855dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_240da60e-bf68-4afa-995c-9060550daa69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_240da60e-bf68-4afa-995c-9060550daa69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b55b6225-4d41-4820-917d-67b1727b5e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_b55b6225-4d41-4820-917d-67b1727b5e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3cd39274-e136-4167-9336-3c2013e62274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3cd39274-e136-4167-9336-3c2013e62274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0686253d-7559-4b30-9783-2a0dd6d4c3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0686253d-7559-4b30-9783-2a0dd6d4c3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_646e103b-c3cc-42a4-8263-cb84b8ec7e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_646e103b-c3cc-42a4-8263-cb84b8ec7e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e24e6088-6008-4dbf-941b-4a562adab670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_e24e6088-6008-4dbf-941b-4a562adab670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8482c250-8db8-4381-a98d-0aefe794bc3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8482c250-8db8-4381-a98d-0aefe794bc3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_45b32275-86b8-47fe-9288-d6277c3e8a15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_45b32275-86b8-47fe-9288-d6277c3e8a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_5892f5f0-2019-4bf3-ac4a-83b879c28b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_OperatingLeaseLiability_5892f5f0-2019-4bf3-ac4a-83b879c28b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCommitmentAmount_cc2fd39e-20dc-4274-a393-abb3a6605db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCommitmentAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_ShortTermLeaseCommitmentAmount_cc2fd39e-20dc-4274-a393-abb3a6605db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c181b43-c927-4827-9aea-3fd3d8da7cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5c181b43-c927-4827-9aea-3fd3d8da7cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiDisputedCosts_e99bff22-73a1-4680-96f1-bc56d6c0e3d2" xlink:href="lxrx-20220331.xsd#lxrx_SanofiDisputedCosts"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_4bf90b39-00b3-4deb-8b2f-e608aed13106" xlink:to="loc_lxrx_SanofiDisputedCosts_e99bff22-73a1-4680-96f1-bc56d6c0e3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_0f58877f-af0c-440c-a5ff-c5bc7287025c" xlink:href="lxrx-20220331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c7a58cb6-d43c-4e45-80a3-e8933fc41e61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_0f58877f-af0c-440c-a5ff-c5bc7287025c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c7a58cb6-d43c-4e45-80a3-e8933fc41e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#CollaborationandLicenseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:href="lxrx-20220331.xsd#lxrx_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_Sanofiterminationcashpayment_7f0d8811-4008-4da3-9b40-72e77a9dc9f6" xlink:href="lxrx-20220331.xsd#lxrx_Lxrx_Sanofiterminationcashpayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_Lxrx_Sanofiterminationcashpayment_7f0d8811-4008-4da3-9b40-72e77a9dc9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SanofiRevenueRecognized_c7d7943b-2c90-4cc3-987d-63b3ff6091f0" xlink:href="lxrx-20220331.xsd#lxrx_SanofiRevenueRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_SanofiRevenueRecognized_c7d7943b-2c90-4cc3-987d-63b3ff6091f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenTotalPayments_b8eb540e-5b70-4040-a15c-5074aeb19655" xlink:href="lxrx-20220331.xsd#lxrx_IpsenTotalPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_IpsenTotalPayments_b8eb540e-5b70-4040-a15c-5074aeb19655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMaximumSalesMilestones_32397cda-bfb0-4219-a299-2a7dd4d1ab44" xlink:href="lxrx-20220331.xsd#lxrx_IpsenMaximumSalesMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_IpsenMaximumSalesMilestones_32397cda-bfb0-4219-a299-2a7dd4d1ab44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePayment_036f0d40-a96d-474f-beea-1d7a78d2c2c1" xlink:href="lxrx-20220331.xsd#lxrx_IpsenMilestonePayment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_IpsenMilestonePayment_036f0d40-a96d-474f-beea-1d7a78d2c2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenMilestonePaymentReceived_1a7ecaf7-bb62-4cf6-aeef-2a50f8e1cd7a" xlink:href="lxrx-20220331.xsd#lxrx_IpsenMilestonePaymentReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_IpsenMilestonePaymentReceived_1a7ecaf7-bb62-4cf6-aeef-2a50f8e1cd7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_b4d11e92-91dc-4d9d-9c0d-41a40ce446d1" xlink:href="lxrx-20220331.xsd#lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable_b4d11e92-91dc-4d9d-9c0d-41a40ce446d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_IpsenRevenueRecognized_1295b091-27fd-4aaf-bd92-e77f4eaf0dda" xlink:href="lxrx-20220331.xsd#lxrx_IpsenRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_IpsenRevenueRecognized_1295b091-27fd-4aaf-bd92-e77f4eaf0dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_Lxrx_sanofiInitialCashPayment_aec10b54-dc9f-419f-a8fd-58f6deafc6a2" xlink:href="lxrx-20220331.xsd#lxrx_Lxrx_sanofiInitialCashPayment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_Lxrx_sanofiInitialCashPayment_aec10b54-dc9f-419f-a8fd-58f6deafc6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SettlementPaymentFromTermination_1f0c62a9-d03e-4160-96c9-bf1a42edc7dc" xlink:href="lxrx-20220331.xsd#lxrx_SettlementPaymentFromTermination"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_lxrx_CollaborationAndLicenseAgreementsAbstract_1df30f21-105d-4f6f-8e90-bee0e659b05d" xlink:to="loc_lxrx_SettlementPaymentFromTermination_1f0c62a9-d03e-4160-96c9-bf1a42edc7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="simple" xlink:href="lxrx-20220331.xsd#OtherCapitalAgreements"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6b73a472-4afe-43ee-a458-de1c4e723d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_OtherCapitalAgreementsTextBlock_297aabf2-5a55-424e-b8ab-143e64917f7c" xlink:href="lxrx-20220331.xsd#lxrx_OtherCapitalAgreementsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6b73a472-4afe-43ee-a458-de1c4e723d5b" xlink:to="loc_lxrx_OtherCapitalAgreementsTextBlock_297aabf2-5a55-424e-b8ab-143e64917f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="simple" xlink:href="lxrx-20220331.xsd#OtherCapitalAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.lexpharma.com/role/OtherCapitalAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ATMOfferingTotal_8206dbab-4db3-460b-b5f0-8fa152a06e13" xlink:href="lxrx-20220331.xsd#lxrx_ATMOfferingTotal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_ATMOfferingTotal_8206dbab-4db3-460b-b5f0-8fa152a06e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInNov2020ATMOffering_e3a02b60-12e7-4c52-afe9-7f86c70d59ae" xlink:href="lxrx-20220331.xsd#lxrx_SharesSoldInNov2020ATMOffering"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_SharesSoldInNov2020ATMOffering_e3a02b60-12e7-4c52-afe9-7f86c70d59ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInNovember20ATMOffering_bab1d5f0-2951-4e60-815b-9dfb741c9b41" xlink:href="lxrx-20220331.xsd#lxrx_SharePriceInNovember20ATMOffering"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_SharePriceInNovember20ATMOffering_bab1d5f0-2951-4e60-815b-9dfb741c9b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromNov2020ATMOffering_e88060c1-eb8b-4a7d-a74e-7e265a2761e6" xlink:href="lxrx-20220331.xsd#lxrx_ProceedsFromNov2020ATMOffering"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_ProceedsFromNov2020ATMOffering_e88060c1-eb8b-4a7d-a74e-7e265a2761e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInJanuary2021ATMOffering_b0aafcb3-61c3-486a-9ada-abb0c16da433" xlink:href="lxrx-20220331.xsd#lxrx_SharesSoldInJanuary2021ATMOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_SharesSoldInJanuary2021ATMOffering_b0aafcb3-61c3-486a-9ada-abb0c16da433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInJanuary2021ATMOffering_faf107b2-2a8a-4448-917e-18b2294190c6" xlink:href="lxrx-20220331.xsd#lxrx_SharePriceInJanuary2021ATMOffering"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_SharePriceInJanuary2021ATMOffering_faf107b2-2a8a-4448-917e-18b2294190c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromJanuary2021ATMOffering_c3a000f3-56d7-4d20-b823-14ac21d7bfa5" xlink:href="lxrx-20220331.xsd#lxrx_ProceedsFromJanuary2021ATMOffering"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_ProceedsFromJanuary2021ATMOffering_c3a000f3-56d7-4d20-b823-14ac21d7bfa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharesSoldInSeptember2021ATMOfferring_bc881285-5d3c-4499-b2b0-fbe9bf4f54a5" xlink:href="lxrx-20220331.xsd#lxrx_SharesSoldInSeptember2021ATMOfferring"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_SharesSoldInSeptember2021ATMOfferring_bc881285-5d3c-4499-b2b0-fbe9bf4f54a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_SharePriceInSeptember2021ATMOfferring_44adc449-5b0e-469a-8246-4f97600a785c" xlink:href="lxrx-20220331.xsd#lxrx_SharePriceInSeptember2021ATMOfferring"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_SharePriceInSeptember2021ATMOfferring_44adc449-5b0e-469a-8246-4f97600a785c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_lxrx_ProceedsFromSeptember2021ATMOffering_1f69946d-3689-4009-b2d0-468e7bd5a65d" xlink:href="lxrx-20220331.xsd#lxrx_ProceedsFromSeptember2021ATMOffering"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f6d130c8-d6a5-4714-b89d-8c08f3c7a0b5" xlink:to="loc_lxrx_ProceedsFromSeptember2021ATMOffering_1f69946d-3689-4009-b2d0-468e7bd5a65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726227547912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>May 04, 2022</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Lexicon Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001062822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">76-0474169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2445 Technology Forest Blvd.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">11th Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">The Woodlands<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">77381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">863-3000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LXRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">149,593,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726226968984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets-Unaudited - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 59,520<span></span>
</td>
<td class="nump">$ 64,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">26,982<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,892<span></span>
</td>
<td class="nump">2,164<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">88,431<span></span>
</td>
<td class="nump">88,921<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net of accumulated depreciation and amortization of $4,962 and $4,853, respectively</a></td>
<td class="nump">1,142<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">44,543<span></span>
</td>
<td class="nump">44,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">136,178<span></span>
</td>
<td class="nump">136,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">9,321<span></span>
</td>
<td class="nump">9,152<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">9,584<span></span>
</td>
<td class="nump">12,972<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,905<span></span>
</td>
<td class="nump">22,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">43,480<span></span>
</td>
<td class="nump">23,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 225,000 shares authorized; 150,082 and 150,082 shares issued, respectively</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,605,898<span></span>
</td>
<td class="nump">1,608,749<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,511,252)<span></span>
</td>
<td class="num">(1,487,776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(37)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 488 and 1,165 shares, respectively</a></td>
<td class="num">(2,061)<span></span>
</td>
<td class="num">(7,518)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholder's equity (deficit)</a></td>
<td class="nump">92,698<span></span>
</td>
<td class="nump">113,595<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">136,178<span></span>
</td>
<td class="nump">136,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred issuance costs</a></td>
<td class="nump">$ 23,477<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726227519528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets Parentheticals - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedBalanceSheetsAbstract', window );"><strong>Consolidated Balance Sheets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation and amortization, property and equipment</a></td>
<td class="nump">$ 4,962<span></span>
</td>
<td class="nump">$ 4,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="nump">225,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">150,082<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedBalanceSheetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Balance Sheets [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedBalanceSheetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726225876840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss-Unaudited - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalties and other revenue</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development, including stock-based compensation of $1,032, and $1,286, respectively</a></td>
<td class="nump">14,926<span></span>
</td>
<td class="nump">12,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Sellinggeneralandadministrativeexpenses', window );">Selling, general and administrative, including stock-based compensation of $1,740, and $1,565, respectively</a></td>
<td class="nump">8,491<span></span>
</td>
<td class="nump">8,257<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">23,417<span></span>
</td>
<td class="nump">20,866<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(23,380)<span></span>
</td>
<td class="num">(20,839)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(110)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,476)<span></span>
</td>
<td class="num">$ (20,958)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per common share, Basic</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net loss per common share, Basic</a></td>
<td class="nump">149,150<span></span>
</td>
<td class="nump">143,379<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">$ (27)<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(23,503)<span></span>
</td>
<td class="num">(20,947)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalIncomeStatementElementsAbstract', window );"><strong>Supplemental Income Statement Elements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">1,740<span></span>
</td>
<td class="nump">1,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 1,032<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Sellinggeneralandadministrativeexpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Sellinggeneralandadministrativeexpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalIncomeStatementElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalIncomeStatementElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726225904344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss Parentheticals - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConsolidatedStatementsOfOperationsAbstract', window );"><strong>Consolidated Statements of Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense', window );">Stock-based compensation expense associated with research and development expense</a></td>
<td class="nump">$ 1,032<span></span>
</td>
<td class="nump">$ 1,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense', window );">Stock-based compensation expense associated with selling, general and administrative expense</a></td>
<td class="nump">$ 1,740<span></span>
</td>
<td class="nump">$ 1,565<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConsolidatedStatementsOfOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Consolidated Statements of Operations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConsolidatedStatementsOfOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense included in research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock-based compensation expense associated with selling, general and administrative expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726227608040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (23,476,000)<span></span>
</td>
<td class="num">$ (20,958,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">109,000<span></span>
</td>
<td class="nump">37,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">2,772,000<span></span>
</td>
<td class="nump">2,851,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase) decrease in accounts receivable</a></td>
<td class="num">(23,000)<span></span>
</td>
<td class="nump">294,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">(Increase) decrease in prepaid expenses and other current assets</a></td>
<td class="nump">273,000<span></span>
</td>
<td class="nump">1,095,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease in other assets</a></td>
<td class="nump">207,000<span></span>
</td>
<td class="num">(74,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Decrease in accounts payable and other liabilities</a></td>
<td class="num">(3,308,000)<span></span>
</td>
<td class="num">(8,418,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(23,421,000)<span></span>
</td>
<td class="num">(25,159,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Cash and Cash Equivalents, Period Increase (Decrease)</a></td>
<td class="num">(4,545,000)<span></span>
</td>
<td class="num">(28,611,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">59,520,000<span></span>
</td>
<td class="nump">97,652,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_InitialRecognitionOfRightOfUseAsset', window );">Initial recognition of right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims', window );">Issuance of Stock and Warrants for Services or Claims</a></td>
<td class="nump">698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="nump">700,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Stock Issued During Period, Value, Treasury Stock Reissued</a></td>
<td class="nump">6,321<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Business Exit Costs</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="num">(864,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(76,000)<span></span>
</td>
<td class="num">(38,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(17,816,000)<span></span>
</td>
<td class="num">(21,686,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">13,484,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(4,408,000)<span></span>
</td>
<td class="num">(17,724,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,947,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(864,000)<span></span>
</td>
<td class="num">(2,675,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from debt borrowings, net of fees</a></td>
<td class="nump">24,148,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="nump">23,284,000<span></span>
</td>
<td class="nump">14,272,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="num">(4,545,000)<span></span>
</td>
<td class="num">(28,611,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">64,065,000<span></span>
</td>
<td class="nump">126,263,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">59,520,000<span></span>
</td>
<td class="nump">97,652,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_InitialRecognitionOfRightOfUseAsset', window );">Initial recognition of right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="num">$ (864,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_InitialRecognitionOfRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial recognition of right of use asset</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_InitialRecognitionOfRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726227718440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Gain (Loss)</div></th>
<th class="th"><div>Treasury Stock</div></th>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2020</a></td>
<td class="nump">$ 156,371<span></span>
</td>
<td class="nump">$ 142<span></span>
</td>
<td class="nump">$ 1,561,096<span></span>
</td>
<td class="num">$ (1,400,018)<span></span>
</td>
<td class="num">$ (6)<span></span>
</td>
<td class="num">$ (4,843)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,851<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,851<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(2,675)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,675)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,958)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(20,958)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">145,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2021</a></td>
<td class="nump">152,547<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
<td class="nump">1,580,891<span></span>
</td>
<td class="num">(1,420,976)<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="num">(7,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 548<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">547<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="nump">150,082<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Dec. 31, 2021</a></td>
<td class="nump">$ 113,595<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">1,608,749<span></span>
</td>
<td class="num">(1,487,776)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="num">(7,518)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">2,772<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under Equity Incentive Plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under Equity Incentive Plans, value</a></td>
<td class="num">(864)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(864)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(23,476)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23,476)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="num">$ (27)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Balance, shares at Mar. 31, 2022</a></td>
<td class="nump">150,082<span></span>
</td>
<td class="nump">150,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance, value at Mar. 31, 2022</a></td>
<td class="nump">$ 92,698<span></span>
</td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">1,605,898<span></span>
</td>
<td class="num">(1,511,252)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="num">(2,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</a></td>
<td class="nump">$ 698<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 698<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726226669160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#8220;Lexicon&#8221; or the &#8220;Company&#8221;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information, refer to the financial statements and footnotes thereto included in Lexicon&#8217;s annual report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of 9% at the commencement date in determining the present value of future payments. </span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform the following five steps in determining the amount of revenue to recognize as we fulfill our performance obligations under each of our contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the three months ended March&#160;31, 2022 and 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of stock option activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2022:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March&#160;31, 2022, Lexicon granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments.  The following is a summary of restricted stock units activity under Lexicon&#8217;s stock-based compensation plans for the three months ended March&#160;31, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726227007192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements Level 1 (Notes)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_RecentAccountingPronouncementsAbstract', window );"><strong>Recent Accounting Pronouncements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy</a></td>
<td class="text">Recent Accounting Pronouncements<div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on our condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_RecentAccountingPronouncementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Recent Accounting Pronouncements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_RecentAccountingPronouncementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726227516376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents Disclosure</a></td>
<td class="text">Cash and Cash Equivalents and Investments<div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of cash and cash equivalents and investments held at March&#160;31, 2022 and December&#160;31, 2021 are as follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,539&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,502&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no realized losses during either of the three months ended March&#160;31, 2022 and 2021, respectively.  The cost of securities sold is based on the specific identification method.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726226711048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock', window );">Fair Value, Measurement Inputs, Disclosure</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - significant unobservable inputs </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2022 and December&#160;31, 2021.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2022 or December&#160;31, 2021. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementInputsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI https://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementInputsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726226658472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_DebtObligationsAbstract', window );"><strong>Debt Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure</a></td>
<td class="text">Debt Obligations<div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 17, 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#8220;Oxford&#8221;) that provides up to $150&#160;million in borrowing capacity (the &#8220;Oxford Term Loans&#8221;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#8217;s option to 48 months if Lexicon maintains compliance with a financial covenant relating to net sales of sotagliflozin following regulatory approval. The interest-only period will be followed by principal payments of $8.7&#160;million, $13.0&#160;million, and $4.8&#160;million during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first $25&#160;million tranche was funded at closing. The second $25&#160;million tranche is available for draw at Lexicon&#8217;s option prior to August 31, 2022, but within 30 days of acceptance of filing by the U.S. Food and Drug Administration of Lexicon&#8217;s resubmission of its application for U.S. regulatory approval of sotagliflozin for heart failure. The third $50&#160;million tranche is available for draw at Lexicon&#8217;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. The fourth $50&#160;million tranche is available for draw at Lexicon&#8217;s option, subject to Oxford&#8217;s consent, at any time prior to the expiration of the interest-only payment period.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan and security agreement provides that, upon funding of the first three tranches, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 3.50%, 1.75% and 0.875%, respectively, of each such tranche, as determined by reference to a 10-day average closing price of the shares. Each warrant will have an exercise price equal to such average closing price, be exercisable for a five-year period from the date of issuance and feature a net cashless exercise provision. Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase 420,673 shares of Lexicon&#8217;s common stock at an exercise price of $2.08 per share. The warrant is exercisable through March 1, 2027 and is classified as an equity instrument.  The Company allocated the proceeds from the first tranche to the warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants.  The fair value of the warrant of $0.7&#160;million was recognized as equity with a corresponding debt discount of $0.7&#160;million.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing.  As of March&#160;31, 2022, the interest rate was 8.14%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to 6% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to 7% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $1.5&#160;million was recorded as a debt discount on the closing date of the first tranche.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During March 2022, in connection with the first tranche of the loan and security agreement, the Company received cash proceeds of $24.2&#160;million, net of debt issuance costs of $0.4&#160;million and a facility fee of $0.5&#160;million. The debt issuance costs and facility fee have been recorded as a debt discount on the Company&#8217;s condensed consolidated balance sheet, which together with the final payment exit fee of $1.5&#160;million and warrant fair value of $0.7&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.  As of March&#160;31, 2022, the balance of the debt discount was $3.0&#160;million. During the three months ended March&#160;31, 2022, the Company recognized interest expense of $0.1&#160;million.  As of  March&#160;31, 2022, the carrying value of the Oxford Term Loans was $23.5&#160;million.  The fair value of the Oxford Term Loans approximates its carrying value and was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#8217;s estimated current incremental borrowing rate.       </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Lexicon&#8217;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenant, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of March&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-bottom:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Convertible Debt.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#8220;Convertible Notes&#8221;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#8217;s condensed consolidated balance sheets.  </span></div>In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes. In 2020, the Company issued 10,368,956 shares of the Company&#8217;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes. In December 2021, the remaining balance of $11.6 million was repaid in cash.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_DebtObligationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Obligations [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_DebtObligationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726226696536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure</a></td>
<td class="text">Commitments and Contingencies<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Lease Obligations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;Lexicon&#8217;s operating leases include office space in The Woodlands, Texas and Basking Ridge, New Jersey and will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2022, the right-of-use assets for the office space leases had a balance of $2.1 million, which is included in other assets in the condensed consolidated balance sheet. Current and non-current liabilities relating to the leases were $0.9 million and $1.1 million, respectively, which are included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheet, respectively.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at March&#160;31, 2022:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"/><td style="width:80.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">874&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted operating lease liability</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,319&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount of lease payments representing interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(281)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future lease payments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,038&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: short-term operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(940)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Legal Proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726229517464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative Arrangement Disclosure</a></td>
<td class="text">Collaboration and License Agreements&#160;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and License Agreements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI https://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726227002728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OtherCapitalAgreementsTextBlock', window );">Other Capital Agreements</a></td>
<td class="text">Other Capital Agreements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:  In 2020, Lexicon entered into an Open Market Sale Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) relating to the shares of its common stock. In January 2021, Lexicon sold 2,000,000 shares of its common stock at a price of $8.463 per share pursuant to the Sales Agreement, resulting in net proceeds of $16.4&#160;million. The net proceeds are reflected as issuances of common stock in the accompanying condensed consolidated financial statements. </span></div>In August and September 2021, Lexicon sold an aggregate of 4,176,953 shares of its common stock at a price of $4.732 per share pursuant to the Sales Agreement, resulting in net proceeds of $19.1 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OtherCapitalAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Capital Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OtherCapitalAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726225915064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash, Cash Equivalents and Short-Term Investments:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#8217;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#8217; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We perform the following five steps in determining the amount of revenue to recognize as we fulfill our performance obligations under each of our contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In agreements in which a license to the Company&#8217;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  </span></div>The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#8217;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#8217;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;</span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#8217;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination </span></div>behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#8217;s stock price.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock', window );">Recognition of Asset and Liability for Lease of Acquiree</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.</span>Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of 9% at the commencement date in determining the present value of future payments.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SummaryOfSignificantAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Significant Accounting Policies [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SummaryOfSignificantAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election not to recognize asset and liability at acquisition for lease with remaining lease term of one year or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 25<br> -Paragraph 28B<br> -URI https://asc.fasb.org/extlink&amp;oid=128091968&amp;loc=SL77931625-128468<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726229621304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract', window );"><strong>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued liabilities: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accrued liabilities consisted of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:60.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.963%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued research and development services</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,669&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,711&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short term lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,584&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,972&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:51.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.738%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.916%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Volatility</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Risk-free Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expected Term</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Dividend<br/>Rate</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2022:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 31, 2021:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Officers and non-employee directors</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:66.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.470%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,865&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(308)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,784&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at March 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,093&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:65.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.829%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.497%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(980)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,949&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726230586168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract', window );"><strong>Cash and Cash Equivalents and Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:52.047%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,533&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,522&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,019&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,539&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,502&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities maturing within one year:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,562&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,687&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,753&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_CashAndCashEquivalentsAndInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash and Cash Equivalents and Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_CashAndCashEquivalentsAndInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726226518152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FairValueMeasurementsAbstract', window );"><strong>Fair Value Measurements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Fair Value, by Balance Sheet Grouping [Table Text Block]</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of March 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,980&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,522&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,502&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:46.623%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets and Liabilities at Fair Value as of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,065&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash and cash equivalents and investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,626&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,117&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,743&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FairValueMeasurementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Measurements [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FairValueMeasurementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726226954232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details) - Equity Option [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees</a></td>
<td class="nump">104.00%<span></span>
</td>
<td class="nump">105.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726225653272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</a></td>
<td class="nump">11,784<span></span>
</td>
<td class="nump">8,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.46<span></span>
</td>
<td class="nump">$ 6.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</a></td>
<td class="nump">3,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 12.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</a></td>
<td class="nump">308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</a></td>
<td class="nump">5,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</a></td>
<td class="nump">$ 7.57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</a></td>
<td class="nump">2,949<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.20<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</a></td>
<td class="nump">2,110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 2.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</a></td>
<td class="nump">980<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 4.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</a></td>
<td class="nump">$ 3.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726226997176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Accrued Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedLiabilitiesLineItems', window );"><strong>Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent', window );">Accrued research and development services current</a></td>
<td class="nump">$ 5,308,000<span></span>
</td>
<td class="nump">$ 3,669,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_AccruedCompensationAndBenefitsCurrent', window );">Accrued compensation and benefits current</a></td>
<td class="nump">2,616,000<span></span>
</td>
<td class="nump">5,711,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating Lease, Liability, Current</a></td>
<td class="num">(940,000)<span></span>
</td>
<td class="num">(1,089,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other Accrued Liabilities, Current</a></td>
<td class="nump">720,000<span></span>
</td>
<td class="nump">2,503,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent', window );">Accrued Liabilities</a></td>
<td class="nump">$ 9,584,000<span></span>
</td>
<td class="nump">$ 12,972,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_LexiconIncrementalBorrowingRate', window );">Lexicon incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedCompensationAndBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued compensation and benefits current - due within 1 year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedCompensationAndBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_AccruedResearchAndDevelopmentServicesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development services current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_AccruedResearchAndDevelopmentServicesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_LexiconIncrementalBorrowingRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lexicon incremental borrowing rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_LexiconIncrementalBorrowingRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726225731496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember', window );">Cash and Cash Equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">$ 59,520<span></span>
</td>
<td class="nump">$ 64,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">59,520<span></span>
</td>
<td class="nump">64,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">12,486<span></span>
</td>
<td class="nump">7,562<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(26)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">12,460<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember', window );">Total Short-term Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">27,019<span></span>
</td>
<td class="nump">22,687<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">26,982<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">86,539<span></span>
</td>
<td class="nump">86,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">86,502<span></span>
</td>
<td class="nump">86,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">14,533<span></span>
</td>
<td class="nump">15,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Estimated Fair Value</a></td>
<td class="nump">$ 14,522<span></span>
</td>
<td class="nump">$ 15,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_InvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726226711048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents and Investments (Details 2) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentsLineItems', window );"><strong>Schedule of Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized Investment Gains (Losses)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726227667336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">$ 59,520<span></span>
</td>
<td class="nump">$ 64,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">26,982<span></span>
</td>
<td class="nump">22,678<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">86,502<span></span>
</td>
<td class="nump">86,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">59,520<span></span>
</td>
<td class="nump">64,065<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">12,460<span></span>
</td>
<td class="nump">7,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">71,980<span></span>
</td>
<td class="nump">71,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">14,522<span></span>
</td>
<td class="nump">15,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">14,522<span></span>
</td>
<td class="nump">15,117<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and Cash Equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Short-term Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Total Cash and Cash Equivalents and Investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726224648328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt Obligations (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2027</div></th>
<th class="th"><div>Dec. 31, 2026</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 28, 2020</div></th>
<th class="th"><div>Nov. 20, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
<td class="nump">$ 87,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage', window );">Conv Debt Instrument Interest Rate Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.25%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,082,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeRemainingNotes', window );">Convertible debt exchange Remaining Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount', window );">Convertible debt exchange - Total Principal Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of deferred issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23,477,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-Term Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanB', window );">Term Loan B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanC', window );">Term Loan C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanD', window );">Term Loan D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OxfordLoanFacility', window );">Oxford Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanA', window );">Term Loan A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanABWarrant', window );">Term Loan A&amp;B Warrant %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanCWarrant', window );">Term Loan C Warrant %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanDWarrant', window );">Term Loan D Warrant %</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanAWarrantsNumber', window );">Term Loan A Warrants Number</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">420,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanAWarrantExercisePrice', window );">Term Loan A Warrant Exercise Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Adjustments to Additional Paid in Capital, Warrant Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.01%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubordinatedBorrowingInterestRate', window );">Subordinated Borrowing, Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.14%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FinalPaymentWithNoExtention', window );">Final Payment % with no extention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_FinalPaymentWithExtention', window );">Final Payment % with extention</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanAFinalPayment', window );">Term Loan A Final Payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanANetCashReceipt', window );">Term Loan A Net Cash Receipt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanADebtIssuanceCosts', window );">Term Loan A Debt Issuance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_OxfordFacilityFee', window );">Oxford Facility Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanADebtDiscount', window );">Term Loan A Debt Discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_TermLoanAInterestExpense', window );">Term Loan A Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_A2026OxfordPrincipalPayments', window );">2027 Oxford Principal Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_A2027OxfordPrincipalPayments', window );">2027 Oxford Principal Payments2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2026OxfordPrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2026 Oxford Principal Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2026OxfordPrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_A2027OxfordPrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>2027 Oxford Principal Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_A2027OxfordPrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvDebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvDebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeRemainingNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange Remaining Notes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeRemainingNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ConvertibleDebtExchangeTotalPrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible debt exchange - Total Principal Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ConvertibleDebtExchangeTotalPrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalPaymentWithExtention">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final Payment % with extention</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalPaymentWithExtention</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_FinalPaymentWithNoExtention">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final Payment % with no extention</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_FinalPaymentWithNoExtention</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OxfordFacilityFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Oxford Facility Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OxfordFacilityFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_OxfordLoanFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Oxford Loan Facility</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_OxfordLoanFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanABWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A&amp;B Warrant %</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanABWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanADebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanADebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanADebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Debt Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanADebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAFinalPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Final Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAFinalPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Interest Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanANetCashReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Net Cash Receipt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanANetCashReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAWarrantExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Warrant Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAWarrantExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanAWarrantsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan A Warrants Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanAWarrantsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan B</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanC">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan C</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanC</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanCWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan C Warrant %</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanCWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan D</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_TermLoanDWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term Loan D Warrant %</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_TermLoanDWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubordinatedBorrowingInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stated interest rate of the subordinated debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubordinatedBorrowingInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726221971800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term Debt and Lease Obligation</a></td>
<td class="nump">$ 1,098,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months</a></td>
<td class="nump">874,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">Lessee, Operating Lease, Liability, Payments, Due Year Two</a></td>
<td class="nump">531,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">Lessee, Operating Lease, Liability, Payments, Due Year Three</a></td>
<td class="nump">544,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">Lessee, Operating Lease, Liability, Payments, Due Year Four</a></td>
<td class="nump">370,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Lessee, Operating Lease, Liability, Payments, Due after Year Five</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Lessee, Operating Lease, Liability, Payments, Due</a></td>
<td class="nump">2,319,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</a></td>
<td class="nump">281,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating Lease, Liability</a></td>
<td class="nump">2,038,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCommitmentAmount', window );">Short-term Lease Commitment, Amount</a></td>
<td class="nump">900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918705-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.1</span><table class="report" border="0" cellspacing="2" id="idm139726227129112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Capital Agreements (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInJanuary2021ATMOffering', window );">Shares sold in January 2021 ATM offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInJanuary2021ATMOffering', window );">Share price in January 2021 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.463<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromJanuary2021ATMOffering', window );">Proceeds from January 2021 ATM Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharesSoldInSeptember2021ATMOfferring', window );">Shares sold in September 2021 ATM Offerring</a></td>
<td class="nump">4,176,953<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_SharePriceInSeptember2021ATMOfferring', window );">Share Price in September 2021 ATM Offerring</a></td>
<td class="nump">$ 4.732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_lxrx_ProceedsFromSeptember2021ATMOffering', window );">Proceeds from September 2021 ATM Offering</a></td>
<td class="nump">$ 19.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_ProceedsFromSeptember2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from September 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_ProceedsFromSeptember2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share price in January 2021 ATM Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharePriceInSeptember2021ATMOfferring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Price in September 2021 ATM Offerring</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharePriceInSeptember2021ATMOfferring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInJanuary2021ATMOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in January 2021 ATM offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInJanuary2021ATMOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_lxrx_SharesSoldInSeptember2021ATMOfferring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Shares sold in September 2021 ATM Offerring</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">lxrx_SharesSoldInSeptember2021ATMOfferring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>lxrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>lxrx-20220331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:lxrx="http://www.lexpharma.com/20220331"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lxrx-20220331.xsd" xlink:type="simple"/>
    <context id="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ideb90240455b438fb9d26eff699c0fbc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30be9c3664634c46b415c3eebd5c5d7e_I20220504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-05-04</instant>
        </period>
    </context>
    <context id="i56bf863e5c644f1fb5924d8588e1edf8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i26b3a1ab655c4f5e98599da965af2bc0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i54962a8013d14e668867895265609fcc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9dad627e685144ca94f9ab63453ba29a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i2e8b6089596d46158956c93da1f84cfc_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ieddfc4a55e8f4430b5893c77932b3f88_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4d4e9a8b9a234321879ba71b0048f67c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia0ffc3b01ab14d17ac3cdd4433fe2c5b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i65c3369eb679457a8913dcaac302427c_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib10db76d45214c05b5efdc7b1a3cf613_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib9d4d096474c4686a816df94e033a651_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9fa5363cf9e946eeb5596f97e3ae590b_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2e6608c1aca34ce99ff1ae370e6c325e_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ibb0c568977f34053900263e77db2baaf_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i10dfe24fc01a400fa7a0f7e7f958ad59_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic1a7dafcc5d543b98462aceef262d219_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id67531ad05e34e068f1cd490b916866a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66c91f48540d48699c74344733fb3ac1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4089c48d67b44b789b49ff9231f66610_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i085ee5a7929c45f489a3aecd04578b4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id365c25fcd8b48c0a0cf24853ebcfebe_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i848b624644c646a58412c3b2725ab8b5_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ic9bc9c0e23174f2995a516bfe55e91bb_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia6ada97105dc41999a86e557839e78a1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4691328755b94be283e8d276e74feb5d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia1cfae56d0154e63a47ec27ca3d5dab8_I20210301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2021-03-01</instant>
        </period>
    </context>
    <context id="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id22fce593ee9499987972bc373045887_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia8243aca9d564e4f83796530f13c3383_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="iab72bef6ac48400897e99aead8b76e9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i873df727915d4fd29cd485502b673a49_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i613127c1d0fe4c42bf53196b80bab0cc_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="icc65cb33f8614f8686cae6c8db601bbf_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i269a16b2bad547b0933a05089ed034c8_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id6057d7870b34586857e2a54b3264dea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i4831626629fd4c0f89f3ee0635c996ea_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i754d1c94079544c5a4dbeca0b1a7070c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40803427d7d242d4aa9bd89cc640ef9c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2818027b81e84d5f83d453920e2c236a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia06866a79907412da012da019c3bdbf0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:InvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d1d7ebd972347b28a0590be373807d1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib8839e3922754606a106d63fa91f9257_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0a3594e189984ab887b31949bdb42d39_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i63fccb8bd5334396afb7e01493bc4ff0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i107e88057aa14de4a9bfdadf17dea0e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i345a5ef75eae4b1dbfc66924f9141439_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i65072cfc026e48afbf7cc86311e0945f_D20250101-20251231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="ibb0a7747800c4993a006e9573429f517_D20260101-20261231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-12-31</endDate>
        </period>
    </context>
    <context id="i32ff79bcead3411f88004dea3607340e_D20270101-20271231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2027-01-01</startDate>
            <endDate>2027-12-31</endDate>
        </period>
    </context>
    <context id="ibea33cce1ed8454ba1e53a958924c502_D20141101-20141130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2014-11-01</startDate>
            <endDate>2014-11-30</endDate>
        </period>
    </context>
    <context id="i9ede230fc7714aa6adbaa82ca6308ad6_I20141120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2014-11-20</instant>
        </period>
    </context>
    <context id="ic85a31856cf447f699a3d934334e07e1_I20200928">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <instant>2020-09-28</instant>
        </period>
    </context>
    <context id="if5e01daa001c4e169e255a6c6475516d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001062822</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="rate">
        <measure>utr:Rate</measure>
    </unit>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV81LTQtMS0xLTIzNTk2_5e25db49-2bf8-4e4a-b006-a73939c3b0c9">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV85LTQtMS0xLTIzNTk2_82a4c9f9-218a-496b-856b-151f123237ee">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV8xMC00LTEtMS0yMzU5Ng_3a187d7f-9548-4ab6-8800-cd15dde50427">2022</dei:DocumentFiscalYearFocus>
    <dei:CurrentFiscalYearEndDate
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV8xMS00LTEtMS0yMzU5Ng_a0e92405-1fe1-4f14-af14-04e01a0fdb9d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityCentralIndexKey
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180L2ZyYWc6NzYzMTI4ZjA5OGUzNGY3Y2I5NWU1NjY1M2QxNTQwYzgvdGFibGU6MDIyYzE3YjM0YjZlNDk4NmI1NWU2YmFkM2VkMWNjMjUvdGFibGVyYW5nZTowMjJjMTdiMzRiNmU0OTg2YjU1ZTZiYWQzZWQxY2MyNV8xNC00LTEtMS0yMzU5Ng_cc3e956a-f14b-4456-be4b-6ae151c4b8cd">0001062822</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV84Mg_827e9927-f001-49cc-a0a6-b990f0ff8a58">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6M2M5MGMzZDI0MTJmNDc5YjgwOTFkM2NhMzE5YzY4YTkvdGFibGVyYW5nZTozYzkwYzNkMjQxMmY0NzliODA5MWQzY2EzMTljNjhhOV8wLTAtMS0xLTIzNTk2_a47de830-9089-4cb3-9e05-e720961996ba">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8xMjk_49ac049a-fb52-431f-8ffc-cb3b005e9fb4">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MDg4MTllZmIxYzczNDRiMWI0NmMxNjVlMTE0OGU1YTUvdGFibGVyYW5nZTowODgxOWVmYjFjNzM0NGIxYjQ2YzE2NWUxMTQ4ZTVhNV8wLTAtMS0xLTIzNTk2_39ad3bb6-1876-42ad-bcac-2f9390044e83">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yMjU_489b5716-9647-4353-8368-b7f9620e2e3a">000-30111</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yMjg_51a839d2-2f52-47c6-bde5-3750f828d044">Lexicon Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6M2M1Y2UwOTczYmFhNDI5OGFiYjhmZjBiYTZhM2M5NDEvdGFibGVyYW5nZTozYzVjZTA5NzNiYWE0Mjk4YWJiOGZmMGJhNmEzYzk0MV8wLTAtMS0xLTIzNTk2_e48495ce-f0e8-40c6-8a4a-926bde9c32fb">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6M2M1Y2UwOTczYmFhNDI5OGFiYjhmZjBiYTZhM2M5NDEvdGFibGVyYW5nZTozYzVjZTA5NzNiYWE0Mjk4YWJiOGZmMGJhNmEzYzk0MV8wLTEtMS0xLTIzNTk2_b45c2791-6b3b-4389-a302-a0bf6bb1d770">76-0474169</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yODc_cd9b6677-2701-4022-9bd5-4053e5d8af89">2445 Technology Forest Blvd.</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yOTA_2445950b-e6f8-4cef-9587-4e9ca3084011">11th Floor</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yOTM_76d62733-d3eb-48b5-a28d-346184e7f1b6">The Woodlands</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yOTc_aa08be66-2fea-49ca-8763-1f72bc37d4aa">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8zMDA_caaf770f-dfed-4a31-a5f4-33ff673c3c38">77381</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8zNTg_ab4c7b28-2700-4399-afe3-cb84ccbe6d02">281</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8zNjI_957c2712-be83-49ea-ad09-b117a369ce19">863-3000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MGFhY2I1ODRmNjU5NGJkMjlhNWM2NWIzNzIwZTEyMGMvdGFibGVyYW5nZTowYWFjYjU4NGY2NTk0YmQyOWE1YzY1YjM3MjBlMTIwY18xLTAtMS0xLTIzNTk2_89b7b234-0c62-484e-9850-be5531701139">Common Stock, par value $0.001</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MGFhY2I1ODRmNjU5NGJkMjlhNWM2NWIzNzIwZTEyMGMvdGFibGVyYW5nZTowYWFjYjU4NGY2NTk0YmQyOWE1YzY1YjM3MjBlMTIwY18xLTEtMS0xLTIzNTk2_1259781c-6fd9-431f-9595-136e43f86dc4">LXRX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MGFhY2I1ODRmNjU5NGJkMjlhNWM2NWIzNzIwZTEyMGMvdGFibGVyYW5nZTowYWFjYjU4NGY2NTk0YmQyOWE1YzY1YjM3MjBlMTIwY18xLTItMS0xLTIzNTk2_f41f069f-810d-4f4a-b7a3-eeffa9089e77">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6YzY3ZTNlY2I5YWU5NDllNGE4Mjk3ODA4YTk1MGI4YzAvdGFibGVyYW5nZTpjNjdlM2VjYjlhZTk0OWU0YTgyOTc4MDhhOTUwYjhjMF8wLTAtMS0xLTIzNTk2_412e7864-8802-4b84-a38a-b0a4d34abbca">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6YWMzNzYwNzZiMjA0NGI2Yzk1MTI2YTljYjQ3YTVkNWMvdGFibGVyYW5nZTphYzM3NjA3NmIyMDQ0YjZjOTUxMjZhOWNiNDdhNWQ1Y18wLTAtMS0xLTIzNTk2_ca11dc4b-171e-45d0-a941-507e52cbbc0a">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ideb90240455b438fb9d26eff699c0fbc_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8xNjQ5MjY3NDQzOTU2_9a4e54ef-2121-4414-820a-7ae51211d713">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yMjg5_a837f423-ae7e-4581-a3fc-e80a2d133157">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8yMjg4_248ae881-abff-4c63-9df5-7bed80d8c041">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGFibGU6MDYxMzk5NWE5MjhhNDQ4OWE0ZmJmNDdkYjhiMjMzYWQvdGFibGVyYW5nZTowNjEzOTk1YTkyOGE0NDg5YTRmYmY0N2RiOGIyMzNhZF8wLTEtMS0xLTIzNTk2_0f8fe12f-d87f-40fd-85c7-7c5349c10821">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i30be9c3664634c46b415c3eebd5c5d7e_I20220504"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xL2ZyYWc6MzMxZWE5MDAwZjY3NGQ1ODk3ZTcxNDhkYTdjYTA5YTEvdGV4dHJlZ2lvbjozMzFlYTkwMDBmNjc0ZDU4OTdlNzE0OGRhN2NhMDlhMV8xNjQ5MjY3NDQ0MDA3_0d469bd4-9849-4b88-b80d-f7dbb7de48d0"
      unitRef="shares">149593551</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNC0yLTEtMS0yMzU5Ng_c1656806-2582-4659-a133-0bf415f46b66"
      unitRef="usd">59520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNC00LTEtMS0yMzU5Ng_f0b5098c-ad8e-4c78-ac16-be8387f47045"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNS0yLTEtMS0yMzU5Ng_320406a0-4515-4735-adcc-7b06743d03a8"
      unitRef="usd">26982000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNS00LTEtMS0yMzU5Ng_4803fc94-cb65-4da4-af60-c0a48311d48c"
      unitRef="usd">22678000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNi0yLTEtMS0yMzU5Ng_b6b30ca7-7f18-47e6-a8f0-64f5c1614676"
      unitRef="usd">37000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfNi00LTEtMS0yMzU5Ng_a1758dba-6df7-4351-a141-b5ac7665dd11"
      unitRef="usd">14000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfOS0yLTEtMS0yMzU5Ng_6629b0fb-b86f-4216-bf9b-8f27ca15c976"
      unitRef="usd">1892000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfOS00LTEtMS0yMzU5Ng_970f8bd7-1672-4eff-90d6-13b177073f13"
      unitRef="usd">2164000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTAtMi0xLTEtMjM1OTY_5edbb90f-48b1-4bd0-8ed1-380922eadef2"
      unitRef="usd">88431000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTAtNC0xLTEtMjM1OTY_8366de68-5f5f-42d3-b062-a4c3a415422e"
      unitRef="usd">88921000</us-gaap:AssetsCurrent>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjozMjkxZDQ2YWQzODY0ZjhjOWY5ZmI0ZTg3YzdhODhjYl84MA_f7a41966-1acb-4563-8f6f-c5f5e6c346c2"
      unitRef="usd">4962000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjozMjkxZDQ2YWQzODY0ZjhjOWY5ZmI0ZTg3YzdhODhjYl84Nw_f785b651-72c9-43d1-8f05-e8a2b994c41e"
      unitRef="usd">4853000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTEtMi0xLTEtMjM1OTY_1e1998f9-ef60-4201-b020-1e7bfa2a82b8"
      unitRef="usd">1142000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTEtNC0xLTEtMjM1OTY_2985f7ee-2aeb-4110-8560-91b3a38dd575"
      unitRef="usd">1176000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Goodwill
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTItMi0xLTEtMjM1OTY_b2b47290-6f63-4df7-9436-5d87037e15b7"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTItNC0xLTEtMjM1OTY_3bfa0095-24e0-4f07-af90-bdf129151e2d"
      unitRef="usd">44543000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTQtMi0xLTEtMjM1OTY_5b8a583f-0309-49f7-b5b1-0c87ed4c11a6"
      unitRef="usd">2062000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTQtNC0xLTEtMjM1OTY_5d65b399-3462-4f65-9988-571216203a1c"
      unitRef="usd">2269000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTUtMi0xLTEtMjM1OTY_d873751d-9157-44ad-89db-fe8feed6f95c"
      unitRef="usd">136178000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTUtNC0xLTEtMjM1OTY_611ab307-fd47-4b96-9dab-867c42d28a6d"
      unitRef="usd">136909000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTgtMi0xLTEtMjM1OTY_4537641f-58f8-45a0-a6b0-617609c3142d"
      unitRef="usd">9321000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTgtNC0xLTEtMjM1OTY_27abd26f-8006-4663-9ccb-356335fb87ab"
      unitRef="usd">9152000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTktMi0xLTEtMjM1OTY_c9976a20-633c-41b1-b49b-a5a0e605904d"
      unitRef="usd">9584000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMTktNC0xLTEtMjM1OTY_d5008b8e-0913-461f-8799-6cddbe868a2d"
      unitRef="usd">12972000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjItMi0xLTEtMjM1OTY_49225f8d-6ab7-4f3a-9fbe-d91d5974bdd0"
      unitRef="usd">18905000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjItNC0xLTEtMjM1OTY_85a34ad3-243b-4f38-b3d2-0cdc3301e1ed"
      unitRef="usd">22124000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjQtMi0xLTEtMjM1OTY_13a24b41-a4e6-481b-8637-657aebcb9580"
      unitRef="usd">23477000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjQtNC0xLTEtMjM1OTY_d20592d6-4ffd-43dc-8129-620acf3ec10c"
      unitRef="usd">0</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjYtMi0xLTEtMjM1OTY_1870b738-0213-43ae-8479-b622b61d97cf"
      unitRef="usd">1098000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjYtNC0xLTEtMjM1OTY_41620b4b-a23c-4d1e-b8d4-ba4af126e77d"
      unitRef="usd">1190000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjctMi0xLTEtMjM1OTY_ebfa8727-d06a-4786-9787-47140af4a860"
      unitRef="usd">43480000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjctNC0xLTEtMjM1OTY_d793edba-8fb0-4637-9730-d4f5020a3028"
      unitRef="usd">23314000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjgtMi0xLTEtMjM1OTY_120459e3-fe26-4e07-816f-a0967f75f9b9"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMjgtNC0xLTEtMjM1OTY_e18764fb-f3bc-459f-a4c7-e716b18b2038"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl8yMg_60efd6c9-c5ef-4590-8395-c81a6d96af6c"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl8yMg_c199501c-6893-49bd-8a77-0fb5030859db"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl8zNg_27ca4b00-af4f-4763-9c79-0719fd3eef36"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl8zNg_d4fde9b3-a255-4800-8c1d-310849ddaa29"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl81OA_4b77ac6f-b196-47ab-8221-573623e447d9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl81OA_7ab81dfc-2e03-4689-941e-9f5353cba75c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl81OA_84ffd390-5644-4232-8ea3-645c8d357bfc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjoyOTI5YjhlMjYxZmI0NTQ0OTgxNGNkM2RlNGIzZDljZl81OA_e7e2cea2-16be-44f9-a3a4-3757fbc47f52"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtMi0xLTEtMjM1OTY_7b3b8206-5318-4076-bc0e-815d253307da"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzAtNC0xLTEtMjM1OTY_c7c6789d-02ba-40d9-97ed-738d07c603f5"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y18xOA_4fce9f91-6ead-444e-b2b3-6d94f68d468c"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y18xOA_a37bad3f-5fe5-4b7b-b6da-e390eaf87ce7"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y18zMg_67b02031-2082-446f-9567-b3c52bd24335"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y18zMg_6d0c10b3-d7a6-40ca-9548-8236afa66aa7"
      unitRef="shares">225000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y181NA_7b1586f3-3138-4b9d-ac48-ff14078a9fa3"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpjOGY4NjZlM2VmMzI0YTA1YTNjZTA0ZDIyOGY3YjU5Y182MQ_f7393268-e8dd-4ec7-9d49-623e2b07e9c4"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtMi0xLTEtMjM1OTY_9fa2bd42-c80f-4589-b325-222b9605ba46"
      unitRef="usd">150000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzEtNC0xLTEtMjM1OTY_6c078099-694c-4d01-89e8-2a22e99bf0f6"
      unitRef="usd">150000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzItMi0xLTEtMjM1OTY_d302624b-da5c-4b58-8cbf-d905ab813b51"
      unitRef="usd">1605898000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzItNC0xLTEtMjM1OTY_9dc27558-ffba-4173-90ee-50a190d40f74"
      unitRef="usd">1608749000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzMtMi0xLTEtMjM1OTY_3bc1e73b-7a58-4783-8592-88619b9e9dc0"
      unitRef="usd">-1511252000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzMtNC0xLTEtMjM1OTY_5a4b0519-ad1c-4a69-8d55-c913464b34c0"
      unitRef="usd">-1487776000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzQtMi0xLTEtMjM1OTY_d0d7368d-36bf-4564-8f7c-60ea295ae276"
      unitRef="usd">-37000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzQtNC0xLTEtMjM1OTY_49821aca-2081-41bb-a724-09fc8d34d0e6"
      unitRef="usd">-10000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockShares
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzUtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpmYjQwNzQ4MmMxMDE0Y2EwODIxMGMzYjNhODY1NjU3YV8yOQ_d5c96559-8b9f-4958-bb1a-03baac11e1a0"
      unitRef="shares">488000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzUtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjpmYjQwNzQ4MmMxMDE0Y2EwODIxMGMzYjNhODY1NjU3YV8zNg_341f165b-b2f6-4686-ab4e-914d30190669"
      unitRef="shares">1165000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzUtMi0xLTEtMjM1OTY_d4d146eb-3f56-438c-8394-2527f959a35e"
      unitRef="usd">2061000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzUtNC0xLTEtMjM1OTY_e20937ae-9bca-408c-bba7-d6b60fa7308b"
      unitRef="usd">7518000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzYtMi0xLTEtMjM1OTY_ecb524d1-0e33-46d8-a608-67338d7289ad"
      unitRef="usd">92698000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzYtNC0xLTEtMjM1OTY_012e8d60-4efe-4a7d-82f0-246ff4a6c3e1"
      unitRef="usd">113595000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzctMi0xLTEtMjM1OTY_ef64ecd9-3ae2-4f00-afac-e052be3b64f6"
      unitRef="usd">136178000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18xOS9mcmFnOmQ1OGRmM2Q0MWY4ZDRlNjViMDEwNjJlMmM3ZDZhNzIyL3RhYmxlOjc4NWUxZGNhYWUyODQ4YjA4MzgwODM4NDk1NDVkNTlhL3RhYmxlcmFuZ2U6Nzg1ZTFkY2FhZTI4NDhiMDgzODA4Mzg0OTU0NWQ1OWFfMzctNC0xLTEtMjM1OTY_c9ba2245-74d2-472f-a2bf-88460f1b7654"
      unitRef="usd">136909000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfNS0yLTEtMS0yMzU5Ng_d7179f12-db7b-40ff-83a3-5b0ab1c93568"
      unitRef="usd">37000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfNS00LTEtMS0yMzU5Ng_3b35b516-9b5d-4425-9831-c471a19aa69b"
      unitRef="usd">27000</us-gaap:RoyaltyIncomeNonoperating>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfOS0wLTEtMS0yMzU5Ni90ZXh0cmVnaW9uOmEwNjBlNTJlYzI3NDQ2OTg4NjljMzkwM2M0YzAxZDdlXzY4_29ec2c2c-0bb6-41ee-a0bf-0f1f81b355d1"
      unitRef="usd">1032000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfOS0wLTEtMS0yMzU5Ni90ZXh0cmVnaW9uOmEwNjBlNTJlYzI3NDQ2OTg4NjljMzkwM2M0YzAxZDdlXzcy_e6cf1fda-16af-44c7-8dc5-695367cf35fc"
      unitRef="usd">1286000</lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfOS0yLTEtMS0yMzU5Ng_e52926b8-e722-4760-b50a-96511fa709ba"
      unitRef="usd">14926000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfOS00LTEtMS0yMzU5Ng_e5f2de20-f721-4ed8-a27c-4397364fe386"
      unitRef="usd">12609000</us-gaap:ResearchAndDevelopmentExpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjo3NzBlNGMwMTQ4MGQ0ODA2ODY4ZDcyNTBlZGM0MTFiMV83OQ_7612fb95-def9-4426-9a54-7ac36cf67b56"
      unitRef="usd">1740000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTEtMC0xLTEtMjM1OTYvdGV4dHJlZ2lvbjo3NzBlNGMwMTQ4MGQ0ODA2ODY4ZDcyNTBlZGM0MTFiMV84Mw_40eeefe1-dadb-4042-8bcf-eae28c995207"
      unitRef="usd">1565000</lxrx:Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTEtMi0xLTEtMjM1OTY_88403866-b70d-4b0d-958f-2f7328c1323f"
      unitRef="usd">8491000</lxrx:Sellinggeneralandadministrativeexpenses>
    <lxrx:Sellinggeneralandadministrativeexpenses
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTEtNC0xLTEtMjM1OTY_35dc77a4-7d7e-43b0-bead-344932e8e42d"
      unitRef="usd">8257000</lxrx:Sellinggeneralandadministrativeexpenses>
    <us-gaap:OperatingExpenses
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTUtMi0xLTEtMjM1OTY_87c6ca64-f648-4559-89f3-3f868fa10780"
      unitRef="usd">23417000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTUtNC0xLTEtMjM1OTY_99a070d7-5707-478d-9063-606f1a348b3e"
      unitRef="usd">20866000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTgtMi0xLTEtMjM1OTY_12b0596f-5705-4074-b6f0-01eb2787da17"
      unitRef="usd">-23380000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMTgtNC0xLTEtMjM1OTY_b31026f8-ef6f-41d4-b3f9-5b1792e582a7"
      unitRef="usd">-20839000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjEtMi0xLTEtMjM1OTY_80d0b81c-3b11-4d8e-889f-dad173e53a4d"
      unitRef="usd">110000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjEtNC0xLTEtMjM1OTY_d96ccf1b-d0e3-4a2f-b76a-898469883646"
      unitRef="usd">167000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjItMi0xLTEtMjM1OTY_3973431e-6e29-4b89-9075-20164fd27ba0"
      unitRef="usd">14000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjItNC0xLTEtMjM1OTY_a759f2bf-a64b-41a3-84b8-5112e1ee66c6"
      unitRef="usd">48000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjUtMi0xLTEtMjM1OTY_b380f98f-8a06-4181-8084-d399b01dbf1a"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjUtNC0xLTEtMjM1OTY_2ce698ce-bfe4-4290-a9c3-0d078e75af56"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjYtMi0xLTEtMjM1OTY_7bc0c84a-e859-4363-9cef-84624e6b8173"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjYtNC0xLTEtMjM1OTY_4e10d254-6e83-4311-97cc-b374b4d97ef1"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjktMi0xLTEtMjM1OTY_6f840ea5-0a8b-4e06-a6fe-1297217e953f"
      unitRef="shares">149150000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMjktNC0xLTEtMjM1OTY_dcc4b34c-eba2-45c3-af39-a75de5ce588c"
      unitRef="shares">143379000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMzMtMi0xLTEtMjM1OTY_004f8ef1-2ee6-4065-900b-42af1d680fc7"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMzMtNC0xLTEtMjM1OTY_938fc17e-70a5-4f27-a96a-0af17e3c2c5e"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMzQtMi0xLTEtMjM1OTY_604317df-eec6-4d18-8475-4c909af01e8c"
      unitRef="usd">-23503000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yMi9mcmFnOjMyMTM5NjRkYWU4MzQwMTNiMDI3MmJlOGYxZTI5YmM1L3RhYmxlOmI1MDAxZWVkYzI4ZjQ0NzFiZWQ1OGUyZTY3MDA3ZjQwL3RhYmxlcmFuZ2U6YjUwMDFlZWRjMjhmNDQ3MWJlZDU4ZTJlNjcwMDdmNDBfMzQtNC0xLTEtMjM1OTY_7670de56-7403-439a-8fb0-a50a3e3bed93"
      unitRef="usd">-20947000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="i54962a8013d14e668867895265609fcc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi0yLTEtMS0yMzU5Ng_b16f2ea1-e18c-4f88-a6c7-5ca789e8fd71"
      unitRef="shares">142289000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i54962a8013d14e668867895265609fcc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi00LTEtMS0yMzU5Ng_931a7b28-2841-4010-8732-7eee9e6557b2"
      unitRef="usd">142000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9dad627e685144ca94f9ab63453ba29a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi02LTEtMS0yMzU5Ng_66c42efa-73f5-4faa-9ed9-83f4c783db0f"
      unitRef="usd">1561096000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e8b6089596d46158956c93da1f84cfc_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi04LTEtMS0yMzU5Ng_21efeb19-c1c3-4141-99c8-3c6928618e48"
      unitRef="usd">-1400018000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ieddfc4a55e8f4430b5893c77932b3f88_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi0xMC0xLTEtMjM1OTY_7da4e5ff-48ce-4e6e-907d-ff67872dcbf5"
      unitRef="usd">-6000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4d4e9a8b9a234321879ba71b0048f67c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi0xMi0xLTEtMjM1OTY_394d7467-eb18-4691-8574-4e200ac3b17e"
      unitRef="usd">-4843000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia0ffc3b01ab14d17ac3cdd4433fe2c5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMi0xNC0xLTEtMjM1OTY_34084bea-9d57-4061-8e9b-2d947dd75c38"
      unitRef="usd">156371000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS00LTEtMS0yMzU5Ng_faa53902-792d-4229-9019-ecc7389f1011"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS02LTEtMS0yMzU5Ng_eff3d3a7-19c8-4808-8f66-ac218e837105"
      unitRef="usd">2851000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS04LTEtMS0yMzU5Ng_d795c450-ffdb-4f73-92ac-0ef1bfe7f3d3"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS0xMC0xLTEtMjM1OTY_ed93ae52-5fac-4857-8171-6823237fbf50"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS0xMi0xLTEtMjM1OTY_3e5479b2-e1f0-4347-b551-5874d6231f1e"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNS0xNC0xLTEtMjM1OTY_1afbdb52-64fc-457c-a412-6364bc79e182"
      unitRef="usd">2851000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi0yLTEtMS0yMzU5Ng_7a3f52d5-1343-4138-879c-ad33d8f0dab7"
      unitRef="shares">1263000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi00LTEtMS0yMzU5Ng_d2610954-4ac0-4afc-9869-9842078ba744"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi02LTEtMS0yMzU5Ng_c0495935-bd92-4546-ac29-62429f9113f2"
      unitRef="usd">547000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi04LTEtMS0yMzU5Ng_cb95653c-978d-49f2-bbaa-5cfe86cd9b21"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi0xMC0xLTEtMjM1OTY_2278e263-16cc-4bec-9f37-a6c97f002433"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi0xMi0xLTEtMjM1OTY_b51f484d-57fa-4104-a6fe-2d235c0002b4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfNi0xNC0xLTEtMjM1OTY_4d9dc2d5-cb90-4077-a71b-5f8324467cbb"
      unitRef="usd">548000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC00LTEtMS0yMzU5Ng_17b4a6b4-560a-446c-871d-2d9373dc217d"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC02LTEtMS0yMzU5Ng_be0815f0-9b30-4c79-88d6-7adf19a07204"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC04LTEtMS0yMzU5Ng_fed717f3-5789-4520-84e8-2434e979b745"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC0xMC0xLTEtMjM1OTY_136aa02e-7cbf-4312-9efc-fa45207dbd3f"
      unitRef="usd">0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC0xMi0xLTEtMjM1OTY_86f04d62-fda5-424d-b209-98b05ea3a6b6"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOC0xNC0xLTEtMjM1OTY_15c962ba-47c6-4641-bdd4-0add55f4e95a"
      unitRef="usd">2675000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:NetIncomeLoss
      contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS00LTEtMS0yMzU5Ng_21b1f06a-b2a6-4a22-aafa-3fe25ea56058"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS02LTEtMS0yMzU5Ng_024736bb-4ee2-4d55-b29f-8c03ae2605ec"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS04LTEtMS0yMzU5Ng_337a217b-41c6-448d-8361-ba6c1a0acbbb"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS0xMC0xLTEtMjM1OTY_fe6c68a9-5891-4c85-9157-a37e37c26d2e"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS0xMi0xLTEtMjM1OTY_216860f8-d7e3-46c1-83fa-8c5c2b2e4af2"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfOS0xNC0xLTEtMjM1OTY_fa009bd5-c248-470c-8439-4e003f4de0e7"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i65c3369eb679457a8913dcaac302427c_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtNC0xLTEtMjM1OTY_63a3f6b3-ee6c-42de-a5ea-62fff0571fb6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ic8d8b24d5a1941ff915abea3bd0b7172_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtNi0xLTEtMjM1OTY_f48c49ad-5745-41ec-bc3f-c7f6869c1520"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ia2fae2eb17944b23bb5cd6eec03efaaf_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtOC0xLTEtMjM1OTY_0c5c5a3d-8dad-485b-8e7f-8260a4627897"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="idad465e4b4644d2a98e6ff5ff02f3fbb_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtMTAtMS0xLTIzNTk2_d1bf9169-5bc0-4b5e-bd4c-be75269737a6"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i04011818eb994fbbba1c14b5c78295c6_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtMTItMS0xLTIzNTk2_df4779f9-caba-42a9-847a-7df2338a9a46"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTAtMTQtMS0xLTIzNTk2_4db4c8d3-5cdb-4d79-ba60-36cbefee7523"
      unitRef="usd">11000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib10db76d45214c05b5efdc7b1a3cf613_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItMi0xLTEtMjM1OTY_6b04f64b-42e8-456a-82a7-c81eb1c8a3ee"
      unitRef="shares">145552000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib10db76d45214c05b5efdc7b1a3cf613_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItNC0xLTEtMjM1OTY_0e4aa28c-6ef1-4cba-bacb-65de1e589800"
      unitRef="usd">145000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib9d4d096474c4686a816df94e033a651_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItNi0xLTEtMjM1OTY_0475dec6-16c8-47ae-be0f-8edffed16dd9"
      unitRef="usd">1580891000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9fa5363cf9e946eeb5596f97e3ae590b_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItOC0xLTEtMjM1OTY_80d2be8a-c17e-4ae0-9e9d-b5f48350a2ad"
      unitRef="usd">-1420976000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e6608c1aca34ce99ff1ae370e6c325e_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItMTAtMS0xLTIzNTk2_9780c5b5-6e9e-4bc0-a646-49d43a94af4b"
      unitRef="usd">5000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibb0c568977f34053900263e77db2baaf_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItMTItMS0xLTIzNTk2_aaf6b1a3-9fe0-4d14-8ace-966bec8db3ae"
      unitRef="usd">-7518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i10dfe24fc01a400fa7a0f7e7f958ad59_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOjMyNTllNzRkZTI3ODQzMGNiYjcxOGFmODAxNTVhYTI4L3RhYmxlcmFuZ2U6MzI1OWU3NGRlMjc4NDMwY2JiNzE4YWY4MDE1NWFhMjhfMTItMTQtMS0xLTIzNTk2_8d18f398-a837-4099-a1b8-4f35b4aad379"
      unitRef="usd">152547000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesIssued
      contextRef="ic1a7dafcc5d543b98462aceef262d219_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi0yLTEtMS0yMzU5Ng_c426133f-70cd-46fa-a5c3-a54366f21ccb"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic1a7dafcc5d543b98462aceef262d219_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi00LTEtMS0yMzU5Ng_3a922dbe-5117-42e4-80fd-45f6851d7a05"
      unitRef="usd">150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id67531ad05e34e068f1cd490b916866a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi02LTEtMS0yMzU5Ng_6cfd64f2-c276-4562-b1c1-53d22b9c5f20"
      unitRef="usd">1608749000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i66c91f48540d48699c74344733fb3ac1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi04LTEtMS0yMzU5Ng_4de7d30a-2526-4357-9e51-f9ca4bab3a3b"
      unitRef="usd">-1487776000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4089c48d67b44b789b49ff9231f66610_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi0xMC0xLTEtMjM1OTY_ebb52557-d8c2-497a-9dae-8134cd09ad7d"
      unitRef="usd">-10000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i085ee5a7929c45f489a3aecd04578b4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi0xMi0xLTEtMjM1OTY_1e2c885b-b39e-41c5-9058-e22734144fd8"
      unitRef="usd">-7518000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMi0xNC0xLTEtMjM1OTY_88d8c6dc-50b6-404f-897c-e9b4885f84f2"
      unitRef="usd">113595000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC00LTEtMS0yMzU5Ng_5fcc3b82-ffd7-4795-b79d-e13bb1d8c6ee"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC02LTEtMS0yMzU5Ng_4c45a19f-3a91-4a08-b270-470ebbc0684b"
      unitRef="usd">2772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC04LTEtMS0yMzU5Ng_1fc4ef28-e0c8-438d-a399-76b468311205"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC0xMC0xLTEtMjM1OTY_c32c5cea-3bec-481a-a7de-9c9494bfe810"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC0xMi0xLTEtMjM1OTY_f22a2d97-9f21-4750-b6a6-05d158b5172c"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNC0xNC0xLTEtMjM1OTY_768ec413-a310-4282-9245-093a627a50d0"
      unitRef="usd">2772000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS0yLTEtMS0yMzU5Ng_07376fae-29bc-454e-8d58-29dd73fc476a"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS00LTEtMS0yMzU5Ng_19dd7bcb-ae01-4189-8a45-1881612ce5d4"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS02LTEtMS0yMzU5Ng_8b782e30-5768-4656-8d2d-f4fe28788f78"
      unitRef="usd">698000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS04LTEtMS0yMzU5Ng_0de71033-a80d-45d2-a65b-a619be986fbe"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS0xMC0xLTEtMjM1OTY_0c4671f7-e150-45a9-8e88-635099c9fa64"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS0xMi0xLTEtMjM1OTY_b08b9403-67e4-439a-8057-1301044399c5"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNS0xNC0xLTEtMjM1OTY_fa640ff8-7223-497d-a865-13191da3eafe"
      unitRef="usd">698000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi0yLTEtMS0yMzU5Ng_523d3927-9206-47fe-be4e-7cb0176fc4a6"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi00LTEtMS0yMzU5Ng_58a3c159-f95c-479e-90dc-55fb7591cdf3"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi02LTEtMS0yMzU5Ng_a77efdb7-b1cc-4b2e-934a-98fe18f54b99"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi04LTEtMS0yMzU5Ng_ece941c2-ee81-420e-a879-e1c78fc5633e"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi0xMC0xLTEtMjM1OTY_ddd35d6a-e152-466b-bf90-300f28be5ffd"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi0xMi0xLTEtMjM1OTY_dcccfb10-a053-4cc1-b948-71490477f928"
      unitRef="usd">-864000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfNi0xNC0xLTEtMjM1OTY_4c6613b1-f486-4160-8d0c-38d88419d91e"
      unitRef="usd">-864000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:NetIncomeLoss
      contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS00LTEtMS0yMzU5Ng_b02ad329-4bc1-4777-8a4f-29063d7e6015"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS02LTEtMS0yMzU5Ng_b0e19de0-3220-4f91-82b9-80691b355759"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS04LTEtMS0yMzU5Ng_9573563d-4e42-4604-bae8-28d81de80148"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS0xMC0xLTEtMjM1OTY_a88bd696-cecc-447b-bc98-f9244d4778b6"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS0xMi0xLTEtMjM1OTY_d101316a-d0e1-4005-9058-5fa1d2dd3676"
      unitRef="usd">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfOS0xNC0xLTEtMjM1OTY_92af4eee-f1d6-4697-b120-a7381d536dc3"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i981a5b1d30004aa28eb70a009a0bbe26_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtNC0xLTEtMjM1OTY_a65776ce-db32-4183-9f03-668b7d738779"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i473949bfa48b4891a63f6e4e82d28b57_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtNi0xLTEtMjM1OTY_404363b2-57fe-49a9-85e1-8be7c138cf94"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i8890b0df3ffc482f82f643b8fddb3512_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtOC0xLTEtMjM1OTY_381cadb9-237c-4203-9108-fd605008dd1b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i88d416eb7d9e4fe39e872fb999fe9d28_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtMTAtMS0xLTIzNTk2_2685761c-2e2c-47e6-a9c2-4db27d75913a"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ib95c4ccc96fd4a50acd4da130b164417_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtMTItMS0xLTIzNTk2_2eecddb3-a6d7-4925-b44f-cd65362647d4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTEtMTQtMS0xLTIzNTk2_6e5f871e-214b-4283-a09b-ae5e38042f46"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:CommonStockSharesIssued
      contextRef="id365c25fcd8b48c0a0cf24853ebcfebe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItMi0xLTEtMjM1OTY_7f87c4a8-0cc3-458e-9d4f-84072125c275"
      unitRef="shares">150082000</us-gaap:CommonStockSharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id365c25fcd8b48c0a0cf24853ebcfebe_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItNC0xLTEtMjM1OTY_b015aaf1-1abf-49f7-a53d-05ba9dba8965"
      unitRef="usd">150000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i848b624644c646a58412c3b2725ab8b5_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItNi0xLTEtMjM1OTY_4fe3bd36-bebf-4f8f-bdc3-bc7fbbaebd46"
      unitRef="usd">1605898000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic9bc9c0e23174f2995a516bfe55e91bb_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItOC0xLTEtMjM1OTY_1d325fce-d0d6-4cc1-afe6-8ee45cf3da02"
      unitRef="usd">-1511252000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6ada97105dc41999a86e557839e78a1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItMTAtMS0xLTIzNTk2_6dfd546f-d168-413d-9a48-80980e243268"
      unitRef="usd">-37000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4691328755b94be283e8d276e74feb5d_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItMTItMS0xLTIzNTk2_aeddc497-71fa-4931-9527-df86cace6c67"
      unitRef="usd">-2061000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yNS9mcmFnOjExY2U4OGUyZjBiYzRiZTM4MjFiM2E4NzhlYThhMjk2L3RhYmxlOmYwNWM5YzFiYTM3NzQ3MmU5Y2EzM2RiYjM5ZWVjZTM5L3RhYmxlcmFuZ2U6ZjA1YzljMWJhMzc3NDcyZTljYTMzZGJiMzllZWNlMzlfMTItMTQtMS0xLTIzNTk2_e0defc75-3805-4e10-91f9-14930a5cf9c9"
      unitRef="usd">92698000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMy0yLTEtMS0yMzU5Ng_5b51fa61-3295-4297-b976-59b9e97c10c7"
      unitRef="usd">-23476000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMy00LTEtMS0yMzU5Ng_e7edc028-f544-484a-9912-39bc5a06e0e6"
      unitRef="usd">-20958000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNS0yLTEtMS0yMzU5Ng_c7f0a426-02d3-400e-b953-f94ed51227b7"
      unitRef="usd">109000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNS00LTEtMS0yMzU5Ng_d1f95f9f-143e-4cf5-a358-e6e4d641d3e9"
      unitRef="usd">37000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNi0yLTEtMS0yMzU5Ng_3882f2b3-69a7-4262-8e4e-433dce5e9195"
      unitRef="usd">2772000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNi00LTEtMS0yMzU5Ng_fc621269-6c4c-45c1-ba23-de455fe08546"
      unitRef="usd">2851000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNy0yLTEtMS0yMzU5Ng_1efd1db8-4a96-49a4-9f58-8db55c0a73e0"
      unitRef="usd">25000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNy00LTEtMS0yMzU5Ng_5eaff012-a7af-48a1-9300-0398a9c53d91"
      unitRef="usd">14000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTItMi0xLTEtMjM1OTY_323f3d66-0481-427e-b343-c83274d71d99"
      unitRef="usd">23000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTItNC0xLTEtMjM1OTY_55021d0d-3896-4135-8a03-d3a8947ac16a"
      unitRef="usd">-294000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTQtMi0xLTEtMjM1OTY_ebc9a284-ab42-4956-b16c-54e486175930"
      unitRef="usd">-273000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTQtNC0xLTEtMjM1OTY_bd5026e0-7e18-4c77-8117-5300687dee0f"
      unitRef="usd">-1095000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTUtMi0xLTEtMjM1OTY_3821b932-a575-4ca0-9e93-66004e63b850"
      unitRef="usd">-207000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTUtNC0xLTEtMjM1OTY_fb81fe4b-11e0-4480-a6af-2de23b0ab85f"
      unitRef="usd">74000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTYtMi0xLTEtMjM1OTY_2b90127b-ddd7-4c01-80af-35e415b40405"
      unitRef="usd">-3308000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTYtNC0xLTEtMjM1OTY_6c3be1b4-ea85-426c-9f7a-8bf1de880d96"
      unitRef="usd">-8418000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTgtMi0xLTEtMjM1OTY_eaaf5702-0a3b-4ec7-ab91-a19afef39057"
      unitRef="usd">-23421000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMTgtNC0xLTEtMjM1OTY_b9b80a66-7478-4685-9e87-fba91b1f31f2"
      unitRef="usd">-25159000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjAtMi0xLTEtMjM1OTY_b0bf3a55-361f-4ee7-8ea3-d09d32cd0aa6"
      unitRef="usd">76000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjAtNC0xLTEtMjM1OTY_cfc98aee-b0b1-4ba4-b264-41195eefac31"
      unitRef="usd">38000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjMtMi0xLTEtMjM1OTY_cce488e3-1c2e-4dab-ac65-4e4362d7868e"
      unitRef="usd">17816000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjMtNC0xLTEtMjM1OTY_d21e54a6-52b9-42fb-bb2d-21fba91e13c4"
      unitRef="usd">21686000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjQtMi0xLTEtMjM1OTY_cf08e786-7fd4-49c8-8970-a68edf99ba7a"
      unitRef="usd">13484000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjQtNC0xLTEtMjM1OTY_e396e3ff-71a4-42c1-8415-1594d424006c"
      unitRef="usd">4000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjUtMi0xLTEtMjM1OTY_bd796810-b1f8-4983-949b-58ceed2b436e"
      unitRef="usd">-4408000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjUtNC0xLTEtMjM1OTY_f2d4d589-3bdb-44d3-9a91-ff58ee2ce168"
      unitRef="usd">-17724000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjctMi0xLTEtMjM1OTY_71c1ec7b-40ac-46fb-a9fe-a65ed9fe361d"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjctNC0xLTEtMjM1OTY_84148cc5-5939-4727-a938-118583feae97"
      unitRef="usd">16947000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjgtMi0xLTEtMjM1OTY_36916718-0735-48d8-960c-17a52404aad5"
      unitRef="usd">864000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjgtNC0xLTEtMjM1OTY_a801eed8-0af1-4d7f-8454-f0150922a00c"
      unitRef="usd">2675000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjktMi0xLTEtMjM1OTY_a7717cab-924a-4a66-9b98-9f8271284803"
      unitRef="usd">24148000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMjktNC0xLTEtMjM1OTY_9558d18e-6f2f-43d4-a589-6e8c7163ead4"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzItMi0xLTEtMjM1OTY_f10cc941-7435-4b42-af20-f05a6d5d5b13"
      unitRef="usd">23284000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzItNC0xLTEtMjM1OTY_f687719d-e925-4f27-8ee7-0bb622f8a65c"
      unitRef="usd">14272000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzMtMi0xLTEtMjM1OTY_cee413d5-9f5b-407e-b0ed-15f5aeb3a128"
      unitRef="usd">-4545000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzMtNC0xLTEtMjM1OTY_b62635a0-fd25-41a2-8269-1947935a11d5"
      unitRef="usd">-28611000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzQtMi0xLTEtMjM1OTY_1d856c07-e106-48fd-86f4-5cd60b07cc77"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia0ffc3b01ab14d17ac3cdd4433fe2c5b_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzQtNC0xLTEtMjM1OTY_4a6688d6-0904-41cf-a573-bbfa21f8b1d0"
      unitRef="usd">126263000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzUtMi0xLTEtMjM1OTY_680c8753-6f89-4ade-adcc-39fa2a820cbb"
      unitRef="usd">59520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i10dfe24fc01a400fa7a0f7e7f958ad59_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzUtNC0xLTEtMjM1OTY_479c66b2-7db5-4c71-9d29-e4bb4c82bcb1"
      unitRef="usd">97652000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:InterestPaidNet
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzgtMi0xLTEtMjM1OTY_dc6d71e5-5484-4206-97d5-1e60c747d611"
      unitRef="usd">85000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzgtNC0xLTEtMjM1OTY_bc68ac58-1bff-4592-a234-410042d7580c"
      unitRef="usd">0</us-gaap:InterestPaidNet>
    <lxrx:InitialRecognitionOfRightOfUseAsset
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNDEtMi0xLTEtMjM1OTY_1d4389c0-3550-44c8-8317-19bbbffba62f"
      unitRef="usd">0</lxrx:InitialRecognitionOfRightOfUseAsset>
    <lxrx:InitialRecognitionOfRightOfUseAsset
      contextRef="i10dfe24fc01a400fa7a0f7e7f958ad59_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfNDEtNC0xLTEtMjM1OTY_667af294-5317-4e12-be98-1428c4a366f7"
      unitRef="usd">1700000</lxrx:InitialRecognitionOfRightOfUseAsset>
    <us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzMtMi0xLTEtMjY3ODM_d150a988-d3f2-491c-9e44-8b89d2477da1"
      unitRef="usd">698</us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzMtNC0xLTEtMjY3ODU_bd34e903-bbd1-4908-9123-d9185316f8a4"
      unitRef="usd">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzQtMi0xLTEtMjY3ODc_fbf4c441-0ef8-4305-a162-1f4be37316f3"
      unitRef="usd">6321</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzQtNC0xLTEtMjY3ODk_aeb50159-4224-40d9-93e5-68c1e6ef8948"
      unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:BusinessExitCosts1
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzUtMi0xLTEtMjY3OTE_f951e689-60a1-4429-b767-57933d447915"
      unitRef="usd">1500</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18yOC9mcmFnOjQ1MzFlZjdjZTFlMjQ2OWM4ZmZjNmJiMmYzNGFlMDM0L3RhYmxlOmY1OGRiNzA5MTMzNzRjNDZhYjUxMjYzNDZkYjMwYTFkL3RhYmxlcmFuZ2U6ZjU4ZGI3MDkxMzM3NGM0NmFiNTEyNjM0NmRiMzBhMWRfMzUtNC0xLTEtMjY3OTM_4536dca9-7e61-4766-bcb8-f0f573e355b2"
      unitRef="usd">0</us-gaap:BusinessExitCosts1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4Mjc_68e0012d-1ae9-49b3-999c-243ff6d30d6c">Summary of Significant Accounting Policies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The accompanying unaudited condensed consolidated financial statements of Lexicon Pharmaceuticals, Inc. (&#x201c;Lexicon&#x201d; or the &#x201c;Company&#x201d;) have been prepared in accordance with generally accepted accounting principles for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three-month period ended March&#160;31, 2022 are not necessarily indicative of the results that may be expected for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For further information, refer to the financial statements and footnotes thereto included in Lexicon&#x2019;s annual report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of 9% at the commencement date in determining the present value of future payments. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform the following five steps in determining the amount of revenue to recognize as we fulfill our performance obligations under each of our contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilized the Black-Scholes valuation model for estimating the fair value of the stock option compensation granted, with the following weighted-average assumptions for stock options granted in the three months ended March&#160;31, 2022 and 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of stock option activity under Lexicon&#x2019;s stock-based compensation plans for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended March&#160;31, 2022, Lexicon granted its employees annual restricted stock units. Outstanding employee restricted stock units vest in three annual installments.  The following is a summary of restricted stock units activity under Lexicon&#x2019;s stock-based compensation plans for the three months ended March&#160;31, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MjQ_6bdeac53-0bff-49a5-b367-c88e8d25e38c">The accompanying condensed consolidated financial statements include the accounts of Lexicon and its wholly-owned subsidiaries. Intercompany transactions and balances are eliminated in consolidation.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM3ODg_65eab7b1-f65b-465f-9b74-282b3354d341">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MTM_be375c4e-aa85-461a-8ed3-89b4ad1414b5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash, Cash Equivalents and Short-Term Investments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon considers all highly-liquid investments with original maturities of three months or less to be cash equivalents.&#160;&#160;As of March&#160;31, 2022 and December&#160;31, 2021, short-term investments consisted of U.S. treasury bills and corporate debt securities. The Company&#x2019;s short-term investments are classified as available-for-sale securities and are carried at fair value, based on quoted market prices of the securities.&#160;&#160;The Company views its available-for-sale securities as available for use in current operations as they all contain maturities of less than one year.&#160;&#160;Unrealized gains and losses on such securities are reported as a separate component of stockholders&#x2019; equity.&#160;&#160;Net realized gains and losses, interest and dividends are included in interest income.&#160;&#160;The cost of securities sold is based on the specific identification method.&lt;/span&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MzI_208df8db-17a2-4ad3-9ff9-dff386cb094a">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued liabilities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accrued liabilities consisted of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.961%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.415%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued research and development services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,669&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,711&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short term lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfMy0yLTEtMS0yMzU5Ng_6809caa0-5eed-48ca-895c-fb57b1fb04f1"
      unitRef="usd">5308000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedResearchAndDevelopmentServicesCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfMy00LTEtMS0yMzU5Ng_8a3704ba-7b0d-43a1-9661-02f755f5ed51"
      unitRef="usd">3669000</lxrx:AccruedResearchAndDevelopmentServicesCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNC0yLTEtMS0yMzU5Ng_d436f0bf-59f5-491f-b241-a9a30dc9bf33"
      unitRef="usd">2616000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <lxrx:AccruedCompensationAndBenefitsCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNC00LTEtMS0yMzU5Ng_244cce0d-c1c8-47ee-8f42-cdb99f43b81f"
      unitRef="usd">5711000</lxrx:AccruedCompensationAndBenefitsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNS0yLTEtMS0yMzU5Ng_df620a50-565f-42b4-9c42-a86b98774304"
      unitRef="usd">940000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNS00LTEtMS0yMzU5Ng_1a99a6b2-0248-475e-86ad-03442c6302b8"
      unitRef="usd">1089000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNi0yLTEtMS0yMzU5Ng_3787f235-fc98-4698-b26f-90f2a5bc724b"
      unitRef="usd">720000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNi00LTEtMS0yMzU5Ng_278c32a2-0e0f-4a69-a638-4715f083435d"
      unitRef="usd">2503000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNy0yLTEtMS0yMzU5Ng_352ab6e3-5af4-4fc5-bcc7-e589778cbf9e"
      unitRef="usd">9584000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedLiabilitiesCurrentAndNoncurrent
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOjBjNjY4Mjc4MGVlODQxNDRiMmVhZGNlMjkzODJkNDQ0L3RhYmxlcmFuZ2U6MGM2NjgyNzgwZWU4NDE0NGIyZWFkY2UyOTM4MmQ0NDRfNy00LTEtMS0yMzU5Ng_18067d10-308c-4490-914a-a9231876d9fd"
      unitRef="usd">12972000</us-gaap:AccruedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MDU_cd26de50-9c44-41fe-bb51-421ec346f4d4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Lexicon determines if a contract is or contains a lease at inception or upon modification of the contract. A contract is or contains a lease if it conveys the right to control the use of an identified asset for a period in exchange for consideration. Control over the use of the identified asset means the lessee has both (a) the right to obtain substantially all of the economic benefits from the use of the asset and (b) the right to direct the use of the asset. Lexicon does not apply this accounting to those leases with terms of twelve (12) months or less.&lt;/span&gt;Operating lease right-of-use assets and associated lease liabilities are recorded in the balance sheet at the lease commencement date based on the present value of future lease payments to be made over the expected lease term. As the implicit rate is not determinable in its leases, Lexicon used a borrowing rate of 9% at the commencement date in determining the present value of future payments.</us-gaap:RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock>
    <lxrx:LexiconIncrementalBorrowingRate
      contextRef="ia1cfae56d0154e63a47ec27ca3d5dab8_I20210301"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM3ODI_16c2c40b-2bb7-45a5-a076-2d4242e2ffde"
      unitRef="number">9</lxrx:LexiconIncrementalBorrowingRate>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MDI_95b2a32a-a696-45fa-ac40-4ff81761cc26">&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue Recognition:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We perform the following five steps in determining the amount of revenue to recognize as we fulfill our performance obligations under each of our contracts with customers: (i) identify the contract(s) with a customer; (ii) identify the performance obligation in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligation in the contract, and (v) recognize revenue when (or as) we satisfy the performance obligation. At contract inception, the Company evaluates whether development milestones are considered probable of being reached and estimates the amount to be included in the transaction price using the most likely amount method.  If it is probable that a significant revenue reversal will not occur, the associated development milestone value is included in the transaction price.  Development milestones that are not within the control of the Company or the licensee, including those requiring regulatory approval, are not considered probable of being achieved until those milestones are achieved.  The transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Company recognizes revenue when (or as) the performance obligation is satisfied.  At the end of each reporting period, the Company re-evaluates the probability of achievement of the development milestones and any related constraint, and if necessary, adjusts its estimates of the overall transaction price.  Any such adjustments are recorded on a cumulative catch-up basis, which would affect collaboration revenues in the period of adjustment.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In agreements in which a license to the Company&#x2019;s intellectual property is determined distinct from other performance obligations identified in the agreement, the Company recognizes revenue when the license is transferred to the licensee and the licensee is able to use and benefit from the license.  &lt;/span&gt;&lt;/div&gt;The Company may receive payments from its licensees based on billing schedules established in each contract.  Upfront payments and fees are recorded as deferred revenue upon receipt or when due, and may require deferral of revenue recognition to a future period until the Company performs its obligations under the relevant agreement.  Amounts are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4Mjk_ac7455e6-9812-47af-a61a-5da4f44c9f2d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development Expenses:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Research and development expenses consist of costs incurred for company-sponsored as well as collaborative research and development activities. These costs include direct and research-related overhead expenses and are expensed as incurred.&#160;&#160;Technology license fees for technologies that are utilized in research and development and have no alternative future use are expensed when incurred.  Substantial portions of the Company&#x2019;s preclinical and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors.  For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining.  For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study.  The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to the Company by the vendors and clinical site visits.  The Company&#x2019;s estimates depend on the timeliness and accuracy of the data provided by the vendors regarding the status of each program and total program spending.  The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.&lt;/span&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MDM_8ec980f3-344e-41b2-a0c2-0a30e0afead4">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;The Company recognizes compensation expense in its condensed consolidated statements of comprehensive loss for share-based payments, including stock options and restricted stock units granted to employees, based on their fair values on the date of the grant, with the compensation expense recognized over the period in which an employee is required to provide service in exchange for the stock award.&#160;&#160;Stock-based compensation expense for awards without performance conditions is recognized on a straight-line basis.  Stock-based compensation expense for awards with performance conditions is recognized over the period from the date the performance condition is determined to be probable of occurring through the time the applicable condition is met.&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of stock options is estimated at the date of grant using the Black-Scholes method.&#160;&#160;The Black-Scholes option-pricing model requires the input of subjective assumptions.&#160;&#160;Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management&#x2019;s opinion, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.&#160;&#160;For purposes of determining the fair value of stock options, the Company segregates its options into two homogeneous groups, based on exercise and post-vesting employment termination &lt;/span&gt;&lt;/div&gt;behaviors, resulting in a change in the assumptions used for expected option lives.&#160;&#160;Historical data is used to estimate the expected option life for each group.  Expected volatility is based on the historical volatility in the Company&#x2019;s stock price.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM3OTg_53e69425-0012-4ec4-9c0c-12c88b635a01">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:51.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.738%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.916%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Risk-free Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expected Term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Dividend&lt;br/&gt;Rate&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2022:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;March 31, 2021:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Officers and non-employee directors&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMi0yLTEtMS0yMzU5Ng_119c5c08-02e9-4ea4-bd36-63c8edec33e3"
      unitRef="number">1.04</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMi00LTEtMS0yMzU5Ng_b40e4b27-77f9-4995-8996-0872a7aafe59"
      unitRef="number">0.018</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMi02LTEtMS0yMzU5Ng_3870ae6e-bfd2-4b9c-8e2f-d3afc13eea3f">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMi04LTEtMS0yMzU5Ng_7bb10939-6d87-4085-983f-d9080160d0a0"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMy0yLTEtMS0yMzU5Ng_cf2c4404-2d97-4430-8998-23ef110f25eb"
      unitRef="number">0.91</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMy00LTEtMS0yMzU5Ng_c56b221f-0cf5-4c18-97bf-9677e97f1cf7"
      unitRef="number">0.019</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMy02LTEtMS0yMzU5Ng_976193b6-c3e5-4ecf-8f09-1a11f3c748b7">P7Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="i07ee2544f5814973b10bd77089b44a79_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfMy04LTEtMS0yMzU5Ng_ef00c654-e33e-41fb-8b89-346b1fcc37bb"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees
      contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNS0yLTEtMS0yMzU5Ng_e49e7ff9-3d39-4573-a75d-d2c75e5f27e8"
      unitRef="number">1.05</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee
      contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNS00LTEtMS0yMzU5Ng_6161c508-de3d-45b5-ba4d-83bc481572b6"
      unitRef="number">0.004</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees
      contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNS02LTEtMS0yMzU5Ng_90ea4af9-0d7c-4d79-8aec-051fb0bc60f2">P4Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees
      contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNS04LTEtMS0yMzU5Ng_6498d3ff-9b6a-4c24-b646-118da1f4cc5c"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors
      contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNi0yLTEtMS0yMzU5Ng_1e60bc9e-e56f-41f9-8855-8181dc76fb76"
      unitRef="number">0.90</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors
      contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNi00LTEtMS0yMzU5Ng_aa92c415-1f10-4e68-9cba-1087315ef8d3"
      unitRef="number">0.010</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors
      contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNi02LTEtMS0yMzU5Ng_4e396104-f8da-4c87-93af-00ba24a828f3">P7Y</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors>
    <lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors
      contextRef="ib9c57f15f86e41e2a3c1247b541d63c5_D20210101-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ0NWQ2NGNlMGEzYTQ2MTM4YzRmYmVmYzhmNGUwMTc1L3RhYmxlcmFuZ2U6ZDQ1ZDY0Y2UwYTNhNDYxMzhjNGZiZWZjOGY0ZTAxNzVfNi04LTEtMS0yMzU5Ng_cd090bad-f525-4980-8069-0c735c84d8fd"
      unitRef="number">0</lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MDQ_8bc77e52-315f-4e33-ab5e-655bf6cd50a0">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.935%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.470%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(308)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id22fce593ee9499987972bc373045887_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfMi0yLTEtMS0yMzU5Ng_8f501bb8-6e8a-4630-9d7f-0db138411efa"
      unitRef="shares">8367000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="id22fce593ee9499987972bc373045887_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfMi00LTEtMS0yMzU5Ng_199cf995-1dfd-470f-8f17-681f248f3be4"
      unitRef="usdPerShare">6.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfMy0yLTEtMS0yMzU5Ng_a82c2c6b-5484-47a0-b8f2-1ad2096501e7"
      unitRef="shares">3865000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfMy00LTEtMS0yMzU5Ng_44cdaeca-f804-41e3-aab9-d4aec26d3587"
      unitRef="usdPerShare">3.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNS0yLTEtMS0yMzU5Ng_7cab56b6-d118-4c91-83e1-694fbfe7a74b"
      unitRef="shares">140000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNS00LTEtMS0yMzU5Ng_465c0de5-ddde-4570-93df-d909dee794f8"
      unitRef="usdPerShare">12.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNi0yLTEtMS0yMzU5Ng_8534edf2-7667-4fdc-8491-226fd5e94177"
      unitRef="shares">308000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i53b37480b4d64d26a48e2e1054777920_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNi00LTEtMS0yMzU5Ng_63ae3570-26a2-435f-a0d6-a20b19822b33"
      unitRef="usdPerShare">9.88</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ia8243aca9d564e4f83796530f13c3383_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNy0yLTEtMS0yMzU5Ng_2477db01-0ae8-483f-9c2a-e75cef3c3a5d"
      unitRef="shares">11784000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ia8243aca9d564e4f83796530f13c3383_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfNy00LTEtMS0yMzU5Ng_be76760d-0793-4c12-97da-6f323c6a733c"
      unitRef="usdPerShare">5.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ia8243aca9d564e4f83796530f13c3383_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfOC0yLTEtMS0yMzU5Ng_9b9e41e6-a71a-47c6-bddf-a609e66a9809"
      unitRef="shares">5093000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ia8243aca9d564e4f83796530f13c3383_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmQ1Y2I1NjRiN2QxMDRmMDE4MGFjOTBhYjhhODY2M2U3L3RhYmxlcmFuZ2U6ZDVjYjU2NGI3ZDEwNGYwMTgwYWM5MGFiOGE4NjYzZTdfOC00LTEtMS0yMzU5Ng_596937bb-e7c6-4032-89e8-df6c18b94214"
      unitRef="usdPerShare">7.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM4MzA_0b98ac6f-535d-490a-b0fc-e823d4812805">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.497%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(980)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(35)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iab72bef6ac48400897e99aead8b76e9d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfMi0yLTEtMS0yMzU5Ng_9836636e-c9b0-4bac-bd1d-a9ef8bf07001"
      unitRef="shares">1854000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="iab72bef6ac48400897e99aead8b76e9d_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfMi00LTEtMS0yMzU5Ng_0b035374-c329-4084-a98c-d3f7bcb38c77"
      unitRef="usdPerShare">5.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfMy0yLTEtMS0yMzU5Ng_7f1105d2-83bb-4f21-9f7d-a0e673bcabf5"
      unitRef="shares">2110000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfMy00LTEtMS0yMzU5Ng_9d986a53-b8cf-4181-b320-4129ac592966"
      unitRef="usdPerShare">2.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNC0yLTEtMS0yMzU5Ng_5c0e3996-820f-4911-99cc-36975b36fc8a"
      unitRef="shares">980000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNC00LTEtMS0yMzU5Ng_94e32109-0b84-4fef-b5ae-4d500e5235cb"
      unitRef="usdPerShare">4.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNS0yLTEtMS0yMzU5Ng_76063d83-adb8-45f5-b737-c94e66ca7a80"
      unitRef="shares">35000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i873df727915d4fd29cd485502b673a49_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNS00LTEtMS0yMzU5Ng_84e6c182-1b40-4c9d-a106-d8ff6811ec71"
      unitRef="usdPerShare">3.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i613127c1d0fe4c42bf53196b80bab0cc_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNi0yLTEtMS0yMzU5Ng_77e137ad-4be0-42f2-88b5-382002bbae6c"
      unitRef="shares">2949000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i613127c1d0fe4c42bf53196b80bab0cc_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RhYmxlOmRiOTA5NGQwYTc2YzQ1ZmQ4NDcxNjNlYmQ2MDVhOGQ0L3RhYmxlcmFuZ2U6ZGI5MDk0ZDBhNzZjNDVmZDg0NzE2M2ViZDYwNWE4ZDRfNi00LTEtMS0yMzU5Ng_81ad275a-4993-49eb-95ef-88411dd8bd1f"
      unitRef="usdPerShare">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNC9mcmFnOmUzZDRiMWY2MjBjZDQyNDFhZDU0ZGNlZjhmY2MxNDM0L3RleHRyZWdpb246ZTNkNGIxZjYyMGNkNDI0MWFkNTRkY2VmOGZjYzE0MzRfMTM3OTI_a834a109-1f1c-4f96-9df7-059e95679600">Net Loss per Common Share: Net loss per common share is computed using the weighted average number of shares of common stock outstanding. Shares associated with convertible debt, stock options and restricted stock units are not included because they are antidilutive.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN18zNy9mcmFnOjI3MjBhMjk3NGI2OTQ2ZjY4ODhlMThlZWYyZjFhNzU0L3RleHRyZWdpb246MjcyMGEyOTc0YjY5NDZmNjg4OGUxOGVlZjJmMWE3NTRfODE4_c3c3a461-690d-4c7e-ba74-5905cec046e5">Recent Accounting Pronouncements&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2019-12, Income Taxes (Topic 740) Simplifying Accounting for Income Taxes, as part of its initiative to reduce complexity in the accounting standards. The guidance amended certain disclosure requirements that had become redundant, outdated or superseded. Additionally, this guidance amends accounting for the interim period effects of changes in tax laws or rates, and simplifies aspects of the accounting for franchise taxes. The guidance is effective for annual periods beginning after December 15, 2020, including interim periods therein. The adoption of ASU 2019-12 in the first quarter of 2021 did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40), which removes the separation models for convertible debt with cash conversion or beneficial conversion features. ASU 2020-06 also requires the application of the if-converted method for calculating earnings per diluted share, as the treasury stock method will no longer be permitted for convertible instruments. The adoption of ASU 2020-06 during the first quarter of 2022 did not have a material impact on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsDisclosureTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RleHRyZWdpb246ODBjZjQ0NDcxYmViNDY0OTgzMmQ1NzlmNTQyYTg2NTZfMzI5_4fa21748-1aab-4fcc-8743-d3643ec94ec9">Cash and Cash Equivalents and Investments&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of cash and cash equivalents and investments held at March&#160;31, 2022 and December&#160;31, 2021 are as follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no realized losses during either of the three months ended March&#160;31, 2022 and 2021, respectively.  The cost of securities sold is based on the specific identification method.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RleHRyZWdpb246ODBjZjQ0NDcxYmViNDY0OTgzMmQ1NzlmNTQyYTg2NTZfMzM2_ba20877f-19f7-43f2-89c0-0f5b8b748fdf">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:52.047%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Securities maturing within one year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,562&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="icc65cb33f8614f8686cae6c8db601bbf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMy0yLTEtMS0yMzU5Ng_74d46cbb-cf86-4e3a-86db-b4b65d84c420"
      unitRef="usd">59520000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="icc65cb33f8614f8686cae6c8db601bbf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMy00LTEtMS0yMzU5Ng_8cf3c676-057f-450f-b737-377825db8992"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icc65cb33f8614f8686cae6c8db601bbf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMy02LTEtMS0yMzU5Ng_320952ef-fe08-4c4c-9910-6248a572b369"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="icc65cb33f8614f8686cae6c8db601bbf_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMy04LTEtMS0yMzU5Ng_060501a8-3fa4-4854-bb5b-62478d1dee46"
      unitRef="usd">59520000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i269a16b2bad547b0933a05089ed034c8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNS0yLTEtMS0yMzU5Ng_e4b8506d-015d-4c9a-9461-8dd6555bab90"
      unitRef="usd">12486000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i269a16b2bad547b0933a05089ed034c8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNS00LTEtMS0yMzU5Ng_f597f22d-15ba-4f6b-a380-cb01f9cd7f71"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i269a16b2bad547b0933a05089ed034c8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNS02LTEtMS0yMzU5Ng_57b63c26-606a-49e5-a753-1e3f2015a2af"
      unitRef="usd">26000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i269a16b2bad547b0933a05089ed034c8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNS04LTEtMS0yMzU5Ng_e1fcf29a-f9cf-41da-b6bb-533aca6a4249"
      unitRef="usd">12460000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="id6057d7870b34586857e2a54b3264dea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNi0yLTEtMS0yMzU5Ng_f0ca2661-226a-472e-b4bd-b3ec87a81f32"
      unitRef="usd">14533000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id6057d7870b34586857e2a54b3264dea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNi00LTEtMS0yMzU5Ng_f8ea5c96-0e02-467b-9227-ed69575ce93c"
      unitRef="usd">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id6057d7870b34586857e2a54b3264dea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNi02LTEtMS0yMzU5Ng_45a91ef5-0cfc-43bf-8de9-d63006de46c8"
      unitRef="usd">15000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="id6057d7870b34586857e2a54b3264dea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNi04LTEtMS0yMzU5Ng_4b726094-3647-4f0b-a6a4-43eddc64e865"
      unitRef="usd">14522000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNy0yLTEtMS0yMzU5Ng_242961c4-05d9-4767-bdc2-4a89dae3cc59"
      unitRef="usd">27019000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNy00LTEtMS0yMzU5Ng_1a1d71ba-5264-4706-8b9d-a152e9e4e6a1"
      unitRef="usd">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNy02LTEtMS0yMzU5Ng_7a3f939a-9879-437e-8ddc-cd6f1e122b1a"
      unitRef="usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i5be13cc53bbc4af3b0bde88dc97294b3_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfNy04LTEtMS0yMzU5Ng_d14c3909-3538-46c9-a9a3-100ef1e296d7"
      unitRef="usd">26982000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i4831626629fd4c0f89f3ee0635c996ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfOC0yLTEtMS0yMzU5Ng_d5e095c3-6a87-4e6d-a664-9fcbd4b50754"
      unitRef="usd">86539000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4831626629fd4c0f89f3ee0635c996ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfOC00LTEtMS0yMzU5Ng_72345c53-aa6f-483f-aa6b-6169066cfb77"
      unitRef="usd">4000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4831626629fd4c0f89f3ee0635c996ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfOC02LTEtMS0yMzU5Ng_086a1d17-e442-4ecc-a0f4-63f6b706095e"
      unitRef="usd">41000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i4831626629fd4c0f89f3ee0635c996ea_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfOC04LTEtMS0yMzU5Ng_e1087e7a-eea0-4e5e-80db-e429b7bb3b30"
      unitRef="usd">86502000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i754d1c94079544c5a4dbeca0b1a7070c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTMtMi0xLTEtMjM1OTY_96d917ec-45a1-499b-a504-7d0e60052953"
      unitRef="usd">64066000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i754d1c94079544c5a4dbeca0b1a7070c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTMtNC0xLTEtMjM1OTY_7f9f222d-68e0-47d3-8785-d2a6301594ef"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i754d1c94079544c5a4dbeca0b1a7070c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTMtNi0xLTEtMjM1OTY_3015238f-07fd-42e8-b061-35cc73dd2893"
      unitRef="usd">-1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i754d1c94079544c5a4dbeca0b1a7070c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTMtOC0xLTEtMjM1OTY_76c4125c-1a0d-4f99-8ce6-e7c20cc0a0d3"
      unitRef="usd">64065000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i40803427d7d242d4aa9bd89cc640ef9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTUtMi0xLTEtMjM1OTY_27532be0-65e9-41e6-a68e-2a7339d3c4d0"
      unitRef="usd">7562000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i40803427d7d242d4aa9bd89cc640ef9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTUtNC0xLTEtMjM1OTY_8303374a-16e8-4c11-a84e-1ffdcb155297"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i40803427d7d242d4aa9bd89cc640ef9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTUtNi0xLTEtMjM1OTY_d4eeb5f2-ee51-46d9-a866-052203619ee3"
      unitRef="usd">1000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i40803427d7d242d4aa9bd89cc640ef9c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTUtOC0xLTEtMjM1OTY_266fff46-cfab-45f8-a989-06f515a07534"
      unitRef="usd">7561000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="i2818027b81e84d5f83d453920e2c236a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTYtMi0xLTEtMjM1OTY_e3805862-82ba-42b9-8954-acbb809bbd45"
      unitRef="usd">15125000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2818027b81e84d5f83d453920e2c236a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTYtNC0xLTEtMjM1OTY_0aafd82c-da5f-4a83-9b9c-51f8ed476e13"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2818027b81e84d5f83d453920e2c236a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTYtNi0xLTEtMjM1OTY_8c8f003b-02fb-4bb9-b1ae-a9c5683184b8"
      unitRef="usd">8000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="i2818027b81e84d5f83d453920e2c236a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTYtOC0xLTEtMjM1OTY_c8dfff00-7d23-4f84-b417-3db45c357c0d"
      unitRef="usd">15117000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTctMi0xLTEtMjM1OTY_824c4511-f4d3-49d6-a358-01a228bd1837"
      unitRef="usd">22687000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTctNC0xLTEtMjM1OTY_e6666fd1-c685-49e9-99bf-1b1decff5015"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTctNi0xLTEtMjM1OTY_2d65b213-667b-43e7-90bc-f7b1165d433f"
      unitRef="usd">9000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ie0e9ced52a5f46da8ce6ba2dc47be9fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTctOC0xLTEtMjM1OTY_27cbac89-f1b8-422e-a76d-77619bb28206"
      unitRef="usd">22678000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesAmortizedCost
      contextRef="ia06866a79907412da012da019c3bdbf0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTgtMi0xLTEtMjM1OTY_cea0b501-4424-40d4-87f2-fb02ad27cae9"
      unitRef="usd">86753000</us-gaap:AvailableForSaleSecuritiesAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia06866a79907412da012da019c3bdbf0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTgtNC0xLTEtMjM1OTY_f219c3c1-26ab-434d-bc4d-a478999c18e0"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia06866a79907412da012da019c3bdbf0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTgtNi0xLTEtMjM1OTY_06d3eaa5-251f-40eb-84d3-299e9ca8ea26"
      unitRef="usd">10000</us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesCurrent
      contextRef="ia06866a79907412da012da019c3bdbf0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RhYmxlOjQ3MjkxZDM3ZDZlMjRkNjJiMDZmN2Q5YzY0ZTRiNDU5L3RhYmxlcmFuZ2U6NDcyOTFkMzdkNmUyNGQ2MmIwNmY3ZDljNjRlNGI0NTlfMTgtOC0xLTEtMjM1OTY_39f3a904-e8b6-4e56-adc1-06339035fcea"
      unitRef="usd">86743000</us-gaap:AvailableForSaleSecuritiesCurrent>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RleHRyZWdpb246ODBjZjQ0NDcxYmViNDY0OTgzMmQ1NzlmNTQyYTg2NTZfMTcw_5e65bc34-436d-45cf-8aa3-c765594514e8"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180MC9mcmFnOjgwY2Y0NDQ3MWJlYjQ2NDk4MzJkNTc5ZjU0MmE4NjU2L3RleHRyZWdpb246ODBjZjQ0NDcxYmViNDY0OTgzMmQ1NzlmNTQyYTg2NTZfMTcw_cac3eeac-e012-4016-9c2a-84abfc6b602c"
      unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:FairValueMeasurementInputsDisclosureTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RleHRyZWdpb246YzgxNmQ2YzkzZmVhNDNjYWE3NjIyNzFkNTUzMzE1NzJfMTU3Mg_0992631c-725a-4e0b-b51f-523dfe87a168">Fair Value Measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses various inputs in determining the fair value of its investments and measures these assets on a recurring basis.  Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized by the level of objectivity associated with the inputs used to measure their fair value.  The following levels are directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - quoted prices in active markets for identical investments, which include U.S. treasury securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - other significant observable inputs (including quoted prices for similar investments, market corroborated inputs, etc.), which includes corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - significant unobservable inputs &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The inputs or methodology used for valuing securities are not necessarily an indication of the credit risk associated with investing in those securities.  The following table provides the fair value measurements of applicable Company assets that are measured at fair value on a recurring basis according to the fair value levels defined above as of March&#160;31, 2022 and December&#160;31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not have any Level 3 assets or liabilities as of March&#160;31, 2022 or December&#160;31, 2021. Transfers between levels are recognized at the actual date of the circumstance that caused the transfer.  There were no transfers between Level 1 and Level 2 during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 5, Debt Obligations, for fair value measurements of debt obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RleHRyZWdpb246YzgxNmQ2YzkzZmVhNDNjYWE3NjIyNzFkNTUzMzE1NzJfMTU3NA_98e703cd-88a9-4b3d-a6dc-27e9e2a6cfca">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.234%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets and Liabilities at Fair Value as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3d1d7ebd972347b28a0590be373807d1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNC0yLTEtMS0yMzU5Ng_ca83204a-7e03-4777-a309-4277dafffcd0"
      unitRef="usd">59520000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ib8839e3922754606a106d63fa91f9257_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNC00LTEtMS0yMzU5Ng_dbbe8ce6-a512-4b86-9f5a-5fdc3d7fe16a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0a3594e189984ab887b31949bdb42d39_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNC02LTEtMS0yMzU5Ng_75d2f3f2-5d89-4ea5-afa3-5080bc9711c5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNC04LTEtMS0yMzU5Ng_9d324312-d013-48dd-8796-ee00320f1fee"
      unitRef="usd">59520000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i3d1d7ebd972347b28a0590be373807d1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNS0yLTEtMS0yMzU5Ng_faeb9869-ed62-4bab-9476-d5affd6184ed"
      unitRef="usd">12460000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="ib8839e3922754606a106d63fa91f9257_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNS00LTEtMS0yMzU5Ng_b465d199-58a2-4360-be26-c0309e2acba1"
      unitRef="usd">14522000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i0a3594e189984ab887b31949bdb42d39_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNS02LTEtMS0yMzU5Ng_e22b6b3f-c501-4b0b-b743-49f89624d91d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNS04LTEtMS0yMzU5Ng_424a066c-a374-4922-a9b2-65d25ba38a59"
      unitRef="usd">26982000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i3d1d7ebd972347b28a0590be373807d1_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNi0yLTEtMS0yMzU5Ng_3d20d726-c6a3-429a-a35e-1046cf957774"
      unitRef="usd">71980000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ib8839e3922754606a106d63fa91f9257_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNi00LTEtMS0yMzU5Ng_6b2303ad-9a20-4aaa-adf4-b7fe2e9d1b41"
      unitRef="usd">14522000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i0a3594e189984ab887b31949bdb42d39_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNi02LTEtMS0yMzU5Ng_65148c4a-21d7-4f34-a1a9-0cbac995b520"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmI0ODBmZDZlMGFjNTQ3M2M4YTkzZGFhMzM0ZjEwOTIxL3RhYmxlcmFuZ2U6YjQ4MGZkNmUwYWM1NDczYzhhOTNkYWEzMzRmMTA5MjFfNi04LTEtMS0yMzU5Ng_c602acba-709d-45d4-9e42-e9a90ec568d9"
      unitRef="usd">86502000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i63fccb8bd5334396afb7e01493bc4ff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNC0yLTEtMS0yMzU5Ng_05c50d46-b699-4d10-af3c-2f65351ff10d"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i107e88057aa14de4a9bfdadf17dea0e8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNC00LTEtMS0yMzU5Ng_d1d4e378-8a5f-475e-8d67-4dafd4e3b54e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i345a5ef75eae4b1dbfc66924f9141439_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNC02LTEtMS0yMzU5Ng_9b326ad7-0031-47d2-8cd2-a876b6e1131b"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNC04LTEtMS0yMzU5Ng_2bfa6ad2-6966-4d64-8198-ed49c864211a"
      unitRef="usd">64065000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i63fccb8bd5334396afb7e01493bc4ff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNS0yLTEtMS0yMzU5Ng_bae7b8c2-1898-46ec-8a12-c7a498c1b0a0"
      unitRef="usd">7561000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i107e88057aa14de4a9bfdadf17dea0e8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNS00LTEtMS0yMzU5Ng_7293497d-4f72-4680-a430-0aaa9e49aba2"
      unitRef="usd">15117000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i345a5ef75eae4b1dbfc66924f9141439_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNS02LTEtMS0yMzU5Ng_a95d3d52-9543-49ad-b5a1-9dc837e29d95"
      unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
    <us-gaap:AvailableForSaleSecurities
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNS04LTEtMS0yMzU5Ng_23e054e2-1ced-48a7-a4bf-e23ad2832a88"
      unitRef="usd">22678000</us-gaap:AvailableForSaleSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i63fccb8bd5334396afb7e01493bc4ff0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNi0yLTEtMS0yMzU5Ng_3a2b0910-fca9-4de8-9d28-2fe316e51622"
      unitRef="usd">71626000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i107e88057aa14de4a9bfdadf17dea0e8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNi00LTEtMS0yMzU5Ng_698e3ed5-8bb8-4442-93c2-b97859124629"
      unitRef="usd">15117000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i345a5ef75eae4b1dbfc66924f9141439_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNi02LTEtMS0yMzU5Ng_133f9b14-370c-458d-a865-e67edda02686"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180My9mcmFnOmM4MTZkNmM5M2ZlYTQzY2FhNzYyMjcxZDU1MzMxNTcyL3RhYmxlOmM2MzliZTIzZDlkZTQ5YzdiNDJjYTc1NGNlNTlkNzg2L3RhYmxlcmFuZ2U6YzYzOWJlMjNkOWRlNDljN2I0MmNhNzU0Y2U1OWQ3ODZfNi04LTEtMS0yMzU5Ng_0d3bbd03-1f82-47df-8f25-222cc198faab"
      unitRef="usd">86743000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfNDcyNw_4801c260-01bf-44ca-b0ab-e523bc6a6cc6">Debt Obligations&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 17, 2022, Lexicon and one of its subsidiaries entered into a loan and security agreement with Oxford Finance LLC (&#x201c;Oxford&#x201d;) that provides up to $150&#160;million in borrowing capacity (the &#x201c;Oxford Term Loans&#x201d;) available in four tranches, each maturing in March 2027. Monthly interest-only payments are due during an initial 36-month period, which may be extended at Lexicon&#x2019;s option to 48 months if Lexicon maintains compliance with a financial covenant relating to net sales of sotagliflozin following regulatory approval. The interest-only period will be followed by principal payments of $8.7&#160;million, $13.0&#160;million, and $4.8&#160;million during the fiscal years ended December 31, 2025, December 31, 2026 and December 31, 2027, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The first $25&#160;million tranche was funded at closing. The second $25&#160;million tranche is available for draw at Lexicon&#x2019;s option prior to August 31, 2022, but within 30 days of acceptance of filing by the U.S. Food and Drug Administration of Lexicon&#x2019;s resubmission of its application for U.S. regulatory approval of sotagliflozin for heart failure. The third $50&#160;million tranche is available for draw at Lexicon&#x2019;s option prior to June 30, 2023, but within 60 days of U.S. regulatory approval of sotagliflozin for heart failure. The fourth $50&#160;million tranche is available for draw at Lexicon&#x2019;s option, subject to Oxford&#x2019;s consent, at any time prior to the expiration of the interest-only payment period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loan and security agreement provides that, upon funding of the first three tranches, Lexicon will grant Oxford a warrant to purchase shares of its common stock having a value equal to 3.50%, 1.75% and 0.875%, respectively, of each such tranche, as determined by reference to a 10-day average closing price of the shares. Each warrant will have an exercise price equal to such average closing price, be exercisable for a five-year period from the date of issuance and feature a net cashless exercise provision. Concurrent with the funding of the first tranche, Lexicon granted Oxford a warrant to purchase 420,673 shares of Lexicon&#x2019;s common stock at an exercise price of $2.08 per share. The warrant is exercisable through March 1, 2027 and is classified as an equity instrument.  The Company allocated the proceeds from the first tranche to the warrant using the relative fair value method and used the Black-Scholes model to calculate the fair value of the warrants.  The fair value of the warrant of $0.7&#160;million was recognized as equity with a corresponding debt discount of $0.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Oxford Term Loans bear interest at a floating rate equal to the 30-day U.S. Dollar LIBOR plus 7.90%, but not less than 8.01%, subject to additional interest if an event of default occurs and is continuing.  As of March&#160;31, 2022, the interest rate was 8.14%. If an event of default occurs and is continuing, Oxford may declare all amounts outstanding under the loan and security agreement to be immediately due and payable. Lexicon may prepay the Oxford Term Loans in whole at its option at any time. Any prepayment of the Oxford Term Loans is subject to prepayment fees for up to three years after the funding of each tranche of the loans.  A final payment exit fee equal to 6% of the amount funded under the Oxford Term Loans is due upon prepayment or maturity, which final payment will be adjusted to 7% of the amount funded upon extension of the interest-only payment period.  The final payment exit fee of $1.5&#160;million was recorded as a debt discount on the closing date of the first tranche.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During March 2022, in connection with the first tranche of the loan and security agreement, the Company received cash proceeds of $24.2&#160;million, net of debt issuance costs of $0.4&#160;million and a facility fee of $0.5&#160;million. The debt issuance costs and facility fee have been recorded as a debt discount on the Company&#x2019;s condensed consolidated balance sheet, which together with the final payment exit fee of $1.5&#160;million and warrant fair value of $0.7&#160;million are being amortized to interest expense throughout the life of the term loan using the effective interest rate method.  As of March&#160;31, 2022, the balance of the debt discount was $3.0&#160;million. During the three months ended March&#160;31, 2022, the Company recognized interest expense of $0.1&#160;million.  As of  March&#160;31, 2022, the carrying value of the Oxford Term Loans was $23.5&#160;million.  The fair value of the Oxford Term Loans approximates its carrying value and was determined using Level 2 inputs using discounted cash flow analysis, based on the Company&#x2019;s estimated current incremental borrowing rate.       &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Lexicon&#x2019;s obligations under the Oxford Term Loans are secured by a first lien security interest in all of the assets of the Company and its subsidiaries. The loan and security agreement contains certain customary representations and warranties, affirmative and negative covenants and events of default applicable to Lexicon and its subsidiaries. In addition to the financial covenant, additional covenants include those restricting dispositions, fundamental changes to its business, mergers or acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and subordinated debt. The Company was in compliance with its debt covenants as of March&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Convertible Debt.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2014, Lexicon completed an offering of $87.5 million in aggregate principal amount of its 5.25% Convertible Senior Notes due 2021 (the &#x201c;Convertible Notes&#x201d;).  The conversion feature did not meet the criteria for bifurcation as required by generally accepted accounting principles and the entire principal amount was recorded as long-term debt on the Company&#x2019;s condensed consolidated balance sheets.  &lt;/span&gt;&lt;/div&gt;In 2020, the Company entered into separate, privately negotiated exchange agreements to exchange $75.8 million aggregate principal amount of the Convertible Notes for consideration valued at 85% of the principal amount of the Convertible Notes. In 2020, the Company issued 10,368,956 shares of the Company&#x2019;s common stock and paid $50.0 million in cash, which included $1.3 million of accrued interest, to exchange such Convertible Notes. In December 2021, the remaining balance of $11.6 million was repaid in cash.</us-gaap:DebtDisclosureTextBlock>
    <lxrx:OxfordLoanFacility
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDEzNg_087c6cd7-916a-43d3-9655-b88114899c66"
      unitRef="usd">150000000</lxrx:OxfordLoanFacility>
    <lxrx:A2027OxfordPrincipalPayments
      contextRef="i65072cfc026e48afbf7cc86311e0945f_D20250101-20251231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2Mzg5OA_761a326e-b0e9-4880-bdc5-3b04ce0d23bb"
      unitRef="usd">8700000</lxrx:A2027OxfordPrincipalPayments>
    <lxrx:A2026OxfordPrincipalPayments
      contextRef="ibb0a7747800c4993a006e9573429f517_D20260101-20261231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MzkwNg_c430e242-1e2a-4c08-bd5d-cd143b62e374"
      unitRef="usd">13000000</lxrx:A2026OxfordPrincipalPayments>
    <lxrx:A2027OxfordPrincipalPayments
      contextRef="i32ff79bcead3411f88004dea3607340e_D20270101-20271231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2NDE1Mw_a9ae2266-7cee-41eb-b4cb-ffe726598464"
      unitRef="usd">4800000</lxrx:A2027OxfordPrincipalPayments>
    <lxrx:TermLoanA
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDE1Ng_53cb5d44-c591-45eb-98f9-12f80d687d59"
      unitRef="usd">25000000</lxrx:TermLoanA>
    <lxrx:TermLoanB
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDE3NA_afa04c7a-631d-4ec0-af2a-1a1b1acde50a"
      unitRef="usd">25000000</lxrx:TermLoanB>
    <lxrx:TermLoanC
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDE5Mg_c139c5c3-e244-4bd7-b0de-ec6ed871ad12"
      unitRef="usd">50000000</lxrx:TermLoanC>
    <lxrx:TermLoanD
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDIxMA_166cbeb7-5f66-4137-913e-cf8f6c30bbfc"
      unitRef="usd">50000000</lxrx:TermLoanD>
    <lxrx:TermLoanABWarrant
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI4NA_17f03c39-fb12-4522-a981-57e92c7ea285"
      unitRef="number">0.0350</lxrx:TermLoanABWarrant>
    <lxrx:TermLoanCWarrant
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI5MQ_34f936a3-ed6f-43fd-9d2f-7121e0f43828"
      unitRef="number">0.0175</lxrx:TermLoanCWarrant>
    <lxrx:TermLoanDWarrant
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI5OQ_3160ad8d-38ab-440e-ab14-b2ede612983d"
      unitRef="number">0.00875</lxrx:TermLoanDWarrant>
    <lxrx:TermLoanAWarrantsNumber
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTMxNw_595a5042-d3ea-4b43-a47c-df57c2083a37"
      unitRef="shares">420673</lxrx:TermLoanAWarrantsNumber>
    <lxrx:TermLoanAWarrantExercisePrice
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI3NQ_27e80dfc-1e2b-4ea5-99ec-9f6dfcf1dd9d"
      unitRef="usdPerShare">2.08</lxrx:TermLoanAWarrantExercisePrice>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTE3OQ_0bfc7f79-7278-4a38-98ec-1f3a3d88b62b"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1OTI2MA_0bfc7f79-7278-4a38-98ec-1f3a3d88b62b"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDIzNg_ef76ee0a-79bc-4ab4-9b4a-32095d99aec4"
      unitRef="number">0.0790</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtPercentageBearingFixedInterestRate
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDIyOA_fa63d1fd-4f22-4185-81f1-ce8dd1887f75"
      unitRef="number">0.0801</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
    <us-gaap:SubordinatedBorrowingInterestRate
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MzY5NA_8b488589-2dd9-48b1-8148-b0a989c3d259"
      unitRef="number">0.0814</us-gaap:SubordinatedBorrowingInterestRate>
    <lxrx:FinalPaymentWithNoExtention
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDI0NA_5a3d49e1-1b26-4e9b-ab5e-55b516149541"
      unitRef="rate">0.06</lxrx:FinalPaymentWithNoExtention>
    <lxrx:FinalPaymentWithExtention
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDI1MQ_3d6a1038-9403-4941-b1d2-2245fc2a4621"
      unitRef="rate">0.07</lxrx:FinalPaymentWithExtention>
    <lxrx:TermLoanAFinalPayment
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDMwNg_e3cdeece-db89-4b3a-a9c6-a6962b74bde1"
      unitRef="usd">1500000</lxrx:TermLoanAFinalPayment>
    <lxrx:TermLoanANetCashReceipt
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1ODA0MQ_d5c49686-df74-4a0a-81f5-15d6d56fc760"
      unitRef="usd">24200000</lxrx:TermLoanANetCashReceipt>
    <lxrx:TermLoanADebtIssuanceCosts
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1ODA2Mg_97fc09d0-0e10-4e63-922b-203bef7fd94a"
      unitRef="usd">400000</lxrx:TermLoanADebtIssuanceCosts>
    <lxrx:OxfordFacilityFee
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MzgzOQ_e615ab05-0fd7-408d-94cd-30842ef772d8"
      unitRef="usd">500000</lxrx:OxfordFacilityFee>
    <lxrx:TermLoanAFinalPayment
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ1ODA5Mw_e3cdeece-db89-4b3a-a9c6-a6962b74bde1"
      unitRef="usd">1500000</lxrx:TermLoanAFinalPayment>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDUxNQ_0bfc7f79-7278-4a38-98ec-1f3a3d88b62b"
      unitRef="usd">700000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <lxrx:TermLoanADebtDiscount
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDUyMA_dceaafc2-4977-48e5-b0fc-dfcabeb6a016"
      unitRef="usd">3000000</lxrx:TermLoanADebtDiscount>
    <lxrx:TermLoanAInterestExpense
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2MDg0MA_a91487e7-f227-47d5-9679-67f4fc6d36b0"
      unitRef="usd">100000</lxrx:TermLoanAInterestExpense>
    <us-gaap:LongTermDebt
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTY0OTI2NzQ2Mzg2Ng_4e8891a0-65a6-4d9a-9ce5-c5eafe41554c"
      unitRef="usd">23500000</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="ibea33cce1ed8454ba1e53a958924c502_D20141101-20141130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTAz_f67b8381-1074-400b-aba8-525a7fb025fb"
      unitRef="usd">87500000</us-gaap:ProceedsFromConvertibleDebt>
    <lxrx:ConvDebtInstrumentInterestRateStatedPercentage
      contextRef="i9ede230fc7714aa6adbaa82ca6308ad6_I20141120"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTQz_e724d5ec-b644-4ee6-a67a-b30ad9460a4e"
      unitRef="number">0.0525</lxrx:ConvDebtInstrumentInterestRateStatedPercentage>
    <lxrx:ConvertibleDebtExchangeTotalPrincipalAmount
      contextRef="ic85a31856cf447f699a3d934334e07e1_I20200928"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfNTU3_d4cdade4-763e-458e-ace0-6af5c13fd425"
      unitRef="usd">75800000</lxrx:ConvertibleDebtExchangeTotalPrincipalAmount>
    <lxrx:ConvertibleDebtExchangeRemainingNotes
      contextRef="i26b3a1ab655c4f5e98599da965af2bc0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN180OS9mcmFnOjIwY2M2N2E1OTAwZDRmOTJiNDU2MDhiNDg3ZmZkNmFmL3RleHRyZWdpb246MjBjYzY3YTU5MDBkNGY5MmI0NTYwOGI0ODdmZmQ2YWZfMTM1NQ_85f8c510-cb18-40bc-8225-68b2cb9755bf"
      unitRef="usd">11600000</lxrx:ConvertibleDebtExchangeRemainingNotes>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RleHRyZWdpb246NzEwZTVlMmVjY2NlNGFjYjk1MjhlODc5OGQwZGZiNjFfNDE3Mg_c4c2ca36-639c-4fdf-95a9-6e623fea5f6b">Commitments and Contingencies&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Operating Lease Obligations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;Lexicon&#x2019;s operating leases include office space in The Woodlands, Texas and Basking Ridge, New Jersey and will expire in August 2025 and December 2022, respectively. Under its lease agreements, Lexicon is obligated to pay property taxes, insurance, and maintenance costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2022, the right-of-use assets for the office space leases had a balance of $2.1 million, which is included in other assets in the condensed consolidated balance sheet. Current and non-current liabilities relating to the leases were $0.9 million and $1.1 million, respectively, which are included in accrued liabilities and other long-term liabilities in the condensed consolidated balance sheet, respectively.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles the undiscounted cash flows of the operating lease liability to the recorded lease liability at March&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:80.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;874&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;531&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;544&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount of lease payments representing interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(281)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: short-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(940)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Legal Proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Lexicon is from time to time party to claims and legal proceedings that arise in the normal course of its business and that it believes will not have, individually or in the aggregate, a material adverse effect on its results of operations, financial condition or liquidity.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RleHRyZWdpb246NzEwZTVlMmVjY2NlNGFjYjk1MjhlODc5OGQwZGZiNjFfNDMz_ebd82281-36ca-4880-832c-dfdd278da010"
      unitRef="usd">2100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:ShortTermLeaseCommitmentAmount
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RleHRyZWdpb246NzEwZTVlMmVjY2NlNGFjYjk1MjhlODc5OGQwZGZiNjFfNTgw_a6f6960d-b399-40f5-82dc-38c52594e93d"
      unitRef="usd">900000</us-gaap:ShortTermLeaseCommitmentAmount>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RleHRyZWdpb246NzEwZTVlMmVjY2NlNGFjYjk1MjhlODc5OGQwZGZiNjFfNTg3_f7915e79-17ba-4940-8cfa-780487c8861d"
      unitRef="usd">1100000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMi0xLTEtMS0yMzU5Ng_954c1ec0-07c6-4999-960d-b15e899b5c63"
      unitRef="usd">874000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMy0xLTEtMS0yMzU5Ng_57dbc04f-b443-46ac-a27b-b3ce70342494"
      unitRef="usd">531000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfNC0xLTEtMS0yMzU5Ng_fc90de0f-0fa5-4f36-a709-9f9e90bf3c4f"
      unitRef="usd">544000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfNS0xLTEtMS0yMzU5Ng_9fe2a35a-a1ca-4f54-a63a-02d3facbcc3a"
      unitRef="usd">370000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfNi0xLTEtMS0yMzU5Ng_5afb25ba-f13a-4b97-81f5-cc6361783418"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfOC0xLTEtMS0yMzU5Ng_c1348d76-6cf1-415c-a588-15953b15e551"
      unitRef="usd">2319000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfOS0xLTEtMS0yMzU5Ng_3bb31536-1baf-4b17-a5d7-1b986067f896"
      unitRef="usd">281000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMTAtMS0xLTEtMjM1OTY_23d633f0-5c29-4a94-9e0b-c9f9835f3431"
      unitRef="usd">2038000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMTEtMS0xLTEtMjM1OTY_c415e4c1-d0ee-4100-90f1-a8808fecf3d8"
      unitRef="usd">940000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations
      contextRef="i56bf863e5c644f1fb5924d8588e1edf8_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181Mi9mcmFnOjcxMGU1ZTJlY2NjZTRhY2I5NTI4ZTg3OThkMGRmYjYxL3RhYmxlOmE2ODMzZDc5ZWQ4MTRhOTU5MDQ1YWNlY2FjMWNmNGIyL3RhYmxlcmFuZ2U6YTY4MzNkNzllZDgxNGE5NTkwNDVhY2VjYWMxY2Y0YjJfMTItMS0xLTEtMjM1OTY_0b3366a2-b033-4f14-8447-69817d2d3af7"
      unitRef="usd">1098000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181NS9mcmFnOmQwNjM4MTE4MjUyODQzMzU5ZWQxMTUzMzE1N2E2M2Y3L3RleHRyZWdpb246ZDA2MzgxMTgyNTI4NDMzNTllZDExNTMzMTU3YTYzZjdfMjgyNw_03c0d66d-7152-4291-bde1-855bd3ad1334">Collaboration and License Agreements&#160;Lexicon has derived substantially all of its revenues from drug discovery and development alliances, target validation collaborations for the development and, in some cases, analysis of the physiological effects of genes altered in knockout mice, product sales, government grants and contracts, technology licenses, subscriptions to its databases and compound library sales, as well as from commercial sales of our XERMELO product following its commercial launch in February 2017 until our sale of XERMELO and related assets to TerSera Therapeutics, LLC in September 2020.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <lxrx:OtherCapitalAgreementsTextBlock
      contextRef="i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfOTc4_cb0253b6-e8e8-40af-b42a-919915e0a9ef">Other Capital Agreements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:  In 2020, Lexicon entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) relating to the shares of its common stock. In January 2021, Lexicon sold 2,000,000 shares of its common stock at a price of $8.463 per share pursuant to the Sales Agreement, resulting in net proceeds of $16.4&#160;million. The net proceeds are reflected as issuances of common stock in the accompanying condensed consolidated financial statements. &lt;/span&gt;&lt;/div&gt;In August and September 2021, Lexicon sold an aggregate of 4,176,953 shares of its common stock at a price of $4.732 per share pursuant to the Sales Agreement, resulting in net proceeds of $19.1 million.</lxrx:OtherCapitalAgreementsTextBlock>
    <lxrx:SharesSoldInJanuary2021ATMOffering
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNTM3_f9ca20bb-9010-4e98-b91a-624bb15c2422"
      unitRef="shares">2000000</lxrx:SharesSoldInJanuary2021ATMOffering>
    <lxrx:SharePriceInJanuary2021ATMOffering
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNTgx_491d5ca5-2c33-4bda-b9ed-3de449631b7e"
      unitRef="shares">8.463</lxrx:SharePriceInJanuary2021ATMOffering>
    <lxrx:ProceedsFromJanuary2021ATMOffering
      contextRef="i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNjU2_54d7108e-4c89-466e-b7b7-dcda144b8d0e"
      unitRef="usd">16400000</lxrx:ProceedsFromJanuary2021ATMOffering>
    <lxrx:SharesSoldInSeptember2021ATMOfferring
      contextRef="if5e01daa001c4e169e255a6c6475516d_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNzIw_7108be0c-65d4-4151-af41-5add8b6487f7"
      unitRef="shares">4176953</lxrx:SharesSoldInSeptember2021ATMOfferring>
    <lxrx:SharePriceInSeptember2021ATMOfferring
      contextRef="if5e01daa001c4e169e255a6c6475516d_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfNzY0_99cf3156-fbf0-4229-bf2d-b2bddd066af0"
      unitRef="usd">4.732</lxrx:SharePriceInSeptember2021ATMOfferring>
    <lxrx:ProceedsFromSeptember2021ATMOffering
      contextRef="if5e01daa001c4e169e255a6c6475516d_D20210701-20210930"
      decimals="6"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NjM0NThiYTM5NzRmZDY5YWQ3Yzg0ZWViZDE2N2E3L3NlYzoxNjYzNDU4YmEzOTc0ZmQ2OWFkN2M4NGVlYmQxNjdhN181OC9mcmFnOjFjN2ExNDlkNmIzOTRhMzE4NTU2NTUxYTdkY2VkZTU4L3RleHRyZWdpb246MWM3YTE0OWQ2YjM5NGEzMTg1NTY1NTFhN2RjZWRlNThfODQw_877f4e71-cb2e-4deb-b98b-59e3f61dc8df"
      unitRef="usd">19.1</lxrx:ProceedsFromSeptember2021ATMOffering>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>40
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M_7QGV\8@>^//0&R2@VMBEC*7\MW</'HW+<LP$J%PM8'@\&\MQB(,#1+P^+<
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MDW/ZR'.N.1LE&]RQ#1ZGFS9#;NF+28].[WW+J\0G_6/LDL(A&?"\HQD\SC,
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M];VI48=W;QY-P7-R3TUNR5]M[JL0A6>^P<'"BSH>M$AYD;NP.W'6T)V-TMU
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MEZ-K_':>)G: L_@F^*/>NT;6E7LI?]B;C^7E*+&(>,4+8Z=@\+/A<UY5=B;
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M$?^X!R$&V^FR/5YP,O/I\\WH9)"Z20=V$@5[9V3QX]S6I1(5LH9BK0=Q3CP
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MM@;P_X649G=C7] =X%[]"U!+ P04    "  @@:54)W!KX.,%  #J&P  &
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MKY)\5T?]A5 7%TG*3MXNVH<6)P/Y.U<Y "T?Y,(]R!0(VQ+[I6D*3<AA'SI
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MDBM)@Z^V.FHE(TO18?R+-F>"?6/X3L<MUE,"ZAXR[$B/Z0M6UJTN%-(GA0)
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M#A6$-IYI =<<V@QUP36 ,ECJI92E5F32,RO=[3<E44>!D$,K&.1_;^)^)?I
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M2P(X7QFXVGR0@>ZWT-D_4$L#!!0    ( ""!I51U$3Z*30H  !H;   9
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M6/")MN$38 QQPW5)YRP.P+1>B [*C97D1:F3(=N/'B*F&K%!+?W@!-'U./#
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M GR_="Z.#\0@_R+KU?\!4$L#!!0    ( ""!I50#T[/MA 0  ( +   9
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MW]<5*/V-6W^*>NZ*(0/NXE[<AJO1JN :N#+CS?@P+\1<-?$:IJCBZ*X[Y]*
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M M-S;IJU?K]!C^>IHP[-[33$7>H>.P]/SI<\;K#C86R=@NP[QH/4<8=F[/=
M=\W\" =GF<<-\_BB;=*B[8,<=S;I-)J$7<JNG>=/RWSZ,2<-YF00<P5OC)H-
MS#B58(\@R=!62./%[A*S6:"O,0W[- L^POAS7[]P6PW?WLZFA^T95RB#Q+C"
MH[%9!UG=>-5 BZ*\ [9"FQNE?$S-1P)(:V#>)T+HCX&]5IK/CL5?4$L#!!0
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M!JILGK\]Y!O)-N8 _LRD.LZ;9:3>N C7 /5\Q9A\W^@S??D.-_D+4$L#!!0
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MGE+U:RN0+TKY )GO&%-H+'+",REVKY19V;5G3[L8T\N]>[?^DJ7G&TKV>\-
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M,]TS_BAR (F>RX**F9-+65VYKDAR*+$8L JH>I,Q7F*INGSGBHH#3HVH+-S
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M*MORM<V(HA)FV:8*H:HF%\KY()&%&IKR=?N>^E<OZJ'7SN-&,33'W!>811W
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M>), O1GU9@%Z,^K- O3FEX]M 7HSZLT"]&;4FP7HS:@W"]";46\6H#>CWBQ
M;T:]^9UZ.W]OC5MZ'FN\_YU4^^E=LUP_+Q^;*&$RXZSAW\KQ%U!+ P04
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MZ[\9[5H8J>S!GW6_C&:?4$L! A0#%     @ ((&E5 =!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  @
M@:54X\#$<NX    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  @@:54F5R<(Q &  "<)P  $P
M@ ', 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( ""!I532)SU)
M<@4  -46   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  @@:54/ZC3A*(%  "0%0  &
M@(&U#0  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ ((&E
M5)*YP5\+ P  (@H  !@              ("!C1,  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( ""!I53V2FW2D 0  +L/   8
M      " @<X6  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  @@:5488&48IH"  !@!@  &               @(&4&P  >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ ((&E5._I0<L4!P  S!T  !@
M             ("!9!X  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( ""!I50G<&O@XP4  .H;   8              " @:XE  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  @@:54C8SAG1<1  "J
M+P  &               @(''*P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ ((&E5/UJYK"=!   ,@H  !@              ("!%#T
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( ""!I53A=V*>
MG ,  '4)   9              " @>=!  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ ((&E5$QZFC4M!0  %PT  !D
M ("!ND4  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  @
M@:54=1$^BDT*   :&P  &0              @($>2P  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ""!I53HG%9+HP0  '8*   9
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M970Q-RYX;6Q02P$"% ,4    "  @@:54R^@YZ4D#  !E"   &0
M    @($N<P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M ""!I50>1]&3WP(   $'   9              " @:YV  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ ((&E5'WCO$A8 P  J@X  !D
M             ("!Q'D  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  @@:549 /B;9$$   4%P  &0              @(%3?0  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( ""!I503#;I7Y@(
M (((   9              " @1N"  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ ((&E5,W$\98K!   GQ,  !D              ("!
M.(4  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  @@:54
M-R%=!C<"   @!0  &0              @(&:B0  >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( ""!I51/3+B!*P,  ,\-   9
M      " @0B,  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ ((&E5(J4N_3]!0  %QH  !D              ("!:H\  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  @@:54^_9M+0(#   ."@
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M+G)E;'-02P$"% ,4    "  @@:545.J]N?P"  "D$P  #P
M@ $ H   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ ((&E5"\ @E1, 0
M:Q$  !H              ( !*:,  'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR
M96QS4$L! A0#%     @ ((&E5"+@:-=[ 0  .A(  !,              ( !
MK:0  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     "0 ) "S"0  6:8

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>70</ContextCount>
  <ElementCount>213</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>16</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Consolidated Balance Sheets-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Consolidated Balance Sheets-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Consolidated Balance Sheets Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Consolidated Balance Sheets Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity/Deficit-Unaudited</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</Role>
      <ShortName>Summary of Significant Accounting Policies (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes</Role>
      <ShortName>Recent Accounting Pronouncements Level 1 (Notes)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2110103 - Disclosure - Cash and Cash Equivalents and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</Role>
      <ShortName>Cash and Cash Equivalents and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2114104 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2117105 - Disclosure - Debt Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligations</Role>
      <ShortName>Debt Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2120106 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2122107 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2125108 - Disclosure - Other Capital Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreements</Role>
      <ShortName>Other Capital Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables</Role>
      <ShortName>Summary of Significant Accounting Policies Equity Incentive Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2311302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2315303 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurements</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2404401 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1</Role>
      <ShortName>Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2</Role>
      <ShortName>Cash and Cash Equivalents and Investments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2416408 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2419409 - Disclosure - Debt Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/DebtObligationsDetails</Role>
      <ShortName>Debt Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/DebtObligations</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/CommitmentsandContingencies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="lxrx-20220331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2426412 - Disclosure - Other Capital Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.lexpharma.com/role/OtherCapitalAgreementsDetails</Role>
      <ShortName>Other Capital Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.lexpharma.com/role/OtherCapitalAgreements</ParentRole>
      <Position>28</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="lxrx-20220331.htm">lxrx-20220331.htm</File>
    <File>exh101oxfordloanandsecurit.htm</File>
    <File>exh311certificationofprinc.htm</File>
    <File>exh312certificationofprinc.htm</File>
    <File>exh321certificationofprinc.htm</File>
    <File>lxrx-20220331.xsd</File>
    <File>lxrx-20220331_cal.xml</File>
    <File>lxrx-20220331_def.xml</File>
    <File>lxrx-20220331_lab.xml</File>
    <File>lxrx-20220331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="363">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>46
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lxrx-20220331.htm": {
   "axisCustom": 0,
   "axisStandard": 4,
   "contextCount": 70,
   "dts": {
    "calculationLink": {
     "local": [
      "lxrx-20220331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lxrx-20220331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "lxrx-20220331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lxrx-20220331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lxrx-20220331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "lxrx-20220331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 346,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 5
   },
   "keyCustom": 45,
   "keyStandard": 168,
   "memberCustom": 0,
   "memberStandard": 16,
   "nsprefix": "lxrx",
   "nsuri": "http://www.lexpharma.com/20220331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Document and Entity Information",
     "role": "http://www.lexpharma.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110103 - Disclosure - Cash and Cash Equivalents and Investments",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments",
     "shortName": "Cash and Cash Equivalents and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114104 - Disclosure - Fair Value Measurements",
     "role": "http://www.lexpharma.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117105 - Disclosure - Debt Obligations",
     "role": "http://www.lexpharma.com/role/DebtObligations",
     "shortName": "Debt Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120106 - Disclosure - Commitments and Contingencies",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2122107 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.lexpharma.com/role/CollaborationandLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:OtherCapitalAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125108 - Disclosure - Other Capital Agreements",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreements",
     "shortName": "Other Capital Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "lxrx:OtherCapitalAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables",
     "shortName": "Summary of Significant Accounting Policies Equity Incentive Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311302 - Disclosure - Cash and Cash Equivalents and Investments (Tables)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables",
     "shortName": "Cash and Cash Equivalents and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2315303 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Consolidated Balance Sheets-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
     "shortName": "Consolidated Balance Sheets-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i07ee2544f5814973b10bd77089b44a79_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404401 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Valuation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i07ee2544f5814973b10bd77089b44a79_D20220101-20220331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "ia8243aca9d564e4f83796530f13c3383_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
     "shortName": "Summary of Significant Accounting Policies Stock-based Compensation Summary (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "ia8243aca9d564e4f83796530f13c3383_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails",
     "shortName": "Summary of Significant Accounting Policies Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:AccruedResearchAndDevelopmentServicesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "icc65cb33f8614f8686cae6c8db601bbf_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Cash and Cash Equivalents and Investments (Details 1)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
     "shortName": "Cash and Cash Equivalents and Investments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "icc65cb33f8614f8686cae6c8db601bbf_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Cash and Cash Equivalents and Investments (Details 2)",
     "role": "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2",
     "shortName": "Cash and Cash Equivalents and Investments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RealizedInvestmentGainsLosses",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416408 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.lexpharma.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "ibea33cce1ed8454ba1e53a958924c502_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419409 - Disclosure - Debt Obligations (Details)",
     "role": "http://www.lexpharma.com/role/DebtObligationsDetails",
     "shortName": "Debt Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "ibea33cce1ed8454ba1e53a958924c502_D20141101-20141130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromConvertibleDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Commitments and Contingencies (Details)",
     "role": "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SharesSoldInJanuary2021ATMOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426412 - Disclosure - Other Capital Agreements (Details)",
     "role": "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails",
     "shortName": "Other Capital Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i4e381ca07bf548dbbece7a040bcabe02_D20210101-20210331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:SharesSoldInJanuary2021ATMOffering",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Consolidated Balance Sheets Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
     "shortName": "Consolidated Balance Sheets Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i56bf863e5c644f1fb5924d8588e1edf8_I20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyIncomeNonoperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Consolidated Statements of Comprehensive Loss-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
     "shortName": "Consolidated Statements of Comprehensive Loss-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyIncomeNonoperating",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "lxrx:StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Consolidated Statements of Comprehensive Loss Parentheticals",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
     "shortName": "Consolidated Statements of Comprehensive Loss Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i54962a8013d14e668867895265609fcc_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "role": "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
     "shortName": "Consolidated Statements of Stockholders' Equity/Deficit-Unaudited",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i54962a8013d14e668867895265609fcc_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies (Notes)",
     "role": "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes",
     "shortName": "Summary of Significant Accounting Policies (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109102 - Disclosure - Recent Accounting Pronouncements Level 1 (Notes)",
     "role": "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes",
     "shortName": "Recent Accounting Pronouncements Level 1 (Notes)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lxrx-20220331.htm",
      "contextRef": "i485301bd9bc1494b82ccb49ce6ebb3b2_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 16,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "lxrx_A2025OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2025 Oxford Principal Payments",
        "label": "2025 Oxford Principal Payments",
        "terseLabel": "2026 Oxford Principal Payments"
       }
      }
     },
     "localname": "A2025OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2026OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2026 Oxford Principal Payments",
        "label": "2026 Oxford Principal Payments",
        "terseLabel": "2027 Oxford Principal Payments"
       }
      }
     },
     "localname": "A2026OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_A2027OxfordPrincipalPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2027 Oxford Principal Payments",
        "label": "2027 Oxford Principal Payments",
        "terseLabel": "2027 Oxford Principal Payments2"
       }
      }
     },
     "localname": "A2027OxfordPrincipalPayments",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ATMOfferingTotal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Offering Total",
        "label": "ATM Offering Total",
        "terseLabel": "ATM Offering Total"
       }
      }
     },
     "localname": "ATMOfferingTotal",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedCompensationAndBenefitsCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued compensation and benefits current - due within 1 year",
        "label": "Accrued compensation and benefits current",
        "terseLabel": "Accrued compensation and benefits current"
       }
      }
     },
     "localname": "AccruedCompensationAndBenefitsCurrent",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedInterestOnConvertible": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued interest on convertible",
        "label": "accrued interest on convertible",
        "terseLabel": "accrued interest on convertible"
       }
      }
     },
     "localname": "AccruedInterestOnConvertible",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_AccruedLiabilitiesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued liabilities",
        "label": "accrued liabilities [Axis]",
        "terseLabel": "Accrued Liabilities [Axis]"
       }
      }
     },
     "localname": "AccruedLiabilitiesAxis",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Domain]",
        "terseLabel": "Accrued Liabilities [Domain]"
       }
      }
     },
     "localname": "AccruedLiabilitiesDomain",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "lxrx_AccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities",
        "label": "Accrued Liabilities [Line Items]",
        "terseLabel": "Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "AccruedLiabilitiesLineItems",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "accrued liabilities [Table]",
        "label": "accrued liabilities [Table]",
        "terseLabel": "Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "AccruedLiabilitiesTable",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "lxrx_AccruedResearchAndDevelopmentServicesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development services current",
        "label": "Accrued research and development services current",
        "terseLabel": "Accrued research and development services current"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentServicesCurrent",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_CashAndCashEquivalentsAndInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash and Cash Equivalents and Investments [Abstract]",
        "label": "Cash and Cash Equivalents and Investments [Abstract]",
        "terseLabel": "Cash and Cash Equivalents and Investments [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAndInvestmentsAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_CollaborationAndLicenseAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration and License Agreements [Abstract]",
        "label": "Collaboration and License Agreements [Abstract]",
        "terseLabel": "Collaboration and License Agreements [Abstract]"
       }
      }
     },
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedBalanceSheetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Balance Sheets [Abstract]",
        "label": "Consolidated Balance Sheets [Abstract]",
        "terseLabel": "Consolidated Balance Sheets [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedBalanceSheetsAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Operations [Abstract]",
        "label": "Consolidated Statements of Operations [Abstract]",
        "terseLabel": "Consolidated Statements of Operations [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfOperationsAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConsolidatedStatementsOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "label": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]",
        "terseLabel": "Consolidated Statements of Stockholders\u2019 Equity [Abstract]"
       }
      }
     },
     "localname": "ConsolidatedStatementsOfStockholdersEquityAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_ConvDebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conv Debt Instrument Interest Rate Stated Percentage - contractual interest rate for convertible debt bonds under the debt agreement",
        "label": "Conv Debt Instrument Interest Rate Stated Percentage",
        "terseLabel": "Conv Debt Instrument Interest Rate Stated Percentage"
       }
      }
     },
     "localname": "ConvDebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange",
        "label": "Convertible debt exchange",
        "terseLabel": "Convertible debt exchange"
       }
      }
     },
     "localname": "ConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeRemainingNotes": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange Remaining Notes",
        "label": "Convertible debt exchange Remaining Notes",
        "terseLabel": "Convertible debt exchange Remaining Notes"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeRemainingNotes",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberCashPortion": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange- September cash portion",
        "label": "Convertible debt exchange- September cash portion",
        "terseLabel": "Convertible debt exchange- September cash portion"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberCashPortion",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ConvertibleDebtExchangeSeptemberSharePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange - September share payment",
        "label": "Convertible debt exchange - September share payment",
        "terseLabel": "Convertible debt exchange - September share payment"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeSeptemberSharePayment",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_ConvertibleDebtExchangeTotalPrincipalAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible debt exchange - Total Principal Amount",
        "label": "Convertible debt exchange - Total Principal Amount",
        "terseLabel": "Convertible debt exchange - Total Principal Amount"
       }
      }
     },
     "localname": "ConvertibleDebtExchangeTotalPrincipalAmount",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_DebtObligationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Obligations [Abstract]",
        "label": "Debt Obligations [Abstract]",
        "terseLabel": "Debt Obligations [Abstract]"
       }
      }
     },
     "localname": "DebtObligationsAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_FairValueMeasurementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Measurements [Abstract]",
        "label": "Fair Value Measurements [Abstract]",
        "terseLabel": "Fair Value Measurements [Abstract]"
       }
      }
     },
     "localname": "FairValueMeasurementsAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_FinalPaymentWithExtention": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Payment % with extention",
        "label": "Final Payment % with extention",
        "terseLabel": "Final Payment % with extention"
       }
      }
     },
     "localname": "FinalPaymentWithExtention",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_FinalPaymentWithNoExtention": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Final Payment % with no extention",
        "label": "Final Payment % with no extention",
        "terseLabel": "Final Payment % with no extention"
       }
      }
     },
     "localname": "FinalPaymentWithNoExtention",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_FutureConvertibleDebtExchange": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "future convertible debt exchange",
        "label": "future convertible debt exchange",
        "terseLabel": "future convertible debt exchange"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchange",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_FutureConvertibleDebtExchangeShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Convertible debt exchange shares",
        "label": "Future Convertible debt exchange shares",
        "terseLabel": "Future Convertible debt exchange shares"
       }
      }
     },
     "localname": "FutureConvertibleDebtExchangeShares",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_GainOnSaleOfNonFinancialAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on sale of non-financial assets",
        "label": "Gain on sale of non-financial assets",
        "negatedTerseLabel": "Gain on sale of non-financial assets",
        "terseLabel": "Gain on sale of non-financial assets"
       }
      }
     },
     "localname": "GainOnSaleOfNonFinancialAssets",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_InitialRecognitionOfRightOfUseAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial recognition of right of use asset",
        "label": "Initial recognition of right of use asset",
        "terseLabel": "Initial recognition of right of use asset"
       }
      }
     },
     "localname": "InitialRecognitionOfRightOfUseAsset",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMaximumSalesMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the maximum sales milestones payments.",
        "label": "Ipsen Maximum Sales Milestones",
        "terseLabel": "Ipsen Maximum Sales Milestones"
       }
      }
     },
     "localname": "IpsenMaximumSalesMilestones",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the milestone payments received under the agreement.",
        "label": "Ipsen Milestone Payment",
        "terseLabel": "Ipsen Milestone Payment"
       }
      }
     },
     "localname": "IpsenMilestonePayment",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenMilestonePaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl outside the United States and Japan. This represents the amount of milestone payments earned during the period.",
        "label": "Ipsen Milestone Payment Received",
        "terseLabel": "Ipsen Milestone Payment Received"
       }
      }
     },
     "localname": "IpsenMilestonePaymentReceived",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueAllocatedtoDevelopmentDeliverable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the amount of the upfront payment allocated to the development services deliverable.",
        "label": "Ipsen Revenue Allocated to Development Deliverable",
        "terseLabel": "Ipsen Revenue Allocated to Development Deliverable"
       }
      }
     },
     "localname": "IpsenRevenueAllocatedtoDevelopmentDeliverable",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat etiprate (LX1032) outside the United States and Japan. This represents the revenue recognized in the period.",
        "label": "Ipsen Revenue Recognized",
        "terseLabel": "Ipsen Revenue Recognized"
       }
      }
     },
     "localname": "IpsenRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_IpsenTotalPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In October 2014, Lexicon entered into a License and Collaboration Agreement with Ipsen Pharma SAS for the development and commercialization of Lexicon's drug candidate telotristat ethyl. This represents the total payments received to date under the agreement.",
        "label": "Ipsen Total Payments",
        "terseLabel": "Ipsen Total Payments"
       }
      }
     },
     "localname": "IpsenTotalPayments",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_LexiconIncrementalBorrowingRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lexicon incremental borrowing rate",
        "label": "Lexicon incremental borrowing rate",
        "terseLabel": "Lexicon incremental borrowing rate"
       }
      }
     },
     "localname": "LexiconIncrementalBorrowingRate",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_LiabilitiesAssumedByTerSera": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities assumed by TerSera",
        "label": "Liabilities assumed by TerSera",
        "terseLabel": "Liabilities assumed by TerSera"
       }
      }
     },
     "localname": "LiabilitiesAssumedByTerSera",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_Sanofiterminationcashpayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_Sanofi termination cash payment - represents the cash payment from Sanofi to terminate the collaboration alliance",
        "label": "lxrx_Sanofi termination cash payment",
        "terseLabel": "Sanofi termination cash payment"
       }
      }
     },
     "localname": "Lxrx_Sanofiterminationcashpayment",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails",
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Lxrx_sanofiInitialCashPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "lxrx_sanofi initial cash payment",
        "label": "lxrx_sanofi initial cash payment",
        "terseLabel": "lxrx_sanofi initial cash payment"
       }
      }
     },
     "localname": "Lxrx_sanofiInitialCashPayment",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Netproductrevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net product revenue - amount of revenue recognized from product sales, net of discounts. Sales process constitutes an earnings process.",
        "label": "Net product revenue",
        "terseLabel": "Net product revenue"
       }
      }
     },
     "localname": "Netproductrevenue",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OtherCapitalAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Capital Agreements",
        "label": "Other Capital Agreements [Text Block]",
        "terseLabel": "Other Capital Agreements"
       }
      }
     },
     "localname": "OtherCapitalAgreementsTextBlock",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "lxrx_OxfordFacilityFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Facility Fee",
        "label": "Oxford Facility Fee",
        "terseLabel": "Oxford Facility Fee"
       }
      }
     },
     "localname": "OxfordFacilityFee",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_OxfordLoanFacility": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oxford Loan Facility",
        "label": "Oxford Loan Facility",
        "terseLabel": "Oxford Loan Facility"
       }
      }
     },
     "localname": "OxfordLoanFacility",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_PrincipalAmountOfConvertibleNotes": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "principal amount of convertible notes",
        "label": "principal amount of convertible notes",
        "terseLabel": "principal amount of convertible notes"
       }
      }
     },
     "localname": "PrincipalAmountOfConvertibleNotes",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromJanuary2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from January 2021 ATM Offering",
        "label": "Proceeds from January 2021 ATM Offering",
        "terseLabel": "Proceeds from January 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromNov2020ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Nov 2020 ATM Offering",
        "label": "Proceeds from Nov 2020 ATM Offering",
        "terseLabel": "Proceeds from Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ProceedsFromSeptember2021ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from September 2021 ATM Offering",
        "label": "Proceeds from September 2021 ATM Offering",
        "terseLabel": "Proceeds from September 2021 ATM Offering"
       }
      }
     },
     "localname": "ProceedsFromSeptember2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_RecentAccountingPronouncementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recent Accounting Pronouncements [Abstract]",
        "label": "Recent Accounting Pronouncements [Abstract]",
        "terseLabel": "Recent Accounting Pronouncements [Abstract]"
       }
      }
     },
     "localname": "RecentAccountingPronouncementsAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_SanofiDisputedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sanofi Disputed Costs",
        "label": "Sanofi Disputed Costs",
        "terseLabel": "Sanofi Disputed Costs"
       }
      }
     },
     "localname": "SanofiDisputedCosts",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SanofiRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In November 2015, Lexicon entered into a Collaboration and License Agreement with Sanofi for the worldwide development of Lexicon's diabetes drug candidate sotagliflozin. This represents the revenue recognized in the period.",
        "label": "Sanofi Revenue Recognized",
        "terseLabel": "Sanofi Revenue Recognized"
       }
      }
     },
     "localname": "SanofiRevenueRecognized",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Abstract]"
       }
      }
     },
     "localname": "ScheduleofSharebasedPaymentAwardStockOptionsValuationAssumptionsAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_Sellinggeneralandadministrativeexpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Selling, general and administrative expenses - the expenses related to selling Lexicon's product as well as general and administrative costs.",
        "label": "Selling, general and administrative expenses",
        "terseLabel": "Selling, general and administrative, including stock-based compensation of $1,740, and $1,565, respectively"
       }
      }
     },
     "localname": "Sellinggeneralandadministrativeexpenses",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SettlementPaymentFromTermination": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement Payment from Termination",
        "label": "Settlement Payment from Termination",
        "terseLabel": "Settlement Payment from Termination"
       }
      }
     },
     "localname": "SettlementPaymentFromTermination",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the employees' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateEmployees",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the officers' and non-employee directors' option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermEmployees",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expected term assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTermOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For officers and non-employee directors, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For employees, the estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, ExpectedVolatilityRate, Employees"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedvolatilityrateEmployees",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for employees.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateEmployee",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares for officers and non-employee directors.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Officers and Non-employee Directors"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateOfficersAndNonEmployeeDirectors",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_SharePriceInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in January 2021 ATM Offering",
        "label": "Share price in January 2021 ATM Offering",
        "terseLabel": "Share price in January 2021 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharePriceInNovember20ATMOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share price in November 20 ATM Offering",
        "label": "Share price in November 20 ATM Offering",
        "terseLabel": "Share price in November 20 ATM Offering"
       }
      }
     },
     "localname": "SharePriceInNovember20ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharePriceInSeptember2021ATMOfferring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Price in September 2021 ATM Offerring",
        "label": "Share Price in September 2021 ATM Offerring",
        "terseLabel": "Share Price in September 2021 ATM Offerring"
       }
      }
     },
     "localname": "SharePriceInSeptember2021ATMOfferring",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SharesSoldInJanuary2021ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in January 2021 ATM offering",
        "label": "Shares sold in January 2021 ATM offering",
        "terseLabel": "Shares sold in January 2021 ATM offering"
       }
      }
     },
     "localname": "SharesSoldInJanuary2021ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInNov2020ATMOffering": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in Nov 2020 ATM Offering",
        "label": "Shares sold in Nov 2020 ATM Offering",
        "terseLabel": "Shares sold in Nov 2020 ATM Offering"
       }
      }
     },
     "localname": "SharesSoldInNov2020ATMOffering",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_SharesSoldInSeptember2021ATMOfferring": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares sold in September 2021 ATM Offerring",
        "label": "Shares sold in September 2021 ATM Offerring",
        "terseLabel": "Shares sold in September 2021 ATM Offerring"
       }
      }
     },
     "localname": "SharesSoldInSeptember2021ATMOfferring",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/OtherCapitalAgreementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense included in research and development expense.",
        "label": "Stock-based compensation expense associated with research and development expense",
        "terseLabel": "Stock-based compensation expense associated with research and development expense"
       }
      }
     },
     "localname": "StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock-based compensation expense associated with selling, general and administrative expense",
        "label": "Stock-based compensation expense associated with selling, general and administrative expense",
        "terseLabel": "Stock-based compensation expense associated with selling, general and administrative expense"
       }
      }
     },
     "localname": "Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_SummaryOfSignificantAccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Significant Accounting Policies [Abstract]",
        "label": "Summary of Significant Accounting Policies [Abstract]",
        "terseLabel": "Summary of Significant Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesAbstract",
     "nsuri": "http://www.lexpharma.com/20220331",
     "xbrltype": "stringItemType"
    },
    "lxrx_TermLoanA": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A",
        "label": "Term Loan A",
        "terseLabel": "Term Loan A"
       }
      }
     },
     "localname": "TermLoanA",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanABWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A&amp;B Warrant %",
        "label": "Term Loan A&amp;B Warrant %",
        "terseLabel": "Term Loan A&amp;B Warrant %"
       }
      }
     },
     "localname": "TermLoanABWarrant",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_TermLoanADebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Debt Discount",
        "label": "Term Loan A Debt Discount",
        "terseLabel": "Term Loan A Debt Discount"
       }
      }
     },
     "localname": "TermLoanADebtDiscount",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanADebtIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Debt Issuance Costs",
        "label": "Term Loan A Debt Issuance Costs",
        "terseLabel": "Term Loan A Debt Issuance Costs"
       }
      }
     },
     "localname": "TermLoanADebtIssuanceCosts",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAFinalPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Final Payment",
        "label": "Term Loan A Final Payment",
        "terseLabel": "Term Loan A Final Payment"
       }
      }
     },
     "localname": "TermLoanAFinalPayment",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAInterestExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Interest Expense",
        "label": "Term Loan A Interest Expense",
        "terseLabel": "Term Loan A Interest Expense"
       }
      }
     },
     "localname": "TermLoanAInterestExpense",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanANetCashReceipt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Net Cash Receipt",
        "label": "Term Loan A Net Cash Receipt",
        "terseLabel": "Term Loan A Net Cash Receipt"
       }
      }
     },
     "localname": "TermLoanANetCashReceipt",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanAWarrantExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Warrant Exercise Price",
        "label": "Term Loan A Warrant Exercise Price",
        "terseLabel": "Term Loan A Warrant Exercise Price"
       }
      }
     },
     "localname": "TermLoanAWarrantExercisePrice",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "lxrx_TermLoanAWarrantsNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan A Warrants Number",
        "label": "Term Loan A Warrants Number",
        "terseLabel": "Term Loan A Warrants Number"
       }
      }
     },
     "localname": "TermLoanAWarrantsNumber",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "lxrx_TermLoanB": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan B",
        "label": "Term Loan B",
        "terseLabel": "Term Loan B"
       }
      }
     },
     "localname": "TermLoanB",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanC": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan C",
        "label": "Term Loan C",
        "terseLabel": "Term Loan C"
       }
      }
     },
     "localname": "TermLoanC",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanCWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan C Warrant %",
        "label": "Term Loan C Warrant %",
        "terseLabel": "Term Loan C Warrant %"
       }
      }
     },
     "localname": "TermLoanCWarrant",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "lxrx_TermLoanD": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan D",
        "label": "Term Loan D",
        "terseLabel": "Term Loan D"
       }
      }
     },
     "localname": "TermLoanD",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "lxrx_TermLoanDWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term Loan D Warrant %",
        "label": "Term Loan D Warrant %",
        "terseLabel": "Term Loan D Warrant %"
       }
      }
     },
     "localname": "TermLoanDWarrant",
     "nsuri": "http://www.lexpharma.com/20220331",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r157",
      "r162",
      "r163",
      "r164",
      "r165",
      "r182",
      "r218",
      "r233",
      "r242",
      "r244",
      "r277",
      "r278",
      "r279",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r378",
      "r379",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r157",
      "r162",
      "r163",
      "r164",
      "r165",
      "r182",
      "r218",
      "r233",
      "r242",
      "r244",
      "r277",
      "r278",
      "r279",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r378",
      "r379",
      "r405",
      "r406"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r96",
      "r101",
      "r161",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r96",
      "r101",
      "r161",
      "r243",
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Statement, Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r23",
      "r335"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r144",
      "r145"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r355",
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.",
        "label": "Accrued Liabilities",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r7",
      "r155"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation and amortization, property and equipment"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r17",
      "r40",
      "r41",
      "r42",
      "r368",
      "r384",
      "r385"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r39",
      "r42",
      "r48",
      "r49",
      "r50",
      "r88",
      "r89",
      "r90",
      "r300",
      "r332",
      "r380",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Gain (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r15",
      "r335"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r281",
      "r282",
      "r283",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r246",
      "r285",
      "r286"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r221",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Payments of Stock Issuance Costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r178",
      "r221",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "terseLabel": "Adjustments to Additional Paid in Capital, Warrant Issued"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "auth_ref": [
      "r72",
      "r202",
      "r211",
      "r212",
      "r325"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "terseLabel": "Amortization of debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r72",
      "r154"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset Impairment Charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r10",
      "r84",
      "r130",
      "r133",
      "r139",
      "r148",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r297",
      "r301",
      "r315",
      "r333",
      "r335",
      "r350",
      "r366"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r22",
      "r84",
      "r148",
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r297",
      "r301",
      "r315",
      "r333",
      "r335"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.",
        "label": "Available-for-Sale Securities",
        "terseLabel": "Short-term Investments"
       }
      }
     },
     "localname": "AvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-Sale Securities, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt and equity securities classified as available-for-sale.",
        "label": "Available-for-Sale Securities, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAmortizedCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the cost of debt and equity securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.",
        "label": "Available-for-Sale Securities, Amortized Cost Basis",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.",
        "label": "Available-for-Sale Securities, Current",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardDateAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Axis]",
        "terseLabel": "Award Date [Axis]"
       }
      }
     },
     "localname": "AwardDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardDateDomain": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date or year award under share-based payment arrangement is granted.",
        "label": "Award Date [Domain]",
        "terseLabel": "Award Date [Domain]"
       }
      }
     },
     "localname": "AwardDateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Business Exit Costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r6",
      "r74"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents at beginning of period",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.",
        "label": "Cash and Cash Equivalents Disclosure [Text Block]",
        "terseLabel": "Cash and Cash Equivalents Disclosure"
       }
      }
     },
     "localname": "CashAndCashEquivalentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.",
        "label": "Cash and Cash Equivalents, Period Increase (Decrease) (Deprecated 2022)",
        "terseLabel": "Cash and Cash Equivalents, Period Increase (Decrease)",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r82",
      "r84",
      "r104",
      "r105",
      "r106",
      "r108",
      "r110",
      "r116",
      "r117",
      "r118",
      "r148",
      "r167",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r315",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r292",
      "r293",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaborative Arrangement Disclosure"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CollaborationandLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r33",
      "r356",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r158",
      "r159",
      "r160",
      "r166",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies Disclosure"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r88",
      "r89",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r14",
      "r335"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 225,000 shares authorized; 150,082 and 150,082 shares issued, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r44",
      "r46",
      "r47",
      "r54",
      "r358",
      "r375"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r78",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r234",
      "r241",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r56",
      "r348"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales (including finite-lived intangible asset amortization)"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r196",
      "r203",
      "r204",
      "r206",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Disclosure"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionPrice1": {
     "auth_ref": [
      "r181",
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the debt instrument.",
        "label": "Debt Instrument, Convertible, Conversion Price",
        "terseLabel": "Debt Instrument, Convertible, Conversion Price"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionPrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DebtInstrumentConvertibleConversionRatio1": {
     "auth_ref": [
      "r30",
      "r181",
      "r222",
      "r223",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount.",
        "label": "Debt Instrument, Convertible, Conversion Ratio",
        "terseLabel": "Debt Instrument, Convertible, Conversion Ratio"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r194",
      "r209",
      "r210",
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Debt Instrument, Fair Value Disclosure"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateDuringPeriod": {
     "auth_ref": [
      "r29",
      "r199",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average effective interest rate during the reporting period.",
        "label": "Debt Instrument, Interest Rate During Period",
        "terseLabel": "Debt Instrument, Interest Rate During Period"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r29",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Debt Instrument, Interest Rate, Stated Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r31",
      "r83",
      "r86",
      "r179",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r186",
      "r192",
      "r193",
      "r194",
      "r195",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r205",
      "r209",
      "r210",
      "r211",
      "r212",
      "r222",
      "r224",
      "r225",
      "r226",
      "r323",
      "r324",
      "r326",
      "r327",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r72",
      "r129"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r55",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r102",
      "r104",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r306",
      "r307",
      "r359",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per common share, Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r55",
      "r93",
      "r94",
      "r95",
      "r96",
      "r97",
      "r104",
      "r108",
      "r109",
      "r110",
      "r113",
      "r114",
      "r306",
      "r307",
      "r359",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r48",
      "r49",
      "r50",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r115",
      "r149",
      "r221",
      "r227",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r305",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r332",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r308",
      "r313",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r308",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table Text Block]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r194",
      "r209",
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r309",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r194",
      "r234",
      "r235",
      "r240",
      "r241",
      "r309",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r194",
      "r209",
      "r210",
      "r234",
      "r235",
      "r240",
      "r241",
      "r309",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r194",
      "r209",
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r309",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis.",
        "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]",
        "terseLabel": "Fair Value, Measurement Inputs, Disclosure"
       }
      }
     },
     "localname": "FairValueMeasurementInputsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r194",
      "r209",
      "r210",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r72",
      "r213",
      "r214"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedTerseLabel": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r8",
      "r150",
      "r151",
      "r152",
      "r153",
      "r335",
      "r349"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Decrease in accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "(Increase) decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "(Increase) decrease in inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Decrease in other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "(Increase) decrease in prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r51",
      "r128",
      "r322",
      "r325",
      "r360"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r67",
      "r69",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r308"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets held for their financial return, rather than for the entity's operations.",
        "label": "Investments [Member]",
        "terseLabel": "Total Cash and Cash Equivalents and Investments"
       }
      }
     },
     "localname": "InvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims": {
     "auth_ref": [
      "r72"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.",
        "label": "Issuance of Stock and Warrants for Services or Claims",
        "terseLabel": "Issuance of Stock and Warrants for Services or Claims"
       }
      }
     },
     "localname": "IssuanceOfStockAndWarrantsForServicesOrClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due after Year Five"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Four"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Three"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "Lessee, Operating Lease, Liability, Payments, Due Year Two"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r26",
      "r84",
      "r134",
      "r148",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r298",
      "r301",
      "r302",
      "r315",
      "r333",
      "r334"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r84",
      "r148",
      "r315",
      "r335",
      "r352",
      "r370"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r5",
      "r28",
      "r84",
      "r148",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r298",
      "r301",
      "r302",
      "r315",
      "r333",
      "r334",
      "r335"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityFairValueOfAmountOutstanding": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of the amount outstanding under the credit facility.",
        "label": "Line of Credit Facility, Fair Value of Amount Outstanding",
        "terseLabel": "Line of Credit Facility, Fair Value of Amount Outstanding"
       }
      }
     },
     "localname": "LineOfCreditFacilityFairValueOfAmountOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r24"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of Credit Facility, Maximum Borrowing Capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r11",
      "r193",
      "r207",
      "r209",
      "r210",
      "r351",
      "r367"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-Term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Long-term Debt and Lease Obligation"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r25"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Current portion of long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r11"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "negatedTerseLabel": "Long-term debt, net of deferred issuance costs",
        "terseLabel": "Long-term debt, net of deferred issuance costs"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtPercentageBearingFixedInterestRate": {
     "auth_ref": [
      "r29"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.",
        "label": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate",
        "terseLabel": "Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate"
       }
      }
     },
     "localname": "LongTermDebtPercentageBearingFixedInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtTerm": {
     "auth_ref": [
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of long-term debt, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Long-Term Debt, Term",
        "terseLabel": "Long-Term Debt, Term"
       }
      }
     },
     "localname": "LongTermDebtTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r68",
      "r70",
      "r73"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r43",
      "r45",
      "r50",
      "r53",
      "r73",
      "r84",
      "r91",
      "r93",
      "r94",
      "r95",
      "r96",
      "r99",
      "r100",
      "r107",
      "r130",
      "r132",
      "r135",
      "r138",
      "r140",
      "r148",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r307",
      "r315",
      "r357",
      "r374"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Pronouncements, Policy"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/RecentAccountingPronouncementsLevel1Notes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r130",
      "r132",
      "r135",
      "r138",
      "r140"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating Lease, Liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r329"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Operating Lease, Liability, Current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r27"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other Accrued Liabilities, Current"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesAccruedLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r21",
      "r335"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Commitments [Line Items]",
        "terseLabel": "Other Commitments [Line Items]"
       }
      }
     },
     "localname": "OtherCommitmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherCommitmentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about obligations resulting from other commitments.",
        "label": "Other Commitments [Table]",
        "terseLabel": "Other Commitments [Table]"
       }
      }
     },
     "localname": "OtherCommitmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r37",
      "r38",
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r13",
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r13",
      "r335"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value; 5,000 shares authorized; no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from Convertible Debt"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r64"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from debt borrowings, net of fees"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "terseLabel": "Proceeds from Sale of Productive Assets"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r156",
      "r335",
      "r363",
      "r371"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net of accumulated depreciation and amortization of $4,962 and $4,853, respectively"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "terseLabel": "Realized Investment Gains (Losses)"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election not to recognize asset and liability at acquisition for lease with remaining lease term of one year or less.",
        "label": "Recognition of Asset and Liability for Lease of Acquiree [Policy Text Block]",
        "terseLabel": "Recognition of Asset and Liability for Lease of Acquiree"
       }
      }
     },
     "localname": "RecognitionOfAssetAndLiabilityForLeaseOfAcquireePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of debt borrowings, net of fees"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r288",
      "r347",
      "r407"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development, including stock-based compensation of $1,032, and $1,286, respectively"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r16",
      "r227",
      "r335",
      "r369",
      "r383",
      "r385"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r149",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r305",
      "r380",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r126",
      "r127",
      "r131",
      "r136",
      "r137",
      "r141",
      "r142",
      "r143",
      "r230",
      "r231",
      "r348"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Collaborative agreements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r52",
      "r84",
      "r126",
      "r127",
      "r131",
      "r136",
      "r137",
      "r141",
      "r142",
      "r143",
      "r148",
      "r167",
      "r168",
      "r169",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r315",
      "r361"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "terseLabel": "Royalties and other revenue"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Schedule of Cash, Cash Equivalents and Short-term Investments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Investments [Line Items]",
        "terseLabel": "Schedule of Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInvestmentsTable": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A container table for all schedule of investment items. It ties in the \"Legal Entity [Axis]\" to all of its contained line items.",
        "label": "Schedule of Investments [Table]",
        "terseLabel": "Schedule of cash and cash equivalents and investments",
        "verboseLabel": "Schedule of Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1",
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r252",
      "r268",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesEquityIncentiveAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuredLongTermDebt": {
     "auth_ref": [
      "r31"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.",
        "label": "Secured Long-Term Debt, Noncurrent",
        "terseLabel": "Secured Long-Term Debt, Noncurrent"
       }
      }
     },
     "localname": "SecuredLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r265"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r262",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r266"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r251",
      "r274",
      "r275",
      "r276",
      "r277",
      "r280",
      "r284",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r21",
      "r353",
      "r354",
      "r365"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Total Short-term Investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCommitmentAmount": {
     "auth_ref": [
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease commitment.",
        "label": "Short-Term Lease Commitment, Amount",
        "terseLabel": "Short-term Lease Commitment, Amount"
       }
      }
     },
     "localname": "ShortTermLeaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r77",
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesNotes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r12",
      "r13",
      "r14",
      "r82",
      "r84",
      "r104",
      "r105",
      "r106",
      "r108",
      "r110",
      "r116",
      "r117",
      "r118",
      "r148",
      "r167",
      "r171",
      "r172",
      "r173",
      "r176",
      "r177",
      "r216",
      "r217",
      "r219",
      "r220",
      "r221",
      "r315",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails2",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r35",
      "r48",
      "r49",
      "r50",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r100",
      "r115",
      "r149",
      "r221",
      "r227",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r305",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r332",
      "r380",
      "r381",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r88",
      "r89",
      "r90",
      "r115",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r221",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r13",
      "r14",
      "r221",
      "r227",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r13",
      "r14",
      "r221",
      "r227"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock under Equity Incentive Plans, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r13",
      "r14",
      "r227",
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r13",
      "r14",
      "r221",
      "r227",
      "r228"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Stock Issued During Period, Value, Treasury Stock Reissued"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r14",
      "r18",
      "r19",
      "r84",
      "r146",
      "r148",
      "r315",
      "r335"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total stockholder's equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r49",
      "r84",
      "r88",
      "r89",
      "r90",
      "r92",
      "r98",
      "r148",
      "r149",
      "r227",
      "r281",
      "r282",
      "r283",
      "r289",
      "r290",
      "r295",
      "r296",
      "r303",
      "r305",
      "r315",
      "r316",
      "r317",
      "r321",
      "r332",
      "r381",
      "r382"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance, value",
        "periodStartLabel": "Balance, value"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubordinatedBorrowingInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stated interest rate of the subordinated debt.",
        "label": "Subordinated Borrowing, Interest Rate",
        "terseLabel": "Subordinated Borrowing, Interest Rate"
       }
      }
     },
     "localname": "SubordinatedBorrowingInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/DebtObligationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalIncomeStatementElementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Income Statement Elements [Abstract]",
        "terseLabel": "Supplemental Income Statement Elements [Abstract]"
       }
      }
     },
     "localname": "SupplementalIncomeStatementElementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeAxis": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of trading activity.",
        "label": "Trading Activity [Axis]",
        "terseLabel": "Trading Activity, by Type [Axis]"
       }
      }
     },
     "localname": "TradingActivityByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TradingActivityByTypeDomain": {
     "auth_ref": [
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains and losses on trading activities (including both derivative and nonderivative instruments) recognized in the statement of financial performance, separately by major types of items (such as fixed income/interest rates, foreign exchange, equity, commodity, and credit).",
        "label": "Trading Activity, by Type [Domain]",
        "terseLabel": "Trading Activity, by Type [Domain]"
       }
      }
     },
     "localname": "TradingActivityByTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r34",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r34",
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r34",
      "r228",
      "r229"
     ],
     "calculation": {
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 488 and 1,165 shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r221",
      "r227",
      "r228"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofStockholdersEquityDeficitUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r85",
      "r234",
      "r241",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury Securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/CashandCashEquivalentsandInvestmentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r119",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r269",
      "r270",
      "r272",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationSummaryDetails1",
      "http://www.lexpharma.com/role/SummaryofSignificantAccountingPoliciesStockbasedCompensationValuationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r103",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted Average Number of Shares Outstanding, Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r102",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing net loss per common share, Basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.lexpharma.com/role/ConsolidatedStatementsofComprehensiveLossUnaudited"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 5
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031898-161870"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12317-112629"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126972273&loc=d3e12355-112629"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "https://asc.fasb.org/topic&trid=2122478"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28B",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128091968&loc=SL77931625-128468"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "https://asc.fasb.org/topic&trid=5833765"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "820",
   "URI": "https://asc.fasb.org/topic&trid=2155941"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918705-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611133-123010"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r408": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r409": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r410": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r411": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r412": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r413": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r414": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>47
<FILENAME>0001062822-22-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001062822-22-000022-xbrl.zip
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M78+TPXHLD#_PJR^(<7U'=7-\KV[NU8W;"#L@0G=?W1SOC+KQT.=>["J.!A6
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MFO(N"B_A>OC"\VSM]1AE1C N)@F:SK-LAES:XV _#,^'29@]"QR#&;QEF$G
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MP,U8ZU>4/<.OZ$[ZYE_P=H2OHIANV#>/2BC8>O/2#?!:+2<'Q[)&J@^8-O:
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M\5Y_M\$X&YV>+1V5KD]B:]29VI-"53V4H7U5]K+YP5!DR(+#OC>N4:J% '9
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MC2"^&^W9>PS,KF%@=KA]X3!8[*@L'&>M/8PVI*20WMZ6!F!*<K0?!$7+H<K
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MMCB:POZ#A:A<%^%:<LLKKGA1Q112=/A*;PZW<-!;XB_L<<+;65_1P,+C&I.
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ME_\XB8[>_N/DS>&;L]/OL'EVP?KN7[RN^^*SQ*(WPX&:P5 S)L32,BS04\B
M@K0Y5S]0NHY?OE=W2;0^U3_=89_HV=Y@6O@XJU6#;SLO<506EV85@^6%" 3,
M[)N8VW?,.*-6$X]R(.A3&CXW3D3 #J=_\U4<[0 VYTS&OB, G>KZLQ>=N>EF
M)C N:V4VL*!="E<%4, G()K6.]04$*;*>H^YOUE/L._JP.'#J[(J(CSO1#R&
MH65P #'8LYB3\T673L?>$]LL_"1ZPE=42MO?2RY!KNW%]$J_<I"OY'^U[V>M
MCA" X/&]$'BZ!2URT6A,'=*HTS&WQBT*^8[\@7<VAHT.)=S8?8"36#?.F_ O
MI1+EVHM"F;%X&VYF&!+%X3DP?C@>B7U0)*@6,D%N1K_?BLX)X*O5R^8NAZ*>
M[0VGBJ5%+_)#R]Z/P1PMDG.!0+_5F!X=7 MR?J4)_2W+:CS;)\6YL =O)%J,
MO1PO<G+$9T\R]G/D:Z(?$.C#)Z]QT+16Q5C9"N;D3*_ B3DG6?(,1$@J/P#]
M46/O"?X:Z_I!H%"C,ACC?QG+\22$1ZB3E-A!-(T_3!S4W"YB*T=$#6T&BOFS
MV@,4]D0PVD&+ /1N,R;2*7CD4G2<F?O#=8B\,PTBQXYK DW<Y7R>2!#4:VLF
M5!(2F[+[OM7WC%^-0EQ-.?UX4>9:->"*M2Y*&$#%VB"X*IO#'"*3%M43>T D
MAO;2# 4CNO+3641*$A78I\LFLA[_Y+)8ER6WI<<G!@/R'\LA.BDNT)AJV?/H
MRDZ!FY3V52'UWV0EH;^\G\( #XVK<E8F8V5L*6$L%>5N,/.67>(*>5S&,[U.
M[L)SAR81-E>?)HNL(?H:U._4]L?EC]P\H"9#:NZZ5SK0' [>,%@O;.HNU1ET
MS-V4C#L=[]A[4Z=KD#%]+3U?WW!'B@:L+TJ"$,.FR,K4@^Q0&3D+J2Y09RQL
M%H=C[ )(>0 EMB;Q; G@N'B-<Y-)527*#J1L+9\)"HU&(LLM'FGM34B;X%"P
MO)U^=X,.1S;_[XSMX("LP6Q96$ B![J/F6.(++,?UCEVN5]M2M\@N425U50B
MR$GVLCI/BNQ?"3,88A;7N]C_DAJ'5LLI[5O<HJL%.'RCX^ '.1B7.35$8%%X
M8K^E%P]O5RSG$P3<9(2*'(O+J,T%U@_U;ANJ@RG3UZ8Z%]_(0S1NV_RD44EN
M#NPW,N<V]'#GO3^U^1@6'6SUQ1X0:<.[VZO%?6[AZ9BWEN&T+*=)Z9&Y4IG.
M.4^*UG"<SO(-ML1S![U%VHL.?; #,8#WO+S*3[ZY#P:T)BE+ZV5UR=K7!V*A
M"22AE@X04F(/(1X2 1#VQ@DK5?A+'.]5KP+V@5?V9F/+)$H .WB)<1MV8SP4
MG@#6W5NP9$'%V@B*"ANNK(%N9(K<( P7:U6I#L)] J*%N^PE6@U.WV+CCB^@
MS_Q#2)?!OG,O87 3V+:%WPQ]2]%'0D^1RE]RM'&IA:J&N@()N1W3 KIAMP5#
MB!).P4(M@X/KQW1Z7OY.[H_!9F(GL!CSR2ZT$VMO#V[O3!(>[7]&E" ,Q*4T
MO7;%*U8E9(Z(^+TTW &"B9V(0H* !OB$<FY\V]-W3O G2@>[H4Z2/>C%:#N!
MQO ^GL6-AB/'"KP@IW/\AEN4V&XF* /!D!T-/]X%90,0KPM#=- RUINWS\?,
M\7I\#KO2+8\A<9P#ZN#'/EFT]25\_T%?1:MGO@8?VKC#*L[^>IIANW-M<&K_
M!=M*N.E$HU)X1G+J,_LU;I[-.M)RBVS:G^3*@O/>G"?G]#<!#NDO6E..'?<B
M6.\Q)K<&8[(S@!+8E<C9(:=S2AZ<)9NY&9]D+QK9"KZD)@O.QB.=L ES-!KU
M5'Z-%(YK88N0MIE/;,G-K9>[9'?<:1YL]O(Z(?9*[;C5P^2^;?]Y/0>]'IEK
MFP$_W7LJQ^5N[X1!DOEC9(#6KLT</O-2N=O=!9C#>R=]R-*,F#_3,##N/M46
M;J[ *PA@,!^9]O9*O9=F]I^5-LSQ^HQ2H!ZS,PB9;3*. <*.FUY@%)?;'GJ/
M" :&,=7*Z,7U\$95SL68\R<YQF(X[X>6%.H2NK=]+"HACM.#^8VQ@4O#W9[C
M36^ES2O1)JHRKO;A+ZKN9\L"36[+LQW[69=(:''E\?B #+9!4DFGZC*P2NLX
M"L,U_O2 !^!5N9P1=U8W^/PH"#Z/,$7%MB1W!50@--N*OD]RR:W#=8+DW<BJ
MM\T-T;S%XIP>X,""<-$6,> BUW6W%11B*&Q)G]N>G,GU^J//D]1P&P!>'M]^
M#E@(O&!ZAZBO$Q'SKJ8=C^GD 0O='@9WW(>B %8<W,2?N]OR=I#K]LS/\9%+
M=3C###(6"&Y9YQ[W;Q3/(W6K3_V.8$/3-G#X9R_-:=U%^WX;)H:"0 "J@" M
M:EWQ8:S6]19Y3T_UF(GY9MC4%<^W5Z3)LMH^N"@Y2T8NM1+XKB,2H?/$%9#8
MR77B]<>!_ZOFKK.X*<Z;BYY9Q+[*$KI.=#93&W3'0PZ/XYG +X[-I D4A8-F
M>3@5C^5>,[%92-O2G[*;ME8DF9>>%Q_UM;BCU:;+VHRB7ENBQG=])#X0=BG=
MH!CI+LB60=+=SB;8 0S6:U0SH=:P[5H+C4>'HXY5<R5S)7YV!*[B$EB@C<_)
M3'B;SD'@.!6?/["9*H9(H8+GUK8*<<(]RE46!.:P-7&UO6/& !GM;A)4VU^Y
M1CE^!P&/$L-Y^<ZQ=_7,7B"Q]<B8(U@P\#2#4^KPQ=;<2ORPH\>HV9V+K%:;
MY6X?H6'*RJ,2C,1L!^+YSX6^I=#LI1/CV#=K := TY>X<_4S!I4@T)QBU!O\
M//9VH6<+'LG]#MD9VO_I\4-F!9E3UPO:AO1#9K>IJ6NZJ/,,6TV0^T$@1(8D
M$3B/T@6\E:F(U7-KIN LH"U1G6/;!/:HB-]EINKRO3E?YGP,/S@&+VS0#O_@
MVJRRLH?H!?AN%7$#8!LCD PK< +F'&77MI#M/O9'/+(3'&JMO9A(\TME+'O(
MV%^;4_6&9<0\*[+Y<A[-EOR&(:G@+#IY__+T,+9"$,9$$X3&@V1Q*XP'JL[S
MC,0X"N= [H3&&*9ZW7AZ;'.?X:P7&4[-9^BWR":$.W_ED(LZ?R_0)'J%1*/8
M[J-(8;YKWA55=)F5N0+^6";ER14[DKI4Q(E! #"Z%B?URXK?^)5QF&G%#QM,
M;MJ+R"/$*H%LFBV$LZVPZT%?<#DT30+"^,,6#O[DDM7I>MG+SN&W=Q307B>!
M6%08<UXL>&>1-XQI%@16<#@YI58'%3</F^-U_'CTIF-5?-KLWMR<^#TPU3%A
M;)OD;625NW0?D]WK[T7KO9,3\US21Q8O<516"X^D-F/ *G+D21&#F[ZPOE(+
M.>^XJAJLC'*J2AS)HLG$2SB#;01S5\_AX%YMVZ_LX"O1A)H(\1I*H<WZ1ZH8
M#N)H;4$[. <,H!EN6ECF(!K$Q5D@*!,!DW%/=\<0H\[>7!Q=XN2LQ'.D1DY3
MU(S8\@I;4LY=_PNU7-6<1#9<AY[=;"HD\Y-19]X"15IN&T'XSQ/$.V=?"R(.
M0(.:H=O!P;_QXZ)6MS#_L?12U%B#&U7V-5>2=Q:!QLU<>CK&#N_I*+IY:]N8
M+F'L\"8054^QN"A&:&!M<ALJ&>T-KL31QX)*1\,XB^_AU'Z^'[>Q:WI8.@AQ
MW4G/YQG%/ 73__;%X5'T"CZJ]V[4KS5 N \Q)6:SM?$/#+'B:PJCET^;:W/^
M(>]J;\@HQK,W]%:1Q(J8K.B20]@:' &-GJ3UM\Z,TAU_QGQ -MU +A;P9.[+
MAD:TV:J(Q@V*<9VLIKUI)P\G-:6/,9#/2&7<,TQB1<RR!:*=*ZX4NRQS B[.
MP14 "R$A]T :M2PJZ2<+UC^-'<WGUG7?XTS'_8?Z'AAR#PRYZ1Q^744@51C4
M\"&L/ZQ:E8FM8J+4)+F2#]#WSW/PG;WXL#7<7:T,50&+>\8U@1_EG'(2S6NH
M2&]I<Z4S<G'A%&$7SUH*NRZIN(3S XHF\U!D?6.B]!F.G/RPTJ^8'WY9+]:G
M/I5"T2L+\Z(HMOUB(L_U[<836S7RML+ QYMR+]I_='#P6)=.XVI>>4DEX' V
M=H:L$BV&R\;>6PB8?8$)Y$Z5J?]ZI!G-99)*P/RRS%).N2F 3H(0E#>&ZV3)
MZ$):7OQ'@XT^F2),O//8CP=8Y!U&+8,J\+73LOZ][[B'-EA$[5DU;[6M)5O.
MAU0VM55R/U"V98," >L_K%_/"]UMF!9 6ZD^A"Q/Y#QE&FH7('E%FWFHGCIV
MO52))=,A6&E*8A**EUFZI((41J\&Z?C8I[8,"??/3-%/B^GH]O$TE7DJF>\>
M.-XV]O*6MNZ/>[>+RNCD'R=OSD[!ZH^.3UX<?GAU=O,IWGTI,\!JAD>SL'TK
M'.60U/T'[<F,%@:E4A@T<FF ;<)#VP5+NT [TYM?ONMT3#\.TS&]D^3MCK5Q
MQ2P&V3P8!+#0)IMIGKG(E6\K:@JZD_8IN55]NF3F!9N17@@:D366GP!>W_91
MR $H,N+_"O$D^!"*.@J"<:1$"'UWP@J'J=&"=$=:AES]W#J97YG'+F&2UTG#
MI1#*0N(8)688<3.YV":]+7U^VMNG6>7$-U;A'[O.:5@;*:-A3P(78LF6+GU'
M-J<L0^KJ%&G,W4:*,,G@G11E=T4HG#@QC)M+>P? U=]W^M@.T_E(_\6=Z5B)
MT8'=8W'>Q(EG40,7%.8<C4?+QLSMD^!']H![A1MU]'3O(!JYCIBGX'\K,/:]
M,O(>@06*'8L1#0C&ZM.]Q]'H+/DD_W@2C5X60@Q.'SR-1N)7P&E0Y#Y]\RP:
M@4';&,LDT$^$_YX0O/2+GZ+1&VF'.M2SFZ[;?^B_A>XK_@H$Q29=W/ABF(U-
M^Q$1EA5YT^'1'89T^M(NG/B\M<0N9-?[!33*I/05=NZM/0'#--4;5N.M.0-Q
M]-$89@4K)PR]<"H3T^JQ<R\)JLZ=PF*W6J4/:1)F$N6O"EQ1&6+8U,26RFLB
M155+0.2%813I#^[=6C?)CVH7>AFNFP^="8B1OX?U%+:D25B </;0:D@=HZ71
M G,!?-G1?I?_VX,>"!9M;=L;15_H$V XU+*!^4:*A+A-='S.BD$ !#Z?*734
MWB"4#OV>QY-FL+N)<4NC3GX@M'U7FLOVJUGCP>83/2LASSZ:7)I9A?=* H N
M=6QN@JZ#;!HQDJ2P[>A 8LFKB)7E+"@)4U 7.:E#:!,)C6E+\:O:Y?/'S&_A
MOVYKE/KT(4M)WSWHK2$$83<QEVI'+^8;3 P>\2PF,.9^]0Q*C_C"<XOT4+2L
MS5@@O7JLD#:>@$0SJQWT6+1@'N[C( ")5"3R*+0WDTDIM'?;EM1;->F&B6^N
MX0;?CD=V. 3;8L%5W]OH@UPCA]31V5''OC*7TM+L/99E8=24Z/O$';PWX7MG
M$?-H9XBAYKR4K1!#/C1C/@I4G+MGQT3C4,&[<=,L6[_&/^#$"26\-B4U8Y(%
M_)9Y>T2.2JJP?9?NSY'ZD7+&+IVG[2?]IC 6M^0A)?C[25)\=#'U3,*"9,@W
M _WM^MY#8_1(%M0MOW6DCXGRZ,%-\LP42(M]:<E$8 [G IIB<LWD'.^Y4=MD
MB5-DE2(I,3,E;',3CL*<6[@@W!@L(F%):K1+BIIPDVF>,#$>\:9*\9Y6T3/[
M7-QK>_4%<?J-,$SLU@R%(#NI;I*5(3/#B'ZLRN4Y(VN1M5,SK-&D+-(@ 3H>
MM.<V5_3,<3SP(KX%8$F9O[F.O0=2[#Z08F?$^[!_JM3'%LCLM2[O*_P;D"Y:
M_B<"!1%.I!&(F=? 4%.29)D#0F$U1LWP/-B+*-JTO;6O0:0&N?(D9,&UB8V
M"$R!S.ZUU%\GF;(;592UJ3<2C01G%["('O<^#OQ[ZWF0N.ME0;3:H#1VH$@N
M &2NK:2,J8E<P2Q^5Q<EM6Z75@"\0_7%&D<HOLF6FIASTO9%Y&8&XX3"N!_0
MCP]=A".!^RR+&^EY?$UT*D%_SC,X6+[Z5)V,_,Q^N]'18PV,;.H!@^F3NVH8
M&&D<A TWFVLT%F(WP_@K"EU2*523Y:Y"8W!^[%O>9RN&Z6G><HC7(IVW?$3/
MT,0C'=&36[_.I!\YJ]%\6F1:",-.@I_-J\<:@^JIY]SD(!'5*2/II6P< UBI
M?$0T)Q55XG%)$&U(BJ01P9]VH>W_#587L"%;5D+58:HI6*MIS*RRDD0T B>4
MA*.\ID\DJ77O7'P;P'<VH9S6>KRO4$-VI\_>("'0?R[3\UTX=+@98+&)I/]W
M'5/,1A0+[]1,X9S4%G+J9?L96>[OM$UP9;A;E41^D[TXPH. P<Q*&+QA71>&
M%I>/D:@LK6Z1C)7D)OA@NSHZRT2#AVG1>(VAW2^Q1C9#;A>KW"HN'[B9:^T:
MGE4&/7W07MR)/,/SO"PN$\Q :HVOZ&+BEK69@%G47!DL[QL=/.SD*. +XKV0
M[ARN<PB>W%YE':3W@X8 ?HOT.**196*2X\!L\P3=([$#Z_(&N5>TPVPTK[.Z
M,E*9NA-M>S8,#'EU3@F[0#/?FEL;V/HHR>'PQ6-LH$ %JS[!@N;H8=-2I3'%
MP;J)R+B;AA0)@Y]CQPD<HFOJ,M #6&U)(9"(^!!DZ.9U>SO[/_!8)QAXVW0@
M;;VY4B_K=J/9H#HA:BL\[586:^'S%>;C\#S?G[];P]AR^(T-7,X!26 V-'4[
MK?&NT5\45Q%.E$VC\Z1_I.-&\ODL*V1=]W5M#]A?9!QVC)9N3@9 QP[MDQO=
M-\+ X?1"9)AEC>&;>?A5\-;O])$;9GA18H(=B/L@JMOR)+1:GVD&YKK>9TI4
MP8J1&L#5M@\ ^T=R1PRD+,',@B^G##D50FXZ3J@!;%,H.RB!:CK5U5.CW1Z2
M"SPE[OW0'"M-K1UV^\!RI4,&>!)"A^+::=*IRBI085BY,D6 1#VMLDE E%Q'
M/^X]BN$_C_$_3_ _S^A,@C6D8JC%TQ$.UU:_XNMI2SY6C1F7RRP9Y!0RA3 M
MGL\,8N]XKP>'N2SZ.ZMO71NN^EN^^^@B<MDJ<UE^1(<)=M,T8WZD>EDOA"II
M7J869T9H)(Y%P! +217@L0!7SERY/HUM9D/VO^@$XY;;L7)V+X6XE<42(_:R
M5/^05J)FI!XO!?_-:S&U(L=1*]+\)SGI: Z1\6*07-J89&<];='GPT[_& )@
M$*!.K4G>2;>,+==%'FJKE"GU5$G#_E 3OP0D]/E8+/CEB<H4YA=H84?CC(D4
M4!/R)FJU9D$!X%F"5/A;-=8XT*94#5/I!!V>BU("*"4Q@,*O7Q$PHY?<E_N;
M<"@J;'#2Z6"R5O-WRD1#$(-8W@0_]#6WFA?+WD:,-H_K02411T(R%$4QC$T9
M6;)BR4=:T(?4KE/\U9A)Z[BW8O=K=M4SH@#K^7KK.*OMGMA!_.&Q03(6F*KM
MGE;">DESNAEFZ>>ET@<&!$<5=_$E^AC*G[\Y/#T^_/^B(^%P?YU4'PVZH5+.
M/ L NAXWGNPVN(V\?U1;6CR/2U3V-)SV,E^"]5"MY/G$U4 'CK5&?=^8YI;#
M9K:$DI$6M;3U&2I.70,M0Y+34H7T'Z6NX]/RO$" BQP2\TF;F;+9^:$@"DHJ
M3ZI1!>A-PYUN$R5L+%'7 $;HT5UZ#]<UDO36UM'_=,OJZ-^__/7O9Z?1X9OC
MZ/W)ZY/CER>GMU W_31<I+Q-C<0E=63=O<>ZC<Q\/E)[_^&/&YZ%!5:X%.</
M<C.#@>T]@:%><^^GS_"JW<-O?UA(U;*'L27>1*_F5^P]&V3I%,;T$#?.$VVB
MRA2NV@><&9@D>/->8W :;66*L6V2)GRGAE[]ZZ1\40KRQIPJW#3%;H2L7RJ_
M9["EI9 .Z,3Q1)%##R:.%W8*F;P6"D(.)02AT["] @BT'$TY?*A?2._3%'8*
MZA$BEO7ND][0(<8+-438?H[-NZ][H.U(CPD.OF5/F_A68'_LN*/Z7UWB27[(
MD=$V+H1:Q_R>J[C5O9$LT?223@QC(] Y)$)N9>/V$ZC6\5(6KSZ2# 8':)A6
M.'R&TSE]]*M#.<PO7;$_WHST[CN[#=+/W'+#BND+]<D?2UD-H]%_\_GT5#U)
M6ZR>9JNV/,4NJU__Z!%NV/I':4OS#?2A%\*V@X[7*D?\HJT@[U5C5S5R!ZSK
MM.,N'+V'NW_VLL&S!^<&C &LXZ<CX@G.VN1YR"FI^3LN$_<.P_J<W)?.UM<6
M@_L/'VUU+887P_(/$2VSSW $QP"EV23)B:V#91?7.(95E10B[M-87A$D4O<Y
MWNLRKUVO(%1\C"EF=F)[C?"S7G-G9E,+.4S%#I!_)=)Z-"@TDNHYV7G?;*G_
M<!MI>"=A!-<JN4558JJ#:>WZ:RIXH6M!R]O=)+?1ZJC>WWY-\^?;KM=V9?#T
MN]H_M36 L%)WLB5#Z':J]QO$DW9(D\,N:'*N8$]QV%@DM5@VHBS X<_FM>/-
MYKX0(HP1,XEM9 @<0>*?BN@Y*4E%71('K])!%8/B(Z/M" YA5J,+'VNO P]H
MS!K""AAQ&KN;W+J*E*3ES*G0#5H2'.;0QO%)XY#&]:.S:#Y^Q2]"#6T>0-SI
MG3.\==I4CV)?E.H(UU'F+W!AL-9(NDSXW#R8,R>ZM';FW3,KJ7-1WYJ&/_$;
M; @@H*[-G!X3WCOKD9"( B06<WP/>COL57"99#D-E! FN8!<,-G2<P,+4DD-
M0DVILVQ/%YYYHCU'%I699P@;O*)"M_8H:WX@E7KQ=*>.P[E5"^T5(H>WB35"
M%MNF;S&WOZ@;K:^&)<!QL%F&> C!)2P6)N&(S<0X;$.])%@Q8^1[ET:>2$(:
MT3I%317<I#W2/;=*YQ61$76U%>BU*?[*@>KQEJA_%BL?9*P3Z-0&,T'$W">7
M*^7T!X/R0O4F[DQ.'-R?_;6F8GV1+1#H11J"_BBI]!Z;V<+<S[(BJR\<WSA>
ML4BR"DG<X(^*(778(SSVCSFA\YJL]K_NG/"^OE#2UHIV$P',';3,?)KFRSI#
M,Z8J5TGNJIF1Y%5WF86<<T4F[)TE]7EK[:E.3')=&Q\E.@#Q8=!=6L"HJ9!N
M6BY6O.-PANJ/T559?41: FN]"0P"MRWVCHJQ64%*V*.*B-KYG_B5_F.>T"V4
M>D?^R3VG>%*I/0Q2J#F"08]TATDI$Q+:"^Z?5:M3Z8L2Y([G1GUX/_@A$2%(
MIS[_4<$"4UQ '8)0Q,LMB\)X;9<'#ZH]T3+?,F4]E&E@R6ZP7O?@CWOPQTWG
ML.^,!_L0E9X(%BF80>@_EI%>D#)R;<3 8ZIZ\7=Q7S<7SWV[5T^C[')0.U$U
M!6@!(=['T)5MV"MU_N+$>*4>&Y4 ><I*TZL^#Y=5-AH!X_)$(B3+-5&5&K_&
MR<;Y:P9#8K\Y^;=??,*"DZG,@JQ7IT9*F22IW6]IR<]"R7N_?T;#VX?##9%T
ME$12H9:MW5$KS\ORX_V9A#E=&Z8N,[+LE:@)MS41/J$55&"_&IYQ>+=_69.]
MSY61@@.Y2T WNQ(#CM9/N]@2C0QQ0<T7IN&X [)"4>4[V8QD$/'E_S)]<&N2
M&8L%2'7R!7-L.!5VY5W8"DC[6.RSQR]&@MQV%=NH8O*+Z>'^*#MJC1/BD/=*
M,QC&+V// T3&!8</4S?/\^\'*L/97)14A6O7'A)?TSHVVH$;$[58ONUM$.9[
MX$=VB'YQAX,Y/W+78Q2NK).\>P(&*A(;;1&QC=VRI;W1UT.KVSW+[Z71Z9_5
M%]@67?F9X>M.V$'M/[O\%78:QR=UN<]QC.IR^E@ S;+TP>1</Z*^]XA./C%-
M^)%7^X%U-C7ZF+;@S8>V+%"RTH3B,_%6\4YT,.IYD1WH8A3-32*Y5BG?K\(Z
M&PQ\QSK/7MQ325/ZXE(Q+@@\L<"@.W:CP<@!H[N]UO%]O9U5>W)>GG/Q0YR-
M;=7*H>^ZOU4EN"_+=)ESF'..E9@40YS"\Y3Z!<96(S.B$/ K-ZNQ%BV1"NE
MKI*Z\2A<R\H6?6S(*,#<!]Z,BME&6E="I!300YL: 7M)BC596+24@ 3- UX@
M"E\EY]QNB&*?=LW6+]1-RA/MNZ<PL<52VY3 7"Y-=T%N(LIO>:W33\/=<][Q
M-IA%ATU35H79-G> W9D2<LPJKGS%I1<3MR^<7=/^!?M@ML0J17X5H@5(IHTU
M4V@;?Z5D:U,*$CC!CJAIB>6PG\'22JWKQ6F>7ICIQ]JYKL@D0.:LI?^J;"K
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M9%MY2_NC9BH.-NQPT,OKJ&?MA>3^OO->>+\0ID_E(<9LGK;V[^2@/6&EPB=
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M4EYBZ?"M1$R?%D)IWT7:.U'3(NT#V6F[9(,\X_B^E8 /0KA;(=1U"7V0/_%
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MIH@D<7M-M#=1OO+.@MM>R TB'T@J-:^6IIFA$G)=HO WY%Y02M8FKR?&2[C
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MF25.*$!@8#K2C L@["?289]+$5E)3\/):TEP-Z(J1K%0N4\5("T3]:-KUU#
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MA/;]+*H3F0_VWBMPE:)U'-D4?F7U'31NWXW/Z"9[7(L0V<\#4^4!]X@R'5'
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MZ<RG@DR("9^VQSH A_P@%_'P[EMKW*8*_K?TTV-QH[RZQ9/F0OH99]HE8T0
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M_2N]R%MYD5.SP#T0;(;:-^2<"OU2$6?V]#1FN?594P0YOXG4K;@X@:X>!,G
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M;C\,.6O6'CT]J.>W:;;"_742Y=,RRVFG>F=TK#SZN6C?+X3=GRLEB@U/H&V
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M>.Q7WT7)>_@J!"H'R@*W<1.-,TT(LV@7D1]M[ 1!J/L^\):$1S=%.9W8/@Q
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MGV]?AWZ2; JWH9@^A%T9.O-/B[OZ0^?V#_UZ-\R[:#]!:.S[/#2GU&:'[_5
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M$8FEN[_+ SYNV?@-GQ3YCYO._@%02P,$%     @ ((&E5!G$[^RZ!P  ?R0
M !X   !E>&@S,3)C97)T:69I8V%T:6]N;V9P<FEN8RYH=&WM6FMOX[82_=Y?
MP7K1?0!^R8\\G&R -LFBN=CN;G-=+.ZG@A)'%AM*5$G*CN^OOS.D_(H=U(M@
M6V]P%UA'$H?#&<[AF2&E\^^O/EZ.__/IFF4N5^S3;S^]O[EDC5:G\[E_V>E<
MC:_8S^-?WK-!NQNQL>&%E4[J@JM.Y_I#@S4RY\I1IS.;S=JS?EN;26=\VR%5
M@X[2VD);.-&X.*<G^ M<7'QW_GVKQ:YT4N50.)88X X$JZPL)NRS 'O'6JU:
MZE*7<R,GF6.];J_'/FMS)Z<\M#OI%%PL])QWPOUYQP]R'FLQOS@7<LJD>-N0
M)T?'4??X.!U&_>&@.S@^C89Q>L3C0?=XV$U.NK]':&0'Q4,?Z^8*WC9R6;0R
MH/%'@U[[>%BZLYD4+AM%W>X/#2]Z<9[JPN%X!ON'RZ!F6QDW$]07:^=TCAI0
MF8-[U^)*3HJ1][(1M"UZ)%II,WK1]?_.J*65\ERJ^>C56.9@V0>8L5N=\^)5
MTV)D6A:,3(.@E?^%,(B_G04OCE&/D@4LO(IZY,?U?29CZ5@_:O<VG=C;_ 1#
M .8?LO_R^G9\\^[F\L?QS<</_][3@]--!_ZHK)/I_*M[,-CIP4V3_0O2U,"<
MO6^SSUQ DR5@R"+F,NY>OAB>G'V!8R47 I=32T'J1OVCA:NR$!BG42LZ*;\^
MUG9[&K47;OS]HV].2]1M#VD:;EC&I\ ,3"7,D(A<)BW[M>(& :WF[!9*;1S3
M!7NG3<ZB;NM7IE/V'NYE@@\_9=SD/('*R80KVV0W1=+&<)T^CW#U#BY</W&+
M0<*9S^?LKM S!6*"J\5'S818"8TF%!IS"X[ 9<%X,6=5X4P%Z %F&Y]X,(B<
MY7AG)%<LY0D^,DSG2(1.![DM@0(2L):;.8GD_ YPW#6=%I_1TL4AE<]:. 8)
M)-)@ED*Q KNC)0(,FV4RR9BMZ&?5?P8&:B7D0"ZMPG1&F7$F788.VA(2;R#I
M+=$T+=#-*783+)ZO3X,'(7L6*.Q_.R@$ELH"XTR06<6UB1!$<6PV:^VR2)%2
M.-53>)VH2J!.Q,Y:$)N(.TDT5&+H";6$9J56L*P181\,C<@7OE!KDD2E4 "Q
MJ!$P?CCK[4FXS5BJ],PN@&I@(JW#*L\Q3@^#W6AE<PUO=F',EK4!<L\#<X.#
MP]QX(T"O;(VGNDX@CM!I*O$V1/>&<0,>'QAO&2N@.#) 4,9*VHSD22Q'@B22
MI'LA;:*TK; ?4:?1*J@JC4Y X&/+7B,N!"#00O"O[Y.,%Q-@/R(KW58*):(^
M;T7#U_#&=XV&(MR%6TEE8A$ 2OH94=<:;@..R):]!THW!DIQ(/+S(9I1@M+\
MDPJIX>" \,G?'! ^>P.:!]R[82F-\?)9[:_!U*2$F_#*[M^%,E\,;#E2R*6Z
M,J@ V6DJK><\E(+"ZZ'J><66ZXQK0'&/M#J9KM#2K-F8&B4R)]IBM9+"[U-M
M%5LI)#>2') AY?L<4)"FRE(:]BO3^ISM&1(WPF@0[E!]IQ)K2YE4BA.QHUO>
MB%4ZQQZA.%BO:? J!A)$[L7^()Y48QX4DN.#0?)I^^AX&\A[<]86GO=GN[UA
MC4MA*@6AE5M=<*)U;A'I5%H2A+D1"S@AP"6/I9)N3OE]U["TN#SR/*C"NM@0
M72M-??:XKQTJ*U,BJ*VO1Y)$&^$-\$7J! HL,Q1B&UN@I$5#(EB !_SBXI(E
M$OCS07!R, A><C%,N:H\85%\(4VQ2)13C(S=4>QA+;$']8;;W96?QRIV1-JT
MH;Z,=>4>'WN?Y,"7TD#%<_K76QX6+\IRO_SJ.4![0F&* SP+N(F#@=N2,$,X
MMV%!.^^Z</,M#U#W!01)>5PG264H[&M)<T-?KJW#)W0:B5IL@BK^#"<Y[/66
M<(J81;IZ(%>;B7LC\$<$='I05$M;W@1+,FZ75041G<<X")\!O/<U.\^9DG>@
MZO."!_+-)TS(DQ%]4)NMX;>_V?*'B,MUT%Q1$3'C.BY7K$3X^H+B8JM.1:LX
M5JE.UT90JW^ RO)<.@>PD^MCC54"M0B)-OGNKQ&W2*V6J!O_4I6\6&#P9R71
M9+^DJB+QQP=O_K^/^HJYFPYXJ!"4"##:O-(V.)& @*BS\'(_,P-^1VDU%&(^
ML?H2TI]D+@Y[O@AF]=8C'!WL(#$NL*.%)8?M@&1=<J(PH@LKPV;(ZA93NJUR
MQ ;.CW>CSA$[#\2>5\8^O"T.)>;4(%LT,>+@N0TQX\^<:W U0Z:3Q52K*5"Z
M*_BD/CHW-1U"7BH]!VR=93I0(-^ +D+MB9F__2V^S[O".?04R7[A\Y<OHJ/N
MV; 9WF$_ZLZ.E\'.[^_J]AB7$I@6NJ!X:6&TN#C#I%,J/A_)PAOB.YUM3@Z]
MN9Y2ZL)*IQ[##Q>:ZY?:PZC=[?7IO;8S^%\L!JY?>;?]*^^.$]MMIR?MT^[C
MS=UVM&SK>-U!/WI@2UZ\;?0;BPXU5D>]\IY%NUXQ/W0C>/#WA]F[^_+%X/C,
M^M^'[V^78=[#Z3JR3I<C])GYLR:VL/[;FI$GS,+!.>HUCJ3#T9(]7/^$FU9)
MF<;GMLM,0LK>+?GL8Z@6MR>DX]?K?GP0^FY]:K+6Z<'7*J4.G^N,PF'G%+:^
M7UEAT!-%=]6%QPC$RCW>Y;'//Q[]&*;^#9_F^(^$+OX'4$L#!!0    ( ""!
MI531^Y]S%04  (P7   >    97AH,S(Q8V5R=&EF:6-A=&EO;F]F<')I;F,N
M:'1M[5A;;]LV%'[?KSAUL#0%K+OMR+(;H',<U$.:N(F+8$\#+5(145G42#J.
M]^MW2-EID]2MTZYI-M0/AJ3#<_O.A8?L/SL\'4S^& \AU[,"QN]^.QX-H.%X
MWD4T\+S#R2&\GKPYAI;K!S"1I%1<<U&2PO.&)PUHY%I7B><M%@MW$;E"7GJ3
M,\^(:GF%$(JY5-/&0=]\P7]&Z,$O_6>. X<BG<]8J2&5C&A&8:YX>0D7E*GW
MX#BK50-1+26_S#6$?AC"A9#O^16IZ9KK@AVLY?2]^KWO627]J:#+@S[E5\#I
MRP:/XREMM[(HS?9;K3@*NB'SIW&61ET61YV4_!F@D1XNKWF47A;L96/&2R=G
M1G_2"MW]=J5["TYUG@2^_VO#+CWH9Z+4J$\B?_U8B[D1MG'%%V@W1A!YB79,
MA=9BE@0A&J'9M79(P2_+Q*+3J.6L.5)1")GL^/;7,Q0G(S->+)/G$SYC"D[8
M L[$C)3/FPHCZB@F>58O5/QOANZA$ONZJ+W?1SD%+]D:C2 T_@^O<S[E&J+0
M#;[2_!1#Q^0/LG\P/)N,CD:#5Y/1Z<F6#G37]O.2HNU)U*F^/_RM3YH_GDLU
M)ZA7"SAGJ2E+Z/H=$!GHG,$YD5-2,N6<7A=L":]2;2BA[X>P%\3PSCUW!RX$
M4=MO E% J*BP#E\TX5B4)2NP]HA631A+7J:\(@4,KUDZU_R*P6F6\91)(^^8
M7?,4%8]S(F<D9;@@)07RC<K4A;W=G3@,_=YJE7T+>JB#E!1^9UDFT;)C%RX(
M91^K.N(EP4=\NJ^J"8RD.>1,LND2D*9YMD2/B=[=:<>]!\2Q(I1BTW$*EF&*
MA'<BZ_S T ;NVHW'UWX;EC!VVP:&%?C/%;R=$XDU6RSAC%5"8E:5<"3D# +?
M>0N9D#;[*E0M*##$DL(;(M-\=R?H^+TH:-I>7J< 9NXBYQA-G7,% QM+S!^;
MROB!:(VA1@&8GQ\W&]@S*E:Y-;::>+HRYT..9?,"C4S%K"HX@K/@.K>F2?;7
MG$MF=@UE\DJM:B>(]L@+0/MO/K3WZ(N;<L+DE[CW,6-*FI/RDJUK*NA&K=J?
M_T7RA4\N^2:(/R\QM69U:F B:H*<%+_:X-S) <@(-PE:2:9,E)MF'2D*0'Y<
MB6T%"15&&2F&/;MI-RB9V@''AA-7S8LZ200FM%6N/FI%[D,"_D1VC=$)7(PF
M)\/S<[AX/3P;GA[5&,S1,JEP3T94<X)-7C%M"%SB:TF5;;A8KT2M*Z*-]43)
MTKR^(<NZK-V-@'QB9M%D6K U?2HD&N @# 6I%$O6#SW*55609<)+ZXQEZMV&
MUPQF5Z9YX-:STF'5U>35S-;NN*TH-&.;QFE+T[7BU43GVHG.T_0^;=_M=O8W
M4GTWV$C[G-2XZ\91M)58SUI<6XVXJ(J4+QM18\VPJIDDK*XAN#U?F3*Z"TV-
MRN.GGYV9?UO>WJ57KC_,JWIJ?%)^[>ZT]GO*_M\:H&XYNF4<?>-OX[/@K*I%
MBRK!M:!$P2FLO?QO(?<(:#TY0*S$A&O4EFX!T2#G++L_?]]'R[/=<;ON^^63
MYU-HV6'<^9J6';MA>S/U&UIV>TNQ/UOV4ZBSK5OVG;/HSZ[])? >!["O+9-/
M-['O?=GTP*X^QN,%-\<!>]:H>_R]BX\''L5>F=/-OVWHG5/.(VXWWW9S>N?J
MMA+UW74B64',/GKO,O=#G=H]RO_ 0J98K'.]F653FFV\&5[]U_?4]L;\X!]0
M2P,$%     @ ((&E5+_,V"(^#0$ TYL+ !$   !L>')X+3(P,C(P,S,Q+FAT
M;>R]:5<;2](N^OW\"EW>]YZS]UHDSGE@=W,7VV"_]+&$!VPW?/'*$146$JW!
M#+_^1I8D# AL!H$DJ-V],*A*65D9$4\^D1D9\8__[^2P5?L1N[VBT_[G$EG!
M2[7_;^T?_P]"__[[X[O:1L</#F.[7WO=C;8?0^VXZ#=K7T/L?:^E;N>P]K73
M_5[\L B5WWG=.3KM%OO-?HUB2J]<[*X&94EP7B)GC$,<_D"::X<,]=%+B04F
M<GE_52CN#5<8<9;@-D<ETI);I+"*(@;-98K+895(R;C0SC*C> K2V*"\YC&Z
M0*2R*C^VV8>W@S=L]U:+7H=3HOZYU.SWCU9?O3H^/EXY<=W62J>[_XIBS%Z-
M[E@:?>&D5;2_7[K]F)4W$V/,J_+J^-9!OWMCN^857!W?V#KIGERZLQ5/CIJV
M>VA7?.?P51XUS!@9WUZ<]*]OMVC#XV,6T:M^U[9[J0--]$&$N0F,,$6$_FSD
MIKX1=J&A\]?N%=>]-+P)>?7O^KM/OAD/+2K:O;YM^SC^5H@_OU4^H1?]RG[G
MQRNX4+[6Z,:;QS.+ZKP/T$*XTN"H$_+5\.*%(4+PK$OMCI_]JU$B F&-?@[U
MH(?VK3TZ;R?9GBN?.;IP\256)S3CLB+ER\[VS@>GU^U/M@L?7FHS-U'\2CLO
MCOAJR[;W_[D4V^CSIR50\VC#VC\.8]_6\O=1_,^@^/'/I=>==A^,%^V<'L'7
M_/"O?R[UXTG_53G<K];^U__Z7__H%_U67,NJB<8*^(]7PP__\6K8M.N$T[5_
MA.)'K=<_;<5_+H6B=]2RIZOM3CM"!XJ3U7QC[ Y_+4*([?)7N-X !.D6?OC\
MD_['F/ZY5' M&"8N&.<)-]QIZKWCQD<9G6..?MLHNT(P03^-HFT/\Z-CL3K&
MI3=%S]O6>VB_$][ 9[VE6A&@^<"^G+J-SH]W]../758?A(/-'WMOS<'VP29M
M'-1Q8Z=9[.[41>/LX^'>QJ[8_?J![9[MX[VO7XJ]#;B';K)WK-':/>N<- YV
MSQH;G_GNX>;9]H['>X<?Z/;7-]\;M,X;;[^T=@\_P#VAV2 :OZ-[I[M?O6R<
M[9[5=[;XWL&ZV'[[^:SQ=I?MTBW1^/J90'ND3N$[.Q^.X9D_PMLWA7O[6=8W
MMDYWSS;9+O1O]V"OU=CXSAN'6P2^0W</WWROTR_?ZU^A]P>?1]_Y L\2[;V=
MSG']X%\']9U0U,\^%HW#SWA[9Y_N'GPF>SM[!;S;V=[7#R>[M'[:^*+)NYT/
M_?HG?/)N9^NLL?.=?A.1B@"#CZA+&O$(4.O T)!5S##CF</>+*U] *6X)-#'
ME.\Z"#>4 F[9_:7:T'"AV9/^:BI.8D#)MK)]5<+^M;#%A+ UM3"[)A VT19Q
M(QW2 GX001*AC#(5P:#?K+_[M/F$\KYLS[O1=BMKOI6 3^JO,7ZWLYF%?%H_
M^RP:^]^8)5H%E9 1'.S9.N!/&F/D Q$ S )SJI;6LAB>4,*O!]WN)0%OML,&
M4,I*Q+\7\:<)$5L<#>58()(B03P1CFS^@7G$Q.(4G E+:PA8(&)/B=N;;> -
MIZ]!T%W;VFJ'>/)_XVDEXM^*N#%IQ=ZS:(2T".0*7A 7X#9%^$W:"%CM030>
M1(R!EF-)]36V_.HR$^O&%,$"?>Q=0R S8UWME=0>]*!6.C>K?:"-_USJ%8='
MK<PZR\^:W:PFE[CBRDD/.O*/5Y?;&#[_YT-'?>AU!MWRKY+NKHYT;Z@@]]&]
M<4.Q5+SQ7T7(?Z<B=FMEA^*U[L'KK?][>0"O?GEM_-'EUH]*NCG^"UAYMY^1
MK$14!)W#9/R]G]?.NQDNW,I*X[Q\9?SW^"&O+@W4M>,6HC,8T( +X3C3"6R?
MRIB2-,;CY/S5<3,,+_:X&<3P%,:-81>!WDK))>.>2\>) *.++@@O@HK?MLKA
M@OER#H9KZ/[U1R, SBL_;VATY78C,&@7P]?O-2V8X_F;'4;;&W3CVD@ Y<5Q
M$^-KX[]S&]>.*!#)I"6+PDL.DU)R F:IH(76D<20]&A$Y\-P+X_H15N\YX@.
M2AR\/&2C-:75SY\V[CR:5#J@<D#?A/ \B6BT,"98(X5-U'E<CB8!TCYGHTG&
MM..AHPE^_:>LB.>O%XH?T*V+MY:SG>UWNO<<^(GOYP\W8KMS6+2O:_:VYG&I
MB5>7>_\[N?/(-/$6*Y> P ?GHH_*8HZ=MR[BX3Q(QGA.YL2<+N$YN3V>DZG-
M@P*\66HU)BP0'J746BIM!)5"8I.\+^T%/X6]C-XZ[F>?=OAG@(>='+4*7_3K
M\=#!(T(!5X?+[J,UQM5/?7CU_)W-_PPRC^X<'G7:\&=O_:0 J![?!I\?=MJ?
M^AW_?=C6/UY=^XCS43OOR=T,&3_$D"^)!F K2*JBU()P[JWAR0"P,2Z8L]38
M9R.:]1"*O,)L6^]M$;;:K^U1T;>M!1$3C=I)##9C9."2"/A->L.")4ESGYZ/
M!7V,?5NT8]BTW7;1WN\MB'QB",ES*T34B7/@KR AYI4RC#J6M'XV\EGW?G X
M:.4MQ^U^,W;S?=W8S*W]B%MMWSF,"R(R'G@T5CMC*>.,$JV,LXHXC+E.4CT?
MD]KIEC3H=)&F)8M3ROL;0+()#T19SWP(8%DL1>J%>SKAS&H$)'B\3)KHI#)<
M**L-L"=O82 PY53Y&7#-129/LR?!7@?MP.D6EAA.4C)$@--@F0O8*:)FX3P\
M%\HU>^%:FFRDT1$P5NXH<T[X(&/TF,5D;7I^PGU\HC9[J8)OQ*6(W'')>:#6
MZ"A3$BEAFEAR[OE)=2;T;O:"QAP3HHF.SH #[)RSQ!,.-JPT-<++YR?H1R:%
MLQ>I(S@X!=ZRH(1[+)R(*7CEB&4^2<*&:[3/0))/M>9$'K(4?UDT)O" C>0J
M;^YH:361(1D>01I6"O)L1#.+-:?IB<DD*Y@$:S'1<. R3@@CDU&1V2@,=L]&
M3$^ZYC0]^= H)=:>6&\9]]&8E(B-3.$H/:,B/AOYS'K-:8K(Y[ 74ANE$N-8
M,(,QE2PJ%1QUV4UX+B)[NC6GZ0D'"$.*E">/B>48)ZLL3BJJ9(2V09BG$\ZL
M1@"P1 6;O!=!<.:,YI):'V.BD@9*S-/M:S\;SC2MY< @E6#$!BPB Z(D=2(^
M<)B%#0$&)>VS$<UL.-/45FVE-R1Q+3@.7.<X+\49YXJQY)CUY-F(Z8DYT]0V
M?; VGFNP)L>Y4]HX#K3)@#R2E)(\8>3.L^=,TQ(9UB)&896A(#D!MF4L." ^
M8"Z4=CP^&Y$])6>:6OB()E8X$AB,'+>6ZN@4MA@;BYV+5,X@,GB1J</L0Y9A
MJC+<N&0YV)8VQ$J69.11 P'43JCG)]#9[%+-1+A: V$$+X>E!),@3?!_"3Q?
MIQ <$V06<?P+3U/F0:J!$PG &TSD*3(3M:+)&6-2-&"UST^JL]^EFHF@G1&>
M>^^-3(%;@2UX@,$2AAV1G)-GB,U/N4LUFQ-"3 I/1?(A3[<>J)-/-!^WBLZG
MZ.+3G<M89-HTK0,CEV$5&)"D>>??2RZMT)Q0SQQ55%@'5.C9B&86*R[3$Y,W
MSAN/(_A_BB=JC+""2)>B$-$0YYZ-F)YTQ65Z\K'2!FL4P2)XGA/*6"U!-DH#
M3U':DF<CGUFON$Q/9%P:PJA60CC#P8O7+.I E8Q@8-&)\&Q$]G0K+E.T)^*3
MC4(&3 2/DEFNHJ?*6Q9$@(EIO$N%YW&7"M]S!,[/'K8'61HWG(T]@E_'#=SZ
M+"=6,5+!>1*:<*.8(]@%I7!>&N96F04BU>O'MAMR2JG+6EYJ]_91GN*?(X5V
MQ@N5B$@PKW 2J66>4*Z<X"1(YL4"Q>[-7("SB;*E-/DH#(O1<" (6AE%G6>*
M82ZT5O._P'^#W#8/CUJ=TQ@?57Z/LJPOF&.*:^QXD#Q0:;F.- *'XTHI0_'B
M@^*3R&;VX&@UY<QZ:X*0//*DF3)2,)P(\XQI-O]4;DYL:XH$S@&ZQ22MYYIC
MX!DJ@E,4;= .*+8)"PMW'V.OWRT\^#^E4#X#X^I]_/1Y02!/*Q:2HLH0$7@*
MU/C M1"8.JF 9#\#'OAD\ID][$G""/A$). 4N>?4)<&(D0YF-.OP*.%$)<,G
M7ZOS4GC'&%!U G.1U-+;*+T.3F+B7)I_L6RU?X $\I<F9?/:]IH+(@@JC24R
MQQP'H'0.&\8L%C 7Q8 9]T^8#NHQ!/'YT_G"3O2#;M$OXJ*LE@:)A0I**^QR
M"G6IA0*/5G#'*!#Q:!=;,*\[W:-.%S!]([K^PLE&N BLV8-OY#RWB3GL0M0Z
M>'!7#4AHL67SJ=GI]G=B]_#G38LB&*X9D51*:E+@'B=M$HL12R:\,7+1C6;Q
MY*$$#\0;CI41G'MA>7#16^R(55AA/_\>SDRG^:E&.\-T3F%""933P*TU+F@#
M-(SCF,R""^+)I_GI"89JHC%53I.H>1!)L\ %,Q1'ZBE;A-,<\S;-3T\V$4?C
M8Q! NQ*7P6H?I;,T>"#*T:0%-YHGG^:G)QB+RY-.RABL.*'!XN&/7 @CN+0
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M&AO-[[L[X6!W9UWL[FS^"&^_\/ __VKMT=8/=] YJY^]:>WN?#^N;_Q]V#B
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M+J//CXM6Z\*G.:MS.^X/(RB'69YS42$8Y:$PR[B%LH)-MTS5>F'\5R;5(L\
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MMW5+Z-V&\EKP7FB$FQ8%*V6W Z+;^BFY"M"F!FB?)A@7HYAC:3'B@@C$%1,
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MWNJCYJNX11M34\CYZN143Q+3^=\S_=@YM:WSO=+A<>+N4,<>(X#LP<<.YVX
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M4OY=Y(J"_55$]&39MIF":PEBO=H@)Q\JVF7^H4%YK+0]8P_FI>XTEF/<>^P
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MBMXKIDT"#2#G]C]'&<HJ0)@N('@=M*,\"$L,)RD9(BQ0'N8"=HJHNZ<C?%I
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MR_>='SML]S6\X]&K:G?_Y4EYWZ.WU<Z//P]V_GF;=D[PR6(M;R=(LI(@1HU
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MF'5!;ZRZ\\ D)5K@:X%O ?@(#L!L>?) >>%FR2J@P"JJ9(2V09C:AVV!KX'
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M</5K^+OHY]O\3=1/:#R,'3L<QNNY<3>,V#]F2G7>*SX:2G73#<?N]\%WH%$
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M!36'*</,.PFQ-SQ-9G6Q%U-U.ZJULWO0JW7FN0C^H&%NE53LQ=P0 M3].1G
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M&.*1&4DP1P NV475"AEF$\+86<JMICJQZZ6*M<S@<7LK;7+9W5OO8H#)!VS
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M4S8@[B) +$T4:>T$8IIB6'V=!03.6WB&F]5*P*S /-L$L#8![#9)Z?60LDT
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M@0=DT": Z6B9!!X###!+!9K45C4\^F*FE1\2*NH=).&6B$$%-\HGUD@"-9<
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ME"-K@ ^!NQ72*B3/+T:P>H%-N":P--!H4S:P!)M(?!C^BF<%GP[+"1MQ";^
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M=9$/6SO9 87U0.'H^^<T")/(BQSBV!A\L&U,6V 1\5V?A6EBNWZ*#??"%=#
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M(>P@8*D-5- //?<PX,$="218BPY6$LC/3!]G+_^^_AR%84IEZ!">N( #A$P
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M?! )F#M+M?:K3&NOR[1^@$SKCG_WQK^W2/+#8.O;RIM^.*W:\+F[6SX?Y-?
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M&;(8WS"N>;P(7\SL0O(<BZUG,?1UK:;0R>R]F8( L_A)9>=(=R8IYR+TSK&
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M@:]Y<P:P=L\.45(65/P+ B^1 I&C:*B[6=> ?C_ UBJ/!:@>,(C%D&>^.D4
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M1L=W= IO4N@^?>T-!G)FX;"0T3(P6]G]%9&P%SZB /<&=S2\)C(V>42N+G4
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MLG[O7\'UO$Z:LR^.=D^XO<PXPM,XO-R>-\59\H"B116W2M@PO_[FD< &@XU
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MAJAW X;Q>#B]D ZI;L,4J)#3=1! (1J(T0K(7GOI$[+,6X]]7I5B%5R8S[B
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M8YE,\6/X.B@Y>N=) %,45B5)"-()L$8X&SPM!JKUW:C.H)]ML4>2^[BML84
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M$_*!BE**:"-8G6J!6U: G.H"6=*WFI!*;!T(KPWNNS&:+;CHX=+-;:!77O=
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MME;R$G/HO!WW9C+^5&MR5:0W&@^:+&)AW$*NEZ64XPY\,@%RY%%8E26+K>\
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M7HK0&0U.D=..)FAA4K3N;@'M57<35K_DL$ENJL(EW';;&KP+[!J68+2<><;
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MR0A)I@1*! 6.HDU(T:GH:IE<_51KWB7&[]&8-N:F83GY3?&^*!0U+$ /O^
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M_<-H#QKU+ZGSTC<==E[J*""/3!*>\+VP)HP%5J-4B>F3^XIU8RS@Z*\D8S/
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MW@JFTS9RV:?KP]=F-],3:B.323]@OO!RV=WTA-M$"^F!^#EN=UI@TK_IV3?
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M3=.MSVU#KQ78Z@V,XD!K#K:JNY9).8N^S;:B;TS'YK-7A-.U1(Q/6*?:Q_,
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M:?H]UG?R61D ,PHO[N]-(PNZW-NIV4C_^PJ(<GT+N(E4$N:4I=;WUF5>:3R
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M&] V(:NMHN#Z/&C.1&<!AR?NZI,T*1U9F/R286QN&1#B:OS/3P5=77_(5]O
MKT449UPD*H$)DTROYI,$LBA*($>2!EF6Q%PRZ]C6HR+F1A'-FLAH":Y!H^>
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M;@KRF\2"5$+,-,]$D@9I1%3 :.;B7#E)GQO9[+[C5V!?_V=?^*T-X+?6"L>
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M%$1?/06&JC%M;X$+P3KH,7#I>)?XAYN^?+](+O.'>L%#%-,X43!+17-*:#H
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MC!.FG3*]>(>8,01CDB8I4DG"8Z=@S!-RYL:[I\LB.;:Y/@&KG4OF :R1V74
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M\B# &8NPR&+';N"G1,WM16Y#3QI]VXI3>QJ[%E(Y":_E,L4+:&,O41JDOKY
M:H1BL.?1\%;JXZ2@B<MRG#/XL(3&V3N&,<7GLN!2BNJ#5K([<+]1;XO[^V+5
M[+8L5)9D,<$QE!DA>B5",HACQ*&D-(GB. IHYM0&^JS$N?%&IS P$[D+]- +
M=]XH#2JCM1N#G(?=CDB\@CDRGSS'\>,>CJV^[>ZQ/UJQQL83NYR7-RG)6)O_
MDFOL;QQ&.2^*]_R\-C2VV?&M;M9U59M(P]7M&UKE?$%PEJ",4$CC((.(H @R
MA0E, Z*"C$HN)'&A'R?I<Z.B34>7KLJ.YI^'=1-I;\IF+HNJ @_:(^]HR5Q\
M!1I#W-C);8;LF&HTW$=FK8,B:JWFVX.P"NPI?PYM9PX;A)HG/G.3/2FW#8+E
M)<\-&V3J,I_-_WS54J]7PG1U^UD_J^\*DT*ZB*02* L2O8HC J(@(I!Q$>M_
M"A9&:<J"R'$IYU_)N3%HHRDPJH+?6@V]-*&\<"9M5XVO.S\C,ZW+U$Q8HO(\
M=J]>B+)'Q3](N<GS(/LK*FDA:QC)_T4/47W27IC^?*S>?S..V3JO[HS@&V4"
MWQ9ZSFD8Z,6SHJ')QTUCB#.&8:1"S"5B5'NU+HQ]5N+<Z-<H#+XS&G\/M(OZ
M7.4N\M^-D,^C3J7*LEAPF# <0J1G &(2:/Q#1#'3_Y\$V8 L:#_@3Y\ _2IS
M8/>%\_H\C_RYN@Q&YP^8-32>OD;GY4WZ:;$V_^5WPO[&8:3_@>:E"463;Y[>
MT*79*_ER)V7]E[)8/^2F6\ NHH.(E-(4TM@<FR9(_Y1IESTD/.:)BN(DM3HV
M=14\MT^ T;N)#)57IICM1G?0* \Z[2\._[6>%CMB&@/LD?G).\[.E.4*FB?F
MLA8[*8&Y@O&2QYSO'Y@-_$CSI7DD/A3E%[J4N]Z#V[Y%*%5*X  &8<@@(JDR
M&[("2AHQA&FJDL I)>*LQ+D1V/NJSN^-LP9VKYACPN]9D.U8R2MT8Z_N.UVA
M*DIHM-WK,#I&-2I;;'PE])Z5-VTFKZWY!RF\UC<.R-TU)]B?"KJZ_BLMF]YK
M[:;K(M6^#Q8(P8"D$42(1Y"D7, H(HR2($2177?B/B%SHY$FL,+H":Y!I^GF
M<,$A*?04HOT$X@NGD3EC7(@<4F0]0#51-NP0R-RR7L]@T9O@>NK>Z7)9SVC_
M+&WUW+4#X_^+^_N\C> QD;M%4\U9KDPMYP5*1*@HYI (F4"4B1@2)!$46&8I
M93'%Q&E_L$?6W.AP3]5-2:(]91UC^GL0MG.L/.$V,CV^A.RM%63N<?KGP? 5
MG=\C:=J8_/,F'T3B6]SB'G^_\;Z>NI1Y<U:QR/3J*Z4HT2LPQ2&*.8>4I"'D
ML0QDE#',E54AIE,"YD8-G8Z@4Q(8+>U#\(^"V$\$/J 9^>UW1,4I"K_/]$%A
M^$<'G"P.O\^<_4#\WNN&)L_\(F]STZ)A53?/G4HD#L,809Q%,41*,4@#2B"+
M@H0C&M(86[5]/B5@;B_O)E=DIZ3CRWL4Q/,O[Z70C/SR.J(R((7FN.D7Y-"\
M&'#B))KCYAQFT9RX;J2HK3-]*_>"R'H[Y>*(4XD4AB1  41(1A K%D-.B0I$
MB&B*G4+L)])[;E1CTX[9MAOSLZ#.:;LP>WJH[%8Z,WQ4QO:;+/HNV[9=]O*4
M^(]E\SMG4X6W>=)Z7A%O?J?".0C.L_B!GU&3-&(R2:1XI_WKU6W;Q+D-M/Y9
M_M[\J5JDL10\C#.($J4]8RE32*)8P2RCC' 5)@'-G+Z"5F+G]A'[>"*_;%,N
MVV3Y:\?QH[Y"^SN/FEOTW9J)FF0/US16NWFQ_)!X1WOL[T"#:JLQ:%4&K<Y7
MF\R.*Z#U;J_PN)WF!I0O\K43.BUW.@%Q0'UN=U\:W'4DY&)3WI@NO]2T;MCV
M+6UI]=.V:E5  Y)@[=EC'H80,1Y#+%4(>: 8-W7"$F[5:=F70G-CNZ$1%!=/
MC!VI30GWR'2W'PYV/!;L"FPM EN30&?32)7)?"'L/79LH#JO%%-V&7BG8\TN
M''=H30*I9%G*MMQCH\@B9)1(@02469QJYS!0$ L:0$8DH8GB'%&G>FA'9,R-
M&[<JM@[@%?B[X(<@! ^T!(]&WW\ R540!!O7#]!U?5>4^7]*\0]@572_S5O_
MQAP/%CMGW[58P>%\V/'GA2B/3(D[@+^T &_HL?4J?!8B.(F"M](#AQ(F+C9P
MTL3#\@*G+[T@I.S=@H1:<QYB2' J(,*:)W!",0P2)071GI:RJTOV?-BYL<(N
MP.?=@!BH=RZ!84ZVC_RN7FKV@& O)_,G#^\Z#<.P<*YWSRGI3 #7NU<(V7KW
MDE%._'4 B33]#[4;D]=TN>VA5NV21,(@$WK=1F <Q@JBB&-(!54P2 7/4A$J
M2:RVIFR$S8UPVJ:>&WUW'>9<>O>=@]>"DSR"-C)3G<(+_.:<S&0%G@.S>01Q
M(KYS?OC<R,\2D%Y*/#?&=$1I:<TS^K2]YP+/[.T",QY',9$P2@)30DXOWD@4
M)S B',5(FN!6^RY<VV'G1I2[;_/; 2[*6Q?/S,GVR3RS868/\,R<S)_<,SL-
MPS#/[*T5#>VNGMXS>WN46@[_.FP[Z!?Y*%=K:<K1F;#:DO+ZKWE]]W9=U<6]
M+-]_X\NUV+2MUO\GOM)O"T8SSK!VV&BB&$0R%I#)V)PJXH"K@ 2!<CI+'*##
MW.AIKU/PXU[+7<<SPR&38;=7-#+$([/@1ONVMF6G?]N%N;/@"FQM )T10%OA
M;Z/I @@];40-T6#2C:H+('JYD77)4!>X4V\6/* \YBF#81IJ=PI'%&+**>2A
M=J7T6E1P8;47_GS8N?'5[H/Z9H!?\<;%G7*R?3)W:IC9 ]PI)_,G=Z=.PS#,
MG7KS)Q=WZLTKN%-O7C+.B;\.S4BX%D)/5?56_WA3?BU^7RVR- DRE3"89/]_
M>]_:)#>N9/?=OX(1]OK.1#2N^0!!8!WAB-9C9GNM*\E2SUYOS(<*/+OI6UW5
M+E9KI/WU!DC6N\@"4"";=[T1$YJ6F@0R#XA$ L@\226 /(. XEC_-<:JX#*!
M*;=BDNSI8VKFI8W ;^6\B8RD&L?(R.J:G7 *:+_Q"033P);("R&/3(5.#*Y(
M5CAM<^1\A4ZE3E,6NA^]AF%AACA#+%82"%X8+T%E ,>R )S"3%&)(";NUV&W
M4YO&>_GN/I0 3CP)$YJ;UZKMPWTP:2^A&P9/=@,G+^'V-1@,>KV$6T\CLMG<
M?%@:3JG5DV'(,_^?9:10A!4"Q$H@;4Z*'! E<R -AR934#%FE73<U<'4#(N1
MKRE^8R2\B<R/;D<E)Q#:G8-< \S 5L<)$^?3BR[% QU-G#0_ZKE#EW+'APJ=
MS_E-XT_/TASX+1[>?S?I(;*Z955]4C'3KD$J<*J RJ">SYSG !<%!2HFF&>4
MHHPX129W]C2UB;T5-)*MI/_H-J^[,;6;X$&0&GBF[T#:"!G]OA$S8/3O12@"
MS?WN?D8U A?5/;8&EU]P/P-XN_PF5Y:?[,GS$_I$:[F"?I6=VGIM1 ];&FW[
M>5:!_4WG^0?\EA>S2MTM=%.ULU]3R<Y0D5 3B0D*!+EV%)D ."<9R/,T13G'
M>2*<KM[.]#&U)66_F'OM(ZTW/E*TD[QJN78=B8S/06RWSEP)W,#3]P2S>R_,
MG)><'E0"+3;G>AAUF>E1\7B!Z7OTBF3?Q^5<OU$UR:IWB_8B[/-R5:<GK]>K
MDKVL36?WRX]:)W-[MISK1A_N%GKJR&H]$Q1!G/ $)%A( !'% %,9 Y8IO?64
M.([S>/;<I/RMZ6IM9TO"".<RBXY%'&Y"M;DZ-TURB$<F\/6#AE#.$(F1B;I(
M <P+":@@&"19SB6-89PGJ!VT]PLQ[2';"/CO>L#L%I+QAV#HM6=/H3^U*?4W
MT5:IJ-4JVE<K6B^C0\6BC6:!<\.#(1TR=_QZH<;/+0\&Y-G<\W"M7YF;?K=X
M?EE7'^0W.<_:*N124)4FF01IDF  9:( Q@P":&J\:_\<)MB)H[^GKZGYXOMY
MSK6<4>:96GX&5SM[&0BM@8W@/E"-H%O !JCQ;H%)Z!3N,SV]3G9VM\J=B=<]
MK_BR3B^JY;P4]87<9_T3_[%+(:$DYFG*<\"@MA00*@28$ 7("BHI2Q.)H!7]
MODUG4[,7![+>1(VTT>_M_[WK#_7B;6=&0J$X^#G<M0!Z,%)?1B88)75/5R-S
M4E]6^I24VN*=$$=_NJ-O4GL^VMUI?JQTAU],M\DLRP4A'"K B"H 9)D .$X@
M0#06-,649<3)NECW/#53<W2X=1/MR;[YBY$^JL6_YIBP;SA\#@\#@3RP)0J$
M[Y5'BA98#7+0V-?O*QX_6L#1?RAITX!O).S[)[EZT%NR7U?+/]:/AD.1+G[,
M,@(AEFD&1);DVAT2!!!S/XXRRN,4%I)2JRH<%_J9FGEJXSTWLD:-L%$KK6M,
M['EH+U\W!@)L8%/CB95'=&PO$E=$R)YO=^0HV5[E3B-E^Q_W+\>S7-0G.I_I
MZM.J9K42]2;LLUS5=((S#A/$$X& ($A[,(IH7Z: #* 4)ECD(DGLF&4<^IR:
M<7B[1T5ZL^.@BI[EJJ&:<B_1<PEUVUU24"P'WRS5,+9\4UI@$U#?B-R<Q1@*
MTH9^-&P!'TN( A;RN=3CZ 5]+"$X5]C']E4_$W2GO9JJ+AUTKQMXJYM_,$1N
M]::M/7AD>@^5290#++&V0+$4@&:B #*A,50L09FR8E"P[W)J!F@G<?3[N^43
M+1>.)S(6*-M9G+#8#6QP=L)6EW%SMBSV4 0R+!8=CFI7[ $X-BL.;P:O,_BN
MK/A\6;VLY#8.4.K-C:2" Y45", D+@!)(0<XBV.D"EAD+ U4>?"T]ZG9FM["
M>M%.?IOHPP!C8^\(#8+X""Y1*+!#UC;L!FWX:H=G^IY*_<-N6!PJ(O8TXEFV
MWA2U>*>-Z.WWLIHI*0M5Q!1(FFMO"<L$4$9C;<QRF&&5IR+-G4K4[[<^-6-5
M"Q<9Z?0,T?(YFJ)#Y.Q,C3<> YL2>RC<R\F?4SE4Z?B#ML<M$W].K9.2\&<?
M\LPK+"DKYW4]>6T43@-I9AP2"!/*08:4U(Z(S/2TQ3%(BI0SDHJ8<KW36:[I
MW&[N7NK0:3IONQWN&[XW?43SG=3UHBAK61WS#R]!;3?90P(X\/S_<(3:^W[4
MW#,4+:$(E;%XJ;MQ,Q@ME3_):+1]S_T2YWY%3<S=UQ]/;#F?<<1$0K,$9#01
M %(* <F@ (QG!"$,8TBM@MY.6I[:BM\*%S72V5_,',)U^2K&&X2!I[FE_DZ7
M+6=U];I>.6QIM N5LPKL7Z&<?\#WYO27<BX_OM2G9@)S2#F#@$J3\"48!2Q'
M' C!",V*@J6%5<+7N<:G-O7:>S\C8-1(Z'HON@><[66H'QSCW(#:(.%QZWFJ
M\A57G7N-C7R_>:K&Z:7FF6<\>'^\*T%N0TYOJ^KEJ2GD8[*-^5H*DY+W_NEY
MOOPA9363!5<Y3#(04T4!Y-HS)Y0)0-*89&E>\)A8'1&.)._43$> ZL2[D.UH
M3_N;:*-_3<BA_[J!P($::(3OI]_<3?"K&-B"_G__03B04$WKPQB+W>I1UAPE
M]4C6*>5TJT2T?J3KJ*RB%_-9E(LZ',,XQ701+9LG]'_ENHJ6?RPVQ<#4<A7)
MC<)_#L28-=[0]%)QC2#&>!Q?XV%Z0!XV8K>^5/"5U"\]WB[$.Y,;LWPV(K3D
M**8 &!%8%8 Q4R/0D$[05!0@SU'"!,R1Y+$;Z7M/;U-S+S;"U@=?8B?NC38.
MF[S6.GJK74GX_HJS5-%_26[B++VI7]<_IQC=1%H^,X:E;LSQ[+%_H.P.'H/!
M/_ Z?H#\GJ0;ZJ20_.X6B 1C<N_K:V3.=@NU3]G9;5[RV&E]J"TE72Q5:=;D
M<E%/(4ZKQ^?&(LZ*F&8P)CE E H B=#>&V<I8(@0AA.*>&Z5\&+7W=0,42-K
MM"=L9*2-6G$=7-#+2%ML*8+B-[ EF>]D'0<_!P\\*(XC.= V>$9 +W//NM<Z
M &6M7>Z#W];U/#9-++>MR.;)74D5W2J=STM#Z!'(K[8&O-<MOMS*>%ZMM48'
M3JG]6]<SW7Z6^LO3G^6#?*,7C[K8]7<I-H0-7_2XSU*80I4E$.0*)@!"*0&F
M10Q@IG^12HP$=G(RW;J?FK$_9H3=:1"U*D2U#ENNE(-'C$;^G+H6@V5YPSW8
M$ Q]WST<^E>Q]]J#. "WKT7GK\;\:P],'R^P0ROAJ&72-D:><Y)10RC#J.'X
MBC,%B(FR0WF1U-<#W,W^]?0U-6-W2BV37D\MDUY-+>.!UL!VJ9M:)AV)6B8=
MC5HFG0JU3.I.+7/\BB?CH^^IX88Z:\OV61>CO7^DBT_-$>*ONHEU=;?X7#/R
MS?(BEWF<*Y!EPN1EXPS@1"J $HP)HEC"S(E(8BS!IV;' EP\-0@<,+4VI9K7
M&H3HT^8>JL'!7$\T2#B2'([U8=G9WBE^+J-<4;ZQ_%+>C/&EN',JCCQLH5@7
MQQ)[7%[&D0?CA+EQ[/Z][[G6J]+<GM7QLK\MRG7UY>MOK:L($Z$RE3+ ](H'
M8)I!_1."0!0<LYPDL?Z=XSU7=V]36[QVPC99]%$M;O23%KCZ^;)WZ0&W]6U5
M&!"'OZVZ!C^?.ZO+N(2[L^KI:^P[J\MJG[FSLGAI*M&![\IOI9 +80X<=D$]
M*4X0IX0!D194.^E%#BA"'&"2\"P1+(^5E7$:6>ZIF;DQ@L,V0-0G@1.*$CO_
M85G<]4WS<QG%1_^/+V4Z<857?S%CQA=6Z_*IIA\2FS%>F>O-GZBA=MI<%2Q5
M?=]9AQ%&SWJ)DC^;VU"F_T)+$?VTC5+<-%+5OV_SO#:OORSTW^8_ZDBD)B"Q
M+N%D?K6-2OQ3&[WXIZJ^:YUTD&+O.(\?K'A>G+_SH,5>C(</7NSOWF]SU_9=
MW2]ON=Y5KN0>1\\LSH0D!2I C$@.(&("L%3O[;*\0 GD!88HFRWD@YFR=KN[
MONZLC!)IC-)^I\/9I,^ZH4=JZ@UJHU'N)'7;T/5";+>?NQJV<5;_C9C&W+:"
M1G<6L#GOXVSP"+2-Z^UJU%V<C=+'FSBK=SQO6EZ>G^>U+:/SNP5?/LF:C*X.
M;&S^?5>+-$V9X)G$@"=I;J)3F+DL02 E>9(B1N("":?+$ON^)[>7VA,]:F2/
MML)'&^F]R9Q<1L7RIF$8K(?>B 2#V?V,WQVP4,?T#CV/>]+N#LG)8;E'$Q[U
M:%]6*]W4+V7%Z?Q?)5V]7]1D,S/)!4YHHD"*8ZY=(80!Y::<$<I8GDF99L(J
MW[2ODZF9JE;.J!$T,I)&[Q<-IY%]IGDGI/WF)Q10 ]L9+XS<B@!? ,&O'G!7
MH^.5!KZ@UD&5X$O/>@;;RJJ2<EO6^H/4KOZ&(.;';PNANUN^+/0VX_UWKA^]
M?3)_F^D=$(&%0B!6,@8PYRD@(BN R&/"XB(G)'8BI_228FJFHE'B)MJ5:J_U
MN(FVFMQ$^[I$C3)1HXUCV*W7L-DY.X,/QL#F:*!Q< _ O0;'4'&X7C*,&XY[
M#4PG4;E7->9G0O_%'-DN'FJZ1IX018HT!BC-&("IS 'FA *<,IXS53#E5N=Q
MK^VIF;M6-"^.RWW([(R2)Q #FQI+#)Q-QQEM QF$_99'G>9G5#J>O.<>\9N2
M[^EJH5NJ-O4 WI7S%SWI9TPR(C.>@5AR"J RA83R+ $Q44(*68@X<0I8[>AG
M:E-U(^:NEL5-U(KJ-F^[<+6;PP'0&G@^^P#E/+DOP!!HHG?U,NJDOZ#JL0&X
M]+A'H,U>L3*3J:.7_4=S_?15"U\'\;REU6-;(GI&$8,4YPI@2,WB305@18Y
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M=ATR(T6F.2'D%G[6K7]OG-F9U\8+*.N6^2!RK.>QZ\HYO6]J9\]8DHDXXRG
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M#.(4$)&IE,2(2^2T'SC?S=2F[3XYY[N&^,]M"G>@:3>5K\=HX"F]$3#:2#A
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M[E@VSV-<[(XMAT5[A$O^&NR-^.:0\2>C@38]/T=;):*=%H,4Y?,',="IGX<
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M6^ 8"E:'Q<0Y!)!@ FC,&:!9422YH)!DSMD,YSJ:F@DYPS#B<2QT$5Z+B_1
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ME@,)N02000APG!9 BD0QFN8,":M-;G\W4_.):RFCG9A1*Z=CEN-Y2.V,S_5
M#6QHG#%RSUGLA2!4@N+Y3L;-1NQ5]"3UL/]ISZ0?_BC%RUQJ3^GL.7SM/[7,
MIBTESH][D[6ZRX=3>2&2 A) >8H S' *F"PR$".>Y+(0<:&< K&N%VEJ9N7L
M5?%^HDRCS<V&7DIO+6J%_',8 PRKG;D:=[!&N?KO26BZ9IS<DYR"01LJ(>IZ
M@<9-G@H&X$FB5;B6KR03:U+.#17#+"EXCHP)YI1Q #DW]7)BI(UQFM,$9ZS
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M^S]?S%>+V337=@X_A5GM5$ [ ]>KW^;A-$_7M\N9AU7]#_C4-K7_VY*_9P>
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MOR[F'^IU] N,E]>(.4=NBS1@M*Z.F",?S),WYIUAQGKE*89K?6S=)6/<>.A
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M<SI\LA:Z2.&]:6T7A](V;@5L=\ \B$K'OJW\1FTP#TJHX@/D6A"A8FWWY9.
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MSP4#:][1YR8%X^)I=TT^ (D=Q-H!*#;[XD58G\F!%^9=UG6D2B0Y1%L@.I6
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MV6D+S#)#[CY+$%%02)V\+=$9H>W3N3J]P]ZP#?C/#)/CXNB/L,5J L&W#9-
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M[:3! RBO;TRF='IR.JLE123CU>JW.85&L\KG7\)T_A.6Q1+?AR^3DJ-W=$R
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M+R,70Q)8T-Q0R*^S)\<QD??HT&;0M2Y:F,2U;.U@/4+.N#AJI/ A,-I!^AT
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M6%.*V1B4A"*+KT,B,P2N,D1?L/:(9S*6_LW-)IY4*HA@!1W2QA.B=77]I9"
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MXY9,FV2KIAAYDX0G@96MSW1VT?TQYO7R'?WD8GG9'8[@!7%UU1581;)^'+T
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M&P$ 97AH,S$R8V5R=&EF:6-A=&EO;F]F<')I;F,N:'1M4$L! A0#%     @
M((&E5-'[GW,5!0  C!<  !X              ( !DR,! &5X:#,R,6-E<G1I
M9FEC871I;VYO9G!R:6YC+FAT;5!+ 0(4 Q0    ( ""!I52_S-@B/@T! -.;
M"P 1              "  >0H 0!L>')X+3(P,C(P,S,Q+FAT;5!+ 0(4 Q0
M   ( ""!I52]Q\<9X@T  (&7   1              "  5$V @!L>')X+3(P
M,C(P,S,Q+GAS9%!+ 0(4 Q0    ( ""!I51L1* 'X \  .Z'   5
M      "  6)$ @!L>')X+3(P,C(P,S,Q7V-A;"YX;6Q02P$"% ,4    "  @
M@:54>EO"E@XZ  #]A ( %0              @ %U5 ( ;'AR>"TR,#(R,#,S
M,5]D968N>&UL4$L! A0#%     @ ((&E5%KW!A"ZH0  4,(& !4
M     ( !MHX" &QX<G@M,C R,C S,S%?;&%B+GAM;%!+ 0(4 Q0    ( ""!
MI533MK=D%5D  +GZ P 5              "  :,P P!L>')X+3(P,C(P,S,Q
>7W!R92YX;6Q02P4&      H "@"Z @  ZXD#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
